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Summary 
 
HCMV encodes a plethora of immune-modulating functions, many of which have yet to 
be assigned to specific genes. In prospect of performing high-throughput screens to 
identify and characterise such functions, a library of recombinant adenoviruses (RAds) 
each encoding a V5 epitope-tagged HCMV protein was generated. Protein expression 
was validated and characterised for the vast majority of RAds by western blot and 
immunofluorescence.  
HCMV has been reported to both upregulate cell surface expression of Fas, and render 
cells resistant to Fas-mediated killing. This thesis demonstrated that Fas levels are 
markedly reduced at the surface of HCMV-infected cells as an early function that 
persists through the late phase. Screening a panel of HCMV deletion mutants 
eliminated 83 genes as not required for Fas downregulation, while screening the RAd 
library did not identify any single HCMV gene as being sufficient for this function.  
Deep sequencing of the HCMV transcriptome recently led to the identification of 
UL150A as a novel protein-coding gene. To test this prediction, UL150A was tagged 
within the strain Merlin genome. UL150A was shown to encode multiple protein 
products, and be expressed with early and late kinetics.  
In a screen of the RAd library, gpUL4 was observed to be secreted from cells. To 
investigate this function in the context of HCMV infection, an epitope-tag was inserted 
at the 3’-end of the UL4 gene in the strain Merlin genome. Tagged gpUL4 was secreted 
from cells infected with strain Merlin. Secreted gpUL4 was more heavily glycosylated, 
and produced in greater abundance than its intracellular counterpart late in infection. 
Active secretion would be consistent with gpUL4 acting as a virokine, cytokine or 
cytokine/chemokine-binding protein. gpUL4 purified from supernatants of Merlin- or 
RAd-UL4-infected cells inhibited NK cell degranulation. Furthermore, gpUL4 did not co-
purify with virus particles, indicating it is unlikely to be a virion component.  
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1.1. History of isolation of HCMV 
In 1881, Ribbert first noted the presence of ‘protozoan-like’ structures in the kidney of 
a still born infant. These findings were not published until 1904 (Ribbert, 1904), whilst 
earlier that year, Jesionek and Kiolemenoglou had reported on the observation of 
these unusual large cells, in the kidneys of an 8 month old fetus suffering from 
hereditary syphilis (Jesionek and Kiolemenoglou, 1904). These cells were later 
concluded to be protozoa, and were named Endameba mortinatalium (Smith and 
Weidman, 1910, Smith and Weidman, 1914). Goodpasture in 1921 provided evidence 
that such structures were not protozoa, but rather abnormal cytomorphosed cells, to 
which he gave the name cytomegalia (large cell) (Goodpasture and Talbot, 1921). 
Example images of these cytomegalic cells are shown in Figure 1.1. By 1950, conclusive 
evidence had been obtained that the aforementioned cellular morphology was caused 
by viral infection (Wyatt et al., 1950). This included identification of similar cytomegalic 
cells containing nuclear and cytoplasmic inclusions, in the cells of other animals such as 
guinea pigs, hamsters, mice, and monkeys, and their constant association with a 
serially transmissible infectious agent able to cause lethal disease (Wyatt et al., 1950). 
The term cytomegalic inclusion disease virus (CIDV) was proposed for the causative 
agent of diseases known as ‘inclusion disease’, and ‘salivary gland disease’ (Wyatt et 
al., 1950). This virus was first isolated from the adenoids of children undergoing 
tonsillectomy-adenoidectomy surgery (Rowe et al., 1953) whilst its serial propagation 
following inoculation of fibroblast cultures was for the first time reported by Smith 
(Smith, 1956). Soon after, 2 other cases of successful recovery of the virus were 
reported (Rowe et al., 1956, Weller et al., 1957). As it was recognised that the 
laboratories had isolated different strains of the same virus (e.g. Davies and AD169), 
and to simplify the nomenclature, the name ‘cytomegalovirus’ was proposed and 
adopted (Weller et al., 1960).  
  
Figure 1.1:  ‘Protozoan-like’ cytomegalic cells
 ‘protozoan-like’ structures were actually HCMV infected cells: large inclusion-laden 
cells containing swollen nuclei lining the kidney tubule.  
a) adapted from Farber and Wolbach 1932      b) adapted from Wyatt et al. 1950
3
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Human Cytomegalovirus (HCMV) infection in vivo gives rise to large, conspicuous oval-
shaped cells containing characteristic intranuclear and cytoplasmic granules or 
‘inclusion bodies’, thought to be respectively areas of virus DNA replication and 
assembly (Iwasaki et al., 1973). 
In 1961, HCMV was classified as a herpes virus, based on evidence that it was a DNA 
virus, and that its size closely resembled that of previously identified herpes viruses 
(Andrewes et al., 1961). Morphological findings achieved by electron microscopy 
supported the above proposal, and HCMV has now been established as the prototype 
β-herpesvirus (Smith and Rasmussen, 1963, Spaete et al., 1994). 
1.2. HCMV Genome  
1.2.1. Genome organization 
HCMV has the largest genome (235 kbp) among all human viruses discovered to date 
(Dolan et al., 2004). The linear double-stranded HCMV genome is of the E class of 
herpesvirus genomes, and is formed by the covalent bonding of two sequences of 
varying length, known as unique long (UL) and unique short (US) (Roizman, 1980). As in 
other herpesviruses of the E class genome, the HCMV UL and US segments are flanked 
by the inverted repeats TRL-IRL, and IRS-TRS respectively (Fleckenstein et al., 1982). 
The TRL-IRL, and IRS-TRS inverted repeats are also referred to as b and c respectively. 
At the termini of the genome, there are direct repeats of a short sequence, termed the 
a sequence, which is also present in an inverted state at the UL-US junction (Spaete 
and Mocarski, 1985). The overall genome configuration therefore is a-TRL-UL-IRL-a’-
IRS-US-TRS-a, or ab-UL-b’a’c’-US-ca, where the prime designation signifies sequence 
inversion (Spaete and Mocarski, 1985). A diagrammatic representation of the genome 
is given in Figure 1.2. The a sequence can vary in copy number depending on the strain 
and passage of the virus (Zaia et al., 1990), and contains two highly conserved cis-
acting elements called pac1 and pac2, adjacent to which the genome is cleaved prior 
to packaging (Kemble and Mocarski, 1989). The ‘a’ sequence has also been 
demonstrated to be indispensable for inversion, amplification, and circularization of 
the genome (Spaete and Mocarski, 1985). Following cleavage, genome circularisation 
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occurs through ligation of single unpaired bases present at each 3’ terminus of the 
HCMV DNA (Tamashiro and Spector, 1986). Recombination between the terminal, and 
internal repeat sequences gives rise to inversion of the two unique segments relative 
to each other, resulting in four equimolar isomers of the HCMV genome (Weststrate et 
al., 1980). It is unknown if isomerisation of the HCMV genome brings about functional 
consequences, although isomer specific long-range splicing may occur (Gatherer et al., 
2011). 
  
 unique region   the ‘a’ sequence 
 IRL and TRL  IRS and TRS 
UL US 
Figure 1.2: Organization of the HCMV genome
Unique long (UL) and unique short (US) regions are flanked by inverted repeats named 
TRL and IRL (also named b and b’), and IRS and TRS (also named c and c’) respectively.  
The ‘a’ sequence is present at the termini of the genome, and also at the UL-US junction in 
an inverted state. The direction of the arrow indicates the direction of the sequence. 
Recombination between a terminal ‘a’ sequence and the inverted ‘a’ sequence at the UL-
US junction gives rise to four equimolar genomic isomers differing in the orientation of 
the unique sequences. The above isomer is conventionally chosen to depict the HCMV 
genome 
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1.2.2. HCMV Strains  
Several different HCMV strains have been studied in detail. The general genome 
organization is remarkably similar between viruses isolated from different patients, 
tissues, and geographical locations. HCMV strains are often referred to as high or low 
passage based on the extent of culture following isolation from clinical samples.  
High passage strains have been extensively passaged in fibroblasts following isolation 
from clinical material, often with the purpose of attenuating the virus for vaccine 
development. Adaptation to continuous in vitro passaging of HCMV isolates resulted in 
significant genetic change, including loss and duplication of large segments of the 
genome, and the accumulation of several frame-shift mutations (Dolan et al., 2004). 
These genetic alterations manifested themselves as changes in the biological 
characteristics of the virus, such as accelerated growth kinetics, and a narrowing of the 
range of cell types the virus is able to replicate in (Cha et al., 1996, Sinzger et al., 2000). 
Indeed an exceptional property of HCMV is its capacity to infect a wide range of cell 
types in vivo. The loss of endotheliotropism in passaged HCMV strains has been linked 
with the UL128 locus genes (UL128, UL130, and UL131A), at least one of which is 
invariably mutated in these strains (Dolan et al., 2004, Akter et al., 2003). All three of 
the above genes are known to be essential for HCMV growth in endothelial cells (Hahn 
et al., 2004), and their function may be disadvantageous to HCMV growth in fibroblasts 
(Adler et al., 2006).  
 High passage strains, and in particular AD169 and Towne were the subjects of the 
majority of HCMV research before the discovery of their major genetic deletions (Cha 
et al., 1996). In AD169, 20 ULb’ genes (UL133-UL150 inclusive) have been replaced by 
an inverted duplication of sequences in the RL region, and genes RL5A, RL13 and 
UL131A are frame-shifted (Dolan et al., 2004). In addition the UL36 gene is inactivated 
by a single amino acid substitution (Skaletskaya et al., 2001). Towne lacks ULb’ genes 
UL147-UL150, and is mutated in genes RL13 and UL130 (Murphy et al., 2003). 
Regrettably, these defective strains have continued to be widely used as research 
materials, despite the availability of more complete strains. This is partly due to their 
efficient replication in fibroblasts, yielding higher titers of virus, and thereby facilitating 
experimentations.  
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Low passage strains contain more complete versions of the HCMV genome. Six such 
strains of HCMV have been cloned in Bacterial Artificial Chromosomes (BACs) and 
sequenced: FIX, TR, PH, Toledo (Murphy et al., 2003), TB40/E (Sinzger et al., 2008) and 
Merlin (Stanton et al., 2010). The first four of the above underwent an undefined 
number of passages before being cloned into BACs. TB40/E was passaged  5 times in 
fibroblasts and 22 times in endothelial cells (ECs). Merlin was sequenced and BAC-
cloned after 3 and 5 passages respectively (Dolan et al., 2004, Stanton et al., 2010). It is 
noteworthy that Toledo has undergone an inversion encompassing  14.4 kb of the 
UL/b’ region, resulting in loss of function of the UL128  gene (Cha et al., 1996, Akter et 
al., 2003). The FIX BAC originated from virus taken from a pregnant mother with 
primary HCMV infection (Hahn et al., 2002, Grazia Revello et al., 2001). TR was isolated 
from the eye of an AIDS patient (Smith et al., 1998), whilst PH and TB40/E were 
removed from transplant patients with HCMV disease (Rice et al., 1984, Fish et al., 
1995, Sinzger et al., 1999). Toledo (Quinnan Jr et al., 1984), and later Merlin (Quinnan 
Jr et al., 1984, Tomasec et al., 2000) were isolated from the urine of two congenitally 
infected children.  
Importantly, during the process of BAC cloning, alterations were made to the genomes 
of most of the viruses in order to accommodate essential BAC vector sequences. In 
Towne and Toledo the BAC sequences replaced US1-US11 and US2-US11 respectively. 
PH and FIX both lack the IRS1-US6 region, and TR is missing US2-US5 (Murphy et al., 
2003).  
Merlin is the only clinical strain BAC-cloned in its entirety  (Stanton et al., 2010). Unlike 
other HCMV BAC clones, the original clinical material from which Merlin was isolated is 
available and can be accessed when required (Dolan et al., 2004). With the exception 
of single point mutations in the RL13 and UL128 genes which have since been repaired, 
strain Merlin contains the full complement of HCMV genes. In addition Merlin is 
designated the prototype HCMV genome sequence by the National Centre for 
Biotechnology Information (GenBank AY446894; RefSeq NC_006273).  
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1.2.3. Number of genes 
1.2.3.1. HCMV gene usage 
Strain AD169 was the first HCMV genome to be completely sequenced, and the 
original annotation identified and designated 208 ORFs (Chee et al., 1990). In this 
annotation, an ORF was ‘designated’ if it encoded at least 100 amino acids, and did not 
overlap a longer ORF by more than 60% of its length. These criteria were based on the 
observation that in previously studied herpesvirus genomes few overlapping ORFs had 
been noted, and that the longest overlapping ORF was normally the coding ORF (Chee 
et al., 1990). It is noteworthy that 14 of the 208 strain AD169 ORFs were present in a 
large repeated sequence in the left hand end of the UL region and therefore diploid. 
Later, 19 additional ORFs were discovered in Toledo, through sequence analysis of the 
UL/b’ region (Cha et al., 1996). The duplication in the UL region is thought to have 
arisen as compensation for the UL/b’ deletion, since encapsidation requires a near full 
length genome (Prichard et al., 2001). When Murphy et al. reported the full 
sequencing of BAC cloned strains Toledo, FIX, PH, TR , Towne and AD169 (Murphy et 
al., 2003), as many as 252 ORFs were designated in low passage strains. To reassess 
the HCMV gene layout, a comparison of the AD169 and Toledo genomes was carried 
out against the closest known relative of HCMV, chimpanzee cytomegalovirus (CCMV) 
(Davison et al., 2003b). Results from other functional and bioinformatic studies, and 
evidence for presence of HCMV-specific genes were also considered. Through this 
analysis,  51 ORFs previously annotated by Chee et al (Chee et al., 1990) were 
eliminated due to their lack of CCMV orthologues, whilst 10 new ORFs were 
delineated. With the exception of HCMV-specific ORFs, this re-annotation predicted 
that wildtype HCMV contains 164-167 protein-coding genes (Davison et al., 2003b). 
Deep sequencing of the HCMV transcriptome during productive lytic infection, 
combined with extensive analysis of HCMV genomic sequences has resulted in some 
amendment to HCMV gene usage, with the most recent update predicting 170 protein-
coding genes (Gatherer et al., 2011). Figure 1.3 displays the current annotation of 
genes for strain Merlin. The possibility that the number of translated genes may vary 
depending on the cell type investigated, between lytic and latent infection, or indeed 
different stages of lytic infection cannot be neglected. Therefore failure to detect 
certain transcripts in deep sequencing of the transcriptome of cells undergoing lytic 
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infection cannot be regarded as absolute evidence that their respective ORFs are non-
coding. For instance, in monocytes which are regarded as a site of HCMV latency, an 
antisense transcript to the UL81 and UL82 genes, named UL81-UL82ast, and its 
resulting protein product, latent undefined nuclear antigen LUNA have been observed 
(Bego et al., 2005). Later, LUNA was shown to be expressed in vivo, and antibodies to 
the LUNA protein were detected in the blood of seropositve, but not seronegative 
individuals (Bego et al., 2011).  
  
Figure 1.3 (adapted from Gatherer et al. 2011):
Diagram of the wildtype HCMV genome (Merlin strain). The linear double-stranded HCMV genome is presented in 
five segments. Genes are shown as coloured arrows, with the direction indicating sense strand. Gene members of the 
same family are matched in colour (see key), and core genes are indicated in brown. The repeat sequences at the 
termini of the genome and at the UL-US junction are colured grey. Non-coding non-overlapping transcripts (NNTs) are 
shown by white arrows, and introns by narrow bars within genes; RNA5.0 is both an intron and an NNT. Origin of 
replication (ori) is presented as a black bar.  
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1.2.3.2. Nomenclature of HCMV genes and proteins 
In the seminal report of the AD169 sequence, Chee et al. proposed an alphanumeric 
nomenclature of HCMV ORFs, based on their position in the UL, US or repeat regions 
that provides the basis for the formal nomenclature used today (Chee et al., 1990, 
Spaete et al., 1994). However, use of various systems in naming HCMV proteins has 
been somewhat confusing. Multiple nomenclatures have been adopted for HCMV 
proteins on the basis of their physiochemical properties, predicted position in the 
virion in case of structural proteins, their temporal expression, function, and homology 
with other herpes virus proteins, in particular HSV (Spaete et al., 1994). In two 
separate workshops in 1993, an attempt was made to introduce a consensus 
nomenclature, and it was agreed that the alphanumeric system described by Chee et al 
would be extended for HCMV protein products in the following way: the prefix ‘p’ 
would be utilised to denote proteins not known to be phosphorylated or glycosylated, 
whilst ‘pp’ and ‘gp’ would precede the ORF name for phosphorylated, and glycosylated 
proteins respectively (Spaete et al., 1994).  
1.2.3.3. Non-coding RNA molecules 
Noncoding RNAs account for the majority of transcription from the HCMV genome, 
and have been divided into 3 main classes (Gatherer et al., 2011, Zhang et al., 2007). 
The most abundant of these are the noncoding nonoverlapping transcripts (NNT) 
which originate from regions of the genome largely void of protein coding ORFs, and 
carry 3’ polyA signals (Gatherer et al., 2011). The expression of 4 NNTs has so far been 
described: RNA2.7, RNA1.2, RNA5.0, and RNA 4.9, where numbers indicate size of the 
transcript in kb (see Figure 1.3). RNA2.7 (β2.7 ) was identified as the most abundantly 
transcribed gene in early stage HCMV infection (Spector, 1996, Greenaway and 
Wilkinson, 1987), and is the best studied of all HCMV NNTs. It is present in a single 
copy in low passage isolates, but the laboratory strains AD169 and Towne became 
diploid for the β2.7 gene following expansion of their TRL regions (described above). 
The longest ORF in strain AD169 β2.7 is 170 amino acid (aa) long (Greenaway, 
Wilkinson 1987). This ORF can be translated in a cell free assay (Bergamini et al., 1998), 
but McSharry and co-workers showed it was not conserved across all strains, and that 
β2.7 was dispensable for replication of strain AD169 in vitro (McSharry et al., 2003). 
Although reporter genes are extremely efficiently expressed when inserted in place of, 
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(or within) β2.7 (Spaete and Mocarski, 1987), translation of  any natural short putative 
β2.7 ORFs within the context of HCMV infection has yet to be described, leading to 
current predictions it is indeed an NNT. More recent findings assigning a function to 
RNA2.7 are described later (section 1.7.1). RNA1.2, also encoded in the TRL region, was 
found to be a highly expressed transcript, but similarly to RNA2.7, its translation into 
protein has only been reported in vitro (Hutchinson and Tocci, 1986). RNA5.0 is 
transcribed with immediate early kinetics (Plachter et al., 1988), and is the intronic 
sequence delimited by the two exons that give rise to the spliced transcript RNA1.1 in 
late stage infection (Kulesza and Shenk, 2004). RNA1.1 is not classed as an NNT as it is 
formed by the splicing together of 2 exons positioned either side of the RNA 5.0 intron, 
yet peculiarly, the 2 molecules have never been detected in a single primary transcript 
(Kulesza and Shenk, 2004). RNA4.9 was recently identified, and like RNA5.0, is of 
unknown function (Gatherer et al., 2011). The above NNTs represent two thirds of the 
total transcribed RNA at 72 hours p.i., with RNA2.7 accounting for over three quarters 
of that amount (Gatherer et al., 2011).  
The second most abundant class of noncoding RNA transcripts are the antisense 
transcripts (AST), which result from transcription of the DNA strand antiparallel to a 
coding region (CR) (Gatherer et al., 2011). These were first revealed through sequence 
analysis of cDNA clones of the HCMV transcriptome (Zhang et al., 2007). ASTs 
complementary to most CRs have been detected, and are generally present in lower 
amounts than their sense strand counterparts (Gatherer et al., 2011). Like NNTs, these 
are polyadenylated, and their potential to encode protein cannot be ruled out. 
Sequence conservation and complex splicing observed in some ASTs suggests they may 
serve functions, with post-transcriptional regulation of the sense transcript being the 
most obvious candidate. 
 The third major group of HCMV noncoding RNA transcripts are microRNAs (miRNAs). 
Potentially, miRNAs provide the virus with a powerful way of exercising temporal and 
spatial gene regulation. Obvious benefits of such regulation include their low biological 
production cost, and the avoidance of immunogenic detection (Dölken et al., 2009). 
The vast majority of virally encoded miRNAs have been discovered in herpesviruses 
(Grey et al., 2007), 14 of which have been characterised in HCMV. These are named 
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according to the name of the gene they oppose, or in the case of those originating 
from noncoding regions, the nearest upstream gene on the same strand.  
 The first 9 HCMV miRNAs were identified by a computer program that searched for 
potential miRNA precursors based on sequence and predicted secondary structure. 
Subsequently, sequencing of cloned small RNA molecules from lytically infected 
primary human fibroblasts (HF) confirmed these predictions (Pfeffer et al., 2005). 
Additionally, cloning and sequencing of 18-24 nucleotide RNA molecules from HCMV 
infected HF cells identified 3 potential miRNAs (Dunn et al., 2005). In silico analysis of 
hypothetical pre-miRNA transcripts giving rise to these molecules supported these 
findings, and their expression by HCMV was confirmed by northern blot. Grey et al. 
used a bioinformatics approach to predict stem-loop structures conserved between 
HCMV and CCMV (Grey et al., 2005). In this study, expression of the predicted miRNAs 
during HCMV infection was also assessed by northern blot analysis, and 2 novel HCMV 
miRNAs were discovered.  
HCMV miRNAs are expressed throughout the genome from antisense, and noncoding 
regions, and some are known to target multiple viral, or both viral and cellular mRNAs 
(Stern-Ginossar et al., 2007b, Grey et al., 2007). Nevertheless, the targets and 
functions of most HCMV miRNAs remain unknown. The best understood HCMV 
miRNAs is miR-UL112, which targets multiple viral and cellular transcripts. Grey et al. 
used a bioinformatics program to search for potential miR-UL112 binding sites within 
3’ untranslated regions (UTRs) conserved between HCMV and CCMV (Grey et al., 
2007). 14 candidates were identified, all of which were cloned into plasmids 
downstream of a luciferase reporter construct. These were then co-transfected into 
293 cells, together with plasmid-based clones of the predicted coding region for miR-
UL112. IE72, UL120/121, and UL112/113 were validated as miR-UL112 targets, as 
luciferase expression was specifically inhibited in the presence of their 3’ UTRs. The 
functional significance of IE72 inhibition by miR-UL112 is still unclear, but the authors 
proposed that since IE72 expression promotes acute viral replication, its negative 
regulation by miR-UL112 may contribute to the maintenance of latent or persistent 
infection. In another study, algorithmic prediction of miRNA target sites identified the 
major histocompatibility complex class I-related chain B (MICB) as a potential target 
for miR-UL112 (Stern-Ginossar et al., 2007b). MICB is a stress-induced ligand of the NK 
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activatory receptor NKG2D, and is important in the NK response against virus-infected 
cells. MICB expression was downregulated by miR-UL112 in the context of viral 
infection, leading to resistance against NK-killing. This represented a novel mechanism 
of immune-evasion by HCMV. Later, it was demonstrated that the UL114 gene too is 
targeted by miR-UL112, reducing its activity as uracil DNA glycosylase, but with 
minimal effect on virus growth (Stern-Ginossar et al., 2009). 
It is difficult to conceive that the majority of noncoding RNAs are not functionally 
important. We have only relatively recently become aware of their existence and their 
host and viral RNA target sequences can be difficult to identify. 
1.2.4. Essential and non-essential genes 
Biochemical, genetic, and bioinformatic studies have identified the function of many 
HCMV genes. Despite this, several HCMV genes have yet to be assigned specific 
functions. In a systematic analysis of the genome, Dunn et al. produced deletion 
mutants of the 162 genes that the Towne strain was thought to encode based on the 
annotation of the strain AD169 genome by Chee et al.1990 (Dunn et al., 2003b). 10 
non-essential genes were replaced in the process of BAC cloning the virus (US1-US12), 
whilst the remaining 152 deletions were made in separate viruses. The ability of the 
mutant viruses to replicate was then tested in each of the resulting mutants. 45 ORFs 
were found to be indispensible for virus replication in fibroblasts, the majority of which 
are conserved at least amongst β-herpesviruses. This is in contrast to the non-essential 
ORFs, which were HCMV-specific in about 70% of cases. Figure 1.4 shows the results of 
this study in diagrammatic form, where genes have been subdivided into groups based 
on the growth properties of mutant viruses. HCMV genes that are nonessential for 
virus replication in vitro are nevertheless expected to play important roles in vivo. A 
group have been found to be important in determining cell tropism, evidenced by 
differential infection and growth in endothelial, epithelial and fibroblastic cells. A 
substantial number of genes are known to direct immunomodulation in the host. 
Intriguingly, the study by Dunn identified 4 mutants that enhanced growth, suggesting 
they act as growth suppressors (Dunn et al., 2003b). Moreover DNA microarray 
analysis of the HCMV transcriptome in different cell types has revealed significant cell 
type dependent differences in gene expression (Towler et al., 2012).  
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HCMV genes essential for virus replication in fibroblast cultures include some major 
structural proteins, surface glycoproteins required for entry, and those acting in DNA 
replication. The majority of essential HCMV genes are clustered together in the central 
region of the genome, whilst the majority of non-essential genes tend to occupy 
peripheral regions (Dunn et al., 2003b).  
  
Figure 1.4 (adapted from Dunn et al. 2003. Copyright 2003, The National Academy of Sciences):      
Effect of deleting individual HCMV genes on virus growth 
 HCMV strain Towne genes colour coded on the basis of the growth properties displayed by their respective 
deletion mutants in fibroblasts.  
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1.2.5. Gene families 
Based on sequence homology, non-essential HCMV genes have been categorised into 
13 families, with the possible exception of UL84 which may be an essential gene (Dunn 
et al., 2003b, Gatherer et al., 2011, Sarisky and Hayward, 1996). Table 1.1 lists the 
different gene families and their members, with a brief description of their functions. 
Members of a family often lie close together in the genome, and can exhibit related 
functions (Chee et al., 1990, Davison and Bhella, 2007, Davison et al., 2003a, Dolan et 
al., 2004). HCMV gene families are thought to have arisen through gene duplication 
with divergence over time. Sequence analysis can be used to estimate a timescale of 
these duplications. The largest and best conserved HCMV gene family is the US22 
family, encoding 13 members which display roles in tropism, pathogenesis, and 
temperance of virus growth (Dunn et al., 2003b).   
Not all non-essential HCMV genes are part of gene families however. Certain genes 
appear to have homologous host counterparts, and are thought to have been 
incorporated through gene capture (Davison and Bhella, 2007). In addition, HCMV may 
have gained or donated genes from/to other viruses; e.g. the RL11 family of 
glycoproteins share an immunoglobulin domain like motif present in some 
adenoviruses (Davison et al., 2003a).   
1.3. Virion structure 
1.3.1. Overview of structure 
The complete HCMV virion measures about 210-230 nm in diameter, and is comprised 
of a nucleocapsid, contained within a partially ordered proteinaceous tegument, which 
in turn is surrounded by an envelope (Gibson, 1981). The first electron microscopy 
(EM) images of the HCMV virion revealed round, near spherical particles containing a 
dense centre, surrounded by what was described as a pale halo (Smith, 1959, Stern 
and Friedmann, 1960). Improved images of virion particles and additional information 
on the fine structure of the virion were later obtained by negative staining electron 
microscopy (Smith and Rasmussen, 1963, Wright Jr et al., 1964). Figure 1.5 shows an 
electron cryomicrograph of 2 adjacent HCMV particles taken at x30,000 magnification. 
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The HCMV DNA molecule has an Mr of 1.5x108 (Kilpatrick et al., 1976), more than 60 
times greater than the total Mr of all virion proteins (Sarov and Abady, 1975). The first 
estimates of the number of virion proteins were between 20 and 35, (Sarov and Abady, 
1975, Kim et al., 1976, Stinski, 1977, Edwards, 1976) ; ranging in size between 22 and 
230 kDa (Fiala et al., 1976). Gibson in 1983 produced evidence of the topological 
position of some of the virion proteins, and recognised the existence of A, B and C 
capsids described below (Gibson, 1981). He also identified a set of proteins, including 
pp65, that were localised between the capsid and the envelope, the fraction now 
known as the tegument (Gibson, 1981). Improved purification techniques, and the 
availability of the AD169 sequence lead to the recognition of 6 new structural proteins; 
and their corresponding genes (Baldick and Shenk, 1996). Later, a mass spectrometry 
approach discovered 24 novel structural proteins, increasing the number of virion 
proteins to 59 (Varnum et al., 2004). More recently, RL13 and gpUL1 have been 
identified as envelope glycoproteins (Shikhagaie et al., 2012a, Stanton et al., 2010).  
  
Gene 
family 
Family members Functions 
RL11 RL5A, RL6, RL11, RL12, RL13, UL1, UL4, UL5, 
UL6, UL7, UL8, UL9, UL10, UL11  
Mostly membrane glycoproteins 
UL14 UL14, UL141  Membrane glycoproteins containing an 
immunoglobulin domain 
UL18 UL18, UL142  MHC-I-related membrane glycoproteins
UL25 UL25, UL35  Tegument proteins 
GPCR UL33, UL78, US27, US28  Chemokine receptors
DURP UL31, UL72, UL82, UL83, UL84  Some are tegument proteins
UL120 UL120, UL121, possibly UL119  Membrane glycoproteins
UL146 UL146, UL147  CXC chemokines 
US1 US1, US31, US32 Related to TT virus ORF2 
US2 US2, US3 Membrane glycoproteins
US6 US6, US7, US8, US9, US10, US11  Membrane glycoproteins
US12 US12, US13, US14, US15, US16, US17, US18, 
US19, US20, US21  
Multiple transmembrane proteins 
US22 UL23, UL24, UL26, UL28, UL29, UL36, UL43, 
US22, US23, US24, US26, IRS1, TRS1  
Tegument proteins  
Table 1.1 (adapted from Davison and Bhella 2007):
 HCMV gene families, their members, and their encoded functions                                                         
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Figure 1.5 (adapted from Bhella et al. 2000):
Electron cryomicrograph of 2 adjacent HCMV particles 
 The darkly stained central region represents the nucleocapsid. The 
tegument is formed around the nucleocapsid and is in turn 
surrounded by the more sharply stained envelope 
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1.3.2. Nucleocapsid 
The nucleocapsid is icosahedral (T=16) with a diameter of 130 nm, and consists of 150 
hexameric, and 12 pentameric capsomeres, forming the faces and edges, and the 
vertices respectively (Chen et al., 1999). Each hexon is made of 6 copies of the major 
capsid protein (MCP; pUL86) and 6 copies of the small capsid protein (SCP; pUL48A) at 
the tips, whilst MCP is the sole element in pentomeric capsomeres (Chen et al., 1999). 
Capsomeres are connected together by a total of 320 triplexes, which are heteromers 
consisting of 2 copies of the minor capsid protein (mCP; pUL85), and 1 copy of the 
mCP-binding protein (mC-BP; pUL46) (Chen et al., 1999). Three different species of 
capsids have been isolated from HCMV infected cells all containing an identical 
arrangement of the 4 integral capsid proteins (Gibson, 1981). ‘A’ capsids lack viral DNA 
and are essentially empty proteinaceous shells (Chen et al., 1999). B capsids also lack 
DNA, but in addition to the capsid icosahedron they also contain copies of the capsid 
scaffold proteins pUL80 and pUL80.5 (Chen et al., 1999). It is thought that B capsids 
undergo DNA encapsidation and lose the internal scaffold proteins to give rise to 
mature C capsids. C capsids act as precursors of the infectious virion, and are 
associated with certain tegument proteins. The viral DNA enters the nucleocapsid 
through a portal complex adjacent to one of the pentomers (Dittmer and Bogner, 
2005) and is tightly packaged into regularly arranged duplexes separated only by 23 A⁰ 
(Zhou et al., 1999, Bhella et al., 2000). Following encapsidation 90% of the internal 
volume of the capsid is predicted to be occupied by the viral DNA (Yu et al., 2003). 
Furthermore although all nucleocapsids appear uniform in size, their relative location 
inside the virion has been shown to vary (Chen et al., 1999).  
1.3.3. Tegument 
The tegument accounts for approximately 100 nm of the diameter, and 40% of the 
total protein mass of the virion (Gibson, 1996). Thus far more than 35 HCMV tegument 
proteins have been identified, several of which are phosphorylated and highly 
immunogenic (Kalejta, 2008). No common sequence has been identified between 
tegument proteins that would guide virion constituents into the tegument. Many 
HCMV tegument proteins are encoded by a cluster of HCMV genes, and this feature 
has been used to predict additional members of the tegument entity (Mocarski, 1993). 
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The variation in the relative position of nucleocapsids in the virions, and the flexibility 
in the size of the tegument suggests most tegument proteins lack icosahedral 
symmetry and are not in rigid contact with the nucleocapsid (Spaete et al., 1994, Chen 
et al., 1999). 3D density mapping of the HCMV virion has revealed disconnected 
densities within the envelope and the majority of the tegument, supporting this notion 
(Chen et al., 1999). The only icosahedrally structured portion of the tegument appears 
to be the capsid-proximal region, forming a thin net-like layer of loosely connected 
densities, which is absent from the B capsids but present in C capsids and the intact 
virion as evidenced by difference mapping studies. These data suggest the capsid acts 
as a scaffolding base around which the tegument is sequentially built, explaining why 
the ordered tegument layer has never been observed independently of the capsid 
(Chen et al., 1999). It has been proposed that these densities are formed by the basic 
phosphoprotein (BPP; pp150, UL32), the upper matrix protein (UM; pp71, UL82), and 
pp28 (UL99). These 3 proteins are present in large quantities in the tegument, and 
furthermore they have been shown to associate most stringently with the 
nucleocapsid after detergent treatment of the virions (Chen et al., 1999, Gibson, 1996). 
Also, immunoelectron microscopy of purified virions suggested a capsid proximal 
location for pp28 (Landini et al., 1987), whilst pp150 and pp71 have both been shown 
to be present in approximately equimolar quantities to the MCP (Chen et al., 1999). 
The ordered tegument consists of 960 identical copies of a cluster formed between 
these proteins, each one making contact with a triplex, and a penton or hexon. A 
prediction of the interaction between the nucleocapsid and the ordered tegument is 
given in Figure 1.6. The other 3 major tegument proteins are the high molecular weight 
protein (HMWP; pUL48), its binding protein (HMWP-binding protein; pUL47), and the 
lower matrix protein (LMP; ppUL83; pp65). Despite being the most abundant protein 
species in the tegument, pp65 is non-essential for virus replication and the production 
of infectious virus progeny (Schmolke et al., 1995b). This suggests pp65 serves to fill 
the tegument volume thereby assisting with the assembly of virus particles (Liu and 
Zhou, 2007). The immune-modulating function assigned to pp65 is discussed in 
(Section 1.7.3.1.1). pp71, the upper matrix protein (UMP) encoded by UL82 relieves 
transcriptional repression of the immediate early (IE) genes by degrading DAXX 
(Bresnahan and Shenk, 2000b). Other tegument proteins include pUL35 and pUL69 
(Winkler et al., 1994, Winkler and Stamminger, 1996) which are activators of viral gene 
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expression, the anti-apoptotic proteins pUL36 and pUL38, and pUL44 and pUL54, the 
processivity and catalytic subunits of the HCMV DNA polymerase (Kalejta, 2008). pIRS1 
and pTRS1 have been demonstrated to be associated with virions and dense bodies, 
which lack capsids. Treatment of intact HCMV particles with trypsin did not degrade 
virion pIRS1 and pTRS1, suggesting they are located within, and not outside the 
envelope, and that they may be tegument proteins. In the presence of UL69, these 2 
proteins can promote the expression of reporter genes containing IE gene promoters, 
and have therefore been implicated in early HCMV gene expression (Romanowski et 
al., 1997).   
  
Figure 1.6 (adapted from Chen et al. 1999): 
Capsid proteins interact with the ordered tegument 
densities  
Interactions between capsid and tegument proteins 
Viewed from top (a) or side (b): Region of capsid 
shown contains one penton (red), one hexon (blue), 
and 2 adjacent triplexes labelled Ta and Tc (green). 
Penton and hexon subunits contain upper (U), middle 
(M), lower (L), and floor (F) domains. A cluster of 
tegument densities is shown in yellow, whilst 
elevated and lower ends of one of the tegument 
densities are labelled * and # respectively. Tegument 
densities are bridged over the intercapsomeric space, 
and are attached by their elevated end to a penton 
or hexon, and by their lower ends to a triplex which is 
used as a pier.  No direct contact is observed 
between tegument densities of a single cluster.  
a 
b 
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1.3.4. Envelope 
The HCMV virion envelope is a lipid bilayer derived from the host intracellular 
membranes, containing at least 25 HCMV glycoproteins (Vanarsdall and Johnson, 
2012), and numerous host proteins such as CD55, CD59, and annexin II (Grundy et al., 
1987, Wright et al., 1995). It is thought the host proteins in the viral envelope help to 
induce host cellular responses in combination with some viral encoded G-protein 
coupled receptors (Compton et al., 2003, Zhu et al., 1998).  
Envelope glycoproteins are important targets of the host neutralising antibody 
response and their interaction with the host cell is indispensable for virus entry 
(Mocarski, 2001). Many HCMV virion glycoproteins have been shown to form disulfide-
linked complexes. The best characterised of these include glycoprotein complex I (gCI), 
gCII, and gCIII (Britt and Boppana, 2004). gCI consists of 55 kDa and 116 kDa gB 
isoforms, gM-gN heterodimers give rise to gCII, and gCIII is formed by interaction 
between gH, gL and gO. Of the aforementioned glycoproteins, gB, gM, gN, gH and gL 
are essential for virus replication (Hobom et al., 2000). In wildtype virus, rather than 
complexing with gO, gH and gL bind the UL128 locus (128L) proteins, UL128, UL130 
and UL131A. This pentomer is essential for entry into epithelial, endothelial and 
certain myeloid cells, but prevents virus growth in fibroblasts (Stanton et al., 2010). 
Upon passaging of HCMV in fibroblast cultures, UL128L genes rapidly mutate, leading 
to loss of the above pentamer. Viruses with the mutated UL128L can then infect 
fibroblasts through the formation of gCII. This represents an example of tropism-
specific complex formation at the HCMV envelope.  
gCII (gM/gN) is the most abundant glycoprotein complex at the virus envelope. gM is 
predicted to have 7 transmembrane domains, and undergo a single N-linked 
glycosylation (Britt and Boppana, 2004), whilst gN is thought to be a type I glycoprotein 
containing O-linked modification. gM and gN form a complex in the ER, and are both 
essential for virus replication. Between different HCMV strains, very little sequence 
variability has been observed in the case of gM, in contrast with gN, which is highly 
variable in its sequence (Britt and Boppana, 2004, Dal Monte et al., 2001). This 
variability suggests gN is under selective pressure from the immune system, and it has 
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been proposed that glycosylation protects gN from antibody binding (Wei et al., 2003, 
Britt and Boppana, 2004).  
gB encoded by the UL55 gene is the best conserved, and one of the most immunogenic 
HCMV glycoproteins (Cranage et al., 1986). For these reasons gB has been the prime 
subunit vaccine candidate (Spaete et al., 1994). Cleavage of the 150 kDa type I gB 
precursor by the Golgi localised protease furin, gives rise to two cleavage products 
measuring 93 and 55 kDa. These cleavage products are linked by disulfide bonding to 
form a heterodimer at the envelope and undergo phosphorylation, and N- and O –
linked glycosylation (Britt and Boppana, 2004).  
1.3.5. Other virion components 
Evidence has been obtained of the selective incorporation of cellular, and virus-
encoded RNAs in the HCMV virion (Greijer et al., 2000). The presence of HCMV-
encoded RNAs was first noted in virion purification experiments, and was evidenced by 
gene array experiments (Bresnahan and Shenk, 2000a). The abundance of these 
transcripts in the virion has been shown to correlate with their intracellular 
concentration, and their packaging into the virion likely involves non-specific 
interaction with structural proteins (Terhune et al., 2004). Virus-encoded RNAs in the 
virion include the transcript encoding the UL22A secreted protein (R27080), and the 
1.2 kb, 2.7 kb and 5kb NNTs (Bresnahan and Shenk, 2000a). GAPDH, B-actin and cyclin 
G1 are amongst the cellular RNA transcripts detected in the virion (Terhune et al., 
2004). Although it has been demonstrated that HCMV consistently incorporates the 
above transcripts into the virion, it is likely that at least some of these RNAs serve no 
particular structural function, and that their packaging is nonspecific, resulting either 
from accidental affinity to certain virion proteins, or their high concentration in the cell 
(Greijer et al., 2000). One obvious advantage of carrying polyA containing RNAs in the 
infectious particle would be their immediate expression in the infected cell prior to the 
initiation of transcription from the viral genome.  
Over 70 cellular proteins have been reported in HCMV virions, including structural 
proteins, enzymes and chaperon proteins, most of which are likely contaminants 
(Varnum et al., 2004). Some cellular proteins found in the virion, including actin-
related protein (ARP) and polyamines may act to stabilise the virion. ARP is thought to 
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reside in the capsid-distal portion of the tegument, whilst positively charged 
polyamines may facilitate packaging and carriage of viral DNA by neutralising its highly 
negative charge (Gibson and Roizman, 1971). 
1.3.6. Dense bodies and NIEPs 
In addition to complete virions, 2 other types of enveloped particles are recovered 
from the culture of HCMV-infected cells. Dense bodies (DBs) are spherical particles 
comprised largely of the pp65 tegument protein encased within the envelope, but 
lacking the nucleocapsid. The diameter of DBs is highly heterogeneous and is typically 
much larger than that of virions (250-600 nm) (Sarov and Abady, 1975). Noninfectious 
enveloped particles (NIEPs) also lack genetic material, but in contrast to DBs, these are 
almost identical in protein architecture to the infectious virion, except they contain B-
capsids (Irmiere and Gibson, 1983). Virions, DBs and NIEPs are distinguishable under 
the electron microscope, and can be separated by density gradient centrifugation 
(Irmiere and Gibson, 1983, Talbot and Almeida, 1977). Figure 1.7 compares 
electromicrographs of virions and DBs, and a Coomassie stained gel of proteins in 
virions, DBs and NIEPs is shown in Figure 1.8. The production of DBs and NIEPs by 
infected  cells can exceed that of infectious virions by up to 20 times; yet It is unknown 
if they represent products of aberrant virus assembly, or serve specific functions 
(Gibson, 1996, Steven and Spear, 1997). It has been suggested that DBs and NIEPs may 
serve as decoy targets of the immune system (Gibson, 1996, Steven and Spear, 1997).  
  
Figure 1.7 (adapted from Varnum et al. 2004): 
Electron micrographs of HCMV virions and dense body (DB) 
particles 
 Magnification, x8,400. The heterogenous and larger size of 
DBs relative to virions are noticeable.  
29
Figure 1.8 (adapted from Baldick Jr and 
Shenk 1996): 
Visualization of proteins in HCMV particles by 
Coomassie staining 
Coomassie-stained gel of virions, NIEPs and 
DBs purified by gradient centrifugation. Near- 
identical protein profiles are noticeable 
between NIEPs and virions, with only notable 
difference being the concentration of the 
capsid assembly protein (AP) which is present 
in the B-type capsids of NIEPs and not in the C-
type capsids of mature virions. Also of note is 
the scarcity of capsid proteins, and the high 
concentration of tegument proteins 
(particularly pp65) in DBs.  
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1.4. Life cycle and gene expression 
1.4.1. Tropism 
Efficient HCMV replication is restricted to human and chimpanzee cells in vitro, but 
investigations of in vivo infections have detected viral replication in an extraordinarily 
wide range of human tissues and cell types. From a purely biological perspective, cell 
tropism is defined by the ability of the virus to infect a particular cell type.  
In vivo, epithelial, endothelial, fibroblast, and smooth muscle cells are thought to be 
some of the most efficient sites of HCMV replication (Sinzger et al., 1995). Infection of 
hematopoietic and endothelial cells facilitates the spread of virus within the host, and 
mucosal epithelial cell infection is important in inter-host transmission. Cell types 
thought not to support HCMV infection include lymphocytes and polymorphonuclear 
leukocytes. Early reports of immediate early (IE) gene expression in lymphocytes (Rice 
et al., 1984) have not been validated (Sinzger et al., 1995). In polymorphonuclear 
leukocytes, despite virus uptake, replication is soon aborted (Grefte et al., 1994, 
Sinzger et al., 1996). Clinical manifestations of HCMV infection appear most frequently 
in the liver, gastrointestinal tract, lung, retina, and the brain (Grefte et al., 1994, 
Sinzger et al., 1996). Within these organs, hepatocytes, alveolar epithelial cells, and 
neuronal cells are often most heavily infected.  
The majority of cell culture research on HCMV is carried out on skin and lung 
fibroblasts. HCMV infection in these cells is by far the most productive, and is the 
standard method of isolation and propagation of the virus (Sinzger et al., 1995). As 
discussed in (Section 1.2.2) extensive passaging of HCMV in fibroblasts causes the 
production of increasingly non-endothelial and non-epithelial tropic virus, whereas 
propagation in endothelial and epithelial cells maintains the broad cell specificity of 
the virus. It is plausible to consider that similar cell type dependent adaptations may 
also occur in vivo (Waldman et al., 1991).  
Apart from the UL128L genes discussed in (Section 1.2.2), other genes have also been 
discovered to play important roles in the determination of HCMV tropism. Dunn et al 
identified 68 ORFs in the Towne strain, the deletion of each of which had no significant 
effect (<10 fold) on the growth rate of the virus. 15 of these mutants were also tested 
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in cell cultures of clinically relevant retinal pigment epithelial (RPE), and human 
microvascular endothelial cells (HMVEC). Two mutants were identified, one which 
conferred a severe growth defect in HMVECs (UL24), and another which resulted in a 
growth defect RPE cells (UL64) (Dunn et al., 2003b). Conversely, viruses carrying UL10 
and US16 mutations grew to 100 and 500-fold higher titers in RPE and HMVEC cells 
respectively, compared to HFFs (Dunn et al., 2003b). These were the first findings of 
tropism determining genes outside of the UL128L. More recently, RL13 was reported 
to severely impair virus replication in cultures of fibroblasts and epithelial cells 
(Stanton et al., 2010). Growth suppression by specific viral genes and in specific cell 
types may be important in vivo, for example in moderating viral load in order to 
optimise transmission. 
1.4.2. Entry  
Entry of the HCMV particle into the cell is a complex, multistep process that initiates 
with the sequential binding of viral envelope glycoproteins to cell surface receptors. 
Direct fusion between the virus envelope and the plasma membrane at neutral pH 
promotes entry into the cell (Compton et al., 1992). Membrane fusion in RPE and 
endothelial cells differs from this model however, as it requires acidification (Ryckman 
et al., 2006).  
A comprehensive list of HCMV genes essential for entry is not available, but gB, gH and 
gL are certainly required (Isaacson and Compton, 2009, Bowman et al., 2011, 
Vanarsdall and Johnson, 2012). The UL128L products are essential for entry into 
epithelial and endothelial cells (Akter et al., 2003, Dolan et al., 2004, Hahn et al., 2004, 
Patrone et al., 2005), and gO-mutants give rise to undersized plaques in fibroblasts 
(Wille et al., 2010). gB is involved in initial attachment and subsequent fusion, whilst 
gM/gN also act in attachment. gH is a fusion receptor, which together with its 
chaperone protein gL, either binds gO to give rise to gCIII, or with the UL128L products 
to form a pentamer conferring tropism in endothelial and epithelial cells (Ryckman et 
al., 2006).  
At least in vitro, cell surface heparin sulphate proteoglycans (HSPGs) are essential for 
HCMV entry into the cell (Compton et al., 1993). The association between HSPGs and 
envelope glycoproteins gB and gM is thought to allow later events by stabilizing the 
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virion at the cell surface (Compton et al., 1993). The quest for other HCMV receptors 
though has yielded little success, and HSPGs remain the only molecules known to be 
indispensible for virus entry. Three integrin heterodimers (α2β1, α6β1, αVβ3) have 
been demonstrated to be HCMV receptors, as virion entry levels are reduced in their 
absence, and restored by their subsequent addition (Feire et al., 2004). Numerous 
other candidates have been proposed and later discounted upon further investigation, 
including β2-microglobulin, CD13, and MHC Class I molecules (E. Murphy 2008). 
Annexin II, and an uncharacterised 92.5 kDa cell surface protein may enhance binding 
and entry (Adlish et al., 1990, Keay and Baldwin, 1995), whilst promising initial reports 
on the role of epidermal growth factor receptor (EGFR) (Wang et al., 2003) have since 
been contradicted (Isaacson et al., 2007). Furthermore EGFRs cannot be considered 
universal HCMV receptors as they are not expressed by all HCMV permissive cells (Real 
et al., 1986). Soroceanu et al. reported that platelet-derived growth factor-α receptor 
(PDGFR-α) was phosphorylated by HCMV in a wide range of cell types, and that its 
genetic deletion or functional blockage prevented HCMV infection in fibroblasts 
(Soroceanu et al., 2008). Furthermore addition of PDGFR-α to knockout cells restored 
infectivity to these cells, and gB was demonstrated to interact directly with PDGFR-α. 
Strong evidence therefore exists for the important role this receptor plays in HCMV 
entry, although myeloid cells which are important sites of latency and reactivation 
(Section 1.4.4) do not express PDGFR-α (Chan et al., 2009, Inaba et al., 1993).  
1.4.3. Productive infection/ lytic cycle 
1.4.3.1. Overview 
The lytic cycle starts from the time of virus entry into the cell, and lasts until exit of 
virus progeny. The HCMV lytic cycle is relatively slow, and new virus progeny are not 
released until 48-72 hours p.i. (Rice et al., 1984). In HFs, peak levels of virus release are 
reached at about 72-96 hours p.i., and productive infection can continue for several 
days, until cell death (Stinski, 1983).  
After virus entry, the HCMV genome must be transported into the nucleus in order for 
viral transcription to occur. Gene expression then occurs in a tightly regulated cascade, 
which with the aid of metabolic inhibitors has operationally been divided into 
immediate early (IE), early and late stages (Wathen and Stinski, 1982). IE viral 
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transcription occurs from restricted regions of the genome, independently of de novo 
viral protein synthesis. Early genes expression requires de novo viral protein synthesis, 
occurs before viral DNA replication, and is dependent on the presence of IE proteins. 
Early gene products are in turn required for late RNAs synthesis, which begins after the 
onset of viral DNA replication (Wathen and Stinski, 1982, Demarchi et al., 1980).  
1.4.3.2. Nuclear transport of viral DNA 
 Once inside the cell, the majority of tegument proteins are released into the 
cytoplasm (Ogawa-Goto et al., 2003). The nucleocapsid together with some tightly 
associated tegument proteins, then deliver the genome to the nucleus using the 
intracellular transport machinery, and through the nuclear pore complex (Greber and 
Way, 2006). A functioning microtubule network is essential for the nuclear transport of 
viral DNA, as its chemical disruption inhibits HCMV gene expression (Ogawa-Goto et 
al., 2003). The tegument proteins that accompany the nucleocapsid on its journey to 
the nucleus include pp150, pUL47, pUL48, pp71, and pp65. The nonessential pp65 
protein contains a nuclear localisation signal (NLS) (Schmolke et al., 1995a), and 
accumulates in the nucleus within minutes of virus entry into the cell, where it 
suppresses the induction of many interferon-responsive, and proinflammatory 
chemokine transcripts (Browne and Shenk, 2003). pUL47 and pUL48 form a complex 
known to be important in virus entry, and injecting viral DNA into the nucleus (Bechtel 
and Shenk, 2002), while an interaction between pp150 and the microtubule network 
promotes intracellular transport of capsid particles (AuCoin et al., 2006). In addition 
pp71 brings about IE genes expression by degrading the transcriptional repressor DAXX 
(Bresnahan and Shenk, 2000b, Woodhall et al., 2006). 
1.4.3.3. Immediate early (IE or α) genes 
 
At least four distinct regions in the HCMV genome are expressed with IE kinetics; these 
are schematically represented in Figure 1.9. IE gene products promote efficient virus 
replication and counter host intrinsic, innate, and adaptive immune responses 
(Dimitropoulou et al., 2010).  
  
Figure 1.9 (adapted from Stinski and Meier 2007): 
Schematic representation of IE regions of the HCMV genome:          
Immediate early (IE) regions are indicated with arrows.  
IE-B 
IE-A (MIE) 
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Expression from the major immediate early (MIE)  gene is under the control of a 
complex promoter region containing a TATA box, an imperfect dyad symmetry 
element, and a strong enhancer comprising 17, 18, 19 and 21 bp repeat motifs 
(Boshart et al., 1985, Thomsen et al., 1984). The MIE region contains MIE genes 
IE1(UL123) and IE2 (UL122), which are alternatively spliced from a single transcript, 
and give rise to the well characterised IE72 and IE86 proteins respectively, although 
other smaller IE2 gene products are also expressed (Akrigg et al., 1985, Wilkinson et 
al., 1984). IE72 and IE86 are localised in the nucleus, and play key roles in regulating 
viral and cellular gene expression. IE72 is not essential for in vitro virus replication, but 
its absence results in severe growth defect at low multiplicity of infection (Greaves and 
Mocarski, 1998, Mocarski et al., 1996). Numerous functions have been described for 
IE72. on its own, IE72 is a strong activator of the MIE promoter (Cherrington and 
Mocarski, 1989) and a weak transactivator of several cellular and viral promoters 
(Wilkinson et al., 1998). IE72 does not directly bind DNA, but physically associates with 
several cellular transcription factors and nuclear proteins (Nevels et al., 2004). Direct 
binding to the CCAAT-box binding protein (CTF1) and E2F-1 activates the human DNA 
polymerase α and dihydrofolate reductase genes, both essential for DNA replication 
(Hayhurst et al., 1995, Margolis et al., 1995). IE72 targetting of p107 results in the de-
repression of E2F-responsive promoters, and the subsequent induction of numerous 
genes associated with cell cycle progression (Poma et al., 1996). Strong evidence 
therefore exists for the contribution of IE72 to cell cycle progression, and viral DNA 
replication.  
IE72 co-localises with condensed chromatin during mitosis, and disrupts ND10 (PML-
bodies), resulting in the uniform dispersal of PML throughout the nucleus (Kelly et al., 
1995, Wilkinson et al., 1998). ND10 are normally seen as spherical intranuclear 
structures found in association with PML and other cellular proteins including hDAXX, 
sp100, p53, STAT1 and STAT2, and have been implicated in transcription, chromatin 
structure, DNA repair and apoptosis (Dimitropoulou et al., 2010). During viral infection, 
PML acts as a mediator of the interferon-induced antiviral response, and its RNAi 
knockdown, and that of hDAXX have been shown to enhance HCMV replication (Wang 
et al., 1998, Tavalai et al., 2006). ND10 are therefore recognised as an intrinsic defence 
mechanism against viral infection (Dimitropoulou et al., 2010). Moreover, live cell 
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imaging of an IE1-EGFP fusion protein during infection demonstrated that IE72-
mediated disruption of ND10 is not limited to the displacement of PML. STAT2 and 
sp100 also associated with IE72 on metaphase chromatin although the latter later 
underwent progressive degradation until almost complete elimination from the nuclei 
of infected cells. hDAXX was released into the nucleoplasm, this is significant because 
hDAXX also contributes to the intrinsic antiviral defence described above. Furthermore 
the presence of IE72 enhances transactivation by IE86 (Malone et al., 1990). 
IE86 is a prolific transactivator of viral and cellular genes, and also negatively 
autoregulates the MIE promoter (Hermiston et al., 1990, Pizzorno et al., 1988, 
Stenberg et al., 1990). IE86 is essential for HCMV replication, and regulates gene 
expression in multiple ways (White et al., 2004). Repression of the MIE promoter 
occurs through direct binding to the cis repression sequence (CRS), which is located 
between the promoter TATA box and the transcription start site (Arlt et al., 1994). This 
autorepression is concomitant with the recruitment of chromatin-remodelling 
enzymes by IE86, to establish a repressive chromatin state at the MIE promoter 
(Reeves et al., 2006). IE86-mediated transactivation of cyclin E is also through direct 
DNA attachment (Arlt et al., 1994), whilst protein-protein interactions have been 
reported between IE86 and several transcription factors including Dr1, the TATA-
binding protein (TBP), TFIIB, the retinoblastoma protein (RB), CREB, C-Jun, and JunB 
(Caswell et al., 1996, Caswell et al., 1993, Furnari et al., 1993, Hagemeier et al., 1994, 
Jupp et al., 1993, Lang et al., 1995, Scully et al., 1995, Sommer et al., 1994). In contrast 
to its role in promoting a repressed chromatin state at the MIE promoter, IE86 is able 
to physically interact with the histone acetyltransferase P/CAF, leading to the 
formation of active chromatin at its responsive promoters (Bryant et al., 2000). This 
explains at least partly, the capacity of IE86 to act as a promiscuous gene 
transactivator, and highlights its pleiotropic functionality in gene regulation.  
The IE-B region of the HCMV genome gives rise to three known protein products, from 
genes UL36, UL37 and UL38. Although transactivating roles have been described for 
these molecules, it is likely their main functions are anti-apoptotic (see Section 1.7.1).  
TRS1 and IRS1 proteins are incorporated into the virion tegument, and viruses 
harbouring mutations in both of these genes show defective growth (Blankenship and 
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Shenk, 2002). Furthermore at least one of these two genes is required for orilyt-
dependent DNA replication (Pari et al., 1993). Together with the MIE gene products, 
and or pUL69, pIRS1 and pTRS1 activate early gene expression (Romanowski et al., 
1997). In addition, pIRS1 and pTRS1 counteract the interferon response induced by 
viral infection (Child et al., 2004). Interferon induction in infected cells is designed to 
shut off protein synthesis, and thereby impede virus replication. Examples of such 
interferon induced pathways include the protein kinase R (PKR) activation pathway 
which results in inhibition of translation initiation, and the oligoadenylate synthetase 
(OAS) pathway which causes degradation of rRNA and tRNA. pIRS1 and pTRS1 block 
these 2 processes, and ensure viral protein synthesis, although the mechanisms of 
these actions have yet to be elucidated.  
1.4.3.4. Examples of Early (β) gene functions 
Most regions of the HCMV genome are expressed during the early phase, and the 
majority of proteins synthesised with early kinetics function mainly in one of two ways: 
either by direct involvement in synthesis, cleavage and packaging of the viral DNA and 
virion assembly, or by providing the correct cellular environment for these events to 
happen (White and Spector, 2007). Early genes whose products are directly involved in 
DNA replication include the viral DNA polymerase (pUL54) and its processivity factor 
(ppUL44), the single stranded DNA binding protein (ppUL57); and the pUL70, pUL102, 
and pUL105 proteins which form the heterotrimeric helicase primase complex 
(McMahon and Anders, 2002, Anders and Gibson, 1988, Ertl and Powell, 1992). UL84 is 
also expressed early in infections, and interacts with IE86 to promote replication from 
the oriLyt region (He et al., 1992). UL56 and UL89 gene products engage in DNA 
cleavage (Buerger et al., 2001), and the UL51, UL52, UL77 and UL104 gene products 
are predicted to play roles in the transport of the empty capsid to the site of 
encapsidation, and packaging of the newly replicated DNA molecules (White and 
Spector, 2007).  
1.4.3.5. Late gene expression 
Late HCMV genes predominantly encode structural proteins, and/or those involved in 
the assembly and egress of the virus (Demarchi et al., 1980, Wathen and Stinski, 1982). 
Although strictly defined, late genes are expressed after the onset of DNA replication, 
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only 2 HCMV genes are known to be expressed with true late kinetics. In contrast, 
genes encoding most late proteins are active in early infection. The first, pp28, is 
encoded by UL99, and its expression absolutely requires DNA replication, as a DNA 
replication-negative mutant failed to produce pp28-encoding mRNA (Depto and 
Stenberg, 1992). Pp28 is a phosphoprotein component of the tegument, essential for 
virus replication. Cells infected with a mutant HCMV lacking the UL99 gene produced 
normal levels of viral DNA and late protein, but tegument-associated capsids failed to 
acquire envelopes, suggesting pp28 is required for virion envelopment (Silva et al., 
2003). The other true-late HCMV gene, UL94, also resides in the tegument of virions, 
and may have zinc/DNA binding properties (Wing et al., 1996). Some genes, whose 
products are synthesised late, are also transcriptionally active early on in infection. 
pUL69 and pUL44 are present in very low amounts at early time points, but are among 
the most abundant of all infected cell proteins at late points (Geballe et al., 1986). 
Nevertheless their transcripts are present in equally high concentrations at early and 
late time points. This suggests post-transcriptional rather than transcriptional 
regulation is responsible for the late appearance of some late proteins.  
1.4.3.6. Assembly and egress 
The complex assembly pathway of the HCMV virion takes place both in the nucleus 
and the cytoplasm, and without arrest of host protein synthesis (Britt, 2007). Final 
virion assembly takes place in virion assembly complexes (ACs), which are large, highly 
vacuolated circular structures generally present in one copy per infected cell, and that 
appear as cytoplasmic inclusions characteristic of HCMV-infected cells (Das et al., 
2007). Capsid assembly begins in the cytoplasm, concludes in the nucleus, and requires 
the presence of the major capsid scaffold protein (pUL80.5) and the minor capsid 
scaffold protein (pUL80), as well as the final nucleocapsid components (Gibson, 1996). 
The major capsid protein (MCP, pUL86) lacks a nuclear localization signal (NLS), and its 
nuclear translocation requires complex formation with pUL80.5 (Plafker and Gibson, 
1998). Transport of MCP into the nucleus is followed by further interactions with 
pUL80 (Plafker and Gibson, 1998). Triplex formation also occurs in the cytoplasm; a 
homodimer of the minor capsid protein (mCP; UL85) enters the nucleus bound to a 
single mCP-binding protein (mC-BP; UL46) (Baxter and Gibson, 1997). Extensive 
intranuclear interactions between MCP, pUL80, pUL80.5, mCP, and mCP-BP then gives 
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rise to the B-capsid (see 3.2), which becomes the mature C-capsid (nucleocapsid) 
through DNA encapsidation, and loss of the assembly proteins (Gibson, 1996). Loss of 
the assembly proteins without DNA packaging leads to the formation of defective A-
capsids (Gibson, 1996). Elimination of the scaffold proteins is realised by the 
proteolytic activity of UL80, which cleaves itself, and pUL80.5. This catalytic activity 
appears limited to post capsid assembly times, and acts as a trigger for DNA packaging 
(Gibson, 1996). DNA enters the empty capsid through a portal complex formed by 
pUL104, which occupies a single vertex in the capsid icosahedron (Dittmer and Bogner, 
2005). Unit length DNA molecules are then encapsidated by the cleavage/packaging 
enzyme complex, which is comprised of UL56 and UL89 (Poon and Roizman, 1993).  
DNA-lacking capsids are not detected in the cytoplasm, despite the availability thereof 
all procapsid constituents. This may be due to insufficient cytoplasmic concentrations 
of capsid proteins, or the requirement for conformational changes in capsid 
components brought about during nuclear translocation (Gibson, 1996). 
Nuclear egress of the nucleocapsid is not well understood, but the most popular model 
seems to be that the nucleocapsid undergoes an envelopment step to reach the 
perinuclear space, followed by a de-envelopment step which releases it into the 
cytoplasm (Severi et al., 1988). The interaction of two HCMV proteins, pUL50 and 
pUL53 has been associated with the envelopment and deenvelopment steps (Gibson, 
1996).  
Perhaps the most poorly defined stage of virion assembly and egress is the 
incorporation of the tegument. It is thought the nucleocapsid acquires at least part of 
the tegument in the nucleus, and subsequently loses this tegument layer before 
nuclear translocation. Strong evidence for partial nuclear tegumentation includes a 
report of positive pp150 immunostaining at the surface of nucleoplasmic 
nucleocapsids (Hensel et al., 1995). Further evidence was provided for the nuclear 
incorporation of pp150, when functional fluorescent tagged-pp150 was shown to 
colocalise with the MCP at nuclear replication compartments (Sampaio et al., 2005). 
Despite these findings, the critical role of pp150 is now thought to be in final virion 
maturation in cytoplasmic AC compartments, and not in initial tegumentation (AuCoin 
et al., 2006, Tandon and Mocarski, 2008).  
41 
 
Envelopment of the fully tegumented particle is thought to occur through budding into 
cytoplasmic tubules or vesicles. pUL99 plays an important role in inducing 
envelopment of particles, as its absence leads to the accumulation of tegumented 
particles inside the cell (Silva et al., 2003). Envelopment appears to cause a 
conformational change in the tegument layer, leading to a more solid association of 
the tegument and envelope proteins, and is followed by subsequent modification 
steps, such as phosphorylation, glycosylation, and redistribution of envelope 
components (Gibson, 1996, Nogalski et al., 2007).  
1.4.4. Latency and reactivation 
Following primary infection, HCMV establishes life-long persistence in the host. HCMV 
can remain latent in permissive cells, in the absence of detectable production of 
infectious virus and global viral gene expression. Latency therefore is non-
symptomatic, and sporadic reactivation of the virus in healthy individuals generally 
leads to sedate symptoms, similar to those found with primary infection. Reactivation 
of the virus can however lead to significant morbidity and mortality in the case of 
immunocompromised or immunosuppressed individuals, such as AIDS and transplant 
patients respectively (Sinclair and Sissons, 2006). 
 Studies on latency and reactivation have identified cells of the myeloid lineage, and 
specifically monocytes/monocyte-derived cells to be the major sites of latent HCMV, 
although many other tissues may also harbour latent HCMV genomes (Taylor-
Wiedeman et al., 1991). CD34+ stem cells which give rise to the myeloid lineage can 
also contain viral DNA, but the virus genome has never been detected in non-myeloid 
CD34+ derived cells. CD34+ progenitors or undifferentiated myeloid cells do not 
support productive viral infection; studies suggest the HCMV genome resides as a 
circular episome in these cells, at frequencies only detectable by PCR amplification 
(about 1 in 10,000 cells) (Bolovan-Fritts et al., 1999, Slobedman and Mocarski, 1999).  
The fact that substantial global gene expression has not been observed during latency 
suggests HCMV can be truly latent, meaning its persistence is not dependent on 
constant low level productive infection (Sinclair and Sissons, 2006). An obvious and 
important question therefore is whether HCMV latency is associated with the 
production of latency-specific transcripts. Addressing this question in vivo has been 
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confounded by the extremely low copy numbers of the virus genome in the blood of 
healthy seropositive persons, and therefore limited mainly to experimental infection of 
myeloid lineage cells (Sinclair and Sissons, 2006). Initially, several cytomegalovirus 
latency-specific transcripts (CLTs) were detected by PCR in the blood of healthy carriers 
(Sinclair, 2008). These included MIE-expressed transcripts, and a viral homologue of IL-
10, transcribed from the UL111A gene (Jenkins et al., 2004). The roles of these CLTs 
have not been clearly defined. Microarray analysis of cDNA clones isolated from non-
permissive CD34+ cells identified a substantial number of genes to be expressed during 
experimental latency (Goodrum et al., 2002). Many of these transcripts are also 
expressed during the lytic cycle, and may have represented low level abortive, or 
undetected productive infection, but the expression of 2 of them was subsequently 
confirmed in naturally latent cells (Sinclair, 2008). The first, UL138, is detectable in 
CD34+ undifferentiated cells, and monocytes of healthy seropositives. UL138 mRNA 
levels decrease upon reactivation of the virus, and its deletion results in restricted 
latency (Goodrum et al., 2007). Later, an antisense transcript to the UL81 and UL82 
genes, named UL81-UL82ast, and its resulting protein product LUNA were detected in 
monocytes carrying latent virus (Bego et al., 2005), and more recently in vivo (Bego et 
al., 2011). The functions of both UL138 and LUNA remain unknown.  
The expression of IE genes seems absolutely required for virus reactivation, as little or 
no RNA from the IE region can be detected in cells of healthy seropositive individuals 
(Sinclair and Sissons, 2006). Hence it seems as long as the IE gene expression is 
sufficiently suppressed, the virus will remain latent, but lytic replication will occur if IE 
genes are allowed to be expressed. Differentiation of myeloid cells into macrophages 
and dendritic cells (DCs) is accompanied by reactivation of IE expression (Taylor-
Wiedeman et al., 1994). This closely resembles the in vitro response of these cells to 
experimental infection, where differentiation of non-permissive monocytic or CD34+ 
progenitor cells into mature DCs or macrophages brings about complete 
permissiveness, and the production of infectious virus progeny. The non-
permissiveness of monocytic and CD34+ progenitor cells has been ascribed to the 
inability of these cells to express viral IE genes, and not to the lack of virus binding and 
entry (Gonczol et al., 1984). Moreover it has now been accepted that both 
differentiation-dependent transcription factors, and chromatin structure around the 
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MIE promoter play a major role in determining IE gene expression (Sinclair, 2010b). An 
increase in the level of DNAse I hypersensitivity in regions of the MIE promoter, 
coincided with differentiation and thereby permissiveness of latent cells (Ghazal et al., 
1990). A number of cellular transcription factors have been found to upregulate MIE 
gene expression in vivo by binding to the MIE promoter (Sinclair and Sissons, 2006). 
Also, sequence analysis has predicted the binding of a number of repressive cellular 
transcription factors to the MIE promoter (Shelbourn et al., 1989). The levels of the 
repressive transcription factor YY1 drop dramatically following differentiation of 
cultured non-permissive NT2D1 cells into HCMV-permissive cells, whilst another 
negative regulator of the MIE promoter, the ERF protein, exerts its influence by 
recruiting histone deacetylaces (HDACs) to the viral MIE promoter (Sinclair and Sissons, 
2006). This repressive effect on chromatin structure can be reversed in vitro by the 
treatment of undifferentiated cells with HDAC inhibitors (Murphy et al., 2002). Such 
functional remodelling of the chromatin around the viral MIE promoter has been 
demonstrated in vivo in CD34+ cells and monocytes of healthy seropositives, the MIE 
promoter was associated with methylated histones, but ex vivo differentiation of these 
cells into mature DCs resulted in demethylation and acetylation of the MIE promoter 
region (Reeves et al., 2005). This is in accord with in vitro chromatin 
immunoprecipitation assays, which showed that the MIE promoter associates with 
chromatin silencing proteins in undifferentiated cells, and with histone markers of 
active transcription upon differentiation and virus reactivation.  
The expression of limited HCMV transcripts during latency indicates that the repressive 
chromatin structure seen around the MIE promoter in undifferentiated CD34+ cells 
cannot exist for the whole genome (Sinclair, 2010a). In correlation with its activity, and 
in contrast with the MIE promoter, experimental infection of CD34+ cells revealed an 
active chromatin structure around the LUNA promoter (Reeves and Sinclair, 2010). 
Observation of binding sites for GATA-1 and GATA-2, important regulators of gene 
expression in haematopoetic cells, in the promoter region of LUNA lead to the 
hypothesis that LUNA expression in latently infected cells may be facilitated by GATA-
mediated recruitment of histone acetylases. Indeed post-translational modifications of 
histones associated with the HCMV genome are now thought to be important not only 
in latency and reactivation, but also in gene expression during productive infection 
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(Sinclair, 2010a). Studies of the relationship between chromatin structure and lytic 
gene expression however, are at an early stage and will likely shed more light on this 
subject in the near future.  
An analysis of the cellular miRNA profile of CD34+ progenitor cells carrying latent virus 
identified a small number of miRNAs that were significantly downregulated during 
latency (Poole et al., 2011). Of these, hsa-miR-92a is a known regulator of 
haematopoiesis and immune function. hsa-miR-92a is known to target GATA-2, which 
in turn activates cellular IL-10 expression. Consistent with this, GATA-2 and cellular IL-
10 levels were found to be upregulated, and it was hypothesised that increased IL-10 
levels helped maintain latent carriage of virus. In accord with this, engagement of 
secreted cellular IL-10 by antibodies caused a fall in the number of latent genomes, 
possibly due to increased cell death. Cellular miRNA expression may therefore be 
modulated to optimise the cellular environment for latency, and thereby promote 
survival of cells harbouring the latent virus.  
1.5. Prevalence, transmission, and 
detection  
1.5.1. Prevalence 
Since both primary infection and superinfection with HCMV are often asymptomatic, 
and overt disease is not associated with pathognomonic symptoms, laboratory testing 
is required to identify carriers. Following primary infection, HCMV-specific antibodies 
persist in the blood, and their detection provides a simple and efficient method of 
identifying carriers (Weber et al., 1999, Cannon et al., 2010). Conventional methods of 
HCMV specific IgM and IgG detection such as the complement fixation (CF) assay, the 
latex agglutination (LA) assay, and indirect haemagglutination assay (Cannon et al., 
2010) have now been replaced by more sensitive enzyme linked immunosorbent 
assays (ELISAs) (Cannon et al., 2010).  
Using such techniques, HCMV seroprevalence is estimated to range between 40% and 
100% among different populations worldwide (Ho, 1990). The incidence is higher in 
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populations living in poor socioeconomic conditions, in developing countries, and in 
women, who tend to be more readily infected (Ho, 1990). Higher incidence in women 
could be explained by their increased susceptibility during sexual transmission, or 
habitual reasons such as higher likelihood of caring for young children, who shed high 
levels of the virus (Cannon et al., 2010). Race has also been shown to correlate with 
seroprevalence, with non-whites consistently appearing more likely to be seropositive. 
It is unclear whether the higher incidence of HCMV in non-whites is solely due to their 
generally lower socioeconomic status, or if other factors such as cultural or customary 
practices also play a role (Cannon et al., 2010).  
1.5.2. Transmission 
Transmission of the virus requires close contact, and can occur horizontally or 
vertically. Horizontal transfer of the virus generally occurs through infected bodily 
secretions, sexual contact, and urine (Brown and Abernathy, 1998). Organ 
transplantations and blood transfusions are also known modes of infection (Brown and 
Abernathy, 1998). Evidence for the sexual transmission of the virus includes 
observation of HCMV disease in two men after sexual contact with a woman diagnosed 
also with HCMV disease (Chretien et al., 1977), higher incidence of the virus in sexually 
active individuals (Jordan et al., 1973), and the presence of identical strains of the virus 
in sexual partners (Handsfield et al., 1985). Transmission through close contact and 
urine is demonstrated by the pronounced rate of seroconversion amongst day care 
workers (Adler, 1990).  
Transplant recipients undergoing immunosuppressive treatment are at a major risk of 
contracting disease. In seropositive individuals, superinfection and reactivation 
together occur up to 100% of the time, although reactivation is thought to account for 
the majority of these cases (Ho, 1990). The frequency of primary infections amongst 
seronegative organ recipients has been estimated at 53%-73% (Ho, 1990). This 
naturally follows receipt of an organ containing latent virus, as evidenced by restriction 
endonuclease analysis (Ho et al., 1975), and the presence of identical strains in the 
donor and the recipient (Chou, 1986). In one report, multiple HCMV strains were 
detected in 5 of the 11 renal transplant recipients studied, all of whom were 
seronegative prior to organ transplantation (Stanton et al., 2005).  
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Vertical transmission of virus from mother to foetus can occur during primary or 
recurrent infection of the mother, and mostly involves passage of HCMV virions from 
maternal blood to the foetus, although entry of infected maternal leukocytes, 
endometrial, or cervical cells into the foetal circulation, or ingestion by the foetus of 
infected placental tissue may also lead to congenital infection (Leguizamon and Reece, 
1997, Alford et al., 1990). Perinatal infection is more common than congenital 
infection, and includes passage through an infected uterine cervix during delivery (Ho, 
1990) and lactation (Stagno et al., 1980b). Infected children are prolific spreaders of 
HCMV, as they shed virus for prolonged periods in their urine and other bodily 
secretions, whereas seropositive adults rarely excrete virus in such high levels and for 
extended periods (Adler, 1989).  
1.5.3. Detection 
Transplant and transfusion recipients, newborns and AIDS patients are in major risk of 
developing HCMV disease (Caliendo et al., 2000). With the availability of better 
antiviral drugs, rapid and reliable detection of HCMV infection in these individuals has 
become imperative, as it identifies patients requiring preemptive HCMV treatment 
(Van der Bij et al., 1988a). Furthermore, timely exclusion of HCMV infection in 
transplant recipients can minimise overtreatment with immunosuppressive drugs (Van 
der Bij et al., 1988a). A number of techniques have been described for the detection of 
HCMV infection. Conventional cell culture techniques involved inoculation of fibroblast 
cells with patient material, and the observation of characteristic HCMV cytopathic 
effect (CPE)(Paya et al., 1987). Although these techniques represent a very reliable 
method of detection, they do not satisfy the need for rapid diagnosis, as definitive 
exclusion of infection necessitates up to 21 days incubation time (Stagno et al., 1980a, 
Goldstein et al., 1982). More rapid methods for diagnosis of HCMV disease have 
therefore been devised. The presence of HCMV particles in blood is an important 
marker for potential disease, and is strongly associated with disease severity (Van der 
Bij et al., 1988a). The HCMV early antigen test identifies HCMV particles in blood by 
immunofluorescence, using anti-IE72 antibody (Schirm et al., 1987). Such recognition 
of viraemia is performed either directly on blood samples (detection of early antigen 
fluorescent foci: EAFF) (Schirm et al., 1987), or indirectly in fibroblasts inoculated with 
purified portions of blood (Stirk and Griffiths, 1987), and can take as little as 24 hours. 
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Even more rapid and sensitive techniques such as the antigenaemia test, which 
involves antibody-mediated detection of HCMV antigens in leukocytes within 3 hours, 
have also been described (Van Der Bij et al., 1988b). Recently several PCR protocols 
were designed to amplify specific DNA and RNA viral sequences both qualitatively and 
quantitatively (Caliendo et al., 2000). Quantitative amplification of viral sequences is 
advantageous as it can be used to monitor response to treatment (Gandhi and Khanna, 
2004). Currently, quantitative PCR (qPCR) assays directed against the viral genome and 
viral mRNA transcripts are the most commonly used methods of identifying patients 
encountering viraemia and in need of treatment (Caliendo et al., 2000). Despite their 
rapidity and sensitivity, even the pp65 antigenaemia test and PCR fail to detect HCMV 
in the blood of some affected patients, such as in 25% of gastrointestinal patients 
(Boeckh, 2011). For this reason, sampling from other sites such as bronchoalveolar 
lavage (BAL) fluid, or specific tissue(s) is also used to document disease (Boeckh, 2011).  
1.6. Clinical manifestations and 
treatment  
Despite major improvements in recent years in its diagnosis and treatment, HCMV 
disease continues to cause major morbidity and mortality. In this section a brief 
account is given of the spectrum of diseases caused by HCMV, and the current 
treatments available.  
1.6.1. Range of diseases 
CMV infections rarely manifest themselves as overt disease in the immunocompetent 
host. However individuals with deficient, suppressed or immature immune defence, 
such as AIDS patients, transplant recipients and unborn and newborn babies are at 
severe risk of developing serious, often life threatening disease. The nature of disease 
is very variable, but commonalities are observed depending on which of the above 
high-risk groups the patient belongs to. The most typical diseases caused by HCMV are 
described below.  
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1.6.1.2. Congenital and perinatal infections 
Immaturity of the immune response makes the foetus and the newborn susceptible to 
HCMV infection (Alford et al., 1990). In fact HCMV is the most common cause of 
congenital viral infection, seen in about 1% of all live births (Weller, 1971). It is thought 
between 5% and 10% of congenitally infected children develop symptoms, and of 
those, 90% suffer from debilitating disease or die soon after birth (Alford et al., 1990). 
Congenital HCMV disease generally affects multiple organs, and commonly causes 
hepatomegaly, splenomegaly, microcephaly and mental retardation (Weller et al., 
1962). Manifestations in children include loss of sight and/or hearing, CNS damage, 
tooth defects and growth retardation, and learning disabilities (Alford et al., 1990). 
Asymptomatic or subclinical congenital infections lead to disease in 5% to 15% of 
cases, with sensorineural hearing loss, motor defects and mental retardation amongst 
the most frequent outcomes, usually appearing within 2 years of birth (Alford et al., 
1990). Like congenital infections, perinatal infections lead to the shedding of virus for 
years, but lower amounts of the virus are secreted (Stagno et al., 1983). Newborn 
children infected with the virus have a far lower risk of developing disease and 
predominantly remain asymptomatic (Alford et al., 1990).  
1.6.1.3. Infections in transplant patients 
Transplant patients routinely undergo immunosuppressive treatment to prevent organ 
rejection. This results in susceptibility to HCMV infection, resulting from reactivation of 
pre-existing virus in the recipient and/or reactivation of latent HCMV in the transplant 
organ (Meyers et al., 1986). Patients in greatest risk are seronegatives receiving an 
organ from a seropositive donor, as they lack pre-existing immunity to HCMV and 
therefore produce higher viral loads. An exception is bone marrow transplants, where 
pre-transplant seropositive recipients are in greater risk of developing HCMV infection 
compared to seronegative patients (Meyers et al., 1986). Seronegative bone marrow 
recipients meanwhile, are more likely to be infected, when their donors are 
seropositive. The most common forms of disease in transplant patients include 
pneumonitis, enteritis and hepatitis (Gandhi and Khanna, 2004).  
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1.6.1.4. Infections in AIDS patients 
Whereas transplant recipients undergo temporary immunosuppression, AIDS patients 
are terminally immunosuppressed, and are therefore at severe risk of developing 
HCMV disease (Jacobson and Mills, 1988). HCMV causes a remarkably different range 
of diseases in AIDS patients compared to other high risk groups. Retinitis is the most 
common manifestation of HCMV disease in AIDS patients, followed by gastrointestinal 
disease and encephalitis (Cunha, 2010). Furthermore subsequent progression to AIDS 
is also accelerated in HIV patients with HCMV disease (Gandhi and Khanna, 2004).  
1.6.1.5. Infections in the Immunocompetent host 
HCMV is well controlled in the immunocompetent host, such that primary infections in 
healthy individuals are predominantly asymptomatic. On occasion however primary 
infection can lead to mononucleosis-like illness (Boeckh and Geballe, 2011), and very 
rarely to pneumonia or gastrointestinal HCMV disease (Cunha, 2010).  
1.6.1.6. Associations with other diseases and cancer 
In addition to the typical HCMV diseases discussed in 1.6.1.2-1.6.1.5, HCMV has been 
linked with a number of other diseases but it is not known whether it is a direct cause 
of these conditions or simply a bystander (Cunha, 2010). HCMV may exacerbate 
prognosis of inflammatory bowel disease, new onset diabetes , and atherosclerosis 
(Cunha, 2010, Lawlor and Moss, 2010). Furthermore it has been suggested that 
constant surveillance of HCMV in seropositive individuals leads to accelerated 
immunosenescence, the term given to the weakening of the immune system with age 
(Pawelec et al., 2010).  
The potential link between HCMV and certain forms of cancer has long been subject of 
debate, and is now gathering evidence (Michaelis et al., 2009). Despite early reports 
that HCMV can transform human embryonal cells in vitro (Geder et al., 1976), 
occurence of such transformation lacks solid evidence (Michaelis et al., 2009). More 
conclusive findings have come in recent years, concurrent with the availability of more 
sensitive methods of detecting HCMV (Michaelis et al., 2009). The presence of viral 
DNA and antigens, as well as low level persistent virus replication in tumour cells but 
not adjacent healthy cells was shown in more than 90% of patients suffering from 
certain types of cancer, such as colon and breast cancer (Söderberg-Nauclér, 2008, 
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Harkins et al., 2002, Cobbs et al., 2002). In addition, patients whose tumours 
harboured lower levels of HCMV survived longer than those with high level infection in 
their tumour cells (Söderberg-Nauclér, 2008). HCMV is generally not regarded as an 
oncogenic virus, but rather an oncomodulator, meaning it can render tumour cells 
more malignant (Cinatl Jr et al., 1996). It is thought HCMV can aggravate malignancy by 
positively contributing to factors such as proliferation, angiogenesis, survival, invasion, 
resistance to apoptosis, and evasion of immune surveillance (Michaelis et al., 2009). In 
addition to oncomodulating functions, HCMV has been shown to induce site specific 
breaks in chromosome 1 at positions 1q21 and 1q42 (Fortunato et al., 2000, Fortunato 
and Spector, 2003). 1q21 strand breaks are thought to affect an unidentified breast 
cancer tumour suppressor gene (Bièche et al., 1995) whilst disruption at position 1q42 
may ablate the function of ADPRT, a gene involved in DNA repair and replication, 
whose malfunction correlates with glioblastoma development (Baumgartner et al., 
1992, Li et al., 1995). With this in mind, it is hereby suggested that HCMV is 
predominantly oncomodulating, and mildly oncogenic.  
1.6.2. Treatment 
Almost all drugs currently used to treat or prevent HCMV disease target the viral 
replication cycle (Boeckh and Geballe, 2011). Ganciclovir (and its oral alternative 
valganciclovir) is a guanosine analogue that is phosphorylated by the viral kinase UL97, 
and causes termination of HCMV DNA replication (Boeckh and Geballe, 2011). 
Cidofovir and foscarnet are nucleoside monophosphate and pyrophosphate analogues 
respectively, which also abolish viral DNA replication, but unlike ganciclovir these do 
not require prephosphorylation (Chou, 1999). Other drugs such as acyclovir have also 
proved successful in restricting HCMV infection in transplant patients (Boeckh and 
Geballe, 2011). Unfortunately resistance by HCMV has been observed against all 
currently available drugs, and is often brought about by mutations in the UL97 kinase 
gene in the case of ganciclovir, or in the DNA polymerase gene for all anti-DNA 
replication drugs (Boeckh and Geballe, 2011). Resistance is most common when the 
levels of the drugs are insufficient to completely suppress HCMV replication. If 
resistant virus progeny arises some time after commencement of treatment, there will 
be an initial lowering of viral load followed by an increase in viral load when the 
resistant form of the virus dominates; or if the virus is resistant to begin with, virus 
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shedding may persist at original levels several weeks into therapy (Chou, 1999). 
Moreover, drug resistance is most frequently observed in severely 
immunocompromised hosts, and those suffering from long term or relapsing HCMV 
disease. Presence of drug resistance should trigger treatment with alternative drug(s), 
whilst certain mutations in the DNA polymerase gene can give rise to resistance 
against multiple drugs (Chou, 1999, Boeckh, 2011).  
1.7. Controlling the host 
1.7.1. Anti-apoptotic functions 
It is well known that apoptosis is used by the host as a method of eliminating virus 
infected cells (O'Brien, 1998). It is also known that viruses including HCMV have 
evolved multiple mechanisms to avoid or delay apoptosis of infected cells 
(Goldmacher, 2005). Apoptosis in response to virus infection can be induced 
intrinsically, or extrinsically. The intrinsic pathway can be initiated by stress sensors 
such as p53, causing the release of pro-apoptotic molecules from the mitochondria, 
and activation of caspases. In the extrinsic pathway, signalling through death receptor 
molecules by soluble death receptor ligands, and cytotoxic immune cells such as 
natural killer (NK) cells and cytotoxic T lymphocytes (CTLs) also leads to caspase 
activation (Goldmacher, 2005). Importantly therefore, intrinsic and extrinsic induction 
of apoptosis share overlapping downstream features, and apoptosis most often 
involves cross-talk between, and convergence of, mitochondrial and death receptor 
signals (Terhune et al., 2007). Caspase activity will then trigger a cascade of reactions, 
leading to events such as DNA fragmentation, loss of cytoskeletal integrity, and 
membrane blebbing; resulting in cell death (Terhune et al., 2007).  
Due to its relatively long replication cycle, HCMV requires lasting survival of the host 
cell following infection. HCMV manages to inhibit apoptosis for prolonged periods by 
encoding an impressive array of anti-apoptotic functions. Interestingly, HCMV anti-
apoptotic proteins show no sequence homology, but obvious functional homology to 
cellular death-suppressor proteins, which suggests such functions have arisen by 
means other than gene capture (Brune, 2011). In addition, most HCMV anti-apoptotic 
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functions discovered so far are expressed with IE kinetics, and some are encoded by 
genes essential for virus replication, highlighting their importance in the life cycle of 
the virus.  
The first anti-apoptotic HCMV proteins to be discovered were IE72 and IE86, each of 
which is sufficient to block TNF-α induced apoptosis (Zhu et al., 1995, Lukac and 
Alwine, 1999). However, IE72 and IE86 are not able to protect cells from apoptosis 
following UV irradiation of the host cell. These molecules are nuclear in localization 
and are unlikely to directly interact with any cytoplasmic molecules. Furthermore the 
levels of transcription of many prominent pro-apoptotic and  anti-apoptotic cellular 
genes remained unchanged following expression of IE1 and IE2 genes, leading to 
suggestions IE72 and IE86 may exert their anti-apoptotic effects through modulation of 
p53 activity (Zhu et al., 1995). HCMV infection of coronary smooth muscle cells (SMCs) 
resulted in the upregulation of endogenous p53, which co-localised with IE86 (Speir et 
al., 1994). Subsequently, the physical interaction between p53 and IE86 was 
demonstrated by immunoprecipitation. Furthermore IE86 abolished the 
transactivating effect of p53 on a reporter gene, when all 3 genes were plasmid-cloned 
and transfected into SMCs. In another study using coronary SMCs, IE86 but not IE72 
expressed from an adenovirus vector (Ad-IE-86) inhibited p53-mediated apoptosis 
when cells were superinfected with Ad-p53, or treated with doxorubicin, a substance 
known to induce the p-53 dependent apoptotic pathway (Tanaka et al., 1999). In both 
cases, control cells showed markedly higher rates of apoptosis than IE86-expressing 
cells. The inhibition of p53 function by IE-86 in SMCs results in continued cell cycle 
progression, and has been linked with coronary restenosis, a condition in which 
excessive proliferation of SMCs leads to narrowing of blood vessels and restricted 
blood flow. Mechanistically, it is known that IE-86 is able to repress p53 function by 
physically binding p300 and CBP, and blocking their transactivation of p53 (Hsu et al., 
2004).   
In a screening experiment carried out on HeLa cells, the protein product of exon 1 of 
the UL37 gene (UL37x1) was identified as an anti-apoptotic gene as it conferred 
resistance to Fas-mediated, and TNF-α mediated apoptosis (Goldmacher et al., 1999). 
Due to its mitochondrial localisation, and its physical interaction with the cellular 
mitochondrial protein adenine nucleotide translocator (ANT), the UL37 protein was 
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called viral mitochondrion-localised inhibitor of apoptosis (vMIA) (Goldmacher et al., 
1999). vMIA displays analogous functions to the cellular anti-apoptotic protein Bcl-2 
which also localises to the mitochondria, such as inhibition of cytochrome C leakage 
from the mitochondria through preserving the integrity of the mitochondrial 
membrane (Goldmacher et al., 1999).  
An early event in extrinsic apoptosis after the engagement of death receptors at the 
cell surface is the recruitment of procaspase 8, and its subsequent proteolytic cleavage 
into active caspase 8. Screening of an expression library of HCMV genes lead to the 
identification of the UL36 gene product as an inhibitor of procaspase-8 activation, and 
its designation as viral inhibitor of caspase-8 activation (Skaletskaya et al., 2001). vICA 
represented the first non-essential IE HCMV function, as inactivating mutations in the 
UL36 gene were reported to be inconsequential to viral replication.  
Infection of human fibroblasts with a library of strain AD169 mutants lead to the 
observation that viruses lacking the UL38 gene underwent excessive cell death, 
characteristic of apoptosis, and failed to produce maximal virus progeny compared to 
intact AD169 (Terhune et al., 2004). UL38 over expression protects cells from apoptosis 
induced by both dl337- a mutant adenovirus known to lack a caspase-inhibiting gene 
that works against intrinsic apoptosis-, and also thapsigargin, which is known to disrupt 
calcium flux in the ER, but not from apoptosis induced by ligation of the Fas receptor 
(Terhune et al., 2004). The target(s) of pUL38, or the mechanism by which this 
molecule performs its death suppressing function remain unknown.  
The β2.7 transcript accounts for >20% of virally encoded mRNAs at early times of 
infection (Section 1.2.3.3), but no protein product has ever been detected for this 
molecule (Greenaway and Wilkinson, 1987, Spector, 1996). Screening a human cDNA 
library with β2.7 identified a subunit of the mitochondrial enzyme complex I as a 
potential interacting partner. Inhibition of complex I activity is known to result in 
apoptosis, and treatment of neuronal U373 cells with rotenone, a complex I inhibitor, 
resulted in substantial cell death. Infection with the intact but not the Δβ2.7 Toledo 
strain of HCMV protected cells from cell death, and β2.7 expression alone was 
sufficient for this protection. Rotenone treatment of uninfected cells, or cells infected 
with the mutant virus coincided with the relocalisation of GRIM-19, an essential 
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subunit of complex I, from a diffuse cytoplasmic location to the perinuclear space. β2.7 
was able to abort this relocalisation, and was found to be associated with GRIM-19 by 
immunoprecipitation. Furthermore this association helped maintain ATP production in 
the face of oxidative stress during HCMV infection (Reeves et al., 2007).  
1.7.1.1. Death receptors and HCMV infection  
Since death receptor induced apoptosis is a mode of removing virus-infected cells, it is 
only logical to predict that HCMV infection may trigger over expression of death 
receptors at the cell surface, or that HCMV may contain specific functions to inhibit 
surface expression of pro-apoptotic death receptors.  
Tumour necrosis factor alpha (TNF-α) receptor I (TNFRI) is a major mediator of pro-
apoptotic and pro-inflammatory signals (Baillie et al., 2003). TNF-α signalling through 
TNFRI has also shown to induce antiviral and cytotoxic effects in the target cell. It may 
therefore be beneficial for the virus to block TNF-α signalling by reducing the levels of 
TNFRI at the cell surface and therefore prevent apoptosis of infected cells (Baillie et al., 
2003). Infection of THP1 myelomonocytic cells, and U373 glioblastoma cells with 
HCMV was shown to significantly downregulate cell surface TNFRI expression (Baillie et 
al., 2003). This function was abolished when UV-inactivated virus was used, confirming 
that viral gene expression was required for this effect. It is not known which HCMV 
gene(s) is responsible for this function.  
CD95 (APO-1/Fas) is the best characterised member of the tumour necrosis factor 
(TNF) superfamily, whose activation by Fas ligand (FasL) can lead to apoptosis (Peter 
and Krammer, 2003). It has previously been shown that adenoviruses inhibit apoptosis 
by removal of CD95 molecules from the cell surface (Elsing and Burgert, 1998, Shisler 
et al., 1997). Surface Fas downregulation by the 10.4K and 14.5K adenovirus proteins 
has been shown to involve internalization, and degradation in lysosomes (Elsing and 
Burgert, 1998). CD95 downregulation by the Myxoma virus leukaemia –associated 
protein (MV-LAP) has also been described, although in the context of viral infection, 
this effect appears counterbalanced by another Myxoma virus factor, which 
upregulates CD95 expression (Guerin et al., 2002).  
Given the diverse anti-apoptotic functions encoded by HCMV, the question of whether 
HCMV downregulates CD95 expression seemed a valid one. Previously, it was reported 
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that infection with the Smith and Eisenhardt clinical strains lead to an upregulation of 
Fas receptor on the surface of HFF cells (Chaudhuri et al., 1999). The authors also 
found that mock-infected cells expressed no/undetectable levels of surface Fas. This is 
unexpected, as abundant Fas expression on the surface of neonatal forskin and adult 
dermal fibroblasts has been reported (Jelaska and Korn, 1998). I therefore sought to 
investigate whether HCMV infection would alter surface Fas levels of cultured human 
fibroblasts.  
1.7.3. Immune-evasion 
HCMV confronts strong innate and adaptive immune responses throughout its life 
cycle (Jackson et al., 2011). The importance of these responses is evident from 
extensive HCMV-related morbidity and mortality in immunosuppressed, 
immunocompromised, and immunonaïve individuals. At the same time, HCMV 
employs a variety of mechanisms by which to evade immune surveillance. The 
efficiency with which HCMV is able to modulate the host’s defence mechanisms is 
exemplified by its life-long persistence following primary infection. Here, a brief 
overview is given of the immune responses that are elicited through HCMV infection, 
and the counteracting measures put up by the virus in return, with special emphasis on 
NK cells.  
1.7.3.1. Innate immunity  
Innate immunity plays a major role in the fight against invading viruses. The innate 
immune response detects viral elements by pattern recognition receptors (PRRs), and 
activates intracellular signalling cascades leading to the secretion of type I interferons 
and inflammatory cytokines. This activates numerous interferon-responsive and 
cytokine-responsive genes, and leads to the establishment of an antiviral state to 
protect neighbouring cells from infection (Takeuchi and Akira, 2009).  
Binding and entry of HCMV particles rapidly initiates many signal transduction 
pathways, leading to a global remodelling of gene expression (Isaacson et al., 2008). 
HCMV infection can induce cellular gene expression in a number of ways. gB and gH 
upregulated transcription of Sp1 and NF-ĸB (Yurochko et al., 1997). Virion proteins 
such as pp71, together with the IE1 and IE2 encoded proteins have been demonstrated 
to activate the expression of a number of cellular genes (Liu and Stinski, 1992, Malone 
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et al., 1990). Differential display analysis identified 15 cellular mRNAs that were 
upregulated 8 hpi, all of which belonged to interferon-responsive genes (Zhu et al., 
1997). Interestingly, these cellular transcripts were also activated by UV-irradiated 
HCMV, suggesting virion components and not viral gene expression were responsible. 
DNA microarray analysis comparing transcripts in mock-infected and HCMV-infected 
cells identified numerous antiviral genes, including interferon-responsive and 
inflammatory cytokine-responsive genes to be induced by HCMV infection (Browne et 
al., 2001, Zhu et al., 1998). Moreover, many genes encoding pro-inflammatory 
cytokines and chemokines are switched on by the NF-ĸB transcription factor, which is 
activated following engagement of receptors such as toll-like receptor-2 (TLR2), by 
viral envelope glycoproteins (Yurochko et al., 1997). Interestingly HCMV has evolved to 
benefit from these early innate responses too. For example, the presence of NF-ĸB 
elements within the MIE promoter indicates NFK-B activation may drive viral gene 
expression and consequently viral replication (Sambucetti et al., 1989). 
1.7.3.1.1. NK-evasion functions 
NK cells are a heterogeneous population of cells which express a wide range of both 
activating and inhibitory surface receptors (Vivier et al., 2011). NK cell cytotoxicity is 
regulated by the balance between activating and inhibitory signals received from the 
target cell. NK cells play a vital role in the defence against HCMV infection; this is 
evidenced by severe HCMV disease in individuals with defective NK-cell functions 
(Biron et al., 1989). The interaction between HCMV-infected cells and NK-cells has 
been the subject of intense research, and has revealed much information not only 
about HCMV infection and pathogenesis, but also about the functioning of NK-cells in 
general (Wilkinson et al., 2008). A brief account is hereby presented of the array of 
functions HCMV uses to protect infected cells from NK-lysis.  
Natural killer group 2, member D (NKG2D) is a potent activating receptor found on NK-
cells and T-cells, which promiscuously binds a number of proteins, such as MICA, MICB, 
and UL16-binding proteins 1-4 (ULBP1-4) (Champsaur and Lanier, 2010). Virus 
infection, and specifically HCMV IE1 and IE2 proteins are known to cause activation of 
NKG2D through upregulation of these ligands (Wilkinson et al., 2008). To defeat this 
susceptibility, gpUL16 prevents the surface expression of MICB, ULBP1 and ULBP2 by 
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direct binding and sequestration in the ER to modulate NK-recognition (Dunn et al., 
2003a).   
An important determining factor in the activation of NK-cells is the level of MHC class I 
molecules at the surface of potential target cells. According to the ‘missing self’ 
hypothesis, constitutive expression of MHC class I molecules on the surface of healthy 
cells prevents NK-mediated killing. On the other hand, removal of MHC class I 
molecules from the surface of infected cells serves as a signal for NK attack (Karre et 
al., 1986). The downregulation of MHC class I molecules on the surface of infected cells 
by HCMV (see 7.3.2) can therefore leave cells susceptible to NK cytotoxicity (Wilkinson 
et al., 2008). To counter this, the virus expresses an MHC class I homologue (gpUL18), 
which like endogenous MHC class I, is able to form trimeric complexes with β2-
microglobulin and endogenous peptides (Beck and Barrell, 1988). gpUL18 binds the 
inhibitory NK receptor LIR1 with 1000 times higher affinity than HLA-I molecules 
(Cosman et al., 1997, Willcox et al., 2003), but importantly is not subjected to the same 
downregulation by the US2, US3, US6 and US11 gene products (Park et al., 2002). 
Inhibition of LIR1+ NK cells by gpUL18 has been observed with multiple donors 
(Prod’homme et al., 2007).  
The inhibitory surface receptor CD94/NKG2A is expressed on the surface of most 
human NK cells, where it interacts specifically with the non-classical MHC class I 
molecule, HLA-E (Braud et al., 1998). Surface expression of HLA-E in turn requires prior 
binding with a peptide derived from residues 3 to 11 of the signal sequence of MHC 
class I molecules (Braud et al., 1997). This binding occurs in the ER, following 
cytoplasmic cleavage and processing of classical MHC class I molecules, and the TAP-
dependent transportation of the signal sequence to the ER. Thus HLA-E recognition by 
NK cells monitors normal MHC Class I synthesis and TAP function. Contrary to 
expectation, TAP-inhibition by US6 (see 1.7.3.2) did not result in suppression of HLA-E 
surface expression during productive HCMV infection (Tomasec et al., 2000). This is 
because the UL40 signal peptide (SP UL40) of HCMV carries a nine amino acid 
sequence, exactly homologous to endogenous HLA-E binding peptides, which strongly 
promotes HLA-E surface expression in a TAP-independent manner (Tomasec et al., 
2000). Moreover, an HCMV UL40 deletion mutant underwent increased NK cytolysis 
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compared to virus expressing a functional UL40 protein (Wang et al., 2002). UL40 
therefore acts as an important NK-evasion function.  
As described in 1.7.3.1, the interferon pathway is important in the innate defence of 
cells against HCMV infection. Interferons secreted from infected cells bind their 
cognate receptors on neighbouring cells, leading to the activation of interferon 
sensitive genes (ISGs). The product of the UL83 gene, pp65, has been shown to block 
the induction of many ISGs and pro-inflammatory genes very early after infection, and 
virus lacking the UL83 gene induced a stronger expression of many interferon 
responsive genes (Browne and Shenk, 2003). To achieve this, pp65 has been proposed 
to inhibit the activation of NF-ĸB and IRF1, but the mechanism of this function remains 
to be elucidated (Browne and Shenk, 2003). In addition to suppressing antiviral gene 
expression, pp65 has been shown to directly bind the activating NK receptor NKp30, 
but remarkably, such binding did not result in NK lysis, but rather diminished the 
potential of NK cells to kill virus-infected cells (Arnon et al., 2005). Since pp65 is neither 
secreted from infected cells nor present on the surface of infected cells, or the viron 
envelope, direct NK binding may require its release by lysis of infected cells (Wilkinson 
et al., 2008). This suggests NK-lysis of some infected cells in an infected tissue may 
benefit the overall survival of the virus, by decapacitating roaming NK cells. The highly 
passaged AD169 and Towne laboratory strains have undergone 15-kb and 13-kb 
deletions corresponding to the UL/b’ region (Cha et al., 1996). Although these strains 
protected cells from NK-killing, this protection occurred to a lesser extent than seen 
with clinical isolates (Cerboni et al., 2000, Wang et al., 2002). This prompted the 
prediction that the UL/b’ region encoded one or more NK-evasion functions that had 
been lost from certain strains through extensive culture in vitro (Tomasec et al., 2005). 
This prediction was validated when a recombinant Towne virus in which the Toledo 
strain UL/b’ had been inserted (Towne/Tol11) displayed protection from NK-killing in 
levels comparable with wildtype virus (Tomasec et al., 2005). Ectopic expression of 
individual UL/b’ genes in fibroblasts then lead to the identification of UL141 as an NK-
evasion gene, as UL141-expressing cells exhibited enhanced resistance to NK-mediated 
cytolysis (Tomasec et al., 2005). The observation that HCMV strains containing UL141, 
but not those lacking the UL141 gene downregulated CD155 expression, and that 
gpUL141 alone could downregulate CD155 demonstrated that CD155 was targeted by 
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gpUL141 (Tomasec et al., 2005). CD155 is a cell surface ligand for the NK-activating 
receptors CD226 and CD96 (Tomasec et al., 2005). It was further determined that 
gpUL141 blocked the maturation of CD155 from an Endo H-sensitive intracellular form 
to an Endo H-resistant cell surface species (Tomasec et al., 2005).  
In addition to binding CD155, CD226 also recognised CD112 expressed on the surface 
of infected cells (Bottino et al., 2003). It was recently shown that CD112 levels are also 
downregulated during the course of HCMV infection, and that UL141 was essential but 
not sufficient for CD112 degradation, suggesting other viral factors are involved 
(Prod'homme et al., 2010).  
Sequence homology between the UL142 gene, also in the UL/b’ region and UL18, and 
the in silico prediction that UL142 encodes an MHC class I-related molecule prompted 
investigations into the potential role of UL142 as an NK-evasion gene (Wills et al., 
2005a). Cells expressing UL142 consistently inhibited NK-killing, and furthermore, small 
interfering RNA (siRNA) knockdown of UL142 lead to increased NK-mediated lysis of 
cells in the context of HCMV infection (Wills et al., 2005a). In a later study UL142 was 
found to downregulate the full length MICA allele, but not its truncated MICA *008 
version from the surface of infected cells, and thus bestowed NK-resistance to infected 
cells (Chalupny et al., 2006). It has subsequently been clarified that downregulation of 
MICA from the cell surface by UL142 is a result of sequestration in the cis-Golgi (Ashiru 
et al., 2009). 
14 HCMV microRNAs (miRs) have so far been discovered (Dhuruvasan et al., 2011). 
Prediction of the target sequences of HCMV miRNAs using an algorithm lead to the 
identification of MICB as a potential target for miR-UL112 (Stern-Ginossar et al., 
2007a). MICB is a stress-induced ligand for the activating receptor NKG2D, and is 
critical for the killing of virus infected cells by NK cells (Stern-Ginossar et al., 2007a). 
Ectopic expression of miR112 resulted in MICB downregulation in various human cell 
lines (Stern-Ginossar et al., 2007a). Furthermore, MICB downregulation resulted in 
reduced binding of NKG2D to target cells, and more importantly, in reduced NK-killing 
(Stern-Ginossar et al., 2007a). Inhibition of NK-killing by miR112 revealed a new mode 
of immune-evasion by HCMV. In addition to being very target-specific and non-
60 
 
immunogenic, miRs may be simpler to develop from an evolutionary point of view, 
than functional proteins (Stern-Ginossar et al., 2007a).  
That HCMV devotes a large number of its gene products to escape from recognition by 
NK cells is an indicator of the significance of NK-cells in innate immunity against HCMV 
infection. Nevertheless, it is important to recognise, that many of the functions 
classified above as NK-evasive, are also relevant with respect to other immune effector 
cells (Wilkinson et al., 2008). This is because NK-receptors such as NKG2D and LIR-1 are 
also found on other cell populations including certain subsets of T cells (Wilkinson et 
al., 2008).  
1.7.3.2. Adaptive immunity 
The adaptive immune response can contribute substantially to the control of HCMV 
disease, as evidenced by the therapeutic benefit of administering immunoglobulin or 
adoptive transfer of cytotoxic T lymphocytes (Khan et al., 2002). 
Conflicting reports have been produced on the role of antibodies in the immune 
response against HCMV. Pre-existing maternal antibodies play an important role in 
preventing congenital infection of the foetus (Fowler et al., 1992). Also, infants born to 
seropositive mothers were more resistant to transfusion borne HCMV infection 
(Yeager et al., 1981). In one study, intravenous injection of anti-HCMV antibodies to 
renal transplant recipients reduced the incidence of primary HCMV disease from 60% 
to 21% (Snydman et al., 1987). It is unclear whether antibodies protect allogeneic 
transplant patients from HCMV disease (Jackson et al., 2011). What is clear though is 
that primary infection with HCMV ensues production of antibodies specific to several 
HCMV proteins. These include the pp65 and pp150 tegument proteins, the IE1 protein, 
gB and gH envelope glycoproteins, and also different components of the gH/gL/UL128-
UL131A pentameric envelope complex (Rasmussen et al., 1991, Wills et al., 1996, 
Macagno et al., 2010, Schoppel et al., 1998).  
Primary infection with HCMV elicits extremely strong and broad CD4+ and CD8+ T cell 
responses, which forever leaves a fingerprint in the T cell compartment (van de Berg et 
al., 2008, Sylwester et al., 2005). These changes include much higher frequencies of 
circulating cytotoxic T cells (van de Berg et al., 2008). CD8+ and CD4+ T cells are an 
integral part of the immune response to HCMV (Miller et al., 2001). Administration of 
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ex vivo expanded CD8+ T cells restored immunity to HCMV in immune-deficient 
individuals (Riddell et al., 1992), whilst the reconstitution of CD8+ T cells in transplant 
patients inversely correlated with HCMV viraemia (Barron et al., 2009, Jackson et al., 
2011). Moreover, specific CD8+, and CD4+ T cells have been detected to the majority of 
HCMV ORFs, with the strongest responses occurring against pp65, IE1, pp28, pp150, gB 
and gH (Jackson et al., 2011). Evidence exists for the early and lasting accumulation of 
pp65 specific CD8+ T cells following HCMV infection (van de Berg et al., 2008). It is 
estimated that HCMV specific CD4+ and CD8+ T cells comprise up to 10% of their 
respective populations in the peripheral blood (Sylwester et al., 2005). HCMV specific 
CD4+ T cells appear within a week of detection of viral DNA in blood, and produce T 
helper type 1 (Th1) cytokines, augment CD8+ T cell, and B cell responses, and may also 
contribute to direct killing of infected cells (Jackson et al., 2011, Miller et al., 2001). 
Also, the majority of CD8+ T cells displayed high levels of ex vivo cytotoxicity against 
their respective targets (Wills et al., 1999).  
HCMV subverts detection by CD4+ and CD8+ T cells by a number of mechanisms. The 
downregulation of MHC class I molecules at the surface of HCMV infected cells begins 
at IE times (Yamashita et al., 1993), and leads to complete annihilation of IE antigen 
presentation, and a great reduction in pp65 presentation to CD8+ T cells, (Besold et al., 
2007). For this function, HCMV uses a family of homologous genes in a sequential 
multistep process, each of which is alone able to lessen surface expression of MHC 
class I molecules (Ahn et al., 1996). In noninfected cells, MHC class I heavy chains form 
trimeric complexes with β2-microglobulin and antigenic peptides, which are 
transported to the cell surface, in a transporter associated with antigen processing 
(TAP) dependent manner (Ahn et al., 1996). In HCMV-infected cells, US3 retains class I 
heavy chain molecules in the ER, US6 prevents peptide loading by inhibiting TAP-
mediated transport of peptides into the ER, and US2 and US11 proteins cause the 
specific export of class I heavy chains into the cytoplasm to be degraded by 
proteasomes  (Ahn et al., 1996, Wiertz et al., 1996b, Wiertz et al., 1996a, Jones et al., 
1996). Down-modulation of class I molecules by US2, US3, US6 and US11 proteins 
represents an elegant immune subversion function. Although these proteins are each 
independently capable of causing reduced presentation of antigens, they utilise 
overlapping rather than redundant means of achieving this function, and their 
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coincidence enables the virus to more efficiently downregulate class I surface 
expression (Jackson et al., 2011).  
CD4+ T cells too are targets of HCMV evasion. This includes the inhibition of inducible 
and constitutive MHC class II expression at the transcriptional, post transcriptional, 
and post-translational level (Miller et al., 2001). Furthermore, it was recently 
recognised that during latency, the viral homologue of the IL10 cytokine (CMV IL10), is 
able to downregulate MHC I and II expression, and obstruct cytokine production by 
infected cells; thus tergiversating the CD4+ T cell response (Jackson et al., 2011).  
To summarise, HCMV is a master regulator of the cellular environment, able to 
expertly subjugate the broad, persistent, and powerful response it receives from the 
immune system in admirably artistic ways. In the presence of a healthy immune 
system, these subjugations are sufficient only for the maintenance of the virus in a 
latent state, but lapses in the body’s defence against HCMV quickly and commonly 
lead to productive HCMV infection and disease.  
1.8. Aims 
The HCMV genome encodes at least 170 protein-coding genes (Gatherer et al., 2011), 
many of which remain functionally uncharacterised. Studies aiming to discover HCMV 
gene function are confounded by this large number of genes and their complex 
expression pattern. In addition, though the genes responsible for numerous immune-
modulatory functions have already been discovered, many others await identification. 
In the past, the discovery of most immune-evasive HCMV genes has involved 
algorithmic predictions or fortuitous experimenting (Wilkinson et al., 2008). Some 
HCMV genes carry out essential core functions, and therefore it is not possible to 
generate mutants of every HCMV gene. Also, due to the fact that HCMV grows poorly 
in vitro, HCMV research is largely limited to fibroblasts, and even in these cells 
preparation of high titer virus stocks remains labour intensive. There exists a 
compelling need for a high-throughput system with which to map HCMV functions to 
individual genes. It was hypothesised that if all HCMV genes were individually cloned 
into an efficient mammalian expression vector, they could be rapidly screened for a 
specific immunodulatory action in a gain-of-function assay. The expression vector 
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selected for gain of function screening was the AdZ (adenovirus with zero cloning 
steps) vector generated by Dr Richard Stanton (Stanton et al., 2008b). A second 
approach also available was to use a panel of deletion mutants, each lacking a block of 
non-essential genes, in loss of function assays. The aims of the project are outlined 
below: 
1- Assist in the generation of the AdZ library encoding all HCMV protein coding 
genes 
2- Characterise and validate expression from this library  
3- Investigate results of particular interest 
4- Characterise the HCMV gene function responsible for Fas downregulation 
64 
 
 
2-Materials and Methods  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
65 
 
2.1. Cells 
Human foetal foreskin fibroblasts (HFFFs) selected for efficient growth of HCMV were 
kindly provided by Dr Graham Farrar (Porton Down). HFFFs were immortalised by 
transduction with the human telomerase reverse transcriptase (hTERT), as described 
by McSharry et al (McSharry et al., 2001), by Sian Llewelyn-Lacey and designated HFFF-
hTERTs. To facilitate efficient infection with adenovirus vectors, HFFF-hTERTs were 
engineered to express the human Coxsackie adenovirus receptor (hCAR) (Leon et al., 
1998, Stanton et al., 2008a). 293 cells (Graham et al., 1977) expressing the tetracycline 
repressor protein (293-TREx)were purchased from Invitrogen (Invitrogen, R71007). 
2.2. Cell culture  
Cells were grown in Dulbecco’s modified Eagle’s medium (DMEM, Invitrogen, 41965) 
and kept in humidified incubators at 37⁰C at 5% CO2 concentration. Media was 
supplemented with 2% penicillin streptomycin (Invitrogen, 15070) and 9% FCS 
(Invitrogen, 10500), referred to in the text as complete medium, unless stated 
otherwise.   
Mycoplasma screening was undertaken by Sian Llewelyn-Lacey and using the 
VenorGeM® Mycoplasma PCR detection kit (Biochrom AG, Germany). Any mycoplasma 
positive cell lines or virus stocks provided to the laboratory were cleaned or discarded, 
and only mycoplasma negative stocks were used.  
Cells were routinely maintained in 150 cm2 flasks (Fisher, TKV-123-051F), from here on 
referred to as T150 flasks, or Cell bind T150 flasks (Fisher, TKV-123-050G), and allowed 
to reach confluency. To split adherent cells, media was removed, the monolayer rinsed 
in 10 ml of PBS (Fisher, 14190), and 5 ml of trypsin (Fisher, 25300) was added until cells 
detached (~3 minutes). Cells were then resuspended by the addition of 5 ml of 
complete medium, and the resulting suspension of cells was normally divided by a 
factor of 4 for HFFF cells, and 10 for 293 cells, before being seeded in fresh flasks.  
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2.2.1 Cell counting  
To estimate the number of cells in a suspension, the sample was mixed, and 10 µl were 
immediately removed and used to fill the counting chamber (Fisher, MNK-790-M). 
Cells within a grid representing 0.1 µl were counted under x10 magnification, and the 
average number obtained. Cell numbers per ml of the suspension were calculated by 
multiplication by 104. The required volume of cells was then transferred to the 
appropriate flasks, topped up with more media if necessary, and allowed to adhere 
overnight.  
2.3. Molecular biological techniques 
2.3.1. Polymerase Chain Reaction (PCR) 
PCR was carried out to amplify predefined regions of DNA using specific primers 
purchased from Sigma and Invitrogen, and using the Biometra T3000 Thermal cycler. 
PCR programs were adjusted according to the length of DNA to be amplified, the 
amount of DNA required, and the type of polymerase applied. Concentration of 
template DNA varied depending on preparation used. Buffers, primer, DNA and DMSO 
were defrosted at 37⁰C in the water bath, while dNTPs were defrosted at room 
temperature. All tubes were then kept on ice until returned to -20⁰C. Sample PCR 
reaction mixtures and programs used are listed in appendix I. 
2.3.2. Primer and oligonucleotide design 
Primers were designed to have a melting temperature of at least 60⁰C. Palindromic, 
and dimer-forming sequences were avoided as much as possible, except where 
positions were fixed, such as reverse primers for amplifying Merlin genes, in order to 
clone into the AdZ vector. The sequences of primers and oligonucleotides used are 
listed in appendix II.  
2.3.3. DNA gel electrophoresis 
PCR products were resolved based on size on tris-acetate-EDTA (TAE) gels (Fisher, 
BPE1332-20) containing 0.8-1% agarose (AGTC Bioproducts, A4-0700) and visualised by 
ethidium bromide staining (Sigma, E1510-10 ml) under UV light. Agarose was dissolved 
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in 50 ml of 1x TAE buffer, 2.5 µl ethidium bromide were added in the fume hood (final 
concentration 0.5 µg/ml), and the solution poured into a gel tray taped at either end, 
and containing a comb, and allowed 30 minutes to solidify. The comb and the tapes 
were removed and the tray was transferred into a gel tank containing 1xTAE buffer to 
above the level of the gel. DNA loading dye (Therm-oscientific, R0611) was added at 1x 
working concentration to the DNA samples, which were pipetted into the wells 
alongside 10 µl of molecular weight markers (Eurogentec, MW-1700-10). 
Electrophoresis was undertaken for 1-12 hours and at 10-100 V depending on the 
resolution required.  
2.3.4. Gel purification of DNA  
Under UV light (Spectroline transilluminator, model TVC-312A), appropriate size DNA 
bands were excised, transferred to sterile 0.5 ml Eppendorf tubes, and their weights 
determined. DNA was then purified from the gel using the illustra GFX PCR DNA and 
Gel Band Purification kit (28-9034-70, GE Healthcare). Here, 1 µl capture buffer was 
added for every milligram of the gel, and the gel melted at 60°C. The solution was 
transferred to a column, and placed in a fresh Eppendorf tube. Once 30s elapsed, 
samples were spun at 13K rpm for 30s (Biofuge Fresco, Heraeus). The flow-through 
was discarded and 500 µl of the wash buffer was pipetted onto the column. A further 
30s spin at 13K rpm (Biofuge Fresco, Heraeus) was performed, and the column was 
transferred into a fresh Eppendorf tube. 30 µl of elution buffer were pipetted onto the 
column, and following a further 30s incubation, DNA was eluted by a 1 minute spin at 
13K rpm (Biofuge Fresco, Heraeus). 
2.3.5. Determination of DNA concentration 
DNA concentrations were determined using the NanoDrop ND-1000 
spectrophotometer. 1 µl of water was loaded onto the measurement pedestal to 
initialize the nanodrop. Then 1 µl of the solvent was loaded to establish a blank 
measurement, and finally 1 µl of the sample was loaded onto the nanodrop and DNA 
concentration was obtained in ng/ ul.  
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2.3.6. Propagating SW102 Escherichia coli 
SW102 Escherichia coli contain lambda phage Red recombination genes, which are 
heat activated to mediate recombination between homologous stretches of DNA. 
Propagation at 37⁰C therefore causes inopportune recombination within the E.coli 
genome, culminating in the death of the bacterial culture. For this reason, SW102 
E.coli were grown at 32⁰C. SW102 E.coli contain a chloramphenicol resistance gene, 
and chloramphenicol was always included at 12.5 ug/ml concentration. Ampicillin was 
included in the culture at 50 ug/ml, except where the ampicillin resistance/LacZ/SacB 
cassette had been removed.  
LB broth was prepared by dissolving 20g of LB powder (Melford, Melford laboratories 
Ltd, L1703) per 1L of distilled water. Solutions were autoclaved and allowed to cool to 
at least 32⁰C. Bacteria from a frozen glycerol stock were inoculated into appropriate 
volume of LB, or when being grown using an existing culture, 5 µl were inoculated into 
fresh LB and the culture was grown in a shaking incubator at 32⁰C.  
2.3.7. Generating glycerol stocks 
Bacteria were grown overnight in 5 ml LB containing antibiotic(s). 1 ml aliquots of the 
overnight culture were transferred to fresh 2 ml pre-assembled white-cap tubes 
(Greiner Bio One, 723 261) in triplicates, and vortexed with 0.5 ml glycerol until mixed 
homogeneously. Glycerol stocks were then frozen at -80⁰C. Glycerol stocks were 
generated for all adenovirus (Ad) BAC vectors, and HCMV-BAC recombinants. This is 
important as it provides a reproducible source of the recombinant vector. 
2.3.8. Pouring plates 
LB broth was prepared by adding in 1g of tryptone (Fisher, BPE1421-500), 0.5g of yeast 
extract (Sigma, Y4000), and 1.5 g of agar (Fisher, S/0370/63) per 100 ml of distilled 
water. The solution was autoclaved  and allowed to cool to about 60⁰C. The 
appropriate antibiotics were then added (Chloramphenicol was always included at 12.5 
ug/ ml of the solution), and the solution was poured into Petri dishes (20 ml each, 
Fisher, PDS-140-050F). The agar was allowed to solidify for 20 minutes at room 
temperature. Plates were then inverted and allowed to dry at 32⁰C for a further 20 
minutes, and were subsequently kept at 4⁰C until used.  
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2.3.8.1. Positive and negative selection of the ampicillin 
resistance/LacZ/SacB cassette 
 
The cassette of selectable markers in SW102 E.coli contains a SacB gene, an ampicillin 
resistance gene, and a LacZ gene. SacB encodes levansucrase, which in the presence of 
sucrose efficiently inhibits E.coli growth. LacZ gives rise to blue colonies when X-gal 
and IPTG are available in the media. 
When negatively selecting against these markers, 5% sucrose (Fisher, BP2201) was 
dissolved in the LB broth solution prior to autoclaving. 5-bromo-4-chloro-indolyl-β-D-
galactopyranoside (X-gal, (80 ug/ml final concentration) and Isopropyl β-D-1-
thiogalactopyranoside (IPTG, 200 nM concentration) were also added prior to the 
pouring of plates. This ensured that bacteria containing the selection cassette, but 
mutated in SacB gene were identified by the production of blue colour.  
For positive selection of the above markers, ampicillin was incorporated at 50 ug/ml, 
together with X-gal (80 ug/ml final concentration) and IPTG (200 nM final 
concentration). Here, surviving blue colonies indicated the loss of the selection 
cassette. Figure 2.1 shows an example of a positive selection plate containing blue and 
white colonies.  
  
Figure 2.1 
Screening for bacteria containing the 
selection cassette 
Blue and white colonies represent bacteria 
with and without the selection cassette 
respectively. In positive selection blue 
colonies are picked, whilst white colonies are 
used in negative selection 
70
71 
 
2.4. Purification of BAC DNA from SW102 
cultures 
2.4.1. Minipreparation of BAC DNA 
The AdZ bacterial artificial chromosome (BAC) and the Merlin BAC carried by the 
SW102 E.coli were the targets of gene cloning and manipulation by recombineering. In 
order to identify positive recombinants and verify the BAC sequence following 
recombineering, BAC DNA was purified from 5 ml cultures of SW102 E.coli (Miniprep) 
using the Qiagen 27106 miniprep kit. Colonies were inoculated and grown overnight in 
5 ml of LB containing chloramphenicol (12.5 ug/ml), and where appropriate ampicillin 
(50 ug/ml). Bacteria were centrifuged at 4000 rpm for 5 minutes (Megafuge 1.0 R, 
Heraeus instruments). Supernatants were discarded and the cells resuspended in 250 
µl buffer P1 (27106, Qiagen) , then lysed and their DNA denatured by the addition of 
250 µl S2 buffer (27106, Qiagen) for 4 minutes, before the reaction was neutralised by 
250 µl S3 buffer (27106, Qiagen). Samples were mixed by inversion and centrifuged at 
13K rpm (Biofuge Fresco, Heraeus) for 10 minutes at room temperature (Biofuge 
Fresco, Heraeus). Supernatants were transferred to fresh tubes, and DNA precipitated 
with 0.75 ml isopropanol at 4⁰C by centrifugation for 10 minutes at 13krpm (Biofuge 
Fresco, Heraeus). Pellets were washed in 500 µl 70% ethanol, with recovery ensured 
by centrifugation for 5 minutes  at 13 krpm (Biofuge Fresco, Heraeus), and the pellet 
dried at 37°C in a heating block. DNA was then resuspended in 30 µl of elution buffer 
(EB) (27106, Qiagen). 
2.4.2. Maxiprepreparation of BAC DNA 
In order to obtain transfection quality DNA, recombinant DNA was purified using the 
Nucleobond BAC 100 kit (NZ740579, Fisher Scientific). 250 ml of culture was grown 
overnight, transferred to 250 ml polycarbonate centrifuge bottles (Fisher CFS-300-
520C), and centrifuged at 6000 rpm for 10 minutes at 4⁰C (SLA-1500 rotor, Sorvall 
Evolution RC). Supernatants were discarded and pellets were resuspended in 12 ml of 
S1 buffer. Cells were then lysed with 12 ml S2 buffer for 4 minutes with gentle swirling 
of the tube. 12 ml N3 buffer was then used to neutralise the lysis reaction. The 
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resulting mixture was cooled on ice for 5 minutes and centrifuged at 6000 rpm for 10 
minutes at 4⁰C (SLA-1500 rotor, Sorvall Evolution RC). This allowed separation of solid 
cell debris from released cell contents. The supernatants were passed through a filter-
paper, and the flow-through put through a column, which was previously equilibrated 
with 6 ml N2 buffer. The column was then washed twice in 18 ml N3 wash buffer, and 
the DNA eluted with 15 ml N5 buffer, pre-heated to 50°C. The elution was collected in 
30 ml polypropylene tubes (Thermo Scientific, 03719), mixed with 11 ml room 
temperature isopropanol, and centrifuged at 15000 rpm and 4°C for 30 minutes (SS-34 
rotor, Sorvall Evolution RC). Supernatant was discarded and pellet washed in 5 ml 70% 
ethanol, and centrifuged at 15000 rpm, at 15 minutes (SS-34 rotor, Sorvall Evolution 
RC). Ethanol was allowed to evaporate from the pellet for 15 minutes, and DNA 
resuspended in 100 µl elution buffer. The eluate was then transferred to a fresh tube, 
and DNA concentration was measured. 
2.5. Restriction digest  
BamHI restriction digestion analysis was perfomed on miniprepared BAC DNA to verify 
the integrity of the vector, and also the presence/size of genes cloned into the AdZ 
vector. Predicted molecular weights were obtained for BamHI-digested DNA fragments 
by identifying BamHI sites in the DNA sequence (Vector NTI, Invitrogen).  
8 µl purified DNA were incubated with 1 µl buffer E (Promega, R005A) and 1 µl BamHI 
enzyme (Promega, R6021), and incubated for 2 hours at 37°C. Samples were then 
loaded onto an agarose gel, and electrophoresed at 150V for 90 minutes.  
2.6. DNA sequencing  
Sequencing primers were designed to bind about 100 bp upstream of either end of the 
region to be validated. Sequencing was carried out using the BigDye® Terminator v3.1 
Cycle Sequencing Kit (Applied Biosystems, 4337456). A 10 µl reaction mix was 
prepared containing 4 of BigDye mix, 5 µl purified BAC DNA, and 1 µl primer (3.2 
pmol/µl). The following thermocycling program was used: 
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95°C for 5 minutes, then 100 cycles of 95°C for 30seconds, 55°C for 10 seconds, 60°C 
for 4 minutes. 
Completed reactions were cleaned using Performa DTR Gel Filtration Cartridges 
(EdgeBio, 90780) according to the manufacturer’s instructions. Briefly, cartridges were 
centrifuged for 3 minutes at 3.1 krpm (Biofuge Fresco, Heraeus) transferred to fresh 
tubes, and samples were added to the column. Centrifugation was performed for 3 
minutes at 3.1 krpm (Biofuge Fresco, Heraeus) and the eluate was retained for 
sequencing. Sequencing was carried out by Central Biotechnology Services (CBS, 
Cardiff University), and analysed using the Vector NTI software (Invitrogen).  
2.7. Recombineering  
Recombineering (recombination-mediated genetic engineering) makes use of lambda 
phage red recombination genes in SW102 E.coli, which upon heat-activation; promote 
recombination between DNA sequences with as little as 30bp of homology (heat-
activation occurs at between 37°C, and 45°C, and is optimal at 42°C). This allows one-
step cloning using purified PCR products or oligonucleotides, and enables insertion, 
deletion, or replacement of pre-defined sequences. Figure 2.2 contains a diagrammatic 
representation of these recombineering events.  
  
Recombineering 
Insertion Replacement Deletion 
Single-stranded oligonucleotide (100bp) 
Figure 2.2: Genetic manipulation by recombineering 
Recombineering used to introduce a) insertion using a purified PCR product, or single-stranded 
oligonucleotide if insert length is equal to, or lesser than 100bp b) replacement using a purified PCR 
product, and c) deletion using a single-stranded oligonucleotide homologous to the region before and 
after the region to be deleted 
PCR product 
 
PCR product or oligonucleotide if < 100bp 
 
  a                                 b                      c                   
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SW102 E.coli containing the vector of interest were grown overnight in 5 ml LB 
containing appropriate antibiotic(s). 0.5 ml of the overnight culture was transferred to 
25 ml LB, containing chloramphenicol, and where appropriate ampicillin, and allowed 
to reach the optical density (OD) of 0.6 at 600nm (about 3 h, measured using the 
Ultraspec 3000, Pharmacia Biotech spectrophotomer) in a shaking incubator at 32⁰C. 
The culture was transferred to a 50 ml falcon (Fisher, CFT-900-031F), and the lambda 
phage genes were activated through a 15 minute heat shock in the 42°C water bath. 
The culture was inverted every 5 minutes to ensure good heat-mixing. Bacteria were 
then cooled by rocking on ice for 15 minutes, and centrifuged at 4000 rpm for 5 
minutes at 0°C (Megafuge 1.0 R, Heraeus instruments). Supernatants were discarded, 
and pellets resuspended in 1 ml sterile ice-cold water by gentle shaking. 25 ml of ice-
cold water were added and bacteria were centrifuged at 4000 rpm for 5 minutes at 0°C 
(Megafuge 1.0 R, Heraeus instruments). This wash step was repeated once more, 
supernatant was discarded, and the pellet containing competent bacteria was 
resuspended in 400 µl ice cold water. 25 µl of this resuspension was transferred into a 
fresh tube, and mixed with DNA containing homology to the target sequence in the 
vector (4 µl purified PCR product, or 1 µl oligonucleotide), transferred to a pre-cooled 
0.2 cm gap electroporation cuvettes (Bio-Rad, 165-2082), and left on ice for 5 minutes. 
Electroporation was then carried out using the Biorad Micropulser (program EC2). 
For negative selection (Section 2.3.8.1), electroporated bacteria were transferred to a 
fresh universal tube, diluted in 5 ml LB and following a 3 hour recovery, 100 µl of the 
suspension were plated on selective media. This recovery time is important as it allows 
the loss of SacB gene products from bacteria that have undergone deletion of the 
selection cassette, thus preventing their killing in the presence of sucrose. For positive 
selection using the ampicillin resistance/LacZ/SacB cassette, electroporated bacteria 
were diluted in 1 ml LB and recovered for 1 hour before being plated on selective 
media.  
76 
 
2.8. Procedures using Adenovirus  
2.8.1. Transfection of 293-TREx cells with 
adenovirus BAC DNA 
Recombinant Ad-vectors were replication deficient due to the deletion of the essential 
E1 region. In order to generate adenovirus stocks, Ad-vectors were transfected into 
293-TREx cells expressing E1 functions. 293-TREx cells also express the tet-repressor 
gene, which binds to tet-operons in the vector, preventing transgene expression. This 
provides protection against toxic gene products, or those interfering with Ad-
replication.  
Transfection was carried out using Polyfect (301105, Qiagen), or Effectene (301425, 
Qiagen) transfection kits. Plaques were visible 7-10 days after transfection and cells 
were collected in 2 ml media by scraping, about 12 days post transfection, when 
appearing fully infected. Optimally infected cells were bright, fully rounded-up, losing 
contact with neighbouring cells, and easily detached from flask. Flasks were agitated 
until cells were in a suspension. 
2.8.1.1. Polyfect:  
2x106 293-TREx cells were seeded in a cellbind T25 plate (Fisher, TKV-123-031L), and 
allowed to adhere overnight. 4 µg maxiprepared DNA were diluted in 100 µl DMEM. 40 
µl of polyfect reagent was then added and the solution incubated for 10 minutes at 
room temperature. Cells were supplemented with 3 ml fresh media, and the DNA 
complex was added to cells in 1 ml of fresh media. Media were changed 24 hour post 
transfection.  
2.8.1.2. Effectene 
2x106 293-TREx cells were seeded in a cellbind T25 (Fisher, TKV-123-031L) plate and 
allowed to adhere overnight. On day of transfection, 1 µg of DNA was diluted with the 
DNA condensation buffer to a volume of 150 µl. 8 µl of enhancer solution were added 
and the mixture was vortexed for 5 seconds. Following a 5 minute incubation at room 
temperature, 25 µl of Effectene transfection reagent were added, and samples were 
incubated for 10 minutes at room temperature to allow complex formation. Growth 
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medium was aspirated from the cells, and replaced with fresh medium. 1 ml of fresh 
medium was then used to transfer the transfection complex onto cells.  
2.8.2. Expanding adenovirus stocks 
To obtain high titer stocks of virus for experimental use, 293 TREx cells were grown to 
near-confluency in 5x T150 Cellbind flasks. Cells in each flask were infected with 200 µl 
of the initial virus stock (2.8.1). When the monolayer appeared fully infected (4-10 
days), cells were detached by agitation or using cell scrapers (Greiner Bio one, 
541870). Cells were centrifuged at 1500 rpm for 5 minutes (Megafuge 1.0 R, Heraeus 
instruments), and pellets were combined by resuspension in 20 ml PBS. A further 5 
minute centrifugation was performed at 1500 rpm (Megafuge 1.0 R, Heraeus 
instruments), supernatants were discarded, and the resulting pellet stored at -80°C 
until purified (see Section 2.8.3).  
2.8.3. Purification of adenovirus on Cesium-
Chloride (CsCl) gradients 
In order to eliminate cellular debris, crude virus (see Section 2.8.2) was centrifuged 
through a discontinuous Cesium-Chloride (CsCl, Sigma, C3011-500G) gradient; pure 
virus formed a band at the gradient junction, and was extracted.  
1.6 ml heavy solution (3.6M: 1.45g/ml CsCl in 5mM Tris HCL, pH7.8) were pipetted into 
a 14x 89 mm ultra clear Beckman centrifuge tube (331372, Beckman Coulter), and 
overlaid with 3 ml  of the light solution (1.6M: 1.33g/ml CsCl in 1mM EDTA, 5mM Tris 
HCL, pH7.8) drop by drop, to cause minimal disturbance in the bottom layer. 
To release virus from cells, the cell pellet was resuspended in 7 ml PBS. 7 ml 
tetrachloroethylene was added, and the mixture shaken vigorously for 30 seconds to 
form a single phase, followed by centrifugation at 2200 rpm for 20 minutes (Megafuge 
1.0 R, Heraeus instruments). The tetrachloroethylene descended to the bottom of the 
tube, and was separated by a layer of cellular debris from the top PBS layer which 
contained the virus. The upper aqueous layer containting virus particles was collected, 
and pipetted onto the Cesium-Chloride gradient. Tubes were then centrifuged at 
23000 rpm for 2 hours (SW41 Ti rotor, Ultra Beckman L8-M ultracentrifuge). Following 
centrifugation, the virus was observed as an opalescent band resting at the interface 
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between the 2 CsCl solutions (Figure 2.3). The virus band was then extracted using a 
19G gauge needle inserted in the side of the tube and transferred to a fresh tube.  
  
Figure 2.3: Purification of adenovirus 
by CsCl gradient centrifugation 
Following centrifugation, adenovirus 
virions were visualised as an opalescent 
band residing between heavy and light 
CsCl solutions. Defective virions formed a 
band of lower density than virions, but 
higher density than cellular debris.  
cellular debris 
virions lacking DNA 
mature virions 
79
80 
 
2.8.4. Removal of CsCl from virus stocks by dialysis  
To avoid the toxic effects of cesium on infected cells, CsCl purified virus (see Section 
2.8.3) was dialysed against a buffer solution before being used experimentally. Pores in 
the dialysis tubing allowed free flow of CsCl out of the tube until an equilibrium was 
reached with the dialysis buffer. Sequential dialysis of virus preparation in 1L of dialysis 
buffer (twice) ensured sufficient purification of virus from CsCl.  
The CsCl purified virus was diluted to a total volume of 2 ml in sterile dialysis buffer 
(1mM MgCl2, 135mM NaCl, 10mM Tris HCl, 10% glycerol, pH7.8). Dialysis tubing 
(Medicell International Ltd, DTV12000.01.000) was pre-warmed by submerging in a 
beaker of lukewarm distilled water, and was allowed to cool to room temperature. The 
tubing was then immersed in dialysis buffer and closed at one end by a clip and a knot. 
Virus was pipetted into the tube through the open end, and was subsequently trapped 
by applying a clip and a knot to the opening of the tube. The tube was then placed in 1 
L of dialysis buffer and positioned on a rocker. The dialysis buffer was removed after 2-
5 hours, and replaced with fresh buffer for an overnight incubation at 4°C on rocker. 
Dialysed virus was removed from the tube by cutting below the clip and transferred 
into a fresh tube. Virus was then diluted to 10 ml with sterile dialysis buffer, and 1 ml 
aliquots were prepared in pre-assembled white-cap tubes (Greiner Bio One, 723 261), 
and stored at -80°C. 
2.8.5. Adenovirus titration 
2.8.5.1. Spot assay 
Once recombinant adenovirus (RAd) stocks were generated, it was necessary to 
determine the virus titers. Titration of purified adenovirus stocks was based on the 
spot assay (Bewig and Schmidt, 2000), in which virus particles are quantified 
immunocytochemically, using a primary antibody directed against virus hexon 
proteins, and a horseradish peroxidase labelled secondary antibody. In the presence of 
3, 3’-diaminobenzidine (DAB) substrate, infected cells were stained brown. The spot 
assay has a number of advantages over other common methods of adenovirus 
titration. Compared to the plaque assay which can take up to 10 days, titers can be 
obtained 48 hours after infection. Furthermore titrating adenoviruses by the spot 
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assay is an easier procedure than the fluorescent focus assay, which requires 
fluorescent microscopy. In this method, 293 cells were seeded in 12 well plates (Fisher, 
TKT-520-070H) at 5x105 cells per well in 1 ml complete media, and allowed to adhere 
overnight. Virus was serially diluted to obtain 10-4 and 10-5 dilutions. First, 10 µl of the 
purified virus stock were diluted in 990 µl of media. Then, 10 µl of the resulting 10-2 
dilution were diluted in 990 µl of media to obtain 10-4 dilution of the virus. 100 µl of 
this solution were diluted in 900 µl of media to achieve the 10-5 dilution. 100 µl of each 
dilution were added to wells in duplicates. Plates were gently swirled to ensure equal 
distribution of virus, and incubated at 37°C. 48 hours after infection, culture media 
were aspirated, and the cells were allowed to dry in a laminar flow hood for 15 
minutes, followed by a 15 minute fixation in ice cold 1:1 methanol and acetone at -
20°C. The fixation and all subsequent washes were carried out in 1 ml per well, whilst 
antibody incubations were performed in 0.5 ml for 1h at 37°C and under constant 
rocking. The fixing reagents were aspirated, and cells washed 3 times in PBS containing 
1% BSA (Sigma, A77906-100G). Polyclonal goat anti-adenovirus antibody (Chemicon 
International, AB1056) was added at 1/5000 dilution, cells were washed 3 times in 
PBS/BSA, and incubated with donkey anti-goat HRP (Santa Cruz Biotechnology, SC-
2056), 1/1000 dilution. Three more washes were performed, and Infected cells 
detected by the ImmunoPure metal enhanced DAB Substrate kit (34065, Thermo 
Scientific). A 1x working solution of the DAB/Metal Concentrate was prepared by 
diluting the concentrate in the stable peroxide solution provided. 0.5 ml of the 
resulting mixture was added to each well, and incubated at room temperature for 10 
minutes. The substrate was then aspirated and replaced with 1 ml PBS. Infected cells 
were stained brown, and were counted under the microscope. Titres were calculated 
using the below formula: 
Titer (pfu/ml) =average number of infected cells per field of view x number of fields 
per well /virus volume used (ml) x dilution factor 
2.8.5.2. Picogreen fluorescence 
Unlike the spot assay, which measures the number of infectious particles, RAd titration 
by picogreen fluorescence was used to determine the total concentration of virus 
particles. Picogreen is a fluorescent dye, which displays enhanced fluorescence upon 
binding to double stranded DNA. Therefore the level of fluorescence can be used to 
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determine the amount of virus DNA present, and thereby estimate virus titres 
(Murakami and McCaman, 1999). This method utilises the stoichiometric relationship 
that exists between virus particle number and virus DNA amount. Importantly, using 
this method, titres are calculated with reference to a standard curve, generated by 
applying picogreen to a serial dilutions of a virus of known titre. 
2.8.5.2.1. Generating the standard curve: 
To generate the standard curve, a series of 2-fold dilutions of the reference RAd was 
prepared in TE buffer (10mM Tris / 1mM EDTA, pH 8) to cover the range 107-109 
pfu/ml. This represented the working range of the assay and the plate reader. In a 96 
well plate (Fisher, TKT-180-070U), 45 µl of each dilution were mixed with 5 µl of lysis 
buffer (0.5% SDS in TE buffer), and incubated for 15 minutes at room temperature. 20 
µl of each sample were then added to 180 µl of picogreen working solution (1/360 
dilution of picogreen stock (Invitrogen, P7581) in TE buffer) in duplicates, in black 
MaxiSorp 96 well plates (Thermo Scientific, 456537). Once mixed, samples were 
incubated in the dark for 5 minutes for binding to occur, and absorbance was 
measured at ex485/em538 in the FLUOstar Omega microplate reader (BMG LABTECH). 
The plate reader was adjusted to use auto-gain, and to measure absorbance by 
transmitting 10 flashes from the top of the plate. Lysis and picogreen binding of test 
viruses were achieved as for the reference virus, using 1/10 and 1/100 dilutions. Titres 
were calculated by comparing absorbance against the standard curve. 
2.9. Procedures using HCMV 
2.9.1. Generation of recombinant HCMV from HCMV 
BAC DNA  
Purified HCMV recombinant BACs were transfected into HFFFs to produce new virus 
progeny. Transfection was achieved using the Amaxa™ Basic Nucleofector™ kit for 
fibroblasts (VPL-1002, Lonza) according to the manufacturer’s instructions. Briefly, 106 
HFFFs were centrifuged at 600 rpm for 10 minutes. Supernatant was discarded and 
pellet resuspended in 100 µl of Nucleofector solution. 2 µg of purified HCMV BAC DNA 
were added and the mixture transferred to a cuvette (provided with kit). Cells were 
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electroporated in the Nucleofector II machine (Amaxa Biosystems, program T16). 
Samples were then recovered in 5 ml media and transferred to a T25 flask. Plaques 
appeared about 3 weeks post transfection. Once all cells were detached or appeared 
dead, media containing virus was collected (about 20 ml) and stored at -80°C until 
used to expand virus stock (see Section 2.9.2). 
2.9.2. Preparation of HCMV stocks  
When growing HCMV from a previous stock of known titre, HFFFs were allowed to 
reach confluency and then infected at MOI ≤ 0.01. Cells were grown in 1 or more T150 
flasks, or in Cell Factories (TKT-175-020M, Fisher scientific), depending on the growth 
properties of the virus strain and the amount required. When growing virus from an 
initial transfection-produced stock of unknown titre (see Section 2.9.1), 1 ml was used 
to infect cells in each T150 flask, and 10 ml were used to infect cells in a cell factory. 
Once cytopathic effect (CPE) was observed for about 80% cells, media were collected, 
and centrifuged in 250 ml polycarbonate centrifuge bottles (Fisher, CFS-300-520C) at 
14000 rpm and room temperature. Media was collected every 24-48 hours, until 
complete destruction of the monolayer was observed. Following centrifugation, 
supernatants were discarded and pellets were dislodged with a bacterial inoculation 
loop, and collected in 1 ml fresh media. The remainder of the pellet was then collected 
in a further 1 ml fresh media and added to the collected pellet. To resuspend virus 
present in the pellet, the suspension was homogenised slowly 5-10 times by passing 
through a 21g needle until loss of all visible clumps. Samples were then centrifuged at 
1000 rpm for 1 minute (Megafuge 1.0 R, Heraeus instruments) to pellet the cellular 
debris, and supernatants were transferred to a fresh tube. Virus was then stored at -
80°C until all collections were performed, at which time frozen samples were defrosted 
at 37°C, pooled together, and aliquoted in pre-assembled white-cap tubes (Greiner Bio 
One, 723 261). 
2.9.3. Titration of HCMV stocks by plaque assay 
HFFFs were seeded into 6 well plates (Fisher, TKT-520-030T) at a density of 4x105 per 
well, and allowed to adhere overnight. The next day, 2 ml each of 10-6, 10-7 and 10-8 
dilutions of the virus were prepared, and cells were infected in duplicates of 1 ml with 
each dilution. Virus from a stock of known titer was included as a control for the 
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experiment. Infection was carried out under constant rocking for 2 hours at room 
temperature. Virus was then aspirated and cells in each well overlaid with 10 ml of a 
1:1 mixture of 2% avicel (FMC Biopolymer) and 2X media (see below). Plates were then 
incubated for 2 weeks. The density of the overlay restricted free transfer of released 
virus from infected cells through the media and limited infectivity to cell to cell 
contact. This gave rise to plaques, each one resulting from a single infectious HCMV 
particle. Two weeks after infection the overlay was aspirated and washed away from 
the monolayer with PBS. Plaques were counted under the microscope and averages 
between duplicates were obtained.  
Titre (pfu/ml) = average number of plaques per well / dilution factor (e.g. 106) x 
volume of virus used for infection (ml) 
2% Avicel-type RC591NF stock: 20g of Avicel were resuspended in 1L of water and 
autoclaved.  
2x medium (Per 100 ml): 50 ml sterile water, 20 ml 10x DMEM (Gibco 21430), 20 ml 
FCS (Invitrogen, 10500), 6 ml sodium bircarbonate (Gibco 25080), 4 ml Pen/Strep 
(Gibco15070063), 2 ml glutamine (Gibco 25030024) 
1% overlay was obtained by mixing equal amounts of the 2% Avicel stock solution and 
the 2x medium.  
2.9.4. Purification of HCMV virions on NaT gradient  
To purify HCMV virions from cellular debris and other contaminants, virus was 
centrifuged through a continuous sodium-tartrate (NaT) gradient, forming a band at its 
buoyant density, which was subsequently extracted. 
Na-phosphate buffer: Two 0.04 M solutions of sodium-dihydrogenphosphate (solution 
A) and disodium-hydrogenphosphate (solution B) were prepared in water. 19 ml of 
solution A were mixed with 81 ml of solution B to obtain 100 ml of phosphate buffer 
with pH 7.4.  
Two solutions of differing Na-tartrate solution were then made using the Na-
phosphate buffer: 
35% Na-tartrate: 35 g Na-tartrate, 65 g Na-phosphate buffer 
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15% Na-tartrate: 15 g Na-tartrate, 30 g glycerol, 55 g Na-phosphate buffer 
The linear gradient was created by a gradient-maker (Hoefer SG50), which allowed 
mixing of the light and heavy solutions in different ratios. First, with both stopcocks 
closed, 5 ml of the light solution was pipetted into the reservoir chamber. The 
connector stopcock was briefly opened to allow the light solution to travel to the edge 
of the mixing chamber, and closed again. Then, 4 ml of the heavy solution was added 
to the mixing chamber. Magnetic stir bars were placed in both chambers and the 
gradient-maker was placed atop a magnetic stirrer. Stirring in the mixing chamber 
ensured instant mixing of the incoming light solution with the heavy solution, whilst 
that in the reservoir chamber prevented backflow from the mixing chamber. Both 
stopcocks were opened simultaneously and solution was let out of the gradient-maker. 
The initial concentration of liquid exiting the gradient-maker was equal to the heavy 
solution, and the final concentration equal to that of the light solution. To ensure that 
solutions were delivered uniformly and consistently, a peristaltic pump (P-1, Pharmacia 
Fine Chemicals) was used. Solution pumped out of the gradient-maker was used to fill 
an SW41 ultra-clear tube. 0.5 ml virus (Section 2.9.2) was then overlaid atop the 
gradient drop by drop, and tubes were filled to 5 mm of the top with sterile PBS. 
Samples were centrifuged at 23000 rpm for 45 minutes (Ultra Beckman L8-M 
ultracentrifuge), and virion bands were extracted using 21 g needles (figure 2.4).  
  
Figure 2.4: Visualisation and extraction of 
HCMV viral particles following purification on a Na-
tartrate gradient 
a). NIEPs, virions and dense bodies (DBs) were 
separated and are observed as distinct bands. NIEPs 
have the lowest density and form the top band, 
whilst dense bodies form the lowest band. Virions 
have intermediate density, and form the middle 
band. b) Band extraction using needles.  
      a                b  
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2.10. Infection of cells with Adenovirus 
and HCMV  
The day before infection, cells were counted and seeded, and allowed to adhere 
overnight. When infecting with Adenovirus, the virus was removed from -80⁰C, and 
immediately transferred to a 37⁰C waterbath. Once defrosted, virus was kept on ice, 
mixed by gentle pipetting, and the desired volume diluted in complete media. The 
volume was determined by the following formula: 
Volume (ml) = multiplicity of infection x number of cells / virus titer (pfu/ml) 
Media was removed from cells and replaced with media containing virus. Infections 
were carried out for 2 hours at 37⁰C under continuous rocking, after which virus was 
removed from cells and replaced with complete media. Virus was then returned to -
80⁰C.  
HCMV infections were carried out identically to above, except once defrosted, virus 
was kept at room temperature. 
2.11. Analysis of protein expression 
2.11.1. Immunofluorescence 
Fibroblasts were seeded in 96 well glass bottom plates (Scientific Laboratory Supplies, 
TIS5524) at 5000 per well. The following day, cells were infected with HCMV or 
adenovirus at the desired MOI(s). 72 hours after infection, media was removed and 
cells were then fixed in 4% paraformaldehyde for 10 minutes, with 2 washes in 100 µl 
of PBS either side of fixation. Permeabilisation and blocking were carried out in 100 µl 
of wash buffer for 1 hour with a change of buffer every 20 minutes. All antibody 
incubations and washes were carried out in the wash buffer unless stated otherwise. 
Primary antibody incubation was performed for 1 hour at room temperature or 
overnight at 4°C in 100 µl. Cells were then washed 5 times and the secondary Alexa 
Fluor-594 goat anti-mouse IgG antibody (Invitrogen, A11020) was applied at 1/500 
dilution for 30 minutes at room temperature in a total volume of 100 µl. DAPI (Sigma-
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Aldrich, D-9564), when used, was added together with the secondary antibody at 400 
ng/ml final concentration to visualise the nuclei. Phalloidin stain conjugated to green-
fluorescent Alexa Fluor 488 dye (Invitrogen, A12379) strongly stains F-actin filaments 
and was added together with the secondary antibody to visualise actin filaments and 
the outline of the cell (60 units per 96 well plate). Excess secondary antibody, DAPI and 
Phalloidin stain were removed by 5 washes in the wash buffer. Cells were then washed 
5 times in PBS and fixed in 2% paraformaldehyde for 10 minutes. Fixing solution was 
replaced with 1% paraformaldehyde and fluorescence was detected under a Leica 
fluorescent microscope (Leica, Germany) at 40x magnification with oil. Fluorescent 
pictures were obtained using a Hamamatsu camera (Hamamatsu City, Japan), and 
images acquired with Improvision Openlab 3 software (Improvision, Coventry).  
When capturing images, exposure was adjusted until background level fluorescence 
was minimal or not visible.  
4% Paraformaldehyde: 200 ml of PBS were heated to 70⁰C. In the fume hood, 8 g of 
paraformaldehyde powder (Sigma, P6148) were added to the hot PBS solution. The 
powder was mixed into PBS by swirling, and any remaining residues were dissolved by 
the addition of NaOH (Fisher, S/4800/60). The solution was then placed in ice water, 
and once at about room temperature, the pH was adjusted to 7.0-7.4. The solution 
was then filtered and stored at 4°C. 
IF buffer: PBS, containing 1% BSA, 0.2% Saponin, and 0.05% sodium azide (saponin was 
substituted with 0.2% Triton X-100 when permeabilising cells infected with RAd-UL122 
and UL123).  
2.11.2. Western Blot 
Fibroblasts were seeded at 8x105 per T25 flask, or 4x105 per well in a 6 well plate well 
plates  and infected the following day at the desired MOI(s), in 1 ml or 0.5 ml complete 
media respectively, for 2 hours on an oscillating platform. Virus was removed, and cells 
were rinsed and incubated in 5 ml DMEM. At 72 hours p.i., cells were rinsed, scraped 
off (Greiner Bio one, 541870) in cold PBS, and centrifuged at 1500 rpm (Megafuge 1.0 
R, Heraeus instruments) for 3 minutes. Cell pellets were resuspended in 200 µl of 1x 
NuPAGE LDS sample buffer -made from 4x concentrate (Invitrogen, NP0008) in water- 
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and 50mM DTT. Sonication was carried out for 20s at 20% power (Vibra-Cell, VCX130, 
Sonics and Materials) to shear DNA, and samples were transferred to PCR tubes and 
boiled for 5 minutes. Samples were then centrifuged at 13000 rpm for 10 minutes 
(Biofuge Fresco, Heraeus). Supernatant samples, when analysed were boiled and 
centrifuged in 1x NuPAGE LDS sample buffer and 50mM DTT, but were not sonicated. 
As a standard, 20 µl of the final sample were loaded onto each well of a 10% NuPAGE® 
Novex Bis-Tris gel (Invitrogen, WG1201BOX), and electrophoresed alongside 10 µl of 
prestained protein markers (Invitrogen, LC5800) for 2 hours at 120V. Some proteins 
with small predicted sizes were electrophoresed on 4-12% NuPAGE® Novex Bis-Tris 
gels (NPO321BOX, Invitrogen). Western transfer was carried out for 2 hours at 10 Volts 
in the Trans-Blot SD semidry transfer cell (Bio-Rad) using 2x transfer buffer made from 
20x solution (NuPAGE® Transfer Buffer) in water, membranes were rinsed in distilled 
water, incubated in antibody extender (Thermo Scientific, 32110) for 10 minutes, 
rinsed again 5 times in water, and blocked overnight at 4°C in TBST 5% milk. 
Membranes were then washed 5 times in TBST for 5 minutes each time, and probed 
with primary antibody overnight at 4°C and in block solution. Primary antibodies used 
for western blotting are listed in table 2.1. Unbound primary antibody was removed by 
5 washes in block solution, each one 5 minutes long, and then horse radish peroxidase 
-conjugated secondary antibody was applied for 1 hour at room temperature (goat 
anti-mouse HRP: Bio-Rad, 170-6516 or goat anti-rabbit HRP: Bio-Rad, 170-6515). To 
eliminate excess secondary antibody, 5 repeated TBST washes of the membrane were 
completed. Membranes were rocked in 8 ml of SuperSignal West Pico 
Chemiluminescent Substrate (Thermo Scientific, 34078) for 5 minutes at room 
temperature. Illuminated signals were visualised in the GelDoc-It transilluminator 
(UVP), or exposed to an Amersham Hyperfilm MP (GE healthcare, 28906843) and 
developed by the compact X4 processor (Xograph Imaging systems) 
Transfer buffer (per 500 ml): 50 ml 20x NuPAGE® Transfer Buffer, 50 ml methanol, 400 
ml deionised water 
TBST (per 1 L): 20 ml 1M TRIS (pH 7.8), 29 g NaCl, 0.5 ml TritonX-100 (Fisher, BP151-
500), 0.5 ml Tween 20 (Fisher, BP337500) in water 
Block solution: TBST containing 5% dry milk powder 
  
Table 2.1: Primary antibodies used in immunofluorescence and Western Blot 
Antigen Company, Cat number Dilution  Secondary antibody  
Immunofluorescence    
V5 tag AbD Serotec, MCA1360  1/1000 1/500  Alexa Fluor-594 
anti-mouse IgG  
Strep tag IBA-lifesciences, 21507001 1/1000 1/500  Alexa Fluor-594 
anti-mouse IgG 
IE1, IE2 Pierce-antibodies, MA1-7596 1/1000 1/500  Alexa Fluor-594 
anti-mouse IgG 
UL14 mAb generated in our laboratory 1/5000 1/500  Alexa Fluor-594 
anti-mouse IgG 
Western blot    
V5 tag AbD Serotec, MCA1360 1/2000 1/2000 anti-mouse HRP 
human CD155 A.Nomoto, 5D1 1/10000 1/25000 anti-mouse HRP 
MHC class-I  HC10 1/2000 1/5000 anti-mouse HRP 
human Fas Santa Cruz, Sc-715 
Abcam, ERP5700 
1/2000 
1/1500 
1/2000 anti-rabbit HRP 
 1/2000 anti-rabbit HRP 
UL141 mAb generated in our laboratory,  1/10000 1/10000 antimouse HRP 
pp65 (UL83) Abcam, ab49214-1 1/50000 1/50000 anti-mouse HRP 
gB (UL55) Abcam, ab49214-1 1/25000 1/25000 anti-mouse HRP 
Actin Sigma, A-2066 1/10000 1/10000 anti-rabbit HRP 
GAPDH Abcam, 9485 1/50000 1/50000 anti-rabbit HRP 
Strep tag IBA-lifesciences, 21507001 1/1000 1/2000 anti-mouse HRP 
IE1, IE2 Pierce-antibodies, MA1-82057  1/10000 1/2000 anti-mouse HRP 
UL14 mAb generated in our laboratory 1/20000 1/2000 anti-mouse HRP 
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2.11.3. Deglycosylations 
Where deglycosylation was to be performed, western blot samples were processed as 
above, except they were sonicated, boiled, and centrifuged in 1x glycoprotein 
denaturing buffer (made from 10x concentrate in water: New England Biolabs, 
B1704S). Digestions were performed overnight at 37°C with EndoH (New England 
Biolabs , P0702L) or PNGaseF (New England Biolabs, P0704L) enzymes. G5 buffer (New 
England Biolabs, B1702S) was included in the EndoH reactions, and G7 (New England 
Biolabs, B3704S) and 10% NP40 (New England Biolabs, B2704S) buffers were added to 
the mixture in PNGase digestions, according to manufactuer's instructions. Enzymes 
and buffers amounts used are shown in table 2.2.  
Following digestion, 14 µl of each sample were added to 5 µl of 4x concentrate LDS 
sample buffer (Invitrogen, NP0008), and 1 µl of 1M DTT (50mM final DTT 
concentration), boiled for 5 minutes, and centrifuged for 2 minutes at 13 krpm 
(Biofuge Fresco, Heraeus). Western blot was performed as described in section 2.11.2.     
  
  
 
 
 
 
 
Table 2.2: Deglycosylation reaction mixtures  
 Mock-digested  EndoH-digested PNGaseF-digested 
 Volume (µl) Volume (µl) Volume (µl) 
Sample 11 11 11 
EndoH - 1 - 
PNGaseF - - 1 
G5 buffer 1.5 1.5 - 
G7 buffer - - 1.5 
NP40 - - 1.5 
Water 2.5 1.5 - 
Total volume 15 15 15 
 
92 
 
93 
 
2.11.4. Coomasie staining                                      
Protein samples were prepared, processed and electrophoresed as described for 
western blot (see Section 2.11.2). Following electrophoresis, the gel was incubated in 
fixing solution for 10 minutes on rocker, and at room temperature. The fixing solution 
was then replaced with the staining solution without stainer B for 10 minutes. Stainer 
B was added, and incubation continued for 3-12 hours. Once staining was complete, 
gel was rinsed and kept in deionised water for a minimum of 7 hours, and for up to 3 
days. Images were then obtained by scanning the gels. 
Fixing solution (per 100 ml): 
40 ml deionised water, 50 ml methanol, 10 ml acetic acid.  
Staining solution (per 100 ml):  
55 ml deionised water, 20 ml methanol, 20 ml stainer A (Invitrogen 46-7015), 5 ml 
stainer B (Invitrogen 46-7016) 
2.11.5. Silver staining 
Protein samples were prepared, processed and electrophoresed as described for 
western blot (see Section 2.11.2). The polyacrylamide gel containing protein samples 
of interest was washed in deionised water for 5 minutes, with gentle shaking at room 
temperature. This wash step was repeated, and water was decanted. Samples were 
then fixed in fixing solution for two 15 minutes periods, with a change in solution in 
between. Gel was washed twice with the ethanol wash solution, for 5 minutes each 
time. Two 5 minutes washes were performed in deionised water, and the gel was 
incubated in sensitizer working solution – prepared by mixing 1 part SilverSnap 
sensitizer (Thermo-scientific, 1859065), with 500 parts deionised water (50 µl 
sensitizer with 25 ml water)  for exactly 1 minute. Gel was then rinsed twice in water, 
and incubated for 5 minutes in a 1:100 mix of SilverSnap enhancer (Thermo-scientific, 
1856220), and SilverSnap stain (Thermo-scientific, 1856218) ( 0.25 ml of enhancer and 
25 ml stain), followed by 2, 1 minutes washes in water. Developer working solution 
was prepared by mixing 0.25 ml of enhancer and 25 ml of developer solution (Thermo-
scientific, 1856219), and added to the gel until protein bands of the desired intensity 
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were obtained (normally 1-3 minutes). To stop further staining, the stop solution was 
added, and the gel was scanned to attain image. 
Fixing solution (per 100 ml): 60 ml water, 30 ml ethanol, 10 ml acetic acid 
Stop solution (per 100 ml): 95 ml water, 5 ml acetic acid 
Ethanol wash (per 100 ml): 90 ml water, 10 ml ethanol 
2.12. Flow cytometry 
Cells were seeded and/or infected in T25 flasks or 6 well plates. On the day of staining, 
media were aspirated, and cells were rinsed in PBS. Cells were then detached in 1 ml 
trypsin, which was deactivated by the addition of 5 ml complete media. The 
suspension was transferred to a fresh 15 ml tube, and centrifuged at 1200 rpm for 3 
minutes (Megafuge 1.0 R, Heraeus instruments). Supernatants were discarded, and the 
pellet resuspended in 100-300 µl of cold wash buffer (PBS/1% BSA/0.05% sodium 
azide). Resuspended cells were transferred to a 96 well plate (Fisher, TKT-180-050D) 
and centrifuged at 1500 rpm for 3 minutes (Megafuge 1.0 R, Heraeus instruments), 
and at 4°C. From this point on, all washes and incubations were carried out on ice, and 
using ice cold solutions. Centrifugation steps were all performed at 4°C, 1500 rpm 
(Megafuge 1.0 R, Heraeus instruments), and for 3 minutes. Supernatants were poured 
off and cell pellets resuspended in wash buffer containing the primary antibody. 
Incubation with the primary antibody lasted 20-30 minutes, and at the midway point, 
the suspension was remixed by pipetting. Samples were then centrifuged, and 
supernatants discarded. To remove excess primary antibody, cells were washed twice 
by repeated resuspension in fresh wash buffer, centrifugation, and removal of the 
supernatant. Incubation with the secondary antibody was identical to that with the 
primary, but samples were protected from light throughout. Samples were then 
washed 3 times in wash buffer, 3 times in PBS, and fixed in 2% paraformaldehyde for 
10 minutes. The FACSCalibur (Dakocytomation, Cambridge) or the BD AccuriTM C6 flow 
cytometers was used to detect fluorescence, and results were analysed using the cell 
quest (BDIS, San Jose, USA) and Cflow softwares respectively.  
Primary antibodies (200 µl per well of a 96 well plate):  
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Mouse IgG control (Santa Cruz, sc-2025): concentration matched to experimental 
antibodies 
DX2 anti-Fas monoclonal antibody (R&D Systems, mab142), 1/1000 dilution 
Anti-HLA Class I antibody (Abcam, W6/32), 1/2000 dilution 
Secondary antibodies (100 µl volume per well of a 96 well plate): 
Alexa-Fluor-647 goat anti-mouse IgG antibody (Invitrogen, A21237), 1/500 dilution  
2.13. Casapase-Glo 3/7 assay 
HFFF-hTERTs were seeded in a 96 well plate at 5x103 per well and infected with HCMV 
Merlin virus at MOI 10, or mock-infected. At 60 hours p.i., culture media were 
removed and replaced with 50 µl low fluorescence (LF) media containing 10 µl/ml 
cyclohexamide (Sigma, C6255) and 1µg/ml of one of the following for 12 hours: 
-recombinant human Fas ligand (IBA-lifesciences, 2-3901-002)                                                                                                                                                                             
- recombinant human soluble TRAIL receptor 2 (PeproTech, 310-19)                                                                                                                                                                                      
- Fas mAb (Beckman-Coulter, IM2387)                                                                                                                               
- mouse IgM isotype control (Sigma, M5909)                                                                              
negative control wells containing LF media and cyclohexamide only were also included                  
LF media: Hank’s balanced salt solution (no phenol red, 14025)/ 2% FCS/ 2% sodium 
bicarbonate/ 2% penicillin-streptomycin/ essential amino acids (1/50 dilution, 11130, 
Invitrogen), non-essential amino acids (1/100 dilution, 11140, Invitrogen). 
At 72 hours p.i., Casapase-Glo 3/7 assay (Promega, G8091) reagents were prepared 
according to the manufacturer’s instructions: buffer and lyophilised substrate were 
equilibrated at room temperature, and buffer added to the substrate. 50 µl of the 
resulting solution were transferred to each well of the 96 well plate, and samples 
incubated for 1 hour at 37⁰C. All samples were then transferred to a white-walled 96 
well plate (Thermo scientific, 236105). Blank reactions containing LF media and 
Casapase-Glo 3/7 assay reagents but no cells were also prepared. Luminescence was 
measured by the FLUOstar Omega microplate reader in relative light units (RLU).  
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2.14. Purification of V5-tagged protein 
V5-tagged gpUL4 was purified from the culture media of recombinant Merlin-, and 
RAd-infected cells. For recombinant Merlin-expressed gpUL4, HFFFs were grown to 
confluency in 3x T150 flasks, infected with RCMV1567 at MOI 1, and maintained in 10 
ml complete media per flask. Supernatants were collected 7 days p.i.. For RAd-infected 
cells, HFFF-hCARs were grown to confluency in 3x T150 flasks, infected with RAd-UL4 
at MOI 25 and maintained in 10 ml complete media. Supernatants were collected 3 
days p.i. and replaced with fresh media. 4 days later, a second collection was made 
and cells were re-infected with RAd-UL4 at MOI 50. Supernatants were removed 3 
days later, and pooled with the previous two collections.  
Soluble gpUL4 was then purified using a purification kit (MBL International 
Corporation, 3315A) as described by the manufacturer. Briefly, the wash solution was 
diluted 10 times in distilled water to obtain working concentration. The elution peptide 
was reconstituted with 100 µl distilled water. Culture media were centrifuged at 1500 
rpm for 5 minutes (Megafuge 1.0 R, Heraeus instruments) to remove cell debris, and 
transferred to fresh 15 ml tubes. Anti-V5 tag beads were resuspended by agitation, 
and 20 µl of the resulting solution dispensed into each 15 ml aliquot of supernatant. 
Samples were incubated at 4⁰C for 1 hour with end-over-end mixing, and centrifuged 
at 400 rpm for 5 minutes. Supernatants were discarded, pellet of beads resuspended 
in remaining supernatant (100-400 µl), and transferred to a spin column. Caps and 
bottom plug were removed from column, which was placed in a collection tube and 
centrifuged for 10 seconds (Biofuge Fresco, Heraeus). Flow-through was discarded, 200 
µl wash solution were added, and the spin column centrifuged for a further 10 
seconds. This wash step was repeated two additional times, and the spin column 
transferred to a fresh collection tube. V5 tag beads were resuspended in 20 µl elution 
buffer, incubated at room temperature for 30 minutes and tubes centrifuged for 10 
seconds. This elution step was repeated once more, except with a 5 minute incubation 
time. Elutes were pooled together and soluble gpUL4 concentration measured by the 
Bradford protein assay using the NanoDrop ND-1000 spectrophotometer 
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3.1. Adenoviruses vectors and HCMV 
research 
HCMV encodes an impressive array of immune-evasion functions, some of which have not 
been mapped to specific genes (see section 1.7). Discovering novel immune-evasion HCMV 
functions and mapping genes responsible for known functions can aid our understanding of 
virus life cycle and pathology, and also inform us of the way the immune system operates. 
However, the sheer complexity of the virus hinders identification and analysis of gene 
function. The generation of HCMV mutants harbouring single gene deletions and the 
production of high-titer HCMV stocks is time and labour intensive, and limited to non-essential 
genes. In preference to generating an extremely large number of single-gene-mutant viruses, 
HCMV genes were expressed in isolation as a means to systematically map gene function.  
Replication-deficient Recombinant Adenovirus vectors (RAds) are extensively utilised as gene 
transfer vehicles, and their use in large scale studies of gene function is also increasing. RAds 
provide a number of advantages as a means of gene delivery vectors, such as E.coli -based 
gene cloning and manipulation technologies, the insertion of large inserts, a broad range of 
permissive cell types, efficient gene delivery (up to 100% of target cells), and potential for high 
level gene expression (Wilkinson and Akrigg, 1992). Ad serotype 5 is the best characterised and 
most commonly used Ad vector in gene therapy. High titer Ad 5 stocks (>109 pfu/ml) are 
readily produced, and the technology of generating recombinants of this virus is well 
developed. RAd vectors tend to be deleted in both the essential early 1 (E1A), and the ‘non-
essential’ E3 regions of the Ad genome; thus allowing insertion of transgenes up to 8 kb in size. 
To complement the E1 deletion, Ad vectors must be propagated on E1-expressing helper cells. 
The E1A gene has been stably inserted into the human kidney cell line 293 (Graham et al., 
1977); these 293 cells are well suited to Ad propagation, as they are readily transfectable, and 
facilitate growth of the virus to high titers. Extremely high level, constitutive expression of 
recombinant genes under the control of the HCMV major IE promoter was achieved when this 
promoter was inserted into the Ad 5 genome (Wilkinson and Akrigg, 1992).  
The potential to achieve high-level transgene expression from RAds has previously been 
exploited in studies into HCMV gene function. UL40 expressed from a RAd efficiently 
upregulated HLA-E expression at the cell surface, and elicited protection from NK cell lysis 
(Tomasec et al., 2000). The MHC class I-related molecules gpUL18 and UL142 also inhibited NK 
cells when expressed from RAds (Prod’homme et al., 2007, Wills et al., 2005a). Moreover, RAd-
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expressed US6 functionally mimicked US6 produced during productive HCMV infection, by 
downregulating MHC class I surface expression (Tomasec et al., 2000).  
3.1.1. AdZ: a RAd optimised for high-throughput 
gene cloning and expression 
Although RAd technology has yielded great success in testing predicted HCMV gene functions, 
such studies have generally been carried out sporadically and not on a large scale (Wilkinson et 
al., 2008). This is mainly because traditional gene cloning and generation of RAds remained 
laborious, and unsuitable for high-throughput cloning of large numbers of genes. There was 
therefore a compelling need for an improved RAd cloning and expression system. The recent 
generation of the AdZ (Ad with zero cloning steps) vector in our laboratory overcame 
deterrents such as the need for multi-step cloning protocols (Stanton et al., 2008b), thus 
enabling high-throughput gene cloning by the single step recombineering (recombination-
mediated genetic engineering) method (Lee et al., 2001, Yu et al., 2000). Recombineering 
utilises the λ Red-encoded gene functions expressed from a stably integrated defective λ 
prophage in the E.coli strain SW102. The three λ Red-encoded genes exo, bet, and gam are 
under the control of the strong phage promoter pL, which in turn is stringently controlled by 
the temperature-sensitive repressor cI857 (Warming et al., 2005). λ Red genes are inactive at 
32⁰C, but shifting the temperature of the bacterial culture up to 42⁰C results in their 
activation, and efficient homologous DNA recombination. Recombination occurs between DNA 
sequences with as little as 30 base pairs of homology, and can be used to produce essentially 
any type of modification in a target BAC, such as insertion, deletion, and point mutation. Apart 
from being compatible with the recombineering system, the available AdZ vectors have other 
advantages; transgenes can be cloned in their native form, or directly fused to epitope (strep, 
V5, hexahistidine) or fluorescent (GFP, RFP) tags. In human cells, the I-SceI homing 
endonuclease causes the self-excision of BAC sequences, allowing the linearisation step prior 
to transfection to be bypassed. The presence of tet-operators downstream of the HCMV major 
IE promoter efficiently suppresses transgene expression during virus replication in 293 helper 
cells that express the tet repressor (293TREx). This is important as a proportion of transgenes 
is incompatible with replication of the vector in the helper cell line. Figure 3.1 is a schematic 
representation of the AdZ vector, detailing its key features.  
  
Figure 3.1 (adapted from Stanton et. al 2008):  
Scale diagram showing key features of the AdZ vector 
1- Origin of replication maintains AdZ as a single copy vector in E.coli. 2- E1, E3-deleted Ad5 genome transferred from the 
AdEasy  vector (He et. al . 1998); numbering taken from GenBank sequence AC_000008. 3- Chloramphenicol resistance 
gene in the plasmid backbone allows selection of AdZ-containing E.coli by chloramphenicol. 4- I-SceI homing endonuclease 
expression  is driven by eukaryote-specific respiratory syncytial virus (RSV) promoter. 18 bp long I-SceI restriction sites are 
present at the termini of the Ad5 genome; transfection of the AdZ vector into 293TREx cells releases the adenoviral 
genome in linear form, rendering it infectious. 5- The ampicilin resistance/LacZ/SacB cassette (flanked by red lines) acts as a 
cloning site; it is positioned in place of the deleted E1 gene, and is replaced by the transgene through recombineering.  
BamHI restriction sites are also present either side of the cassette, and  allow restriction digest analysis. 6- The poweful 
HCMV MIE promoter (Strain AD169, -299 to +60) constitutively drives trangene expression in  permissive cells. This 
promoter also contains 2 tetracycline (tet) operator sequences, allowing efficient suppression of transgene expression in 
cells expressing the tet repressor protein. 7- 14 amino acid-long V5 tag is expressed C-terminal to recombinant proteins, 
allowing expression to be detected with the anti-V5 antibody. 8- polyadenylation signal from the AD169 MIE gene is 
present in primary transcripts of the transgene. 
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43712 bp 
 
4- 
3- 
1- 
5 
6- 
7- 
8- 
2- 
100
101 
 
3.2. Generation of a high-throughput gain 
of function screening system 
With the aim of identifying novel HCMV- encoded immune-modulation functions, and in 
particular NK-evasion functions, my research group in Cardiff sought to clone every HCMV 
Merlin gene into the AdZ vector. The library of recombinant adenoviruses would then be used 
in high-throughput gain-of-function screens. In support of this endeavour, the complete strain 
Merlin genome had recently been BAC-cloned to provide a reliable source of wildtype HCMV 
genes (see Section 1.2.2).  
3.2.1. Cloning HCMV genes into AdZ 
HCMV strain Merlin genes were to be cloned into AdZ by recombineering (see Section 2.7) in 
frame with a C-terminal V5-epitope tag, allowing their expression to be validated using a single 
V5 antibody. The C-terminal tag was incorporated into the expression construct primarily as a 
device to validate expression, even though there was potential for some interference with 
gene function as a result of the modification. Moreover, specific antibodies are not available 
for the detection of most HCMV proteins. The V5 tag was chosen based on superior detection; 
when a group of ten HCMV genes was cloned with hexahistine, Strep, and V5 tags in parallel, 
expression of all constructs was observed only with the V5 tag (Dr Richard Stanton, 
unpublished data).  
HCMV Merlin genes were individually amplified from the Merlin BAC, and inserted into the 
AdZ vector. Genes were amplified using primers homologous in their overhanging 5’ ends to 
regions flanking the insertions site, by single run or nested PCR. Primer sequences for genes I 
cloned are presented in Appendix II. Amplified genes were then introduced into the AdZ vector 
by recombineering, replacing a cassette of selectable markers. Figure 3.2 illustrates the 
amplification and cloning of HCMV genes into AdZ. After recombineering, bacteria were 
recovered and plated on negative selection plates (see Section 2.3.8.1). For each gene, 4 white 
colonies were inoculated into 5 ml LB/chloramphenicol, and grown overnight. BAC DNA was 
prepared from the overnight cultures, and BamHI restriction digestion performed. Restriction 
digestion products were then electrophoresed on an agarose gel. The AdZ vector contains 7 
Bam-HI restriction sites in its sequence, including 2 either side of the selection cassette, and 1 
within. Restriction digestion of AdZ vector DNA with Bam-HI generates 18, 11, 7.7, 2.5, 1.7, 0.8 
and 0.6 Kbp DNA fragments; the 2.5 and 1.7 Kbp molecules are formed from excision and 
single-site digestion of the ampicillin resistance/LacZ/SacB cassette. Therefore when a 
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transgene is inserted in place of the cassette by recombineering, the 2.5 and 1.7 Kbp bands are 
lost. The presence of a band corresponding to the size of the transgene, and the absence of 
the 2.5 and 1.7 Kbp bands therefore indicate successful cloning. In these colonies, inserted 
DNA was sequenced using primers that bind the HCMV promoter and polyA sequences.  
  
MIE polyA 
Ampr  LacZ SacB 
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V5 
Gene of interest 
Region in Merlin BAC 
AdZ cloning site 
P
C
R 
Gene of interest 
Gene of interest 
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2- 
Ampr  LacZ SacB 
recombineering 
 
Figure 3.2: Inserting HCMV genes into AdZ by recombineering 
1- Genes were amplified from the Merlin BAC using primers homologous in 
their overhanging 5’ arms to regions flanking the selection cassette. 2- PCR 
products replaced the selection cassette in AdZ through recombineering, and 
positive recombinants were identified by negative selection. Once the sequence 
of the insert was verified, BAC DNA containing the transgene was transfected 
into 293TREx cells and recombinant virus generated 
103
104 
 
3.2.2. Generation, propagation and titration of 
RAds 
Once the sequence of the insert had been verified, recombinant DNA was maxiprepared and 
transfected into 293TREx helper cells. Virus was allowed to propagate, and collected once 
complete destruction of the monolayer was observed. To obtain high-titer stocks, this initial 
virus collection was used to infect cells in larger 150 cm2 flasks, and the subsequent virus 
collection purified on a CsCl gradient, and dialysed to remove toxic Cs. Each virus stock was 
then titrated by the spot assay (Bewig and Schmidt, 2000). In the spot assay, virus particles are 
quantified immunocytochemically, using a primary antibody directed against virus proteins, 
and HRP-conjugated secondary antibody. Addition of 3, 3’-diaminobenzidine (DAB) as 
substrate then results in production of a brown precipitate in infected cells, easily visualised by 
light microscopy as brown spots. In an independent assessment, a subset of viruses was also 
titrated by the picogreen fluorescence method. When a conversion factor was deployed, 
comparable values were obtained for quantification of virus particles/infectious units by the 
spot assay and picogreen fluorescence (data not shown). Picogreen is a fluorescent dye that 
displays up to 1000 times enhanced fluorescence upon binding to double stranded DNA. A 
sample of the purified virus preparation was lysed in a solution containing the picogreen dye, 
and the level of fluorescence measured and compared to that of a reference stock of known 
titre. Titration by picogreen staining effectively generates a total particle count, because 
picogreen indiscriminately binds DNA of infectious and non-infectious particles. Using the spot 
assay however, only infectious particles are accounted for; this is an advantage because virus 
preparations may contain a variable proportion of inactive particles still containing DNA. It was 
decided therefore that titers obtained by the spot assay would be used as benchmark. 
3.3. Library of Ad recombinants 
containing HCMV genes 
Generation of the RAd-library of HCMV genes was a strategic project undertaken by the 
Molecular Virology Laboratory involving many researchers. The project was initiated with the 
cloning of all the UL/b’ genes into the AdEasy 1 vector (He et al., 1998) using a C-terminal Strep 
tag. Both the vector and the epitope tag were not efficient enough to undertake cloning of all 
HCMV genes. The AdZ vector was generated specifically to enable the rapid cloning of HCMV 
genes, and the V5 tag deployed in preference. My contribution towards generation of the 
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library of RAd-encoded HCMV genes included (i) cloning 34 genes into the AdZ vector, (ii) 
generating 85 recombinant viruses by transfection, and (iii) growing, purifying and titrating 125 
viruses. Table 3.1 details the individual contribution made by members of our laboratory to 
this collaborative project. 
To date, 169 genes encoded by strain Merlin have been cloned into Ad vectors, and titrated 
recombinant viruses produced. These include 165 protein-coding genes originally annotated in 
strain Merlin (Dolan et al., 2004), as well as the β2.7 gene (possibly non-protein-coding), and 
newly discovered protein-coding genes RL8A, RL9A and US33A (Gatherer et al., 2011). The 
protein products of all genes are expressed with C-terminal V5 tags, excepting genes UL111A 
and UL141 were Strep-tagged while the UL14, UL122 and UL123 constructs were not tagged 
(specific monoclonal antibodies were available). Barring the UL141 gene that was previously 
inserted into the AdEasy1 vector, all genes were inserted into AdZ. Newly identified genes 
UL74A and UL150A were not cloned; these are predicted to be alternatively spliced from 
multiple upstream exons, and thus present a special challenge (see Section 5). The majority of 
genes were cloned into Ad vectors and expression of their gene products detected without 
issue. Problems arising with specific genes are described below. 
3.3.1. Cloning of genes resistant to recombineering 
 A group of 15 genes was identified as being resistant to insertion into AdZ: UL47, UL48, UL54, 
UL55, UL57, UL70, UL86, UL87, UL89, UL104, UL105, UL131A, UL133, UL136, and UL150. While 
the ampicillin resistance/LacZ/SacB cassette was removed from AdZ, it was not replaced 
with the gene of interest. To overcome this shortcoming, cloning of these genes was 
undertaken by Dr J.Davies using the galK selection method (Warming et al., 2005). The E.coli 
galactose operon is made up of 4 genes, including galK that are indispensible for galactose 
metabolism. SW102 bacteria harbour a precise 1231 bp deletion of galK and therefore cannot 
grow on media containing galactose as the sole carbon source. galK naturally phosphorylates 
galactose to galactose 1-phosphate, but also efficiently phosphorylates 2-deoxygalactose 
(DOG), a galactose analogue, into a toxic product. The galK gene can therefore be selected for 
on minimal media containing galactose, and selected against on minimal media containing 
DOG, and glycerol as the carbon source.  
galK was amplified using primers homologous in their 5’ ends to a site in the middle of the 
target gene, and inserted into the Merlin BAC by recombineering. Recombinants were 
identified by positive selection, BAC DNA was isolated, and the HCMV gene containing within it 
the galK gene amplified by PCR. A second recombineering round was carried out to insert the 
purified PCR product into AdZ, and selection again performed for galK. In a third round of 
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recombineering, galk was removed from AdZ to leave behind the intact transgene, and 
recombinants selected against on media containing DOG. The fact that recombineering by galK 
selection was successful for the above genes argues their sequences were not completely 
prohibitive of recombineering, but that the recombination event was extremely inefficient.  
Some of the aforementioned troublesome genes are amongst the largest in the HCMV 
genome, and recombineering is known to be less efficient with larger genes. However this is 
unlikely to completely account for difficulties in cloning these genes, as other large genes were 
cloned with relative ease. One possibility for this peculiar finding is the formation of complex 
secondary structures in these genes that are incompatible or interfere with recombination. 
The average guanosine-cytosine (GC) content in these genes is higher than that of the Merlin 
genome as a whole (62% compared to 57%). It is well known that high GC content can bring 
about the formation of secondary DNA structures such as stable hairpins or loops, and it has 
recently been suggested that these sequences may also prohibit successful recombineering 
(Nelms and Labosky, 2011).  
3.4. Expression analysis of the RAd-
library 
Once titrated stocks were obtained, it was necessary to validate expression of the cloned 
transgenes in order to provide a secure basis for progressing to functional screening 
programmes. Although not the primary objective, this analysis is invaluable as it has the 
capacity to inform on the gene products of all HCMV genes. Expression from RAds in infected 
HFFF-hCARs was tested by immunofluorescence and western blot using the anti-V5 tag 
antibody. These assays generated a large dataset detailing the intracellular localisation, 
apparent molecular mass, and evidence of post-translational modifications of expressed 
proteins. Of the 169 genes cloned into RAds, expression was confirmed for 160 by a 
combination of western blot (152 genes) and immunofluorescence (155 genes). These 
expression data are presented in Figure 3.3, and described in tabular form in table 3.2. Table 
3.2 also compares the expression data obtained with previous findings reported in the 
literature. A detailed evaluation of the expression of all HCMV gene products lies beyond the 
aims of this study. Nevertheless chapters 4 and 6 contain examples of genes whose functions 
have been tested and compared in the contexts of RAd and HCMV infection, and this subject is 
discussed in more detail in chapter 7.  
Cloned into AdZ/AdEasy vector Generated Ad recombinant Grew, purified, and prepared 
titered stocks
Performed Immunofluorescence 
analysis
Dr Richard Stanton UL111A-UL124 (12 total) UL111A-UL124 (12 total) N/A UL135
Dr Richard Stanton                    
Dr Virginie Prod'homme           
Dr Song Han
RL1-RL6, RL10-UL6, UL9-UL19, UL22A-
UL24, UL30, UL30A, UL35, UL40-UL42, 
UL44, UL46, UL135, UL141, US1-US12, 
US14, US16  (48 total)
RL1-RL6, RL10-UL6, UL9-UL19, UL22A-
UL24, UL30, UL30A, UL35, UL40-
UL42, UL44, UL46, UL135, UL141, 
US1-US12, US14, US16             (48 
total)
N/A N/A
Dr James Davies UL7, UL20, UL21A, UL25-UL28/29, UL31-
UL34, UL37, UL38, UL43, UL45, UL47-UL49, 
UL51-UL57, UL70-UL72, UL74-UL76, UL78-
UL80.5, UL86-UL92, UL94, UL96-UL105, 
UL131A, UL133, UL136, UL150, IRS1, US13, 
US15, US17-US22, US26-US32, US34-TRS1 
(75 total)
UL7, UL20, UL21A, UL26-UL28/29, 
UL31, UL33, UL34, UL37, UL38, UL43, 
UL54, UL55, UL86, UL87, UL89, UL90, 
UL104, UL105, US13, US17-US21 (24 
total)   
RL1-RL6, RL10-UL7, UL9, 
UL13, UL15A- UL31, UL33-
UL35, UL37-UL40, UL42-
UL44, UL46, UL48A            (44 
total)
N/A
Sepehr Seirafian RL8A, RL9A, UL8, UL36, UL50, UL69, UL73, 
UL77, UL82-UL85, UL93, UL95, UL128, 
UL130, UL132, UL138-UL140, UL142-
UL148D, US23, US24, and US33A (34 total)
RL8A, RL9A, UL8, UL14, UL25, UL32, 
UL36, UL45, UL47-UL53, UL56-UL85, 
UL88, UL91-UL103, UL128-IRS1, 
US15, US22 -TRS1 (85 total)
RL8A, RL9A, UL8, UL10, 
UL11, UL14, UL32, UL36, 
UL41A, UL45, UL47, UL48, 
UL49-TRS1 (125 total)
RL1, RL12, UL1, UL10,  UL14, UL18, 
UL26, UL47, UL48A, UL53, UL111A, 
UL122, UL123, US34A (14 total)
Daniel Sugrue N/A N/A N/A UL41A-UL46, UL48, UL49-UL52, 
UL54-UL105, and US2-TRS1           (77 
total)
Sepehr Seirafian (infections 
and staining) and Daniel 
Sugrue (imaging)
N/A N/A N/A RL5A, RL10, RL11, RL13, UL2-UL9, 
UL11, UL13, UL15A-UL17, UL19-
UL25, UL27-UL40, UL112, UL121,  
UL124-UL133, UL136-UL140, UL144-
UL148 (62 total)
Melanie Armstrong, PhD 
thesis, figure 4.3v
N/A N/A N/A UL141
Table 3.1: Contribution of lab members in generating the Ad library of HCMV genes, and immunofluorescence analysis of its expression
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RAd-control 
- 
- 
- 
- 
- 
- 
- 
- - 
- 
- 
- 
Mock-infected 
- 
- 
- 
- 
- 
- 
- 
- - 
- 
- 
- 
Figure 3.3: Expression analyses of HCMV genes inserted into Ad vectors by Immunofluorescence and Western blot                                                                                                               
For immunofluorescence, HFFF-hCARs were infected at MOIs 1, 5, 10 and 20 with RAds encoding HCMV genes. Exceptions were RAds encoding RL12, UL1, UL10, 
UL14, UL18, UL52; these were used at MOI 40. Infection at a range of dilutions was necessary as the level of protein expression varies between different Ad 
recombinants. 3 days p.i., cells were fixed and permeabilised, and the appropriate primary antibody applied against recombinant HCMV proteins. Monoclonal 
antibodies were used to detect UL14, UL122 and UL123 gene expression. Expression from genes UL111A, UL135 and UL141 was detected using a Strep 
antibody, and a V5 antibody was used for all other RAds. An Alexa fluor594 secondary antibody was then added together with DAPI and phalloidin-AF488 which 
stained nuclei and actin filaments respectively. Immunofluorescence was visualised microscopically using a x40 oil objective. RAd expression (red) is shown 
alone in the left hand picture, and where available overlaid with DAPI and/or phalloidin-488 staining in the right hand picture. Images shown are those adjudged 
to be most representative of the whole population, and where expression was observed at different MOIs, the lowest was chosen in order to obtain a closer 
representation of physiological-level expression. Some of the images were provided by other members of our laboratory and are included in order to provide a 
more complete reference of HCMV gene expression (see Table 3.1). Images presented in appendix III are entirely my own work, but are not included in this 
figure as they lack co-staining with DAPI and/or phalloidin. For Western blot, HFFF-hCARs were infected at MOI 10. 3 days p.i., infected cells were lysed, and 
electrophoresed under denaturing and reducing conditions alongside pre-stained protein markers on pre-cast polyacrylamide gels. Following Western transfer, 
membranes were probed with V5 primary and HRP-conjugated anti-mouse secondary antibodies, except Strep-tagged UL111A and UL135 proteins were 
detected using Strep antibody, and monoclonal antibodies were used to detect UL14, UL122, UL123 and UL141 gene expression. The sizes of all protein markers 
are indicated for the RL1 blot as a reference; for all other samples the 40 kDa band is highlighted red and the size(s) of the predominant species indicated by red 
arrows. No sizes are indicated if single band(s) could not be discerned. The US18 blot was provided by Dr Ceri Fielding. For both techniques, mock-infected cells, 
and RAd-control (generated from AdZ not containing a transgene)- infected cells were used as negative controls; representative samples are shown below. 
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Gene 
Predicted 
polypeptide 
size (kDa)
predominant 
Western blot 
specie(s) (kDa)
Western blot: comments
Intra-cellular 
localisation by 
immunofluorescence
published information 
RL1   35 38 Smaller and larger species 
also detected
Nuclear Nuclear expression was observed by immunofluorescence staining of 293T cells 
transiently transfected with an expression plasmid (Salsman et al. 2008). 37 kDa 
band detected by western blot in lysates of insect cells infected with recombinant 
baculovirus (Gao et al. 2005). 
RL5A 11 Not detected N/A Sub-cytoplasmic N/A
RL8A 10 8 N/A Not detected N/A
RL10 19 29 Smaller species also 
detected
Sub-cytoplasmic/ 
perinuclear
22 kDa and 23.5 kDa proteins were detected in lysates of fibroblasts infected with 
strains AD169 and TB40E, and Cos-7 cells transfected with an RL10-expressing 
plasmid (Spaderna et al. 2002). Localisation was sub-cytoplasmic in transfected Cos-
7 cells. 
RL11 27 28, 35 N/A Juxtanuclear IgG Fc-receptor (gp34): 34 kDa protein expressed on the cell surface and 
accumulated in the perinuclear region of HCMV-infected cells (Furukawa et al. 
1975, Keller et al. 1976, Atalay 2002). 
Table 3.2: Description of data from western blot and immunofluorescence analyses of the HCMV RAd-library, and comparison with previous literature                                                    
From left to right, columns contain: gene name, predicted size of the primary translation product based on amino acid sequence (kDa), size of the predominant western blot 
species (kDa) (where more than one major species were observed sizes are given in order of abundance, unless specified otherwise. Very low molecular weight species adjudged 
to be break-down products were omitted), additional comments on the Western blot species detected, description of intracellular localisation observed, and previously 
published information on size and sub-cellular localisation. Where intracellular localisation observed was inconsistent with the previous literature, gene name is underlined. Gene 
name is in bold if the observed Western blot species varied by more than 10 kDa from previous report(s); where no previous reports were found, comparison was made with the 
predicted size. Neither reported nor predicted sizes are available for 16 uncharacterised glycoproteins. UL55 and UL74 genes were codon-optimised and are indicated with 
asterisks. Genes encoding known or putative glycoproteins (as predicted in Table 14.1, Davison and Bhella 2007) are shown in blue background, whilst genes that encode known 
or predicted phosphoproteins are shown in green background. UL32 encodes a protein that is both glycosylated and phosphorylated and is shown in blue background. Red 
background indicates expression was not detected. Please note expression of 8 ORFs was not detected by either western blot or immunofluorescence; these genes are  exlcuded 
from this table.  
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RL12 47 80 N/A cytoplasmic, 
juxtanuclear, 
Sub-cytoplasmic expression was observed by immunofluorescence staining of 293T 
cells transiently transfected with an expression plasmid (Salsman et al. 2008). 
RL13 30 80,55 Smaller species also 
detected
Sub-cytoplasmic The RL13 gene was C-terminally V5-tagged within the Merlin BAC and recombinant 
virus generated (Stanton et al. 2010). Tagged gpRL13 was expressed as 100 kDa and 
55 kDa isoforms, and localised to virion assembly compartments of infected 
fibroblasts.
UL1 25 Not detected N/A Sub-cytoplasmic In AD169-infected cells, HA-tagged UL1 migrated at 55 kDa and co-localised with 
structural proteins at virion assembly compartments (Shikhagaie et al. 2012). 
UL2 7 12 N/A Sub-cytoplasmic 9 kDa band detected by western blot in lysates of insect cells infected with 
recombinant baculovirus (Gao et al. 2005). 
UL4 17 50 N/A Sub-cytoplasmic gp48: 48 kDa glycoprotein detected in lysates of fibroblasts infected with strain 
Towne (Chang et al. 1989).  
UL5 19 16, 18, 23 N/A Juxtanuclear Pan-cytoplasmic expression was observed by immunofluorescence staining of 293T 
cells transiently transfected with an expression plasmid (Salsman et al. 2008). 21 
kDa band detected by western blot in lysates of insect cells infected with 
recombinant baculovirus (Gao et al. 2005). 
UL6 31 50 Larger and smaller species 
also detected
Perinuclear N/A
UL7 24 53 Smaller species also 
detected
Sub-cytoplasmic, 
juxtanuclear
UL7, GFP-tagged at the C-termins was detected around nuclei of transfected cells 
using FITC filter, but at the cell surface using monoclonal UL7 antibody; C-terminus 
shed from surface. Expression not detected in HCMV-infected cells (Engel et al. 
2011). 
UL8 36 33 Many larger and smaller 
species also detected
Cytoplasmic, 
juxtanuclear,      surface
N/A
UL9 27 11, 23, 38, 40 N/A Sub-cytoplasmic, 
juxtanuclear
N/A
UL10 28 40 larger species also 
detected 
Sub-cytoplasmic N/A
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UL11 31 48 N/A Pan-cytoplasmic, 
surface 
Expression detected on surface of AD169-infected cells by flow cytometry; 
intracellular localisation not investigated (Hitomi et al. 1997).
UL13 54 47 Smaller and larger species 
also detected
Pan-cytoplasmic, 
surface
N/A
UL14 36 40 N/A Sub-cytoplasmic In lysates of HCMV-infected fibroblasts, gpUL14 migrated at 35 kDa (Dan Cochrane, 
PhD thesis). Pan-cellular expression was observed by immunofluorescence staining 
of 293T cells transiently transfected with an expression plasmid (Salsman et al. 
2008).  
UL15A 11 15 Smaller and larger species 
also detected
Sub-cytoplasmic N/A
UL16 26 47 Smaller and larger species 
also detected
Juxtanuclear 50 kDa protein detected in AD169-infected cells (Kaye et al. 1992). UL16-EGFP co-
localised with the ER-resident protein disulfide-isomerase (Welte et al. 2002). 
UL17 13 16 Sub-cytoplasmic Pan-cellular expression was observed by immunofluorescence staining of 293T cells 
transiently transfected with an expression plasmid (Salsman et al. 2008). 15 kDa 
band detected by western blot in lysates of insect cells infected with recombinant 
baculovirus (Gao et al. 2005). 
UL18 42 72, 80 N/A Pan-cytoplasmic Cell surface MHC class-I homologue: Vaccinia virus- and RAd-expressed gpUL18 
migrated at 67 kDa (Park et al. 2002). A larger 110 kDa isoform was identified during 
productive Merlin and AD169 infections; RAd-expressed gpUL18 accumulated 
intracellularly when detected by Immunofluorescence  (Griffin et al. 2005).
UL19 11 14 N/A Sub-cytoplasmic Pan-cellular expression was observed by immunofluorescence staining of 293T cells 
transiently transfected with an expression plasmid (Salsman et al. 2008). 13 kDa 
band detected by western blot in lysates of insect cells infected with recombinant 
baculovirus (Gao et al. 2005). 
UL20 38 38 Many larger and smaller 
species also detected
Sub-cytoplasmic 60 kDa and 80 kDa proteins detected in  transfected 293 cells; intracellular gpUL20 
was detected within endosomes and lysosomes (Jelcic et al. 2011). 
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UL21A 14 16 Doublet Pan-cytoplasmic 15 kDa protein detected by immunoblotting AD169-infected fibroblast lysates and 
transfected HeLa cells; pUL21a was localised to the cytoplasm (Fehr and Yu, 2010). 
UL22A 15 23 N/A Sub-cytoplasmic R27080/UL21.5/UL20a: major 45 kDa and minor 25 kDa glycoproteins detected in 
culture medium of AD169-infected fibroblasts; transient expression in Cos-7 cells 
produced 25 kDa secreted glycoprotein (Mullberg et al. 1999). Secreted gpUL22A 
from culture media of AD169-infected cells migrated at 27 kDa (Wang et al. 2004). 
UL22A mRNA packaged into virions was translated into Golgi-localised product at IE 
infection times. RAd-expressed gpUL22A-YFP and HCMV-derived gpUL22A also 
localised to the Golgi (Bresnahan and Shenk 2000). 
UL23 33 28 Many larger and smaller 
species also detected
Pan-cytoplasmic,              
juxtanuclear,           
surface,                         
sub-nuclear
33 kDa protein detected in purified AD169 virions but not infected cell lysates by 
Western blot. Juxtanuclear protein aggregates detected by immunofluorescence 
(Adair et al. 2002).
UL24 34 33 Many larger and smaller 
species also detected
Sub-cytoplasmic 40 kDa band detected in lysates of cells infected with AD169; pUL24 was located in 
a juxtanuclear cytoplasmic compartment (Adair et al. 2002).   
UL25 74 73 Many smaller species also 
detected
Sub-cytoplasmic, 
Perinuclear
Putative phosphoprotein; several proteins detected between 80 kDa and 100 kDa in 
transfected and AD169-infected cells, including a predominant 85 kDa species 
(Battista et al. 1999). Immunofluorescence staining identified perinuclear and 
juxtanuclear cytoplasmic aggregates. 
UL26 21 21 N/A predominantly nuclear Western blot performed on AD169-infected cell lysates identified major 21 kDa, and 
minor 26 kDa species (Stammninger 2002). In transfected cells, the 26 kDa species 
was more prominant. pUL26 localised to nuclei of infected and transfected cells.  
UL27 69 Multiple, 
including          
63
Many smaller species and 
one species >300 kDa also  
detected
Mostly nuclear Locus of maribavir resistance: nuclear and nucleolar localisation observed for pUL27-
GFP fusion protein in transfected cells by immunofluorescence (Chou et al. 2004). 
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UL28/29 79 68 some smaller species also 
detected
Sub-nuclear Eptiope-tagged UL28/29 was detected by Western blot as a 79 kDa protein, and by 
immunofluorescence localised in nuclear viral replication centres (Mitchell et al. 
2009). 
UL30 14 19 Smaller species also 
detected
Pan-cytoplasmic, 
surface
Pan-cellular expression was observed by immunofluorescence staining of 293T cells 
transiently transfected with an expression plasmid (Salsman et al. 2008). 16 kDa 
band detected by western blot in lysates of insect cells infected with recombinant 
baculovirus (Gao et al. 2005). 
UL31 66 68 some smaller bands also 
present
Sub-cytoplasmic, 
perinuclear
N/A
UL32 113 150 N/A Pan-cytoplasmic Major tegument phosphoglycoprotein (pp150): 150 kDa protein detected in 
fibroblasts infected with AD169 (Sanchez et al. 2000). Both nuclear (Hensel et al. 
1995) and cytoplasmic (Sanchez et al. 1998) localisations reported during 
productive HCMV infection. 
UL34 45 54 Doublet Nuclear 43 kDa and 40 kDa proteins detected at early and late times of HCMV infection 
respectively; both proteins localised to the nucleus when expressed from plasmids 
(LaPierre and Biegalke 2001, Biegalke et al. 2004)
UL35 73 70 Many smaller species also 
detected
Nuclear,                   
nuclear membrane, 
juxtanuclear
In fibroblasts infected with the Towne strain, UL35 encoded 22 kDa and 75 kDa 
proteins which localised to nuclei and juxtanuclear compartments repsectively (Liu 
and Biegalke 2002). 
UL36 57 48 Many larger and smaller 
species also detected
Punctate cytoplasmic Viral inhibitor of caspase activation (vICA): 52 kDa doublet of proteins detected in 
the lysates of cells infected with strains AD169, Towne and Toledo (Patterson and 
Shenk 1999). AD169-expressed pUL36 displayed uniform nuclear and cytoplasmic 
staining, whilst pUL36 expressed from Towne and Toledo was present in intense 
cytoplasmic foci. 
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 UL37 56 65 Smaller species also 
detected
Sub-cytoplasmic Viral mitochondira-localised inhibitor of apoptosis (vMIA): in vitro- synthesised 
UL37 primary protein and AD169-expressed  gpUL37 migrated at 60 kDa and 83-85 
kDa  respectively (Al-Barazi and Colberg-Poley 1996). Transfected gpUL37 was 
detected as perinuclear granules, and co-localised with ER and Golgi proteins. Both 
trafficking through ER and Golgi apparatus to mitochondria (Colberg Poley et al. 
2000), and  complete mitochondrial localisation (Goldmacher et al. 1999) have been 
observed. 
UL38 37 40 Doublet Pan-cytoplasmic, 
surface
37 kDa pUL38  identified in the lysates of cells infected with AD169; shown by 
immunofluorescence to accumulate within nuclei, and to a lesser extent the 
cytoplasm of infected cells (Terhune et al. 2007).                                                            
UL40 24 20 Many larger and smaller 
species also detected
Sub-cytoplasmic 25 kDa and 28 kDa bands identified by immunoblotting in RAd-UL40-infected and 
AD169-infected cells (Tomasec et al. 2000). Pan-cytoplasmic expression was 
observed by immunofluorescence staining of 293T cells transiently transfected with 
an expression plasmid (Salsman et al. 2008). 
UL41A 9 16 Smaller species also 
detected
Sub-cytoplasmic N/A
UL42 14 18 Many larger and smaller 
species also detected
Sub-cytoplasmic, 
Perinuclear
N/A
UL43 48 39,50 Smaller species also 
detected
Pan-cytoplasmic, 
surface
48 kDa band detected in lysates of cells infected with AD169; pUL43 was located in 
juxtanuclear cytoplasmic compartments (Adair et al. 2002).   
UL44 46 50 Many larger and smaller 
species also detected
nuclear Processivity subunit of DNA polymerase/polymerase accessory protein (PAP/pp52): 
heterogeneously-sized phosphoprotein most abundantly migrating at 52 kDa, as 
detected in HCMV-infected cell lysates by Western blot (Weiland et al. 1994, Wolf 
et al. 2001). Immunoflupresccence staining revealed punctate localisation for 
ppUL44 in nuclei of AD169-infected cells (Sourvinos et al. 2007). When DNA 
replication was inhibited in cells undergoing productive AD169 infection, ppUL44 
was dispersed throughout the nucleus  (Strang et al. 2012). 
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UL45 102 110, 80 Many larger and smaller 
species also present
Pan-cytoplasmic Large subunit of ribonucleotide reductase: a 108 kDa protein was detected in 
lysates of fibroblasts undergoing productive AD169 infection, which co-migrated 
with pUL45 expressed in transfected HEK-293 cells (Patrone et al. 2003). 
Immunofluorescence analysis showed pUL45 is cytoplasmic during productive 
AD169 infection.
UL46 33 29 many larger and smaller 
proteins also present
Pan-cytoplasmic Minor capsid protein-binding protein (mCP-BP): identified as a 30 kDa protein in  
AD169-infected fibroblasts (Gibson et al. 1996a). 
UL47 110 110 Smaller species also 
detected
Nuclear pUL47 localised to nuclei of fibroblasts infected with AD169, and was detected as a 
110 kDa protein by Western blot (Bechtel and Shenk 2002). 
UL48 253 250 N/A Punctate                     sub-
cytoplasmic
High molecular weight tegument protein: 216 kDa protein identified in the lysates 
of HCMV-infected fibroblasts; diffuse, as well as distinctive circular staining was 
observed in infected-cell cytoplasms (Bradshaw et al. 1994).                                                                                                                  
pUL48 migrated at 250 kDa when extracted from fibroblasts infected with AD169 
(Bechtel and Shenk 2002). 
UL48A 8 8 N/A Sub-nuclear, excluded 
from nucleoli
Small capsid protein (SCP): 9 kDa protein identified in lysates of fibroblasts infected 
with AD169 (Gibson et al. 1996). Nuclear and cytoplasmic staining observed when 
transiently expressed in isolation in Cos-7 cells, but accumulated in the cytoplasm 
when co-expressed with pUL86 (Lai and Britt 2003). Nuclear in AD169-infected 
fibroblasts. 
UL49 64 55 N/A Pan-cellular N/A
UL50 43 44 Smaller species also 
detected
Nucler membrane Inner nuclear membrane protein: Western blot analysis of epitope-tagged pUL50 
transiently expressed in 293T cells identified a major 47 kDa and several faster 
migrating species (Milbradt et al. 2007) . Transiently expressed pUL50 localised to 
nuclear memranes and lamina (Milbradt et al. 2007, Miller et al. 2010).  
UL51 17 22 N/A Pan-cytoplasmic, 
surface
When tagged within AD169, pUL51 localised to the nuclei of infected fibroblasts and 
was detected as a single band by Western blot (size not provided) (Glab et al. 2009). 
19 kDa band detected by western blot in lysates of insect cells infected with 
recombinant baculovirus (Gao et al. 2005). 
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UL52 74 75, 59 A smaller species also 
detected
Nuclear,                     sub-
cytoplasmic
75 kDa protein detected by Western blot in the lysates of fibroblasts infected with 
recombinant AD169. Localisation was nuclear, surrounding the DNA replication and  
packaging compartments (Borst et al. 2008). 
UL53 42 42 N/A Nuclear Nuclear matrix protein: Western blot analyses of transiently-expressed pUL53  
identified a 45 kDa protein and some less abundant, faster migrating proteins 
(Milbradt et al. 2007); or, a  42 kDa protein (Dal Monte et al. 2002).  Transiently 
expressed pUL53 was nuclear,  but  re-localised to the nuclear envelope when co-
expressed with pUL50 (Milbradt et al. 2007, Miller et al. 2010). AD169-expressed 
pUL53 was weakly expressed in the cytoplasm at 48 hours p.i., but became 
juxtanuclear at 72 hours p.i. (Dal Monte et al. 2002). 
UL54 137 140 Smaller species also 
detected
Nuclear Catalytic subunit of DNA polymerase: in vitro translation resulted in expression of a 
140 kDa protein (Ducancelle et al. 2006). Transfected Cos-7 cells expressed pUL54 in 
the nuclei (Alvisi et al. 2006).
UL55* 102 150, 55 Smaller species also 
detected
Sub-cytoplasmic Glycoprotein B (gB): 160 kDa precursor protein cleaved to generate the mature 
gp55-gp116 complex (gCI) incorporated into virion envelopes (Britt and Auger 
1986). When expressed in isolation gB is predominantly in the uncleaved form 
(Wells et al. 1990). gB localised to viral assembly compartments at juxtanuclear 
positions of AD169-infected cells (Womack and Shenk 2010). Localisation was 
perinuclear in transiently transfected Cos-7 cells and during productive HCMV 
infection (Krzyzaniak et al. 2007).  
UL56 96 47, 110 Many larger and smaller  
species also detected
Nuclear Large terminase subunit (p130): 130 kDa protein expressed by the UL56 gene was 
detected in AD169-infected fibroblasts (Bogner et al. 1998). Transiently-transfected 
pUL56 was nuclear but not nucleolar in Cos-7 and U373 cells (Giesen et al. 2000). In 
AD169-infected fibroblasts, pUL56 was (i) present in nuclei, including viral 
replication centres (Giesen et al. 2000), (ii) nuclei and particulary nucleoli at early 
times of infection, but became concentrated in discrete  subnuclear structures and 
excluded from nucleoli at late times post-infection (Krzyzaniak et al 2007). 
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UL57 134 140 Many smaller species also 
detected
Punctate-nuclear Single-stranded DNA-binding protein: 130 kDa protein detected in the lysates of 
fibroblasts infected with strains AD169 and Colburn (Anders et al. 1986). Fibroblasts 
infected with AD169 expressed nuclear pUL57; nuclear staining pattern was diffuse 
at 24 h p.i., but aggregated into focal globular structures at late times of infection 
(Kemble et al. 1987).  
UL69 82 105 Smaller species also 
detected
Punctate-nuclear pUL69 localised to the nuclei of fibroblasts infected with AD169 and migrated at 
105 kDa (Bechtel and Shenk 2002). 
UL70 108 110 Many larger and smaller 
species also detected
Pan-cytoplasmic Component of DNA-helicase complex: Tagged UL70 migrated at ~100 kDa, and was 
predominantly cytoplasmic in transfected UL373MG cells. However, tagged pUL70 
was efficiently imported into the nucleus when these cells were infected with strain 
Towne (Shen et al. 2011). 
UL71 40 49 Some larger species also 
detected
Juxtanuclear GFP-tagged pUL71 localised to viral assembly compartments in fibroblasts infected 
with AD169 (Womack and Shenk 2010). pUL71 was detected in lysates of fibroblasts 
infected with strain TB40, and transiently transfected Cos-7 cells at 48 kDa 
(Schauflinger et al. 2011). 
UL72 43 42 N/A Sub-cytoplasmic, some 
surface
A 46 kDa protein was detected by Western blot in lysates of fibroblasts infected 
with AD169, or transiently expressing the UL72 gene from a plasmid (Caposio et al. 
2004). In both cases, pUL72 showed cytoplasmic immunofluorescence staining. 
UL73 14 17, 34 Intermediately-sized 
species also detected
Juxtanuclear Glycoprotein N (gN): pUL73 expressed in transiently transfected 293T cells migrated 
at 18 kDa, but was post-tranlationally modified when co-expressed with gM (UL100) 
to form a 50-60 kDa product (Mach et al. 2000). The localisation of pUL73 in Cos-7 
cells was limited to the ER and ERGIC when expressed alone, but extended to the 
cellular secretory pathway in the presence of gM.                                                                                                               
AD169-expressed gM/gN complex was detected within juxtanuclear assembly 
compartments of infected Cos-7 cells (Krzyzaniak et al. 2007). 
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UL74* 54 85 Smaller species also 
detected
Pan-cytoplasmic Glycoprotein O (gO): 100-125 kDa glycoprotein in the context of HCMV infection 
(size is glycosylation-state and strain-dependent); forms a complex with gH/gL (220-
260 kDa) which transits through the secretory pathway (Huber and Compton 1998, 
Huber and Compton 1999). localised to juxtanuclear compartments in AD169-
infected fibroblasts (Theiler and Compton 2002). Isolated expression resulted in 
faster migration in gel and incorrect trafficking. 
UL75 84 80 N/A Sub-cytoplasmic, 
nuclear membrane
Glycoprotein H (gH): in the context of HCMV infection, forms complexes with gL/gO 
(220-260 kDa), or gL/UL128/UL130/UL131A, which transit through the secretory 
pathway (Huber and Compton 1999). Detected as an 86 kDa protein in fibroblasts 
infected with AD169, or recombinant vaccinia virus expressing the UL75 gene 
(Cranage et al. 1988). AD169-expressed gH was present at the nuclear membrane, 
cell surface, or in cytoplasmic bodies (now known to be assembly compartments). 
In contrast, gH was present predominantly at the nuclear membrane when 
expressed alone.                                                                                                                                              
Co-expression with gL relieves ER retention and allows cell surafce expression 
(Spaete et al. 1993). 
UL76 36 Not detected N/A Sub-nuclear                   In COS-1 cells transiently expressing UL76,  and AD169-infected fibroblasts, 38 kDa 
pUL77 was detected by Western blot. GFP-tagged pUL76 aggregated in sub-nuclear 
foci of transfected COS-1 cells and fibroblasts (Wang et al. 2000). 
UL77 71 Not detected N/A  Sub-cytoplasmic When tagged within AD169, pUL77 localised nuclei of infected fibroblasts (Glab et 
al. 2009). 73 kDa band detected by western blot in lysates of insect cells infected 
with recombinant baculovirus (Gao et al. 2005). 
UL78 47 40 Some larger species also 
detected
Sub-cytoplasmic  When transiently expressed in HeLa and 293T cells, or during infection of 
fibroblasts with TB40-BAC4-derived-recombinant HCMV; pUL78 localised to the 
cytoplasm and associated mainly with the ER and early endosomes (Wagner et al. 
2012). A 45 kDa protein was detected by Western blot in both settings. 
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UL79 34 32 Doublet; smaller species 
also detected
Nuclear/           
cytoplasmic
HA-tagged pUL79 migrated at 35 kDa and localised to nuceli and nuclear replication 
compartments when stably expressed in fibroblasts. When these cells were infected 
with recombinant AD169 encoding conditionally expressed pUL79, or harbouring a 
UL79 gene deletion, HCMV-expressed-pUL79 could not be detected (Perng et al. 
2011). pUL79 epitope-tagged in strain Towne localised to replication compartments 
during productive infection of fibroblasts, and  migrated at about 35 kDa (Isomura 
et al. 2011). 
UL80 74 78 N/A Nuclear Protease/minor capsid scaffold protein: expressed in the nuceli of cells transfected  
with GFP-tagged pUL80, and fibroblasts infected with AD169 encoding epitope-
tagged UL80 (Nguyen et al. 2008). Synthesised as a 74 kDa protein (Plafker and 
Gibson 1998). 
UL80.5 38 50 N/A Punctate nuclear Assembly protein precursor/major capsid scaffold protein, present in NIEPs but not 
virions (pAP): 40 kDa protein translated in vitro  from cDNA (Roby and Gibson 1986). 
Other studies detected 38 kDa protein; pUL80.5 is present throughout the nucleus 
of transfected Cos-7 cells (Wood et al. 1997, Plafker and Gibson 1998).
UL82 62 60 Many smaller species also 
detected
Punctate nuclear Upper matrix protein (pp71): migrated at 71 kDa when lysates of AD169-infected 
cells were analysed by Western blot (Hensel et al. 1996). Localised to nuclei of 
fibroblasts infected with AD169 (Hensel et al. 1996, Bechtel and Shenk 2001). 
Transiently expressed pp71 localised to discrete dot-like nuclear domains in 
astrocytoma cells (Hensel et al. 1996). 
UL83 63 60 Many larger and smaller 
species also detected
Nuclear Lower matrix protein (pp65): localised to the nuclei of fibroblasts infected with 
AD169, and migrated at 65 kDa (Sanchez et al. 1998, Bechtel and Shenk 2001). 
Transiently-expressed pp65 was evenly distributed in astrocytoma cell nuceli 
(Hensel et al. 1996). 
UL84 65 68 Many smaller species also 
detected
Nuclear 65 kDa protein detected in the lysates of fibroblasts infected with the Towne strain 
(He et al. 1992). Localised to the nucleus and the cytoplam. 
UL85 35 34 Many larger and smaller 
species also detected
Pan-cytoplasmic, 
surface
Minor capsid protein (mCP): expressed predominantly in the nuclei of AD169-
infected fibroblasts (Adamo et al. 2004). 34 kDa protein incorporated into HCMV 
virions (Roby and Gibson 1986). 
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UL86 154 150 N/A Pan-cytoplasmic, 
surface
Major capsid protein (MCP): pUL86 migrated at 150 kDa when extracted from 
fibroblasts infected with AD169 (Bechtel and Shenk 2001). Perinuclear/cytoplasmic 
localisation when transiently expressed in Cos-7 cells but nuclear in the context of 
AD169 infection of fibroblasts (Sanchez et al. 1998, Lai and britt 2003). Nuclear 
translocation requires presence of pUL80.5 (Wood et al. 1997). 
UL87 105 90 N/A Pan-cellular/            sub-
nuclear
The UL87 gene was epitope-tagged within the Towne strain; Western blot analysis 
of infected cell lysates revealed proteins migrating between 100 kDa and 150 kDa 
(Isomura et al. 2011). pUL87 was localised to replication compartements within 
nuclei of infected fibroblasts. 
UL88 48 48 Many larger and smaller 
species also detected
Pan-cellular Coomassie staining of purified AD169 particles revealed a 48 kDa virion component. 
Protein sequencing showed this was encoded by the UL88 gene (Baldick and Shenk 
1996). 
UL89 77 65 N/A Pan-cytoplasmic, 
surface
Small terminase subunit: Western blot analysis of AD169-infected HFF lysates 
detected a 75 kDa protein. Immunofluorescence staining showed pUL89 localised to 
replication compartments within nuclei of infected cells (Thoma et al. 2006). 
UL91 12 12 N/A Sub-cytoplasmic Pan-cellular expression was observed by immunofluorescence staining of 293T cells 
transiently transfected with an expression plasmid (Salsman et al. 2008). 14 kDa 
band detected by western blot in lysates of insect cells infected with recombinant 
baculovirus (Gao et al. 2005). 
UL92 23 20 Many larger and smaller 
species also detected
Pan-cellular Pan-cellular expression was observed by immunofluorescence staining of 293T cells 
transiently transfected with an expression plasmid (Salsman et al. 2008). 25 kDa 
band detected by western blot in lysates of insect cells infected with recombinant 
baculovirus (Gao et al. 2005). 
UL93 68 62 N/A Pan-cytoplasmic/ 
nuclear
Pan-cellular expression was observed by immunofluorescence staining of 293T cells 
transiently transfected with an expression plasmid (Salsman et al. 2008). 71 kDa 
band detected by western blot in lysates of insect cells infected with recombinant 
baculovirus (Gao et al. 2005). 
146
UL94 38 32 Larger and smaller species 
also detected
Nuclear pUL94 detected as a 36 kDa protein by in vitro  transcription and translation of the 
UL94 gene in lysates of 293T cells stably expressing the UL94 gene, and in lysates of 
fibroblasts infected with the Towne strain (Wing et al. 1996). Transiently expressed 
pUL94 localised to nuclei of Vero cells, but was both nuclear and cytoplasmic when 
co-expressed with pp28. pp28-mediated traslocation of pUL94 to juxtanuclear 
assembly compartments during productive HCMV infection of fibroblasts was also 
observed (Liu et al. 2009).  
UL95 57 59 Doublet Pan-cellular 59 kDa band detected by western blot in lysates of insect cells infected with 
recombinant baculovirus (Gao et al. 2005). 
UL96 14 16, 17 N/A Sub-cytoplasmic 15 kDa band detected by western blot in lysates of insect cells infected with 
recombinant baculovirus (Gao et al. 2005). 
UL97 78 90, 57, 27 Many other species also 
detected
Nuclear Serine-threonine protein kinase: 80 kDa protein, and some less abundant faster 
migrating species were detected in the lysates of HCMV-infected fibroblasts by 
Western blot (Littler et al. 1992). pUL97 localised to the nuclei of AD169-infected 
fibroblasts (Michel et al. 1996). Transient pUL97 expression using a plasmid was 
detected in the nuclei of Cos-7 cells (Prichard et al. 2005a). 
UL98 65 25, 62 Many other species also 
detected
Pan-cytoplasmic, 
perinuclear,         
surface
Deoxyribonuclease: 58 kDa protien detected by Western blot in lysates of 
fibroblasts infected with AD169 (Adam et al. 1995). Immunofluorescence staining of 
fibroblasts infected with the Towne and CR208 strains identified pUL98 to be 
nuclear (Gawn and Greaves 2002). 
UL99 21 32 Larger and smaller species 
also detected
Juxtanuclear Myristylated tegument phosphoprotein (pp28): 28 kDa product detected in lysates 
of fibroblasts infected with the Towne strain (Re et al. 1985). Localised to 
cytoplasmic assembly compartments in fibroblasts during the course of AD169 
infection (Sanchez et al. 2000). 
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UL100 43 Not detected N/A Sub-cytoplasmic gM: 45 kDa protein complexed with gN through disulfide linkage (Mach et al. 2000). 
Localised to the ER and ERGIC in Cos-7 cells transiently-transfected with a UL100 
expression vector but was re-localised to compartments of the secretory pathway 
when co-expressed with gN.                                                                          AD169-
expressed gM/gN complex was detected within juxtanuclear assembly 
compartments of infected Cos 7 cells (Krzyzaniak et al. 2007). 
UL102 94 90 N/A Pan-cytoplasmic, 
surface
N/A
UL103 29 32, 38 N/A Sub-cytoplasmic, 
Perinuclear
Localised to juxtanuclear assembly compartments in cytoplasm of fibroblasts 
infected with the Towne strain (Ahlqvist and Mocarski 2011). 31 kDa band detected 
by western blot in lysates of insect cells infected with recombinant baculovirus (Gao 
et al. 2005). 
UL104 79 70 some smaller species also 
detected
Pan-cellular,       surface Portal protein: pUL104 localised to nuclei of fibroblasts infected with AD169;  
diffusely cytoplasmic at early times of infection, but at late times of infection 
aggregated into ring-shaped structures thought to be sites of DNA packaging, as 
well as punctate perinuclear cytoplasmic structures (Dittmer et al. 2005). The 
pUL104 protein migrated at 73 kDa. 
UL105 106 100 some smaller species also 
detected
Pan-cellular,      surface Helicase: migrated at 105 kDa by Western blotting of AD169-infected fibroblast, 
and when transiently expressed (Smith et al. 1996).  
UL111A 20 17, 19 N/A Cytoplasmic CMV-IL10: Cos-7 cells were transiently transfected with a plasmid encoding epitope-
tagged UL111A; a 21 kDa product was detected by Western blot in conditioned cell 
culture media. Minor 30-35 kDa glycosylated species were also detected that could 
be reduced to 21 kDa by PNGaseF treatment (Kotenko et al. 2000). Sub-cytoplasmic 
expression was observed by immunofluorescence staining of 293T cells transiently 
transfected with an expression plasmid (Salsman et al. 2008). 
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UL112 70 42, 82 Other species also present Nuclear,                     
punctate nuclear
During productive infection of fibroblasts with AD169, the UL112 gene encodes 34, 
43, 50 and 84 kDa proteins with common N-termini, translated from a differentially 
spliced mRNA precursor (Wright and Spector 1989). The 43 kDa isoform was the 
most abundant of the four species. pUL112 was detected by immunofluorescene in 
viral replication compartemnts, and on the periphery of PML bodies (Yamamoto et 
al. 1998, Ahn et al. 1999). 
UL114 28 30 N/A Pan-cytoplasmic, 
surface
Uracil DNA glycosylase: Plasmid-expressed UL114 was cytoplasmic, but  recruited to 
the nucleus when co-expressed with UL44 (Prichard et al. 2005). pUL114 tagged 
within AD169 was expressed in infected cell nuclei, and detected by western 
blotting as a 34 kDa product. 
UL115 31 35 N/A Sub-cytoplasmic Glycoprotein L (gL): 32 kDa glycoprotein (Spaete et al. 1993). In the context of 
HCMV infection, forms a trimeric complex with gH/gO (220-260 kDa), or a 
pentomeric complex with gH/UL128/UL130/UL131A; these complexes transit 
through the secretory pathway (Huber and Compton 1999). Localised to 
juxtanuclear compartments in AD169-infected fibroblasts (Theiler and Compton 
2002)
UL116 34 60 N/A Sub-cytoplasmic N/A
UL117 46 47 N/A Sub-nuclear,      
punctate nuclear
In the context of HCMV infection, the UL117 gene produces 35 kDa (pUL117.5) and 
45 kDa (pUL117) proteins which localise to the nuclei of infected cells (Qian et al. 
2008). Nuclear pUL117 associates with viral replication compartments.  
UL119 39 38, 65 N/A Sub-cytoplasmic IgG Fc-binding glycoprotein (gp68): 68 kDa protein, present in the cytoplasm, from 
where passes through endocytic pathway to the surface of HCMV-infected cells; 
Immunofluorescence detecion  not performed (Stannard and Hardie 1991, Atalay 
2002).
UL120 23 15 N/A Pan-cytoplasmic, 
surface
N/A
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UL121 20 8, 12 Smaller species also 
detected
Sub-cytoplasmic Pan-cytoplasmic expression was observed by immunofluorescence staining of 293T 
cells transiently transfected with an expression plasmid (Salsman et al. 2008). 
UL122 63 75 N/A Nuclear IE2: encodes multiple spliced gene products including a major 86 kDa protein (IE 
86), localises to the nucleus (Wilkinson et al. 1985). 82-86 kDa species routinely 
detected by Western blot (Harel and Alwine 1998). 
UL123 55 70 N/A Nuclear IE1: encodes a 72 kDa phosphoprotein (IE72) that localises to the nucleus 
(Wilkinson et al. 1998). 
UL124 17 17, 30, 40 N/A Sub-cytoplasmic Sub-cytoplasmic expression was observed by immunofluorescence staining of 293T 
cells transiently transfected with an expression plasmid (Salsman et al. 2008). 
UL128 20 10 N/A Sub-cytoplasmic The 16 kDa pUL128 forms a complex with gH/gL/UL130/UL131A, which is 
incoporated into virion envelopes (Wang and Shenk 2005). pUL128 expressed from 
a plasmid was detected in the cytoplasm of 293T cells (Gerna et al. 2008).
UL130 25 37 some smaller species also 
detected
Sub-cytoplasmic The UL130 gene produces a 33/35 kDa doublet of proteins (Wang and Shenk 2005). 
pUL130 forms complexes with gH/gL/UL128/UL131A, which are incorporated  into 
virion envelopes. UL130 expressed from a plasmid was detected in the cytoplasm 
and on the surface of 293T cells (Gerna et al. 2008).
UL131A 15 16 Smaller species also 
detected
Pan-cytoplasmic, 
surface
Associates with gH/gL/UL128/UL130 to form a high molecular weight complex 
(Wang and Shenk 2005). 17 kDa pUL131A detected in the lysates of fibroblasts 
infected with TB40. pUL131A expressed from a plasmid was detected in the 
cytoplasm of 293T cells (Gerna et al. 2008).
UL132 30 Not detected N/A Juxtanuclear Two isoforms were detected in AD169-infected fibroblast: a 22-28 kDa species and 
a 45-60 kDa species. Immunofluorescence analysis showed pUL132 co-localised 
with markers of the Golgi apparatus and the trans-Golgi network (Spaderna et al. 
2005). 
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UL133 28 30 Larger and smaller species 
also detected
Pan-cytoplasmic, 
surface
A product migrating near to the 35 kDa marker was detected in TB40E-infected 
fibroblast lysates by Western blot (Petrucelli et al. 2012).                                        A 28 
kDa (excluding the size of the tag) tagged UL133 product was detected by 
immunoblotting of transiently transfected HEK-293 cell lysates (Grainger et al. 
2010).  When UL133 was tagged within he FIX virus, a protein of similar size was 
detected in infected fibroblasts. 
UL135 33 38 Doublet Sub-cytoplasmic, some 
surface
37 kDa doublet detected by Western blot in lysates of fibroblasts infected with 
strain Merlin (Dr Richard Stanton, unpublished data). Localised to Golgi and cell 
membrane
UL136 27 34 some smaller species also 
detected
Juxtanuclear Excluding the size of its epitope tag, a 27 kDa UL136 protein was detected in the 
lysates of transiently transfected 293 cells (Grainger et al. 2010). In fibroblasts 
infected with a recombinant FIX virus encoding an apitope-tagged UL136, a protein 
of identical size was detected, in addition to a smaller protein. 
UL138 19 19 N/A Sub-cytoplasmic Infection of fibroblasts with the FIX strain resulted in expression of a 21 kDa protein 
that was detected by Western blot using anti-UL138 serum (Petrucelli et al. 2009). 
In this context, pUL138 localised to the Golgi of infected cells. 
UL139 14 Not detected N/A Juxtanuclear N/A
UL140 21 30 Doublet Juxtanuclear Pan-cellular expression was observed by immunofluorescence staining of 293T cells 
transiently transfected with an expression plasmid (Salsman et al. 2008). 
UL141 39 41 Doublet Cytoplasmic gpUL141 was detected by Western blot as a 37-40 kDa glycoprotein doublet in the 
lysates of fibroblasts infected with strains Toledo and AD169 (Tomasec et al. 2005). 
gpUL141 localised to the cytoplasm of AD169-infected fibroblasts, and transfected 
293T cells. 
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UL142 35 42 N/A Not detected GFP tagged-UL142 transiently transfected into fibroblasts migrated at just over 67 
kDa, and localisd to the cytoplasm; unpermeabilised cells expressed the fusion 
protein on the surface (Wills et al. 2005). Localisation of a transfected GFP-UL142 
protein to the ER and cis -Golgi apparatus was observed by immunofluorescence in 
both un-infected, and TB40E-infected fibroblasts (Ashiru et al. 2009).  
UL144 20 40 N/A Juxtanuclear Western blot analysis of UL144 gene products in fibroblasts infected with strain 
Fiala revealed a major protein of ~44 kDa, and a minor protein of 38 kDa (Benedict 
et al. 1999). pUL144 could not be detected by flow cytometry, and is likely retained 
intracellularly. 
UL145 15 16 Some larger species also 
detected
Sub-cytoplasmic Pan-cytoplasmic expression was observed by immunofluorescence staining of 293T 
cells transiently transfected with an expression plasmid (Salsman et al. 2008). 13 
kDa band detected by western blot in lysates of insect cells infected with 
recombinant baculovirus (Gao et al. 2005). 
UL147 19 15 N/A Pan-cytoplasmic, some 
surface
N/A
UL147A 8 10 N/A Not detected N/A
UL148 35 35, 37 37 kDa band a doublet Sub-cytoplasmic N/A
UL148A 9 Not detected N/A Sub-cytoplasmic N/A
UL148B 9 3 N/A Sub-cytoplasmic N/A
UL148C 9 3 Larger species up to 250 
kDa also detected
Sub-cytoplasmic N/A
UL148D 7 7 N/A Sub-cytoplasmic N/A
UL150 70 70 N/A Sub-cytoplasmic Pan-cytoplasmic expression was observed by immunofluorescence staining of 293T 
cells transiently transfected with an expression plasmid (Salsman et al. 2008). 73 
kDa band detected by western blot in lysates of insect cells infected with 
recombinant baculovirus (Gao et al. 2005). 
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IRS1 91 90 5 kDa species also 
detected
Cytoplasmic, sub-
nuclear
Molecular mass of pIRS1 detected by Western blot in lysates of AD169-infected 
fibroblasts was consistent with the predicted size of 91 kDa (Romanowski and Shenk 
1997). A smaller 30 kDa protein (designated pIRS1263) was also recognised,  thought 
to be the product of a 263-aa polypeptide utilising an alternative translation start 
site. In transfected HeLa cells, pIRS1 and pIRS1263 were predominantly cytoplasmic 
and nuclear respectively. 
US1 18 18 N/A Not detected N/A
US2 23 17, 20 Some larger species also 
detected
Sub-cytoplasmic 24 kDa glycoprotein, and less abundant 21 kDa and 14 kDa species detected in the 
lysates of fibroblasts infected with strain AD169  (Jones and Sun 1997). Tagged 
gpUS2 expressed from a transfected expression vector was ER-localised in un-
infected and HCMV Towne-infected extravillus trophoblasts and fibroblasts 
respectively (Terauchi et al. 2003). 
US3 22 16, 18 Some larger species also 
detected
Sub-cytoplasmic, 
perinuclear, 
juxtanuclear
Transiently expressed gpUS3 migrated at 22 kDa in Hela cells (Ahn et al. 1997). 22 
kD, 17 kDa and 3.5 kDa species detected in lysates of transfected HeLa cells (Shin et 
al. 2006). gpUS3 was ER-localised in HeLa cells when expressed in isolation , and in 
the context of HCMV-Towne infection (Ahn et al. 1996). gpUS3 expressed from a 
transfected expression vector was ER-localised in uninfected and HCMV Towne-
infected extravillus trophoblasts and fibroblasts (Terauchi et al. 2003). 
US6 21 19 N/A Sub-cytoplasmic Transiently expressed gpUS6 migrated at 22 kDa in Pala  cells  (Lehner et al. 1997). 
Transiently expressed US6 localised to the ER in HeLa cells (Ahn et al. 1997). 
Transiently expressed (HeLa cells), and AD169-derived (fibroblasts) US6 were ER-
localised and migrated at 21 kDa (Hengel et al. 1997). Tagged US6 expressed from a 
transfected expression vector  was ER-localised in uninfected and HCMV Towne-
infected extravillus trophoblasts and fibroblasts (Terauchi et al. 2003). 
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US7 26 28 N/A Sub-cytoplasmic Immunofluorescence staining of RAd-expressed gpUS7 showed it was diffusely 
cytoplasmic, and co-localised with ER-resident proteins (Huber et al. 2002). In these 
cells, gpUS7 migrated closely with the 30 kDa protein marker. 
US8 27 25, 28 Larger and smaller species 
also detected
Juxtanuclear Transiently expressed gpUS8 was detected by Western blot as a 32-30 kDa doublet, 
and localised to ER and Golgi compartments in COS-1 and epithelial cells 
respectively  (Maidji et al. 1998). When expressed from a RAd in HEC-1A cells, US8 
was detected in punctate perinuclear vesicles and showed extensive co-localisation 
with markers of the Golgi apparatus (Huber et al. 2002). 
US10 21 16, 19 N/A Pan-cytoplasmic, some 
surface
Immunofluorescence staining of RAd-expressed gpUS10 showed it was diffusely 
cytoplasmic, and co-localised with ER-resident proteins (Huber et al. 2002). In these 
cells, gpUL10 migrated slightly faster than the 30 kDa markers, but exact size was 
not provided. HA-tagged UL10 protein migrated at 23 kD and was localised to the 
ER, in stably transfected U373 cells (Furman et al. 2002). 
US11 25 24, 30 N/A Sub-cytoplasmic US11 expressed in AD169-infected fibroblasts migrated at 31 kDa (Jones et al. 
1991). US11 was ER-localised in HeLa cells when expressed in isolation, and in the 
context of HCMV-Towne infection (Ahn et al. 1996). Tagged US11 expressed from a 
transfected expression vector was ER-localised in uninfected and HCMV Towne-
infected extravillus trophoblasts and fibroblasts (Terauchi et al. 2003).
US12 32 28, 40->300 Includes continuous smear Sub-cytoplasmic N/A
US13 29 35->300 Includes continuous smear Sub-cytoplasmic N/A
US15 29 35->300 Includes continuous smear Sub-cytoplasmic 55 kDa product detected by western blot in lysates of insect cells infected with 
recombinant baculovirus (Gao et al. 2005). 
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US16 35 35->300 Includes continuous smear Sub-cytoplasmic The US16 gene was HA-tagged within the TR BAC and recombinant virus generated; 
Western blot analysis of infected fibroblast lysates showed pUS16 migrated at 33 
kDa (Bronzini et al. 2012). pUS16 co-localised with gB and pp28 in the cytoplasm of 
infected cells, suggesting it is present in viral assembly compartments. A similar 
cytoplasmic pattern was observed in fibroblasts transiently transfected with a 
pUS16 expression vector. 
US18 30 50->300 Includes continuous smear Sub-cytoplasmic 36 kDa pUS18 detected in lysates of fibroblasts infected with the Towne strain by 
Western blot (Guo and Huang et al. 1993). pUS18 was detected by 
immunofluorescence in the cytoplasm of fibroblasts infected with AD169, 
concentrating at assembly compartments  (Das et al. 2006, Das and Pellett 2007). 
US19 26 21 N/A Sub-cytoplasmic, 
punctate justanuclear
32 kDa pUS19 detected in lysates of fibroblasts infected with the Towne strain by 
Western blot (Guo and Huang et al. 1993). pUS19 was also detected by 
immunofluorescence in these cells but the authors did not show this data. 
US20 29 40->300 Includes continuous smear Sub-cytoplasmic, 
nuclear membrane
43 kDa pUS20 detected in the lysates of fibroblasts infected with the Towne strain 
by Western blot (Guo and Huang et al. 1992). pUS20 was also detected by 
immunofluorescence in these cells but the authors did not show this data. 
US21 27 20->300 Includes continuous smear Sub-cytoplasmic Pan-cellular expression was observed by immunofluorescence staining of 293T cells 
transiently transfected with an expression plasmid (Salsman et al. 2008). 29 kDa 
band detected by western blot in lysates of insect cells infected with recombinant 
baculovirus (Gao et al. 2005). 
US22 65 60 some smaller species also 
detected
Pan-cytoplasmic, some 
surface
Immunoblotting identified a 66 kDa protein in lysates of AD169-infected cells. 
pUS22 was found to be nuclear by immunofluorescence, but partitioned with the 
cytoplasm in fractionation studies (Mocarski et al. 1988). 
US23 69 60 N/A Pan-cytoplasmic, some 
surface
Pan-cellular expression was observed by immunofluorescence staining of 293T cells 
transiently transfected with an expression plasmid (Salsman et al. 2008). 71 kDa 
band detected by western blot in lysates of insect cells infected with recombinant 
baculovirus (Gao et al. 2005). 
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US24 58 57 N/A Sub-cytoplasmic, 
perinuclear
Antibody specfic to pUS24 detected a 58 kDa protein in the lysates of fibroblasts 
infected with strain AD169. In these cells, Immunofluorescently stained pUS24 co-
localised with pp65 in the cytoplasm (Feng et al. 2006). 
US26 70 67 N/A Pan-cytoplasmic, 
surface
Pan-cellular expression was observed by immunofluorescence staining of 293T cells 
transiently transfected with an expression plasmid (Salsman et al. 2008). 
US27 42 40->300 N/A Sub-cytoplasmic, 
perinuclear
Found at the cell surface, and more prominantly in association with perinuclear 
endocytic and lysosomal organelles both in transfected cells, and cells undergoing 
productive HCMV infection (Fraile-Ramos et al. 2002). 44 kDa protein detected by 
western blot in lysates of insect cells infected with recombinant baculovirus (Gao et 
al. 2005). 
US28 41 37 Doublet,                       Many 
larger and smaller species 
also detected
Pan-cytoplasmic, 
surface
pUS28 detected in lysates of AD169-infected fibroblast, and transfected HEK293A 
cells migrated at 36 kDa (Mokros et al. 2002). Tagged pUS28 co-localised with 
markers of early/late endosomes and lysosomes in transfected HeLa cells (Fraile-
Ramos et al. 2001). A pUS28-YFP fusion protein was intracellular in transiently 
transfected fibroblasts even after infection with the Towne strain.                                                                                                                             
pUS28 is present at low levels on the surface of HCMV-infected  (Michelson et al. 
1997, Fraile-Ramos et al. 2001) and transfected cells (Pleskoff et al. 1998), but is 
rapidly endocytosed. 
US29 51 36, 60, 95 N/A Sub-cytoplasmic, 
perinuclear
N/A
US30 39 37 Doublet,                        
other smaller species also 
detected
Sub-cytoplasmic Sub-cytoplasmic expression was observed by immunofluorescence staining of 293T 
cells transiently transfected with an expression plasmid (Salsman et al. 2008). 
US31 19 18 N/A Pan-cytoplasmic, 
surface
Sub-cytoplasmic expression was observed by immunofluorescence staining of 293T 
cells transiently transfected with an expression plasmid (Salsman et al. 2008). 
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US32 22 20 Smaller species also 
detected
Sub-nuclear Sub-nuclear expression was observed by immunofluorescence staining of 293T cells 
transiently transfected with an expression plasmid (Salsman et al. 2008). A protein 
migrating at ~25 kDa was observd by Western blotting after adjusting for the 10 kDa 
SPA tag. 
US33A 7 4 N/A Not detected N/A
US34 17 46 N/A Nuclear 20 kDa band detected by western blot in lysates of insect cells infected with 
recombinant baculovirus (Gao et al. 2005). 
US34A 8 15 N/A Sub-cytoplasmic N/A
TRS1 84 80 Larger and smaller species 
also detected
Sub-cytoplasmic Molecular mass of pTRS1 detected by Western blot in lysates of AD169-infected 
fibroblasts was consistent with the predicted size of 84 kDa (Romanowski and Shenk 
1997). pTRS1 was detected in the nucleus and cytoplasm of infected cells at IE 
times, but predominantly cytoplasmic at late times of infection. Within transfected 
HeLa cells, pTRS1 was also predominantly cytoplasmic. 
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3.4.1. Cloning of codon-optimised UL55 and UL74 
genes 
gpUL55 (gB) and gpUL74 (gO) are well-characterised virion glycoproteins, yet their expression 
was not detectable when the constructs generated for the library were tested. To address this 
issue, de novo-synthesised, codon-optimised UL55 and UL74 genes were cloned into AdZ by 
recombineering by Dr James Davies. Following codon optimisation, expression of these genes 
was readily detected (Figure 3.3). This approach is therefore currently being extended to the 
additional constructs whose expression was not detectable. 
3.4.2. Cytoxic gene products 
 Infection of HFFF-hCARs with RAds was routinely performed at an MOI=10 to ensure efficient 
gene delivery and expression. However, the Ad vectors can drive high level gene expression, 
and HCMV genes can be expected to impact on normal cellular processes. RAd vectors 
containing the following genes were associated with overt cytopathology: RL8A, RL10, RL11, 
UL2, UL5, UL6, UL15A, UL16, UL18, UL19, UL20, UL23, UL26, UL34, UL41A, UL138, US14, US26, 
US28 and US30. To foster survival of the cells for long enough to screen gene function, 
experiments using these RAd constructs were performed at an MOI=1; little cytotoxicity was 
observed at MOI=1 (data not shown).  
3.4.3. Western blot analysis of expressed HCMV 
gene products 
3.4.3.1. Cross-comparison of western blot data with 
published findings 
Expression of 152 HCMV genes was detected in western blot experiments using a V5 
monoclonal antibody, or antibodies specific for HCMV proteins (Figure 3.3). Amongst these, 
the molecular weight of 16 putative HCMV glycoproteins has not been reported: RL12, UL6, 
UL7, UL8, UL9, UL10, UL11, UL116, UL120, UL121, UL124, UL147, UL148, US1, US29 and US30 
(Table 14.1; Davison and Bhella 2007). Major western blot species migrating more slowly than 
predicted from primary translation products were detected for 11 of these (RL12, UL6, UL7, 
UL8, UL9, UL10, UL11, UL116, UL124, UL148 and US29) whilst the other 5 migrated at, or faster 
than their predicted primary translation products.  
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Deglycosylation analysis with EndoH and PNGaseF enzymes was performed on products of the 
first three putative glycoprotein-coding genes, RL12, UL6 and UL7, and the presence of 
carbohydrate moieties confirmed (Figure 3.4). gpRL12 showed sensitivity to EndoH treatment, 
reducing in size from 80 kDa to ~50 kDa, close to the 47 kDa predicted size of its polypeptide 
backbone. Incubation with PNGaseF did not further reduce the molecular weight of gpRL12. 
Native gpUL6 migrated at 50 kDa, although a weakly expressed 60 kDa band was also seen. 
The main 50 kDa species was reduced to 28 kDa upon treatment with EndoH, and to 27 kDa 
after PNGaseF digestion. That both species migrated faster than the predicted 31 kDa primary 
protein indicates they may undergo some degree of cleavage. The 60 kDa band was completely 
resistant to EndoH, and partially sensitive to PNGaseF (37 kDa). The primary translation 
product of UL7 has a predicted mass of 24 kDa. Major and minor bands were observed at 53 
kDa and 80 kDa respectively. The 53 kDa isoform was sensitive to EndoH treatment, migrating 
at 25 kDa, and was further reduced to 24 kDa following digestion with PNGaseF. By contrast, 
the 80 kDa isoform was unaffected by EndoH, but cleaved to 35-40 kDa by PNGaseF. The 
observation that predominant western blot species of gpRL12, gpUL6 and gpUL7 are all 
sensitive to EndoH digestion is consistent with the staining pattern visualised for these 
products by immunofluorescence. All three proteins accumulated in juxtanuclear sites 
resembling the ER (see Figure 3.3). This is most clearly seen with gpUL6, which formed a tight 
ring around the nuclei of infected cells. The presence of weakly-expressed, high-molecular 
weight gpUL6 and gpUL7 is also interesting. Sensitivity to EndoH and partial sensitivity to 
PNGaseF indicates passage of these isoforms through the Golgi, and O-linked glycosylation 
respectively. These heavily glycosylated species may therefore encode distinct functions 
compared with the predominantly expressed variants.  
  
Figure 3.4: Deglycosylation analysis of gpRL12, gpUL6 and gpUL7 
Western blot was performed as described in figure 4.3, on RAd-expressed 
gpRL12, gpUL6 and gpUL7 in native form, or following treatment with EndoH 
or PNGaseF.   
 gpRL12                 gpUL6                gpUL7 
- 
- 
- 
- 
- 
- 
80 
60 
50 
40 
30 
20 
- 
- 
- 
- 
- 
- 
80 
60 
50 
40 
30 
20 
- 
- 
- 
- 
- 
80 
60 
50 
40 
30 
20 
- 
EndoH 
PNGaseF 
+ 
- 
+ 
- 
+ 
- 
- 
- 
- 
- 
- 
- 
- 
+ 
- 
+ 
- 
+ 
160
161 
 
The remaining 136 genes include 116 for which product sizes have been reported (see Table 
3.2), and 20 for which predicted sizes were calculated from amino acid sequence. Major 
western blot species were detected within 10 kDa of the expected size for products of 128 
genes. Of the other 8 (UL28/29, UL56, UL82, UL87, IRS1, US18, US19 and US34; indicated in 
bold in table 3.2), the first 5 encode products in excess of 70 kDa, and had calculated mass 
differences of less than 15 kDa. These differences may be attributable to the accuracy with 
which SDS-PAGE can resolve heavier proteins at the top of the gel. Products with 
approximately appropriate sizes were observed for US18 and US19, however in the case of 
US18 these were accompanied with more abundant high molecular weight species (see section 
3.4.3.5). Finally, US34 migrated at 46 kDa, almost 30 kDa higher than its predicted molecular 
weight of 17 kDa. Although originally not predicted to be a glycoprotein by Davison and Bhella 
(2007), the US34 ORF contains 4 potential N-linked glycosylation sites, all of which are 
conserved amongst HCMV strains, and 3 of which which are conserved in CCMV (Dr Andrew 
Davison, personal communication). High-scoring potential phosphorylation sites are also 
present in the US34 ORF. US34 may therefore encode a glycoprotein, or a phosphorylated 
protein. 
3.4.3.2. Altered processing of virion glycoproteins during 
productive HCMV infection  
A subset of HCMV gene products can be expected to exhibit a different size to that calculated 
from its primary translation product when expressed individually from a vector. This is because 
an HCMV protein expressed individually loses the capacity to interact with any other viral 
counterpart(s) that may induce post-translational modification. Some of these modifications, 
particularly glycosylation and/or proteolytic cleavage, clearly have the capacity to dramatically 
alter the size of the protein detected. Western blot analysis of RAd-derived HCMV genes 
recapitulated reports of altered molecular weight (Table 3.2); some examples are included 
below. 
In HCMV virions, production of functional gCI complexes requires the cleavage of 160 kDa gB 
precursors into 116 kDa-55 kDa mature complexes. Whereas in HCMV-infected cells the 55 
kDa isoform is most abundantly detected, expression in isolatation results in the accumulation 
of the uncleaved precursor. My observation that the predominant RAd-expressed gB isoform 
migrated at 150 kDa on a reducing gel is thus consistent with published findings. While HCMV 
gCII consists of a gM-gN complex, gN expressed alone was reported to have a relative 
molecular mass of 18 kDa (Mach et al., 2000), close to the predicted size of 14 kDa. However 
when co-expressed with gM, glycosylation of gN increases, resulting in migration at 50-60 kDa. 
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Consistent with these findings, gN expressed using AdZ migrated most abundantly at 17 kDa, 
although the detection of additional slower migrating species of up to 34 kDa indicated limited 
gM-independent maturation of gN. Classically, gCIII was recognised to consist of the gH/gL/gO 
trimeric complex. As observed with gN, gO was reported not to be fully processed to its 
mature form (100-125 kDa ) when expressed independently (Theiler and Compton, 2002). 
Detection of a major 85 kDa species from our RAd-UL74 construct is in agreement with this 
finding. 
As shown in Figure 3.5, 55 kDa and 80 kDa protein species were expressed from RAd-RL13, 
whilst 55 kDa and 100 kDa gpRL13 products were detected during productive HCMV infection. 
The 55 kDa species expressed from both viruses were fully sensitive to EndoH digestion, 
indicating ER-retention. The 80 kDa and 100 kDa band proteins were resistant to EndoH 
treatment, and only partially sensitive to digestion by PNGaseF, suggesting mature RL13 
contains O-linked, as well as N-linked carbohydrate moieties.  
  
               RAd gpRL13                          Merlin gpRL13 
Figure 3.5 (adapted from stanton et al. 2010): 
Glycosylation analysis of gpRL13 expressed from a RAd, and in the context 
of HCMV-Merlin infection 
Western blot performed on RAd-expressed, and HCMV Merlin-expressed 
gpRL13  in native form, and following digestion with EndoH or PNGaseF 
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3.4.3.3. Migration of HCMV-encoded phosphoproteins in 
western blot  
14 HCMV genes are known to encode phosphoproteins (green cells in Table 3.2; UL32 encodes 
a phosphoglycoprotein). The majority of HCMV-encoded phosphoproteins are components of 
the virion tegument (Kalejta, 2008). The fact that most tegument proteins exhibit some degree 
of phosphorylation has lead to the proposal that this modification could promote their 
recruitment to this virion compartment; no specific sequence has been identified that targets 
tegument constituents to sites of virus assembly. In contrast with glycosylation, 
phosphorylation rarely results in significant increase in molecular weight. Consistent with this 
notion, RAd-encoded phosphoproteins generally migrated at near their predicted/published 
molecular mass (green cells, table 3.2). Interaction with other HCMV proteins is therefore 
unlikely to result in significant alteration to the molecular weight of phosphoproteins.  
UL112 encodes four phosphoproteins with common N-termini, which are synthesised from a 
single  alternatively spliced transcript (Wright and Spector, 1989). These phosphoproteins 
migrate at 34 kDa, 43 kDa, 50 kDa and 84 kDa in the context of HCMV infection, and almost 
identically-sized products were expressed from RAd-UL112. Also consistent with previous 
reports, the 43 kDa isoform was the most abundant of the four species. This demonstrates that 
neither alternative splicing, nor phosphorylation of UL112 gene products requires the presence 
of other viral proteins. 
3.4.3.4. US12 family of HCMV proteins 
The US12 family consists of 10 adjacent genes positioned between US12 and US21 inclusively, 
all of which remain incompletely characterised. These genes have been predicted to encode 
seven-transmembrane-domain proteins (McGeoch et al., 1985), and also show features 
reminiscent of G-protein-coupled receptors (Lesniewski et al., 2006). Expression from RAd-
US14 and RAd-US17 was not detected, whilst pUS19 migrated at 21 kDa, somewhat faster than 
the 32 kDa protein reported during HCMV infection (Guo and Huang, 1993). The other 7 family 
members (US12, US13, US15, US16, US18, US20, US21) all provided multiple positive signals 
ranging from their predicted protein sizes to very much larger sizes, up to >260 kDa. 
Interestingly, size valuation of some of these proteins in the context of HCMV infection (US16, 
US18, US19, US20) tended to be more in line with their predicted sizes (see Table 3.2). This 
difference implies that this set of proteins is subject to a high level of post-translational 
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modification when expressed in isolation, which is suppressed in the context of productive 
virus infection. The high-molecular weight species of the aforementioned US12 family 
members bear resemblance to the migration pattern observed for ubiquitin-conjugated 
proteins. In support of this notion, immunoprecipitation of pUS20 from lysates of hFFF-hCARs 
infected with RAd-US20 using the V5 antibody, followed by stable isotope labelling by amino 
acids in cell culture (SILAC) analysis revealed pUS20 interacts with ubiquitin, p62 and Tax1-
binding protein 1 (TAX1BP1) (Dr Ceri Fielding, personal communication). p62 is involved in the 
targeting and degradation of polyubiquitinated proteins by proteasome and autophagy 
(Seibenhener et al., 2004, Myeku and Figueiredo-Pereira, 2011) whilst TAX1BP1 is important in 
ubiquitin-mediated signalling, and may also act as a ubiquitin-binding protein adaptor 
(Verstrepen et al., 2011). A subseqeunt study by Dr Ceri Fielding has since demonstrated 
experimentally that pUS20 is indeed polyubiquitinated (personal communication). It is 
predicted that in addition to pUS20, the other 6 US12 family members identified above are 
also ubiquitinated during ectopic expression. This is currently being investigated. Interestingly, 
the HCMV matrix protein UL48 has been shown to be a deubiquitinase (Adair et al., 2002), and 
thus in lytic infection potentially could act to limit post-translational modification of US12 
family proteins. 
3.4.3.5. Efficiency of expression  
It is noteworthy that expression level varied dramatically between different Ad constructs; 
appropriate exposure of western blots was selected so as not to under or over-expose bands. 
The presented results are therefore not quantitative, and should not be interpreted that way. 
Most notably, lysates of cells infected with a subset of RAds were diluted prior to 
electrophoresis due to very strong expression. Compared to the standard protocol specified in 
section 2.11.2, lysates of cells infected with RAds expressing UL14, UL21A, UL26, UL31 and 
UL38 were diluted 100 times, whilst those of UL123, UL138 and UL150 were diluted by a factor 
of 10. 1 in 5 dilutions were prepared for RAds encoding UL25 and UL28/29; and RAd-UL112 
and RAd-UL114 samples were diluted 20 times and 50 times respectively. By contrast, 
expression of the following 14 genes was relatively weak in western blot experiments: UL18, 
UL19, UL30, UL41A, UL48A, UL51, UL72, UL73, UL80, UL80.5, UL117, UL128, UL142 and 
UL148D. To visualise products of these genes, protein concentration or antibody dilution were 
not adjusted; blots were instead exposed for prolonged lengths of time where necessary.  
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3.4.3.6. Western blot analysis of RAd-infected-cell 
supernatants  
Western blot was also performed on the supernatants of RAd-infected cells in order to identify 
novel secreted gene products. Abundant levels of gpUL4 were detected in the culture medium 
of cells infected with RAd-UL4 using the V5 antibody (see Chapter 6).   
3.4.4. Intracellular localisation of RAd-expressed 
HCMV gene products 
3.4.4.1. Cross comparison of immunofluorescence data 
with published findings 
Expression of 155 HCMV genes was detected by immunofluorescence using a V5 monoclonal 
antibody, or antibodies specific for HCMV proteins (Figure 3.3). Overall, intracellular 
localisations correlated well with information in the published literature (Table 3.2). 
Localisations have been reported for 109 of the 155 detected gene products. Data presented 
here closely resembled previous reports in the case of 98 of these, and varied in the case of 11 
others (underlined in table 3.2). Expression was categorised as inconsistent with the literature 
if it was (i) exclusively nuclear but had been reported as cytoplasmic or pan-cellular, (ii) 
exclusively cytoplasmic but had been reported as nuclear or pan-cellular, (iii) pan-cellular but 
had been reported to be either nuclear or cytoplasmic, (iv) pan-cytoplasmic but had been 
reported as sub-cytoplasmic, (v) sub-cytoplasmic, but had been reported as pan-
cytoplasmic/cell surface, (vi) nuclear but had been reported as sub-nuclear, (vii) sub-nuclear 
but had been reported throughout the nucleus. Where distinct sub-cellular localisations had 
been reported during HCMV infection and isolated expression (see Section 3.4.4.4), results 
were compared to the latter group, except if isolated expression was visualised in non-human 
cells.  
Immunofluorescence staining was inconsistent with previous literature for products of the 
following 11 genes: UL38, UL43, UL51, UL77, UL80.5, UL85, UL89, UL98, UL104, UL130 and 
US22. Compared to previous descriptions, pUL43, pUL80.5 and pUL130 were found in the 
correct compartment (nucleus/cytoplasm), but distributed differently within that 
compartment. With RAd-UL43, expression was visualised throughout the cytoplasm including 
the cell surface. pUL43 is a tegument protein previously reported to localise to juxtanuclear 
virus assembly compartments during lytic infection (Adair et al., 2002). When expressed in 
isolation virus assembly compartments are not generated, and pUL43 becomes diffusely 
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cytoplasmic. RAd-expressed pUL80.5 displayed punctate nuclear staining, but has been 
reported to be expressed throughout the nucleus of transfected Cos-7 cells (Plafker and 
Gibson, 1998, Wood et al., 1997). Isolated expression of pUL80.5 in human cells has not been 
reported; the difference in pUL80.5 nuclear localisation could therefore be species-specific. 
RAd-UL130 expression was detected at sub-cytoplasmic regions of infected cells. Gerna et al. 
reported cell surface, as well as cytoplasmic localisation for pUL130 transiently expressed in 
293T cells (Gerna et al., 2008b). It is possible that pUL130 localisation varies depending on the 
cell type used. 
Interestingly, localisations of products of all other 8 genes (UL38, UL51, UL77, UL85, UL89, 
UL98, UL104 and US22) were (i) previously reported to be nuclear or predominantly nuclear, 
but observed to be cytoplasmic in Figure 3.3, and (ii) previously described solely in the context 
of HCMV infection. It is therefore likely that they depend on interaction with other viral 
proteins for nuclear targeting. In this regard, 5 of the aforementioned 8 gene products are 
found in purified virions (UL38, UL77, UL85, UL98 and US22 (Lahijani et al., 1992, Varnum et 
al., 2004), whilst pUL104 is the portal protein of pro-capsids (Dittmer and Bogner, 2005). 
Components of the virion often form complexes which may be important in determination of 
localisation.  
3.4.4.2. Gene products that require other HCMV proteins 
for appropriate localisation  
A number of HCMV gene products have been reported to traffic inappropriately within the cell 
when expressed individually. The specific virus-encoded interacting partners required for 
appropriate translocation of some of these gene products are known, whilst others await 
identification. Immunofluorescent detection of HCMV genes by using AdZ recapitulated 
published findings for this group of proteins, although rescue of localisation by co-expression 
with interacting partner genes was not performed.  
HCMV gene products that localise differently in the absence of known viral co-factors include 
pUL86 (MCP) which depends on the presence of pUL80.5 (pAP) for nuclear translocation, 
pUL53 which requires co-expression with pUL50 for trafficking out of the nucleus and into the 
nuclear membrane, and pUL94 which is exclusively nuclear in the absence of pp28, but pan-
cellular when co-expressed with pp28. In addition, gH and gO both need co-expression with gL 
for movement to the cell membrane whilst gM and gN are localised in the ER and ERGIC during 
ectopic expression, but extended to the cellular secretory pathways when co-expressed.  
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HCMV proteins that localise to inappropriate cellular compartments during ectopic expression 
can also be expected to display aberrant function when expressed alone. This has potentially 
important implications for use of the RAd library in functional screens, and is discussed further 
in chapter 7.  
3.4.4.3. Dependence of intracellular localisation on 
MOI/expression level 
To optimise conditions for image collection, cells were expressed at a range of MOIs, and it 
was clear that the level of expression correlated with the amount of virus in the inoculum. 
Moreover, the intracellular localisation of some proteins was dependent on the MOI used for 
RAd-infection; more specifically, pUL26, pUL27 and pUL28/29 were detected exclusively in the 
nucleus when using an MOI of 1 (Figure 3.6). However, an increase to 5 or 10 pfu per cell was 
associated with cytosolic expression of all three proteins and induction of cytotoxicity. At an 
MOI of 5, UL26 expression was less conspicuous within nuclei, and more pronounced in the 
cytoplasm. Over-expression of pUL27 (10 pfu per cell) led to apparent chromatin 
condensation, as indicated by brighter and more focused DAPI staining. In these cells pUL27 
localised in ring-like structures around the nuclei. pUL28/29 expression at MOI 10 caused 
apparent loss of integrity to the nuclear membrane. UL26, UL27 and UL28/29 encode proteins 
that adopt nuclear localisations in the context of HCMV infection. UL26 encodes a tegument 
protein that can transactivate the IE-promoter (Stamminger et al., 2002), whilst pUL27 is 
responsible for Maribavir resistance, and may play a role in viral replication and egress 
(Komazin et al., 2003). Nuclear and nucleolar expression has previously been reported for a 
UL27-GFP fusion protein in transfected fibroblasts (Chou et al., 2004). pUL28/29 is the product 
of a spliced transcript encoded by UL28 and UL29, present within viral replication 
compartments in infected cell nuclei, where it may play a role in regulating viral gene 
expression (Mitchell et al., 2009).  
  
UL26 UL27 UL28/29 
Figure 3.6: Effect of transgene expression level on protein localisation  
HFFF-hCARs were infected with RAd-UL26, RAd-UL27 and RAd-UL28/29 at MOI 1 (top 
panel) or MOIs 5, 10 and 5 (bottom panel) respectively. Immunofluorescence staining 
was performed at 3 days p.i. As described in figure 4.3.  
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Although the AdZ system is recognised to be capable of providing for very high level 
expression, there was substantial variation among the 170 different constructs analysed. Over-
expression has the potential to saturate cellular pathways, and thereby result in inappropriate 
protein trafficking and toxicity. The clearest and most specific demonstration of intracellular 
localisation tended to be observed when expression levels were modest, and that is most 
clearly demonstrated with UL26, 27 and UL27/UL28. For immunofluorescence data collated in 
Figure 3.3 and table 3.2, infections were predominantly performed at the lowest MOI 
compatible with detecting expression. These results also provide a message for high 
throughput functional screening in that over expression of certain genes could perturb their 
function.   
3.4.5. Constructs lacking evidence of expression 
Since the ß2.7 gene encodes an abundant transcript without an obvious ORF, the RAd-β2.7 
construct was not compatible with epitope-tagging and not shown in Figure 3.3. Expression 
from 8 tagged constructs encoding RL6, RL9A, UL30A, UL33, UL146, US9, US14 and US17 was 
not detected by either western blot or immunofluorescence. It is possible however, that these 
proteins expressed a product that was not detected using the V5-specific antibody. Detection 
of protein expression requires that the C-terminal V5 tag be accessible to the antibody, and 
can be prevented by ill-suited protein folding. Alternatively, C-terminal cleavage of the 
recombinant protein would impede detection of expression, though this is unlikely to be the 
case for protein products of RL6, UL33, US9 and US14, since these proteins have previously 
been detected using C-terminal epitope tags (Salsman et al., 2008). RL9A was recently 
annotated as a protein-coding gene in the Merlin genome, being added together with RL8A, 
UL150A and US33A (Gatherer et al., 2011). RAd-RL8A expression was detcted by 
immunoblotting but not immunofluorescence, whilst UL150A was not cloned into AdZ due to 
uncertainties about the 5’ start site of its major splice variant (see chapter 5). UL30A is related 
to the neighbouring UL30 gene, and is conserved in primate CMVs (Davison, 2010). UL30A is 
predicted to use ACG instead of the conventional ATG as a translation initiation codon; it is 
possible that the non-canonical start codon was not functional in the AdZ vector. It is also 
possible that UL30A could be expressed if supplied with a conventional start codon; this is 
being addressed. Expression of genes RL5A, UL1, UL76, UL77, UL100, UL132, UL139 and 
UL148A was not detected by western blot, and only weakly detected by immunofluorescence; 
the threshold of expression for detection using the V5 antibody may therefore be lower by 
immunofluorescence compared to immunoblotting. The products of RL8A, UL142, UL147A, 
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US1, and US33A were only detected by western blot. One explanation for this may be that 
antibody binding occurred under denaturing and reducing conditions, but not when the 
protein was in native form.  
3.5. Summary 
168 protein-coding genes encoded by HCMV strain Merlin were cloned into Ad vectors to 
generate a high-throughput system for use in functional assays (see Table 3.1 for individual 
contributions). Expression of 160 genes was verified by western blot (152 genes) and 
immunofluorescence (155 genes) whilst codon-optimised versions of the other 8 genes are 
currently being cloned into AdZ to facilitate their expression. This is the first systematic 
analysis of wildtype HCMV gene expression reported to date. Expression data obtained for the 
great majority of HCMV gene products was in accord with previous reports, indicating that this 
library of Ad recombinants can be used with confidence in functional assays. 
 Expression of ORFs encoded by HCMV strains AD169 and Towne (ULb’ ORFs) was undertaken 
by using a baculovirus vector (Gao et al., 2005), and by transient DNA-transfection of 293T cells 
and osteosarcoma cells (Salsman et al., 2008). The Gao et al. paper did not contain the primary 
data but provided the size of all expressed gene products as obtained by western blot; 50% of 
genes tested provided a detectable product. In contrast, transient transfection of the 293T 
cells tracked expression mainly by immunofluorescence only. In the case of non-glycosylated 
proteins, excellent overall co-linearity was observed between data provided by Gao et al. and 
results presented here. However, the baculovirus expression system did not faithfully produce 
glycoproteins of appropriate size. Glycoproteins consistently migrated at or near the predicted 
size of their primary translation products; indeed baculovirus vector-driven expression in 
insect cells is known to cause alterations to glycosylation pathways. It was therefore not 
beneficial to reference glycoprotein sizes from the Gao et al. report in table 3.2. There was 
broad agreement linking immunofluorescence data obtained using Ad recombinants and the 
Salsman et al. (2008) report, although one major inconsistency was observed between the two 
datasets. Several gene products that show specific sub-cellular localisation when expressed 
from Ad recombinants were classified as pan-cellular by Salsman and co-workers. These 
included products that are known not to be expressed throughout the cell: UL20, UL24, UL43, 
UL56, IE2, UL94, UL114, UL138, US24 and US28 gene products (see Table 3.2). Relatively few 
HCMV genes have been detected as showing pan-cellular expression by others and myself. It is 
likely that pan-cellular localisation of some proteins observed by Salsman et al. was due to 
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over-expression of HCMV proteins; this can lead to lack of containment within appropriate cell 
compartment(s).  
Expression analysis of the RAd library of HCMV genes led to characterisation of the 
glycosylation state of 3 predicted glycoproteins (RL12, UL6 and UL7), identification of gpUL4 as 
a potential secreted protein, and identification of pUS12, pUS13, pUS15, pUS16, pUS18, 
pUS20, and pUS21 as potential ubiquitin-binding proteins.  
Expression with 20 Ad recombinants was associated with visible cytopathic effect at MOI=10. 
To avoid this bottleneck, it was decided to administer these Ad recombinants at MOI=1 in 
functional assays. In addition, the localisation of some proteins depends on the level of 
expression, as infection with their containing RAds at a range of MOIs resulted in significant 
variation in transgene distribution within the cell. This was most conspicuous in the cases of 
pUL26, pUL27 and pUL28/29; these proteins were all nuclear at MOI=1, consistent with their 
reported expression during productive HCMV infection. Increase of MOI to 5-10 however 
resulted in segregation from nuclei, as evidenced by lack of co-localisation with DAPI. These 
examples highlight the need to consult independent reports that describe localisation, prior to 
prescribing MOIs of Ad recombinants for use in functional assays.  
Ectopic expression of some HCMV gene products results in altered localisation and/or 
molecular mass. Such alterations may also be accompanied by abrogated function, because 
appropriate trafficking and post-translational modifications are vital to protein function. 
Specific HCMV proteins required for appropriate translocation and/or glycosylation of some 
gene products are known; co-expression of these ‘mediator’ proteins together with their 
target proteins can be beneficial during functional assays. Infection of cells with more than one 
Ad recombinant in this context may however increase cytotoxic affects associated with each 
Ad recombinant.  
Where the viral function of interest necessitates the concerted action of two or more genes, 
gain of function screening of single genes is rendered ineffective. In these instances, co-
infection of cells with multiple Ad recombinants is impractical due the extremely high number 
of possible combinations (>28,000 pair-wise combinations for 168 Ad recombinants).  
The majority of genes were expressed with C-terminal tags. Obvious benefits of this approach 
include the potential to rapidly and efficiently (i) assess gene expression, (ii) purify tagged 
proteins, and (iii) study protein-protein interactions by immunoprecipitation. A disadvantage 
of this epitope-tagging strategy lies in uncertainties about interference of the tag with protein 
function. For a small number of genes such as the MHC class-I-downregulating US2, US3, US6 
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and US11 genes, function of the tagged protein can be tested with ease (see chapter 4), but 
this is not possible for most other gene products.  
Use of the RAd library in functional screening of HCMV genes is detailed in chapter 4, and 
discussed further in chapter 7. 
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4- Regulation of Fas 
expression by HCMV 
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4.1. HCMV and death receptors 
HCMV encodes functions that act to suppress both intracellular, and death receptor-induced 
apoptotic signalling (see Section 1.7). The effect of HCMV infection on the surface expression 
levels of the death receptor molecules has not been fully elucidated. Although infection with 
strain AD169 results in reduced TNFRI expression at the cell surface, the HCMV gene(s) 
responsible has yet to be identified (Baillie et al., 2003). Interestingly, strains carrying an intact 
ULb’ region do not downregulate cell surface TNFRI (Montag et al., 2006). This is because a 
ULb’ gene (UL138) potentiates cell surface TNFRI expression, thus masking the TNFRI-
downregulating function (Le et al., 2011, Montag et al., 2011). 
Fas (CD95, Apo-1) is a member of the TNF receptor superfamily that is capable of promoting 
apoptosis following stimulation by its paired activator, Fas ligand (Kägi et al., 1994). The HCMV 
UL36 and UL37 gene products efficiently inhibit Fas-mediated apoptosis by inhibiting caspase-8 
activation and cytochrome C release respectively (Goldmacher, 2005, Skaletskaya et al., 2001). 
Nevertheless the effect of HCMV infection on expression of Fas itself is poorly understood. 
Chaudhuri et al reported that infection with the Smith and Eisenhardt strains stimulated Fas 
surface expression in fibroblasts leading to their killing, and that Fas could not be detected on 
uninfected fibroblasts (Chaudhuri et al., 1999). This is somewhat surprising given that Fas 
expression has routinely been observed on human fibroblasts by others (Aggarwal et al., 1995, 
Freiberg et al., 1997, Jelaska and Korn, 1998, Tepper et al., 2000). Also, considering HCMV 
elicits broad anti-apoptotic responses, upregulation of Fas in infected cells is counter-intuitive. 
I therefore sought to investigate the regulation of Fas surface expression by HCMV.  
4.2. HCMV downregulates Fas from the 
cell surface 
Fas expression on the surface of strain Merlin-infected and mock-infected fibroblasts was 
analysed by flow cytometry in a time-course assay. As shown in Figure 4.1, Fas was 
consistently downregulated on infected cells at 1, 2, and 3 days p.i.. MHC class-I staining was 
included as a positive control for the efficiency of infection. Genes US2, US3, US6 and US11 are 
all known to decrease MHC class-molecules at the surface of infected cells (see Section 
1.7.3.2). Consistent with this expectation, MHC class-I was efficiently downregulated at all 
three time-points. Comparative levels of Fas downregulation were also observed at the true-
late stage of infection (6 days p.i., data not shown). Downregulation of cell surface Fas is a 
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novel HCMV function, with potential implications in the interaction between HCMV infected 
cells and the host’s immune system.  
4.2.1. Screening a panel of Merlin block deletion 
mutants for loss of Fas downregulation 
 I next aimed to map the gene responsible for Fas downregulation by screening a panel of 
Merlin block deletion mutants in a loss of function assay. Figure 4.2 is a diagrammatic 
representation of the region deleted in each of these mutants. The block deletion mutants 
were all produced in a Merlin ΔUL16, ΔUL18 virus carrying a GFP tag on the end of UL32 
(designated RCMV1278). RCMV1278 was initially designed as a backbone for block deletions 
because of its utility in NK cell modulation. In vitro, cells infected with wild-type Merlin are 
almost completely resistant to NK cell recognition, whereas uninfected cells stimulate NK cell 
activation. UL16 and UL18 are known to contribute to NK cell suppression; infection with 
RCMV1278 therefore results in intermediate NK cell inhibition. Deletion of further NK cell 
evasion genes from 1278 would then result in a virus more sensitive to NK-mediated killing, 
whereas deletion of NK cell activating genes would render the virus more resistant to NK cells.  
It was necessary to first compare Fas cell surface expression between cells infected with Merlin 
and RCMV1278. Comparable levels of Fas and MHC class-I downregulation were observed with 
both viruses at 3 days p.i. (Figure 4.3a). This result established that UL16 and UL18 were not 
required to suppress Fas expression. GFP was observed by immunofluorescence in cells 
infected with RCMV1278, but not in mock-infected, or Merlin-infected cells (Figure 4.3b).  
The block deletion mutants were then tested alongside 1278 by flow cytometry at 3 days p.i.. 
Please note that since deletion of some genes elicits growth defects, the MOIs used in this 
experiment were adjusted, in order to achieve equivalent cytopathic effect, UL32-GFP 
expression and MHC class-I down-regulation. Wildtype-like downregulation of cell surface Fas 
was observed with all deletion mutants tested (Figure 4.4). Also, MHC class-I was 
downregulated by all viruses except the ΔUS2-US11 mutant, which upregulated MHC class I. 
This upregulation was expected, and is attributed to enhanced interferon signalling in HCMV-
infected cells. In this loss-of-function assay, none of the 58 genes deleted from this bank of 
HCMV mutants was found to be required for Fas downregulation.  
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IgG control                            Fas                                         MHC Class-I 
IgG control                           Fas                                          MHC Class-I 
Figure 4.1 
Time-course of Fas downregulation by Merlin  
Fas expression on the surface of mock-infected and Merlin-infected cells (MOI 10) was 
analysed by flow cytometry at 1, 2, and 3 days p.i. Cells were stained with Fas, MHC class-I 
or IgG control primary antibodies, and an Alexa fluor 647 secondary antibody. For each 
time-point, control IgG, Fas and MHC Class-I staining are shown in the left-hand, middle and 
right-hand histograms respectively. Mock and Merlin samples are shown in black and red 
respectively.   
Mock 
Merlin 
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ΔRL1-RL6              ΔRL10-UL1     ΔUL2-UL11       ΔUL13-UL20         ΔUL22A-UL25 
ΔUS2-US11         ΔUS12-US17   ΔUS18-US22                   ΔS27,US28  ΔUS29-US34A    
Figure 4.2 (adapted from Gatherer et al 2011): Diagrammatic representation of the available Merlin block deletion mutants. 
Red rectangles represent the region deleted in each block mutant, and the deleted genes are listed above in red writing. All 
deletions were made in a ΔUL16, ΔUL18, UL32-GFP background; the original virus is designated 1278.  
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Figure 4.3 
Fas downregulation by Merlin and a Merlin ΔUL16, Δ UL18 virus       
a) Fas expression on the surface of cells infected with Merlin and a Merlin ΔUL16, ΔUL18, 
UL32-GFP virus (designated 1278) were analysed by flow cytometry. RCMV 1278 was used 
to generate Merlin block deletion mutants which were used in loss of function screening. 
HFFFs were infected at MOI 10 with Merlin and 1278. 3 days post-infection cells were 
stained with Fas, MHC class-I or IgG control primary antibodies, and an Alexa fluor 647 
secondary antibody. Control IgG (dotted lines), Fas (thick lines) and MHC Class-I (thin lines) 
staining are shown in the left-hand, middle and right-hand histograms respectively. Mock 
samples are shown in black, whilst Merlin and 1278 samples are displayed in red and blue 
respectively. b) Images of cell monolayers were obtained prior to harvest of samples; UL32-
GFP expression was detected in 1278-infected cells and overlaid with phase contrast image. 
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Figure 4.4 
Loss of function screening of Merlin block deletion  
Surface Fas expression was compared by flow cytometry between cells infected with 1278 
and various Merlin mutants each lacking a block of non-essential genes. The region deleted 
in each block deletion mutant is indicated in red writing. Infections were carried out in HFFFs 
at MOI 10, excepting ΔUL13-UL20 and ΔUS27-US29 viruses were used at MOI 50, and ΔUS29-
US34A, ΔRL1-RL6 , and ΔUS18-US22 infections performed at MOIs 15, 25 and 60 
respectively. Cells were harvested 3 days p.i. Infected cells were stained with Fas, MHC class-
I or IgG control primary antibodies, and an Alexa fluor 647 secondary antibody. Control IgG 
(dotted lines), Fas (thick lines) and MHC Class-I (thin lines) staining are shown in the left-
hand, middle and right-hand histograms respectively. Black lines represent mock samples, 
whilst 1278 and deletion mutant samples are displayed in blue and red respectively. Cells 
infected with 1278 or any of the deletion mutants were gated for GFP expression.  
Mock    mutant           1278 
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4.2.2. Gain of function screen using the RAd-library 
Next, the RAd library of HCMV genes (see Chapter 3) was used in a gain-of-function assay for 
Fas downregulation. HFFF-hCARs were infected with Ad recombinants, each at an MOI of 10, 
and Fas expression detected 3 days p.i. by flow cytometry. In line with published results, RAds 
expressing US2, US3, US6 and US11 each downregulated MHC-class I surface expression 
(Figure 4.5). Otherwise levels of surface MHC class-I staining served to provide an indicator of 
cytotoxicity. The screen was repeated at lower MOIs for viruses that perturbed MHC-class I 
surface expression. In addition, a subset of Ad recombinants was associated with overt 
cytotoxicity during expression analysis of the RAd-library (see Section 3.4.2); these constructs 
were also re-screened at an MOI of 1. 
None of the 170 RAds screened was observed to downregulate cell surface Fas; the complete 
negative dataset is not reproduced. For illustration, representative data are shown in Figure 
4.5 for RAds encoding US1-US11, and the vector control. The US1-US11 block was selected to 
illustrate that US2, US3, US6 and US11 all clearly downregulated MHC class-I, a result that 
validates the use of the Ad library in functional screening. 
 The results of the gain-of-function assay suggest expression of no single HCMV Merlin gene is 
sufficient for Fas downregulation. It is possible that the function responsible was not encoded 
by an annotated gene, and thus was absent from the screen. Expression from 8 genes was not 
detected by western blot or Immunofluorescence (see Section 3.3.6). Of these, RL6, US9, US14 
and US17 are deleted in block deletion mutants used in loss-of-function screening. UL146 is 
encoded in the UL/b’ region, and is thus missing from strain AD169. HCMV deletion mutants 
covering RL9A, UL30A and UL33 were not available; nor were constructs of non-coding RNAs 
(except β-2.7) or miRNAs included in this assay. Moreover, it was clear that a number of HCMV 
genes work in combination, often as a multiprotein complex (see Sections 3.4.3.2 and 3.4.4.2). 
If more than one protein-coding gene was required to provide for efficient Fas 
downregulation, then it would not necessarily have been found by screening the Rad library. 
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Figure 4.5 
Gain of function screening of RAd-expressed HCMV genes for Fas downregulation 
Fas expression on the surface of RAd-infected and mock-infected cells was analysed by flow 
cytometry in a gain of function assay. HFFF-hCARs were infected at MOI 10 (except where 
specified otherwise in section 4.2.2) with RAds expressing HCMV genes, or an empty control 
RAd. 3 days p.i., cells were stained with Fas, MHC class-I or IgG control primary antibodies, 
and then an Alexa fluor 647 secondary antibody. Control IgG (dotted lines), Fas (thick lines) 
and MHC Class-I (thin lines) staining are shown in the left-hand, middle and right-hand 
histograms respectively. Staining of mock samples is shown in blue, and infected cell staining 
displayed in red. Infection with the control RAd did not modulate Fas expression; a typical 
histogram is shown. Only RAds expressing genes US1 to US11 are included here.  
Mock RAd 
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4.2.3. Fas downregulation is a conserved function 
between HCMV strains 
I sought to extend loss of function screening to ULb’ genes, and other genes missing/inactive in 
other available HCMV strains. I was also interested to know if Fas downregulation is a 
conserved function between HCMV variants. Cell surface Fas expression was compared 
between cells infected with the Merlin, AD169, FIX and TB40 viruses in HFFF-hTERT, HFFF, and 
primary fibroblasts (donor DC) at 3 days p.i.. As shown in Figure 4.6, Fas was efficiently and 
equally downregulated by all 4 strains. Compared to cells infected with strains Merlin and 
AD169, FIX- and TB40-infected cells displayed incomplete downregulation of MHC class-I 
molecules from mock levels. This is explained by the fact that the BACs from which strains FIX 
and TB40 were derived lack some known MHC class-I-downregulating genes (FIX lacks US2, 
US3 and US6, whilst TB40 is missing US3 and US6.  
Although it was not possible to map the gene(s) responsible for Fas downregulation, loss of 
function screening using a combination of Merlin block deletion mutants, and alternative 
HCMV strains led me to definitively discount 83 of 171 HCMV Merlin genes as not required for 
Fas downregulation. These include 58 genes that have been deleted in our collection of Merlin 
block deletion mutants, UL36, UL131A, and the 20 UL/b’ genes present in Merlin but 
inactive/absent in AD169 (Bradley et al., 2009), IRS1 and US1 which are replaced by BAC 
sequences in FIX and TB40, and UL128 which is mutated in Merlin itself (Dolan et al., 2004).  
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Figure 4.6 
Fas downregulation is a conserved function between HCMV strains 
Reduction of Fas levels on the surface of a) HFFF-hTERTs, b) HFFFs and                                             
c) primary DC fibroblasts by strains Merlin, AD169, FIX orTB40. Cells were infected at MOI 10 
and harvested 3 days p.i.. Infected cells were stained with Fas, MHC class-I or IgG control 
primary antibodies, and an Alexa fluor 647 secondary antibody. Control IgG, Fas and MHC 
Class-I staining are shown in the left-hand, middle and right-hand histograms respectively. 
Staining of mock and infected samples are shown in black and red respectively.  
IgG control                           Fas                                          MHC Class-I 
IgG control                            Fas                                         MHC Class-I 
IgG control                           Fas                                          MHC Class-I 
IgG control                           Fas                                          MHC Class-I 
Merlin  
AD169  
FIX 
TB40 
Mock 
HCMV 
c) DC fibroblasts 
190
191 
 
4.2.4. Fas downregulation requires de novo viral 
protein synthesis 
Prolonged exposure to gamma irradiation is known to cause irreparable DNA damage, and 
ablate de novo protein expression. Infection of cells with gamma-irradiated HCMV allows 
functions that require de novo viral protein expression, to be distinguished from functions 
performed by virion proteins. To examine whether de novo protein synthesis is required for 
Fas downregulation, strain Merlin virus was irradiated overnight with gamma rays, and its 
effect on cell surface Fas expression compared to that of active Merlin virus. Since gamma 
irradiation was performed at room temperature, it was necessary to also include infection with 
a separate Merlin sample that had also been kept at room-temperature. As shown in Figure 
4.7, cells infected with gamma irradiated virus did not show Fas downregulation; in fact an 
upregulation of Fas was observed on the surface of these cells. Surface expression of MHC 
class-I also increased slightly, recapitulating the effect seen with the ΔUS2-US11 mutant in the 
loss of function assay. Cells infected with the room temperature control virus showed efficient 
downregulation of Fas and MHC class-I molecules, demonstrating that incubation at room 
temperature was not responsible for loss of Fas-downregulating function. Taken together, 
these data affirm that de novo HCMV gene expression and protein synthesis are required for 
downregulation of cell surface Fas.  
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Fas downregulation by strain Merlin requires de novo viral gene expression 
Surface  Fas expression was  compared between cells infected with Merlin, Gamma-
irradiated Merlin, and a temperature control for gamma irradiation. At 3 days p.i., cells were 
stained with Fas, MHC class-I or IgG control primary antibodies, and an Alexa fluor 647 
secondary antibody. Control IgG, Fas and MHC Class-I staining are shown in the left-hand, 
middle and right-hand histograms respectively. Mock and Merlin samples are shown in black 
and red respectively.   
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4.2.5. Fas downregulation begins at early times of 
infection 
Fas downregulation was clearly evident as early as 24 hours p.i. (Figure 4.1). To characterise 
the temporal aspect of this function more precisely, the experiment was repeated at earlier 
time-points (Figure 4.8). Fas expression levels remained unchanged compared to mock-
infected controls at 2, 6, 12 and 18 hours p.i., but were markedly reduced at 24 hours p.i.. 
Similarly, infected cells displayed impaired MHC class-I presentation only at 24 hours p.i.. This 
concurs with published reports describing the kinetics of MHC class I downregulation (Ahn et 
al., 1996, Hengel et al., 1996, Park et al., 2002).  
The results of this experiment evinced that Fas downregulation begins at early stages of HCMV 
infection. The fact that no change in cell surface Fas expression was observed 2 hours p.i. or in 
cells infected with gamma-irradiated HCMV virions further suggests virus binding alone is 
insufficient for Fas downmodulation. 
4.2.6. Fas is downregulated at the post-
transcriptional level 
A Q-PCR assay performed at 3 days p.i. showed Fas mRNA levels in fibroblasts were unchanged 
by infection with strain Merlin (Daniel Sugrue, personal communication). It was therefore 
hypothesised that HCMV may regulate Fas at a post-transcriptional level. To investigate 
whether Fas downregulation is limited to surface expression or extends to a reduction in total 
protein levels, Fas levels in lysates of HCMV-infected and mock-infected cells were compared. 
Cells infected with strains Merlin, AD169, FIX or TB40 were harvested on days 1, 2, and 3 p.i.. 
As illustrated in Figure 4.9a, no clear difference in Fas levels was observed between any of the 
5 samples at 1 day p.i.. At 2 days p.i., Fas appeared more abundantly expressed in TB40-
infected cells compared to the other 4 samples, whilst infection with strain FIX resulted in 
some decrease in Fas expression. On day 3, Fas levels appeared modestly diminished in cells 
infected with each of the 4 virus strains. While Fas expression decreased significantly at the 
cell surface, only a modest decrease in absolute levels of Fas in infected cells were observed.   
4.2.6.1. Fas glycosylation state 
 Fas is a type I transmembrane receptor, and has previously been reported to be N-
glycosylated (Keppler et al., 1999, Li et al., 2007, Peter et al., 1995, Shatnyeva et al., 2011). To 
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assess whether surface downregulation of Fas may occur as a results of ER retention, total cell 
lysates were treated with EndoH or PNGaseF enzymes. Proteins tend to become resistant to 
EndoH during maturation through the Golgi apparatus, but remain sensitive if retained in the 
ER. Sensitivity to EndoH in infected cells but not in mock cells would therefore indicate 
retention in the ER compartment. As shown in Figure 4.9b, Fas in Mock and Merlin-infected 
cells appeared resistant to EndoH treatment, but sensitive to PNGaseF treatment. PNGaseF 
treatment reduced the apparent molecular weight of Fas to 34 kDa; this is consistent with the 
predicted size of ~35 kDa for un-glycosylated Fas (Garcia-Fuster et al., 2004). It thus appears 
that HCMV-mediated Fas downregulation is not caused by ER-retention.  
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Merlin Figure 4.8: 24 hour time-course of Fas downregulation by Merlin  
Fas expression on the surface of Merlin-infected cells (MOI 10) was analysed by flow 
cytometry at 2, 6, 12, 18 and 24 hours post-infection. At indicated times, cells were stained 
with Fas, MHC class-I and anti-mouse IgG primary antibodies, and an Alexa fluor 647 
secondary antibody. Control IgG, Fas and MHC Class-I staining are shown in the left-hand, 
middle and right-hand histograms respectively. Mock and Merlin samples are shown in black 
and red respectively.   
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Figure 4.9: Western blot analysis of Fas in lysates of mock and HCMV-infected 
fibroblasts 
a) HFFF-hTERTs were infected with strains Merlin, AD169, FIX and TB40 at MOI 10, or mock-
infected. Total cell lysates were harvested at 1, 2 or3 days p.i. 
samples were electrophoresed in a polyacrylamide gel under reducing and denaturing 
conditions. Proteins were transferred to a nitrocellulose membrane, and probed with Fas or 
GAPDH primary antibodies, and an HRP-conjugated rabbit antibody. The position of the 40 
kDa molecular weight marker is indicated. b) Day 3 Merlin-infected (lanes 1-3) and Mock-
infected cells (lanes 4-6) were treated with EndoH (lanes 2 and 5), or PNGaseF (lanes 3 and 6) 
enzymes. Lanes 1 and 4 are undigested controls. The position of the 30, 40 and 50 kDa 
molecular weight markers is shown. 
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4.2.7. HCMV infection protects against Fas-
mediated apoptosis 
In order to ascertain whether cell surface Fas downregulation by HCMV correlated with 
enhanced resistance to Fas-mediated apoptosis, the activities of effector caspases 3 and 7 
following induction of Fas were compared between mock-infected and Merlin-infected cells. In 
order to induce Fas-signalling, cells were treated with Fas ligand or a cross-linking Fas mAb;  
soluble TRAIL receptor-2 or IgM control antibodies were included to control for the specificity 
of Fas targeting. Caspase 3/7 activity was measured by the Caspase-Glo 3/7 assay. In this assay, 
caspases 3 and 7 cleave a luminogenic substrate in the presence of a recombinant luciferase; 
this reaction results in the generation of a stable ‘glow-type’ luminescent signal. The amount 
of luminescence is proportional to the amount of caspase activity, and can be measured in a 
plate-reader.  
Compared to mock cells, strain Merlin-infected cells were less sensitive to Fas signalling 
induced by either Fas ligand or Fas antibody (Figure 4.10, P=<0.001). No significant difference 
in caspase activity between mock and Merlin-infected cells was observed after treatment with 
media only, soluble TRAIL receptor-2, or IgM control antibody. The results of this assay indicate 
that HCMV infection elicits protection from Fas-mediated apoptosis. In this assay, the anti-
apoptotic contribution of Fas downregulation cannot be distinguished from those of pUL36 
and pUL37. While it is expected that reduced levels of cell surface Fas lead in turn to a 
reduction in Fas signalling, this could only be confirmed using a ΔUL36, ΔUL37 virus. UL37 is 
known to be essential for virus replication in vitro (Goldmacher et al., 1999), whilst 
contradictory reports have been published with regards dispensability of UL36 (Dunn et al., 
2003c, Patterson and Shenk, 1999, Smith and Pari, 1995). Deletion of UL36 from the Merlin 
BAC resulted in a virus with severe growth defect (results not shown). The relative 
contributions of Fas down-regulation, and pUL36 and pUL37 activity towards inhibition of Fas-
mediated apoptosis could therefore not be dissected in the context of HCMV infection.  
  
Figure 4.10: Strain Merlin-infected cells are more resistant to Fas-mediated
apoptosis than un-infected controls 
5x103 HFFF-hTERTs were infected with Merlin at MOI 10, or mock-infected. At 60 
hours p.i., cells were treated with soluble TRAIL receptor-2, Fas ligand, IgM isotype 
control antibody, or Fas mAb. At 72 hours p.i., cells were incubated with Caspase-
Glo 3/7 reagent for 1 hour. Luminescence generated by caspase 3/7 activity was 
measured in relative light units (RLU) in a plate reader. Results are presented as 
means ± SEM of quadruplicate samples. 
P=<0.001 
P=<0.001 
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4.3. Summary 
In short, it was demonstrated that infection of fibroblasts with HCMV results in reduction of 
cell surface Fas expression. This phenotype was first detected at 24 hours p.i., and persisted 
into true-late stages of infection. Moreover, reduced Fas cell surface expression correlated 
with resistance to Fas-mediated anti-apoptotic activity. Loss-of-function and gain-of-function 
screens using available HCMV deletion mutants and RAd-encoded HCMV genes respectively 
could not identify the function(s) responsible. Fas was preferentially removed from the cell 
surface while intracellular stores appeared relatively intact. This argues protein degradation is 
unlikely to be responsible for decreased expression of Fas on the cell surface. In addition, the 
fact that Fas is resistant to EndoH digestion in both un-infected and Merlin infected cells 
suggests ER-retention does not account for HCMV-mediated Fas downregulation. The possible 
mechanism of Fas downregulation is further discussed in chapter 7 
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5.1. Alternative splicing in HCMV 
Alternative splicing is the process by which a single primary RNA transcript (pre-mRNA) is 
differentially spliced to produce multiple mRNA variants. As a mechanism of generating 
functional diversity, alternative splicing has a number of advantages, such as low genetic 
expenditure. Alternative splicing is particularly useful in the case of viruses such as HCMV, 
where genome packaging is under strict size constraint.  
Nuclease mapping first identified the MIE pre-mRNA to be a spliced transcript containing 4 
exons, separated by 3 introns (Stenberg et al., 1984, Akrigg et al., 1985, Wilkinson et al., 1984). 
At least 5 different mRNA molecules are known to arise from the MIE pre-mRNA, including 
transcripts for IE72 and IE86 (Akrigg et al., 1985, Awasthi et al., 2004, Kerry et al., 1995, 
Shirakata et al., 2002). Expression of the US3 gene produces an unspliced mRNA, and 2 
additional spliced variants (Tenney et al., 1993, Weston, 1988). By nuclease mapping, 3 
alternatively spliced transcripts were found to originate from the UL37 gene (Kouzarides et al., 
1988). Subsequent studies on the UL37 gene discovered several additional spliced transcripts, 
many of which are expressed at extremely low amounts during HCMV infection, but whose 
protein products have not been detected (Adair et al., 2003, Goldmacher et al., 1999, Su et al., 
2003). The UL112 transcript undergoes complex splicing; truncated 2.1 kb and 2.2 kb 
transcripts were abundant at early times of infection, but gradually replaced by a larger splice 
variant of 2.5 kb, as well as the unspliced 2.65 kb transcript at late times p.i. (Wright and 
Spector, 1989). Leatham et al. reported that transcription from UL119-UL115 gives rise to 
alternatively spliced transcripts at different times of infection (Leatham et al., 1991). Later, RT-
PCR of cDNA from HCMV-infected cells using primers designed to bind splice sites revealed 
novel splice variants in regions corresponding to the UL22A, UL89, RNA5.0 and UL119 genes 
(Rawlinson and Barrell, 1993). The UL33 gene was also found to undergo splicing (Margulies et 
al., 1996), and more recently, characterisation of RNA5.0 demonstrated that splicing of its 2 
exons generates RNA1.1 (Kulesza and Shenk, 2004). Kotenko et al. demonstrated that the viral 
IL-10 mRNA was formed by the splicing of 2 exons, separated by an intron present in the 
primary transcript (Kotenko et al., 2000b). The spliced UL128 and UL131A genes were 
predicted from sequence comparisons between HCMV and CCMV, and their splicing patterns 
confirmed by mRNA mapping (Akter et al., 2003). Discovery of a polypeptide derived from 
both the UL28 and UL29 proteins prompted the hypothesis that these proteins are expressed 
from a spliced mRNA (Moorman et al., 2008). Subsequently it was shown that the UL28/UL29 
protein is expressed from a primary transcript carrying multiple donor and acceptor sites 
(Mitchell et al., 2009).  
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5.1.1. Novel HCMV spliced transcripts revealed by 
deep sequencing  
In an attempt to better understand HCMV gene expression during productive infection, and 
with particular focus on splicing, Gatherer et al. carried out deep sequencing of viral transcripts 
in human fibroblasts 3 days after they were infected with the Merlin strain (Gatherer et al., 
2011). Analysis of transcripts revealed splicing is more common than previously anticipated; 
following exclusion of probable artefactual reads, a total of 389 potential splice sites including 
229 donor and 132 acceptor sites were identified. Reverse Transcription-PCR (RT-PCR) and 
rapid amplification of cDNA ends (RACE)-analysis strongly supported these findings.  
4 new genes (RL8A, RL9A, UL150A, and US33A) were identified based on information obtained 
from the analysis. Additionally, 5 acceptor sites were found to be spliced from a large number 
of upstream donor sites including exons which may 5’ extend the coding region, and these are 
henceforth referred to as superacceptor site (SASs). SASs are located upstream of RL8A, 
UL74A, UL92, UL124, and UL150A (pair of SASs) predicted coding regions, and except one of 
the pair, all are conserved in CCMV. The SASs in the vicinity of RL8A, UL74A, UL124, and 
UL150A were further characterised. Figure 5.1 illustrates the position of these SASs and their 
predicted donor sites in the Merlin genome.  
Of the 5 coding regions present in the vicinity of SASs, UL92 and UL124 are recognised ORFs. 
RL8A is conserved in CCMV, and its predicted protein product contains potential 
transmembrane regions. 5’ ends of 4 upstream exons were found to be spliced to the RL8A 
SAS, but RL8A appeared weakly expressed, since transcript sizes generated in RACE analysis 
were not detected by northern blotting. UL74A is predicted to encode a membrane 
glycoprotein (Scalzo et al., 2009), whilst UL150A is antisense to UL150. The UL150A coding 
region is made up of two exons separated by an intron, which gives rise to miR-UL148D. 
Furthermore the 2 UL150A exons and their intervening intron are all conserved in CCMV. 
UL74A and UL150A SASs are spliced from the 5’ ends of 4 upstream exons each, and the 
locations of these exons are consistent with the sizes of transcripts detected by northern blot.  
  
Figure 5.1 (adapted from figure S3 of Gatherer et. al. 2011): Splicing of HCMV trancripts identified by deep sequencing 
Deep sequencing the Merlin transcriptome identified 4 novel splice superacceptor sites (SASs) from RNA splicing. 3’ exons of RL8A 
(green), UL74A (red), UL124 (blue) and UL150A (orange) are shown as coloured arrows with diagonal lines at the beginning. The gap 
between UL150A exons represents intronic sequences. An SAS was identified closely upstream of each of these 3’ exons. Exons whose 
5’ ends were found by RACE to be spliced to SASs are shown as arrows beginning with vertical bars. Where in close proximity to each 
other, these upstream exons have been combined. Other donor sites that were located upstream and in the same orientation as their 
corresponding SAS are shown as vertical hockey stick symbols.  
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5.2. Generation of recombinant Merlin 
virus encoding tagged UL74A and 
UL150A genes 
To validate the prediction that UL74A and UL150A are protein coding genes, and to test 
whether alternative splicing of their transcripts may result in the generation of diverse protein 
products, I analysed the expression of these genes in the context of HCMV infection. We had 
previously been successful in the detection of V5-tagged proteins in the Ad-library (see 
Chapter 3). A two-step recombineering approach was used to insert V5 epitope tags at the C-
terminus of the UL74A and UL150A ORFs within the Merlin BAC (separate viruses), and the 
recombinant viruses were designated RCMV1569 and RCMV1571 respectively. In the first 
recombineering round, the ampicillin resistance/LacZ/SacB cassette was inserted after the 
UL74A and UL150A genes, and colonies containing the cassette identified by positive selection 
(see Section 2.3.8.1). In the second recombineering round, the cassette of selectable markers 
was replaced with a V5 tag and recombinants identified by negatively selecting against the 
cassette. Figure 5.2 contains a diagrammatic representation of the cloning steps.  
Since sucrose was used in negative selection to inhibit the growth of SacB-expressing bacteria, 
it was necessary to validate SacB expression after the first recombineering round. This was 
done by assessing the growth of bacteria on media with or without sucrose (Figure 5.3). 
Colonies with mutated SacB genes grew equally well on sucrose and non-sucrose plates, and 
were discarded. However, growth of colonies with fully functioning SacB genes was inhibited 
by sucrose; these were selected for the second recombineering round. The sequence of 
regions undergoing recombineering was then validated, and recombinant HCMV generated 
(see Sections 2.9.1-2.9.3).  
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Figure 5.2: V5-tagging UL74A and UL150A genes 
V5 tags were inserted at the C-terminus of the 
predicted UL74A (nucleotide position 109050) and 
UL150A (nucleotide position 194124) genes 
immediately before their respective stop codons. 1- 
The ampicillin resistance/LacZ/SacB (see Section 
2.3.8.1) was amplified by PCR from the AdZ vector 
(see chapter 3). Primers used to amplify the cassette 
carried 5’ overhangs homologous to regions either 
side of the insertion site. 2- The cassette was 
inserted at the C-terminus of the UL74A and UL150A 
genes in the first recombineering round, and 
recombinants identified by positive selection for the 
cassette. 3- In the second recombineering round, 
overlapping oligonucleotides replaced the cassette of 
selectable markers with a V5-tag. These oligos 
contained the V5-tag at their overlapping 3’ ends, 
and were homologous at their 5’ ends to regions 
upstream and downstream of the insertion site. 
Recombinants were identified by negative selection 
against the cassette.The sequence of regions 
undergoing recombination was validated  before 
generation of recombinant virus. The primer 
sequences used for inserting tags into the Merlin 
BAC, and for validating recombinants are provided in 
Appendix II.  
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Figure 5.3: 
Testing SacB expression in bacteria containing the selection cassette 
 By positive selection, clones 1 and 4 were identified to contain the ampicillin 
resistance/LacZ/SacB/ cassette. Resuspensions of each colony were streaked 
onto +sucrose (b & d), or -sucrose (a & c) media, and plates incubated at 32⁰C 
overnight. Sucrose sensitivity is observed on plate (b) but not plate (d). Clones 1 
and 4 therefore contain functioning and mutated SacB respectively.  
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5.3. Expression analysis of UL74A and 
UL150A gene products 
To characterise protein expression from UL74A and UL150A, HFFF cells were infected with the 
tagged viruses, and immunoflourescence and western blot analyses performed over a time-
course. Using both methods, protein expression was confirmed for UL150A (Gatherer et al., 
2011) but not UL74A (Figure 5.4). For UL150A, a 34kDa doublet was detected 1 day p.i., which 
became more abundant at day 3, and yet more abundant at day 6 (figure 5.4a). Another less 
pronounced also 50 kDa band appeared 3 days p.i.. Particularly when the actin protein loading 
control is considered, this higher molecular weight isoform is more abundantly expressed late 
in infection. The predicted mass of the tagged primary translated protein was 31 kDa, similar 
to that of the most abundant doublet detected. Multiple forms of pUL150A are therefore 
expressed during the early times of infection that become abundant as the infection 
progresses; a result that is consistent with the gene being differentially spliced.  
pUL150A was also detected by immunofluorescence at all three time-points (figure 5.4b). It 
resided in close proximity to the nuclei of infected cells, often forming aggregates resembling 
the ER/Golgi complex.  
Although epitope-tagged UL74A was not detected by western blot and immunofluoresence, 
this protein may still be expressed by HCMV. Lack of detection could be caused by the cleavage 
of the C-terminal tag, or folding of the protein in a manner preventative of antibody binding. 
Summary 
Detection of UL150A protein products in the context of HCMV infection validates the 
prediction of UL150A as a coding region. The main UL150A protein-coding sequence is 
captained within the larger UL150 gene that is present on the opposing DNA strand and 
transcribed in the opposite orientation; yet its amino acid sequence is better conserved than 
UL150. The discovery of this novel gene demonstrates for the first time the presence of 
overlapping coding genes on opposite strands of the HCMV genomic DNA 
  
          d1    d3      d6 
Figure 5.4: Timecourse expression analysis of Merlin UL74A
and UL150A  proteins 
UL74A and UL150A genes were V5-tagged in Merlin to produce 
recombinant viruses RCMV1569 and RCMV1571 respectively. 
HFFFs were infected at MOI=5, and expression of tagged proteins 
analysed at 1, 3, and 6 days p.i. by a) Western blot: membrane 
was probed with V5 or actin primary, and an HRP-conjugated 
secondary antibody; b) immunofluorescence: cells were fixed and 
permeabilised, and HCMV proteins detected using the V5 mAb, 
and an Alexa Fluor 594 secondary antibody. Nuclei were stained 
with DAPI and expression was visualised microscopically using a 
x40 oil objective. No V5 expression was detected in RCMV1569-
infected cells; only RCMV1571-infected cell images are shown.  
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6.1. HCMV secretome 
HCMV has been shown to profoundly affect the secretome of infected cells (Dumortier et al., 
2008); this mostly impacts on release of  immune-suppressant proinflammatory cytokines and 
chemokines. Indeed, a small number of HCMV-encoded proteins have also been reported to 
be secreted from infected cells: (i) US22 is a nuclear protein that was also detected in infected-
cell supernatants (Mocarski et al., 1988). (ii) The glycoprotein product of the UL22A gene, 
originally designated R27080, is a secreted chemokine receptor that selectively binds RANTES 
(Müllberg et al., 1999, Wang et al., 2004). (iii) gpUL111A (cmvIL-10)  is able to bind the IL-10 
receptor in competition with cellular IL-10 (Kotenko et al., 2000a). (iv) UL146 and UL147 
proteins exhibit limited homology to the CXC chemokine IL-8, and are named vCXC-1 and vCXC-
2 respectively (Penfold et al., 1999). vCXC-1 is secreted during late times of infection and binds 
the CXCR2 receptor with affinity comparable to IL-8. (v) More recently, UL7 has been shown to 
encode a type-I transmembrane glycoprotein with structural homology to CD229, a cell surface 
receptor of the signalling lymphocyte-activation molecule (SLAM) family. The ectodomain of 
gpUL7 is shed from the surface of infected cells and binds monocyte-derived dendritic cells 
(DCs) to modulates cytokine production (Engel et al., 2011). I wished to test whether the RAd 
library could be used to identify and characterise novel HCMV secreted proteins 
6.2. Screening for secreted HCMV 
proteins 
As an extension of the expression studies described in chapter 3, supernatants of cells infected 
with the RAd library of HCMV genes were screened by western blot using the V5 antibody. 
Secreted UL22A was not detected using the V5 antibody, but a polyclonal antibody raised 
against RAd-UL22A detected a protein closely resembling in size the reported 45kDa R207080 
(data not shown). Similarly, UL7 was detected by the V5 antibody in the extracts but not the 
supernatants of infected cells (see Figure 3.3, supernatant data not shown). This is in 
agreement with the finding that the UL7 C-terminus remains intracellular following shedding 
of the ectodomain (Engel et al., 2011). Secreted products of UL111A, UL146, and US22 were 
not detected; these proteins may still be secreted at low amounts when expressed using Ad 
recombinants. The secreted product of one other gene (UL4) was also detected in 
supernatants of RAd-infected cells. 
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6.2.1. Secretion of gpUL4  
gpUL4 was identified as being secreted during the screen of the RAd library. On a western blot, 
secreted gpUL4 migrated as a diffuse band corresponding to an apparent molecular mass 
ranging between 52-60 kDa; in comparison with a ~50 kDa species detected in extracts of RAd-
UL4-infected cells (Figure 6.1a). The size difference between the intracellular and secreted 
forms, characteristic of secreted proteins, implied that an additional post-translational 
maturation step was associated with secretion, and the extracellular form did not represent 
contamination arising from spontaneous lysis of RAd-UL4-infected cells. 
 Chang et al. identified a 48 kDa product which they designated gp48 (herein referred to as 
gpUL4) in extracts of infected with HCMV strain Towne, using polyclonal sera raised against an 
in vitro-translated UL4 polypeptide (Chang et al., 1989). The in vitro synthesised polypeptide 
migrated at 17 kDa, consistent with the size predicted for the UL4 primary translation product. 
Treatment of strain Towne-infected cells with tunicamycin, an inhibitor of N-linked 
glycosylation, resulted in accumulation of a smaller 27 kDa protein. This was still 10 kDa larger 
than the primary UL4 translation product, leading the authors to suggest that gpUL4 is possibly 
both N- and O-glycosylated (Chang et al., 1989).  
To characterise glycan modifications of gpUL4 and to test the hypothesis that secreted gpUL4 
is differentially modified, lysates and supernatants of RAd-UL4-infected cells were treated with 
EndoH and PNGaseF enzymes (Figure 6.1b). Cell-associated gpUL4 was almost completely 
sensitive to EndoH treatment, appearing as a 17 kDa species. Treatment with PNGaseF 
reduced intracellular gpUL4 to 16 kDa, which corresponds closely with the 17 kDa predicted 
size of the primary translation product. Taken together these data are consistent with 
intracellular gpUL4 being subjected to only N-linked glycosylation and not being fully 
processed in the Golgi apparatus. In contrast to cell-associated gpUL4, secreted gpUL4 was 
largely resistant to EndoH, observed as an exceptionally diffuse ‘smear’ ranging between 18-60 
kDa. PNGaseF digestion transformed secreted gpUL4 to a product migrating at 17-20 kDa, 
indicating O-linked glycosylation. The difference in sensitivity to EndoH and PNGaseF displayed 
by the two forms of gpUL4 further supported the conclusion that gpUL4 was actively secreted 
from RAd-infected cells. Indeed it is well known that glycosylation plays an important role in 
dictating appropriate transport and targeting of proteins that are destined to be secreted.  
Immunofluorescence staining of RAd-infected cells showed that the intracellular gpUL4 was 
cytoplasmic, in some cells preferentially accumulating in structures proximal to the nucleus 
(Figure 6.1c).   
         a) Western blot analysis of cell extracts (CE) and supernatants (Sn) of RAd-UL4-infected HFFF-hCARs (3 days p.i., MOI 
10) using a V5 antibody. Loading in CE and Sn lanes represents 10%, and 0.3% of total samples respectively. Lanes 
were not adjacent lanes in the original blot and were pasted together. b) RAd-expressed gpUL4 deglycosylation with 
EndoH and PNGaseF enzymes analysed by Western blot using the monoclonal V5 antibody. Cell-associated and 
supernatant gpUL4 were mock-treated, or deglycosylated with EndoH (E) or PNGaseF (P) enzymes. c) Intracellular 
RAd-UL4 expression analysed by immunofluorescence as described in figure 3.3. Mock-infected controls are not 
shown. Nuclei were stained with DAPI (blue),whilst gpUL4 expression was detected using a V5 antibody (red). d) 
Western blot analysis of cell extracts (CE) and supernatants (Sn) of RAd-UL4-infected HFFF-hCARs (3 days p.i., MOI 10) 
using polyclonal sera. Loading in CE and Sn lanes represents 10%, and 0.3% of total samples respectively. Lanes were 
not adjacent lanes in the original blot and were pasted together. 
 
 
Figure 6.1: RAd-UL4 expression and glycosylation analysis 
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6.3. gpUL4 in the context of HCMV 
infection 
I sought to investigate whether gpUL4 is secreted in the context of HCMV infection. Antisera 
were generated against gpUL4 by immunisation of mice with RAd-UL4 (kindly performed by Dr 
Simone Cuff). This polyclonal antibody was able to detect gpUL4 in the cell extract or culture 
medium of cells infected with the Ad recombinant (Figure 6.1d), but not in strain Merlin-
infected cell lysates or supernatants (data not shown). This indicated either low expression 
levels of gpUL4 in HCMV-infected cells or differential post-translational modifications during 
HCMV infection resulting in ‘cloaking’ of antigenic determinants. 
Encouraged by success in detecting V5-epitope tagged proteins using the V5 antibody (see 
Chapters 3 and 5); I decided to generate a recombinant Merlin virus encoding V5-tagged UL4. 
A V5 epitope was fused to the C-terminus of the UL4 gene in the Merlin BAC as described in 
section 5.2 for genes UL74A and UL150A, and the recombinant virus designated RCMV1567. A 
time-course western blot analysis of gpUL4 expression was then performed using the V5 
antibody on lysates and supernatants of HFFFs infected with RCMV1567, alongside HFFF-
hCARs infected with RAd-UL4 (Figure 6.2). To remove contaminating virions, RCMV1567 
supernatant samples were passed through 0.1 µm filters (Milliopore, SLVV033RS) prior to 
loading onto gel. Analysis of RCMV1567-infected cell extracts and supernatants detected 
gpUL4 in cell lysates at 1 day p.i. in the form of a sharp band migrating at 48 kDa; soluble 
gpUL4 could not be detected at this time-point. At 3 days p.i., gpUL4 was detected relatively 
abundantly in both cell lysates and supernatants. Supernatant gpUL4 migrated as a 55-60 kDa 
doublet, significantly more slowly than the cell-associated form. Interestingly, the difference in 
weight between the secreted and retained species was greater than that observed with RAd-
UL4 infections. This demonstrates that secreted gpUL4 is more extensively modified than 
intracellular gpUL4, and that other viral element(s) are required for the completion of this 
action. By day 6, secreted and intracellular gpUL4 increased in abundance. A minor 60 kDa 
product was also expressed in cell lysates at day 6. The expression pattern of RAd-UL4 was as 
previously observed, except at 6 days p.i., several faster-migrating, and one 60 kDa slower-
migrating species were also detected. The smaller proteins likely represent breakdown 
products; the larger band was expressed at very low levels. 
Protein concentration was not normalised between cell extracts and supernatants in Figure 
6.2a; cell extract samples were 20 times more concentrated by volume. Western blot was 
therefore also performed on samples containing equivalent proportions by volume, of cell 
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extract and supernatant preparations (Figure 6.2b). Similar levels of RCMV1567-expressed 
gpUL4 were present in cell lysates and supernatants at 3 days p.i.. However, at 6 days p.i., the 
bulk of gpUL4 appeared accumulated in the culture medium of cells infected with RCMV1567, 
indicating gpUL4 is primarily destined for secretion. gpUL4 expressed by RAd-infected cells also 
accumulated extracellularly. In these cells, intracellular gpUL4 was observed after longer 
exposure times (data not shown).  
In order to characterise the glycan modifications of gpUL4 in the context of HCMV infection, 
deglycosyaltion analysis was performed on RCMV1567-infected cell lysates and supernatants 
at 6 days p.i. (Figure 6.3a). The major 48 kDa species was sensitive to EndoH whist treatment 
with this enzyme did not affect the minor 60 kDa form. Both species were sensitive to 
PNGaseF, migrating at near the predicted 17 kDa size of the primary translation product. As 
seen with RAd-UL4 (Figure 6.1b), secreted gpUL4 was partially sensitive to EndoH, migrating in 
a smear/ladder-like pattern; PNGaseF treatment produced a 17-21 kDa product.  
Intracellular localisation of gpUL4 in the context of Merlin infection was also investigated 
(Figure 6.3b). Immunofluorescently detected gpUL4 aggregated in bright cytoplasmic foci near 
nuclei of infected cells at day 1 p.i.. At 3 days p.i., expression was more granular and less 
distinct, but still limited to perinuclear sites. Visibly stronger gpUL4 expression was observed at 
6 days p.i.. 
  
Figure 6.2: Time-course immunoblot of gpUL4 expressed from RAd-UL4 and RCMV1567 using a V5 mAb 
HFFFs were infected with RCMV1567 at MOI 5, and HFFF-hCARs with RAd-UL4 at MOI 3. a) Cell extracts (CE) and supernatants 
(Sn) were harvested at 1, 3, and 6 days p.i., and analysed by the Western blot technique (supernatants were centrifuged and 
passed through 0.1 µm filters prior to electrophoresis to remove cell debris, and potentially, contaminating virions. Following 
Western transfer, membranes were probed with V5 or GAPDH primary, and HRP-conjugated secondary antibodies. a) In 
experiments detailed in panel a, protein concentration was not normalised between cell extract and supernatant samples. b) 
cell extracts were normalised against supernatants for protein concentration and analysed by Western blot using V5 mAb  and 
HRP-conjugated secondary antibody as described for part a. 
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Figure 6.3: 
Glycosylation and intracellular localisation of 
gpUL4 in HCMV infected cells                                                                                 
a) HFFFs were infected with RCMV1567 at MOI 5. 
At 6 days p.i., cell-associated and supernatant 
gpUL4 were mock-treated, or deglycosylated with 
EndoH (E) or PNGaseF (P) enzymes. b) HFFFs were 
infected with RCMV1567 at MOI 5, fixed and 
permeabilised at indicated times, and gpUL4-V5 
detected using a monoclonal V5 antibody. DAPI 
staining was performed to visualise infected-cell 
nuclei (blue).  
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6.4. gpUL4 is not concentrated in the 
virion 
Chang et al. (1989) detected gpUL4 in purified extracellular viral particles and proposed that 
gp48 is a structural protein, although it was not specified whether gpUL4 was found in virions 
or dense bodies, as these particles were apparently not segregated in the purification process.  
The Chang et al. study lacks important controls required to adduce specific and selective gpUL4 
incorporation into virions. For example the inclusion of a cellular protein known not to be 
virion-associated would indicate the levels of contamination in the purified particle sample. 
However, the authors recognised that in contrast with other structural proteins, gpUL4 levels 
in virions and dense bodies were low, and that UL4 transcripts did not accumulate to high 
concentration at late stages of infection. Also, gpUL4 has not been confirmed as a virion 
protein in subsequent studies on the virion proteome. In a quantitative mass spectrometry 
analysis of protein species present in strain AD169 virions and dense bodies conducted by 
Varnum et al., gpUL4 levels did not meet the criteria of designation as a virion protein (Varnum 
et al., 2004).  
I therefore aimed to determine whether gpUL4 is a virion component. RCMV1567 virions were 
purified on a NaT gradient, and analysed by the western blot technique in parallel with lysates 
and supernatants of cells infected with the said virus. Extracts and supernatants of cells 
infected with RAd-UL4 were also included. Following prolonged exposure to film, very weak 
gpUL4 expression was observed in purified virions compared to cell extract and supernatant 
samples (Figure 6.4). Conversely, pp65, a known tegument protein, was greatly concentrated 
in virions. These data suggest gpUL4 is not specifically packaged into virions; minute amounts 
of gpUL4 detected in purified virion preparations likely represent low-level contamination with 
intracellular or soluble gpUL4.   
  
Figure 6.4: 
gpUL4 is not concentrated in the virion 
 HFFFs were infected with RCMV1567 at 
MOI 5, and HFFF-hCARs with RAd-UL4 at 
MOI 3. Cell extracts (CE) and 
supernatants (Sn) were harvested at 3 
days p.i., normalised by concentration, 
and analysed by immunoblotting 
alongside purified RCMV1567 virions. 
Prior to electrophoresis, supernatants 
were centrifuged and passed through 
0.1 µm filters to remove cell debris  and 
contaminating virions respectively. 
Following Western transfer membranes 
were probed with V5 or pp65 mAbs, and 
HRP-conjugated secondary antibody 
before exposure to film. 3 exposures of 
the same blot are shown for V5 mAb.  
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6.5. Soluble gpUL4 inhibits NK cell 
degranulation 
The UL4 gene is non-essential for virus replication in vitro (Dunn et al., 2003b). Nevertheless, 
its abundant secretion by HCMV raises the possibility that it may be an immune-modulator, 
such as a virokine, chemokine/cytokine binding protein (CKBP), or NK-receptor-binding 
protein. With a view to performing immune-modulation assays, I proceeded to prepare 
concentrated soluble gpUL4. gpUL4 was purified from supernatants of cells infected with RAd-
UL4 and RCMV1567 using a V5-tag purification kit as described in section 2.14. 
To directly investigate the effect of gpUL4 on NK cell function, CD107a mobilisation assays 
were performed on HFFF-hTERTs in the presence or absence of purified soluble gpUL4 (Dr 
Rebecca Aicheler). Receptor-mediated recognition of target cells induces lytic granules within 
NK cells to migrate towards the site of interaction (Kuhn and Poenie 2002). The outer 
membrane of granules then merges with the plasma membrane, releasing its contents into the 
synaptic space in a process termed ‘degranulation’. Degranulation results in exposure of 
CD107a, a glycoprotein normally present on lytic granule membranes, on the surface of NK 
cells. Surface-exposed CD107a thus serves as a marker of NK cell activation, and its detection 
using specific antibodies allows assessment of cell-mediated cytotoxicity (Betts et al. 2003).  
As shown in Figure 6.5, 12.4% of NK cells degranulated in response to control HFFF-hTERTs, 
whilst 9.55% and 9.35% respectively degranulated when RAd-soluble gpUL4 and Merlin-
soluble gpUL4 were included. This represents 23% and 24% inhibition of degranulation 
compared to control cells. The results of this assay indicate soluble gpUL4 is an NK-inhibiting 
molecule.  
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Figure 6.5:  
Soluble gpUL4 inhibits NK cell degranulation in CD107a mobilisation assays 
5x105 IFN-α-activated PBMC (D73)  were incubated with 1x105 HFFF-hTERTs and anti-
CD107a-FITC mAB (BD Biosciences) for 6hr in either just media or media with purified 
sgpUL4 expressed from RAd-UL4 or Merlin-1567  (50 ng/ml final concentration). GolgiStop 
(BD Biosciences) was added for the last 5hr. After 6 hours, cells were stained for CD3 and 
CD56 and analysed on an Acurri flow cytometer. The percentages of CD107+, CD3-,CD56+ 
NK cells were calculated using Cflow software. Results are presented as means ± SEM of 
duplicate samples.  
221
222 
 
6.6. Summary 
It was demonstrated that gpUL4 is abundantly secreted when expressed in isolation from an 
Ad recombinant, and in the context of HCMV Merlin infection. The observed kinetics of 
expression of intracellular gpUL4 are in agreement with the report by Chang et al (1989): 
gpUL4 is expressed at low levels during early stages of infection, accumulating to higher levels 
at late infection times. Compared with cell-associated gpUL4, the secreted isoform is of higher 
molecular weight and produced in greater abundance late in infection. Deglycosylation 
analysis revealed differences in the nature of carbohydrate moieties acquired by cell-
associated and extracellular gpUL4. Moreover, western blot analysis of purified virions argues 
gpUL4 is not a virion component. CD107 mobilisation assays indicate soluble gpUL4 inhibits NK 
cell activation, and hence may play an important role in determining pathogenesis in vivo. 
Higher concentrations of soluble gpUL4 are currently being prepared to further investigate the 
immune-modulating potential of gpUL4.  
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7.1. Cloning and expression of HCMV 
genes by Using an Adenovirus Vector 
Ad vectors have been invaluable in the study of HCMV gene expression and function. Immuno-
modulatory functions were discovered for the products of UL18, UL40, and UL142 when these 
genes were expressed using Ad vectors (Prod’homme et al., 2007, Tomasec et al., 2000, Wills 
et al., 2005a). Faithful to their functions during productive HCMV infection, RAd-derived 
gpUS2, gpUS3, gpUS6, and gpUS11 each independently downregulated cell surface MHC class-I 
expression (Hegde et al., 2002, Rehm et al., 2002, Tomasec et al., 2000, Tomazin et al., 1999). 
Also using this vector system, gpUS2 and gpUS3 were also able to inhibit MHC class-II antigen 
presentation, providing an escape route from recognition by CD4+ T cells (Hegde et al., 2002, 
Tomazin et al., 1999). Huber et al. reported that low level expression of genes US7-US11 
during productive HCMV infection hampered characterisation of their respective products; 
cloning of these genes into Ad vectors allowed expression to be detected (Huber et al., 2002). 
Co-expression of gH and gL from RAds was shown to enhance cell:cell fusion in HCMV-infected 
cells whilst co-infection of RAds expressing gH, gL and gO was shown to be necessary and 
sufficient for the formation of the gCIII complex (Milne et al., 1998, Paterson et al., 2002). 
Furthermore export of the gH/gL complex from the ER to the Golgi was enhanced in the 
presence of UL128, UL130, and UL131A when all five glycoproteins were expressed using RAds 
(Ryckman et al., 2008). Despite such examples, high-throughput generation of RAds for 
systematic screening of the HCMV genome was delayed by the technical limitations of 
standard vectors. Generation of the AdZ vector and the Merlin BAC facilitated large scale 
cloning of HCMV genes. This thesis describes the generation of 169 RAds each encoding a 
single HCMV gene, characterisation of expression of the cloned genes, and use of this RAd 
library in functional assays for the first time. Cloning of genes was carried out by the 
recombineering method; genes were PCR-amplified from the Merlin BAC and inserted into AdZ 
in a single step. Recombineering of 15 genes was extremely inefficient and required the 
insertion of a selectable marker (galK) prior to insertion into AdZ. The relatively GC-rich base 
composition of these genes compared to the rest of the HCMV genome correlated with their 
inefficient cloning.  
225 
 
Following the cloning of all the canonical HCMV genes into Ad vectors, it was important to 
evaluate their capacity to provide for transgene expression. Expression was validated for 160 
out of 168 (95%) protein-coding genes using a combination of immunofluorescence (92% 
positive) and western blot (90% positive) analyses.  
Expression of gB and gO was only detected after codon-optimised sequences of these genes 
were cloned into RAds. Optimisation of codon usage is known to facilitate high-level gene 
expression, and is being extended to the 8 genes whose expression was not detected. Of 
course this is not guaranteed to solve the problem; lack of detection may have been caused by 
other factors, such as cleavage of the C-terminal tag, or protein folding in a manner 
antagonistic to antibody binding. C-terminal cleavage is unlikely in the case of protein products 
of RL6, UL33, US9 and US14 however, because these proteins have been detected using C-
terminal epitope tags (Salsman et al., 2008).  
Excellent agreement was found between expression data presented here and those in 
comparable large scale expression analyses of HCMV genes; although the success rate in 
detecting transgene expression was higher with AdZ. Salsman et al. (2008) detected expression 
of 129 of 140 (87%) plasmid-cloned HCMV ORFs tested by immunofluorescence following 
transient transfection of 293T cells, whereas when HCMV ORFs were inserted into a 
baculovirus expression vector, western blot analysis revealed expression of only 50% of ORFs 
in infected insect cells (Gao et al., 2005).  
7.1.1. Western blot analysis of expressed HCMV 
gene products 
Predominant western blot species were detected within 10 kDa of predicted/reported sizes for 
>94% of constructs (128 of 136). Some interesting observations derived from this analysis are 
discussed: 
Adenovirus replication takes place in the nucleus, so the capacity exists for primary transcripts 
to be spliced by endogenous host cell RNA processing systems; indeed the expression of 
intron-containing transcripts is known to be favoured. While recent studies indicated RNA 
splicing may be much more common than previously believed, it appears to be a relatively rare 
occurrence in the HCMV canonical ORFs. UL112 is known encode 34 kDa, 43 kDa, 50 kDa and 
84 kDa phosphoproteins from a single alternatively spliced transcript (Wright and Spector, 
1989). Products of almost identical size were detected in cells infected with RAd-UL112. 
Similarly, 22 kDa, 17 kDa, and 3.5 kDa proteins are synthesised from alternatively spliced US3 
transcripts (Shin et al., 2006, Tenney et al., 1993). Consistent with this finding, 18 kDa and 16 
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kDa species were detected in RAd-US3 infected cells, as well as a minor species migrating 
closely to the 3.5 kDa molecular marker protein.  
Western blot analysis identified several US12 family members as potential ubiquitin-
conjugated proteins, due to the presence of high molecular-weight complexes characteristic of 
ubiquitinated proteins. This prediction was confirmed in the case of pUS20 (Dr Ceri Fielding, 
personal communication), and is being tested for US12, US13, US16, US18 and US21. 
Interestingly, western blot analysis of pUS16, pUS18 and pUS20 in the context of HCMV 
infection identified only protein singlets migrating near the predicted sizes of the primary 
translation products (Bronzini et al., 2012, Guo and Huang, 1993). This indicates ubiquitination 
of these proteins may be suppressed by other viral co-factors during productive infection, 
potentially to prevent their lysosomal/proteasomal targeting and degradation by the host cell.  
HCMV is predicted to encode at least 50 glycoproteins (Table 14.1; Davison and Bhella 2007). 
Due to increase in mass resulting from glycosylation, the majority of these migrated 
significantly more slowly by SDS-PAGE than indicated by calculating the mass of the primary 
translation product. Of particular interest in the study, 11 out of 16 predicted, yet previously 
uncharacterised glycoproteins were shown to encode products larger than the predicted 
primary translation product. Deglycosylation analysis provided confirmation that RL12, UL6 
and UL7 were glycoproteins. The remaining 5/16 predicted glycoproteins migrated at or below 
the predicted molecular mass of their primary translation products; this does not rule out 
glycosylation, since these products may be subject to proteolytic cleavage. There would be 
merit in undertaking systematic analyses of HCMV gene products expressed using the Ad 
vector for posttranslational processing. 
7.1.2. Intracellular localisation of expressed HCMV 
gene products 
The intracellular localisation of 98 out of 109 gene products (90%) expressed by using the AdZ 
vector was consistent with previous descriptions. In the case of the other 11 genes, products 
of 9 had been described solely in the context of productive HCMV infection. These proteins 
may well require interaction with additional HCMV-encoded proteins for appropriate 
trafficking. The fact that 8 of the 9 proteins in this category are nuclear during productive 
HCMV infection but cytoplasmic using Ad recombinants indicates a large proportion of nuclear 
HCMV-encoded proteins may lack their own nuclear localisation signals (NLS). However, it 
cannot be discounted that for some, nuclear localisation could have been perturbed by the C-
terminal V5 tag. While analysis of the RAd library showed UL89 and UL104 to be cytoplasmic, 
during lytic infection, pUL89 and pUL104 both interact and co-localise with pUL56 in the 
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nucleus (Thoma et al., 2006). pUL56 in turn is nuclear-localised in the context of HCMV 
infection and during isolated expression; nuclear translocation of pUL89 and pUL104 may 
therefore require co-expression with pUL56. Interestingly, a reversal of this possible scenario 
occurs in HSV-1, where during independent expression, the pUL56 homologue (pUL28) is 
cytoplasmic whilst pUL89 and pUL104 homologues (UL15 and UL6 respectively) are nuclear. 
Co-expression with either HSV-1-UL15 or HSV-1-UL6 was sufficient to translocate HSV-1 pUL28 
to the nucleus (Abbotts et al., 2000, Koslowski et al., 1999, White et al., 2003). The prediction 
that pUL56 mediates nuclear translocation of pUL89 and pUL104, needs to be tested 
experimentally.  
The other 2 inconsistencies with regards protein localisation involve pUL80.5 and gpUL130. 
RAd-expressed pUL80.5 staining was punctate PML body-like within the nucleus but has been 
reported as pan-nuclear in Cos-7 cells (Plafker and Gibson, 1998, Wood et al., 1997), however, 
Cos-7 cells are both derived from African Green Monkey Kidneys (i.e. not human) and have 
been transformed with the SV40 Large T antigen. gpUL130 expression was previously 
visualised throughout the cytoplasm and on the surface of transfected 293T cells (Gerna et al., 
2008a). RAd-expressed gpUL130 however, was present only in the nucleus-proximal portion of 
HFFF-hCARs, clearly excluded from the cell membrane. The pentomeric 
gH/gL/UL128/UL130/UL131A complex is packaged into the virions of low passage isolates to 
promote endothelial cell tropism. gL has long been known to provide a chaperon function that 
is required for the appropriate folding of gH, and its subsequent trafficking to the plasma 
membrane and ultimately into virus particles. gH is the only component of the pentomeric 
complex that has a transmembrane domain and thus plays a key role in anchoring the complex 
in membranes. The pentomeric complex provides a clear example of the need for HCMV genes 
to be co-expressed in order to reconstitute multiprotein complexes.  
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7.2. Regulation of Fas expression by 
HCMV 
HCMV infection was demonstrated to result in efficient downregulation of cell surface Fas 
expression that is detectable at early times p.i. (24 hrs), and persists through the late phase. 
The reduction in Fas expression was not mediated by a secreted factor, but was dependent on 
de novo virus-encoded gene expression.  
Fas downregulation was deployed as a pilot study to establish a strategy for mapping HCMV 
gene function. As a first step, a series of 10 HCMV deletion mutants each lacking a block of 
non-essential genes was tested in a loss-of-function assay. Similar levels of Fas downregulation 
were observed between all deletion mutants and wildtype HCMV Merlin, suggesting none of 
the 58 genes absent in these mutants is essential for Fas downregulation by strain Merlin. The 
limitations of this approach include: (i) only approximately 35% of the HCMV canonical genes 
are deleted, (ii) some of the mutants are replication impaired; this can alter the kinetics of 
specific virus-encoded effects, and (iii) a redundant function may give only a partial or no 
phenotype in the screen.  
Subsequently, gain-of-function screening of the panel of Ad recombinants encoding HCMV 
genes also did not identify the gene(s) responsible for Fas downregulation. Having 
characterised the expression of some 170 Ad recombinants, there are a number of reasons 
why this strategy also could miss a prescribed function: (i) the gene responsible may not have 
been annotated and thus not be present in the panel of Ad recombinants. (ii) The function may 
be encoded by a miRNA; the initial strategy for generating the RAd library also included 
insertion of HCMV miRNAs; indeed an AdZ vector has been utilised in RNA interference 
(McLaren et al., 2010).  However, this component was not prioritised as there was no 
immediate prospect of validating RAd-miRNA constructs. The AdZ vector technology is 
currently being optimised for this application. (iii) More than one HCMV gene may be required 
for the function. While systematically analysing the expression of Individual functions for Table 
3.2, it became apparent that a number of HCMV genes act in concert in a reliable and 
reproducible fashion (e.g. the members of the UL128L pentomeric complex). An advantage of 
the Ad vector system is that it permits multiple constructs to be co-delivered. There is 
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therefore merit in developing subroutines in the gene screening strategy that allow sets of co-
operating viral functions to be tested together. With this objective in view, it would be worth 
investigating which pathways could be recapitulated using Ad vectors e.g. glycoprotein 
complexes, DNA replication, capsid/dense body assembly. (iv) The Ad-cloned HCMV gene may 
be expressed at levels inappropriate for the function. The high level of gene expression that is 
usually achieved using Ad vectors may be antagonistic to function. Conversely, expression 
levels of some genes may be insufficient for function of interest. (v) Protein expression in an 
inappropriate compartment. Products of 13 genes are known to localise differently if 
expressed independently of other viral proteins: RL13, UL48A, UL53, UL70, UL73, UL74, UL75, 
UL82, UL86, UL94, UL100, UL114, and TRS1 (see Table 3.2). Moreover, viral factors that 
promote appropriate localisation of 9 of these gene products have been identified, but remain 
unknown in the cases of gpRL13, pUL70, pp71 (UL82), and TRS1. As with genes that act 
cooperatively to encode a function, co-delivery of Ad recombinants can be utilised to promote 
appropriate intracellular localisation. (vii) The C-terminal V5 tag may disable the function.  
Comparable levels of Fas downregulation were observed on the surface of cells infected with 
strains Merlin, AD169, FIX, or TB40; this assay was performed using fibroblast cells of various 
origins. These results demonstrated that Fas downregulation is a conserved function between 
different HCMV variants, and traits specific to a particular batch of cells were not responsible 
for initial observation of this function. In this respect, an independent confirmation of Fas 
downregulation during HCMV infection was provided by SILAC analysis of cell surface 
molecules of fibroblasts (Dr Peter Tomasec personal communication).  
Downregulation of Fas by different HCMV strains is indicative of a potentially important role 
for this novel function in viral replication and pathogenesis. With regards mapping the gene 
responsible for Fas downregulation, results of this assay allowed me to conclude that the 25 
HCMV genes deleted/inactive in strains AD169, FIX and TB40 are not essential for Fas 
downregulation, effectively extending the number of discounted genes to 83.  
Lytic infection of HFFs with strain AD169 was reported to cause a reduction in Fas mRNA levels 
(4.3 fold) (Browne et al., 2001). However, levels of Fas mRNA were not significantly altered 
during lytic infection with strain Merlin (data not shown); downregulation of Fas at the cell 
surface was therefore anticipated to occur at a posttranscriptional level. Western blot analysis 
showed that the clear decrease in Fas levels at the surface of infected cells was not 
accompanied by a global reduction in total Fas protein levels. Although modest fluctuations in 
total Fas expression were seen on days 2 and 3 p.i. in Figure 4.7a, overall, there was no clear 
evidence of the virus either stimulating or suppressing total Fas levels, even at 6 days p.i. (data 
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not shown). HCMV infection thus results in FAS being selectively downregulated at the cell 
surface, and retained in an intracellular compartment. This phenomenon could take place 
through either removal of existing Fas molecules from the cell surface, or blockage of transport 
of newly-synthesised Fas to the cell surface. Fas extracted from mock-infected or HCMV-
infected cells was resistant to EndoH treatment, indicating ER sequestration is not the 
mechanism of retention, since proteins only acquire resistance to EndoH treatment once 
trafficked beyond the ER and into the Golgi apparatus.  
 Fas joins a growing list of cellular proteins that appear redistributed, rather than degraded 
during HCMV infection. These include ULBP2, MICB, CD155, TNFRI and TRAILR2 (Dunn et al., 
2003, Stern-Ginossar et al., 2007b, Tomasec et al., 2005, Baillie et al., 2003, unpublished data). 
While signalling through Fas, TNFRI and TRAILR2 are primarily associated with the induction of 
apoptosis; in their unstimulated form they may provide pro-survival stimuli. Intracellular levels 
of TNFR1, another member of the TNF superfamily that is downregulated from the surface of 
HCMV-infected cells, are also not depleted during infection (Baillie et al., 2003). TNFR1 
proteins were instead relocalised from the cell surface to the TGN, appearing in intensely-
stained perinuclear regions. In addition, the close functional and familial connections between 
Fas and TNFRI dictate speculation that both proteins may be downregulated by the same 
mechanism, and/or the same HCMV gene(s). 
Fas-signalling was stimulated in mock-infected and strain Merlin-infected cells using Fas ligand 
or a cross-linking Fas antibody; infected cells displayed significantly lower caspase-3/7 activity, 
signifying protection from apoptosis. This recapitulated previous findings that infection with 
HCMV renders cells more resistant to Fas-mediated apoptosis. Nevertheless, the contribution 
of Fas downregulation towards enhanced cell survival in this assay cannot be determined 
because two other HCMV genes, namely UL36 and UL37, also protect infected cells from Fas-
mediated apoptosis. In this context, pUL36 inhibits activation of caspase-8 whilst pUL37 
inhibits permeabilisation of the outer mitochondrial membrane by sequestering Bax within 
mitochindria, thus protecting infected cells from apoptosis induced by a range of different 
stimuli (Arnoult et al., 2004, Skaletskaya et al., 2001). Previously, it was assumed that HCMV-
infected cells acquired resistance against Fas-mediated apoptosis first through pUL36 activity 
(24 hrs p.i.), and then through the activity of pUL37 (48 hrs p.i.). However, Fas downregulation 
is also complete at these time-points, and may contribute significantly to protection of 
infected cells from Fas-mediated apoptosis. A recombinant ΔUL36 Merlin virus was generated 
for the purpose of assessing the relative contributions of Fas downregulation and UL36 activity 
on Fas-mediated apoptosis by comparison with wildtype strain Merlin. However, this 
recombinant virus showed severe growth defect and could not be used experimentally. 
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Further investigation is required to determine the HCMV genes responsible for Fas 
downregulation, and the mechanism of this function.  
 
Downregulation of Fas from the cell surface is not a trait specific to HCMV. The adenovirus 
receptor internalisation and degradation (RID) protein, also called the E3-10.4K/14.5K 
complex, inhibits apoptosis by promoting loss of Fas molecules from the surface of infected 
cells (Elsing and Burgert, 1998). Similar to observations made in the current study with HCMV, 
RID does not inhibit Fas expression at the transcriptional level but rather mediates 
internalisation, and subsequent degradation of existing Fas molecules by the lysosomal 
pathway (Tollefson et al., 1998). Contradictory reports have been published with regards total 
levels of Fas following internalisation and degradation by RID. In one study, intracellular levels 
of Fas were not significantly altered after infection with a recombinant adenovirus (Shisler et 
al., 1997), whilst another study demonstrated substantial decrease in levels of Fas in HCMV-
infected cells (Tollefson et al., 1998). The ER-resident Myxoma virus leukemia-associated 
protein (MV LAP) downregulates Fas and MHC class-I molecules from the surface of 
transfected cells (Guerin et al., 2002). Interestingly, Fas levels at the surface of MV-infected 
cells were not affected, implying LAP acts to counter Fas upregulation that may be caused by 
another viral/viral-induced factor. Also of note, is that retention of MV LAP in the ER was 
crucial to its function in preventing Fas expression at the cell surface, yet downregulation of 
Fas or MHC class-I did not occur through ER retention. Abduction of cell surface Fas and MHC 
class-I by MV LAP likely involves exacerbation of endocytosis and subsequent lysosomal 
degradation, and has been proposed to occur through interactions with adaptor proteins of 
the actin cytoskeleton. Nevertheless, precise mechanisms underlying this function have yet to 
be elucidated. Identification of LAP homologues in other poxviruses and several 
gammaherpesviuses including HHV-8 has prompted the designation of these molecules as 
surface cellular receptor abductor proteins (scrapins). No homology was reported between 
scrapin family members and any HCMV genes. From an evolutionary viewpoint, conservation 
or commonality of function within or between species generally infers importance of function. 
Downregulation of Fas at the surface of virus-infected cells could potentially inhibit host-
induced apoptosis, providing infected cells, and effectively the virus, with an escape route 
from recognition and elimination by the host’s immune response.  
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7.3. Characterisation of the novel HCMV 
UL150A gene 
 
Deep sequencing of the Merlin transcriptome was performed by Gatherer et al. (2011) to 
provide a better understanding of HCMV gene content and usage; the analysis was performed 
at 72 hours p.i. in fibroblasts. Great variation exists in the level of transcription across the 
genome, yet nearly every part of the genome is transcribed to some extent. Anti-sense 
transcripts were promiscuously produced from a large proportion of the genome, US33A was 
designated as a novel HCMV gene, and UL30A expression was authenticated. This study also 
uncovered the remarkable statistic that over two thirds of polyA-containing viral transcripts 
represent NNTs. Splicing was found to be much more common than had been appreciated, 
and the majority of previously recognised splice sites were confirmed. Most notable amongst 
the novel spliced transcripts, was the presence of 5 super acceptor sites (SASs), each one 
spliced from multiple upstream donors, and positioned upstream of a potential coding region. I 
investigated the expression of two novel SAS-associated coding regions, namely UL74A and 
UL150A, in the context of HCMV infection. V5 tags were fused to the C-termini of UL74A and 
UL150A in the Merlin BAC, and recombinant viruses generated (designated RCMV1569 and 
RCMV1571 respectively). Western blot and immunofluorescence analyses confirmed pUL150A 
was expressed and the production of multiple species was consistent with fusion to multiple 
upstream ORFs. pUL150A was produced with early/late kinetics, and localised to the ER. By 
western blot, pUL150A migrated as a major 34 kDa doublet, consistent with the predicted 31 
kDa size of the primary translation product, although a minor 50 kDa isoform was also visible 
at late times of infection. Interestingly, the 34 kDa doublet became more abundant from 3 
days p.i. to 6 days p.i., but the expression of the 50 kDa isoform remained constant, suggesting 
potentially distinct regulation of expression. The 50 kDa migrating species may represent an 
alternative splice variant with an extended 5’ terminus, or posttranslationally processed 
pUL150A. Characterisation of UL150A expression marks the first example of a functional ORF 
that is positioned entirely antisense to another larger, unspliced coding region (UL150).  
Strong evidence that UL74A is expressed as part of an alternatively spliced transcript is 
provided by northern blot, RT-PCR, and RACE data (Scalzo et al., 2009, Gatherer et al., 2011). 
However, when UL74A open reading frame was tagged its expression could not be detected by 
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either immunofluorescence or western blot. With tagged proteins, the possibility exists that 
the tag may be lost due to protein cleavage, or its antigenicity destroyed or concealed by 
folding of the fused protein. While tagging of HCMV ORFs is an excellent device for 
demonstrating and characterising expression, a negative result does not necessarily mean the 
gene is not expressed. Insertion of an epitope tag in a region other than the C-terminus of the 
predicted protein could enable detection.  
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7.4. Characterisation of gpUL4  
gpUL4 was readily detected in the culture media of cells infected with RAd-UL4. Three lines of 
evidence suggested supernatant RAd-gpUL4 was not analogous to intracellular gpUL4, and was 
thus actively secreted. First, supernatant gpUL4 consistently migrated more slowly than the 
intracellular form in western blot, indicative of more extensive glycosylation. Second, 
supernatant gpUL4 was more resistant to EndoH treatment than the intracellular form, 
suggesting passage through the Golgi. Third, supernatant but not cell-associated gpUL4 
showed some degree of resistance to PNGaseF treatment, typical for proteins with O-linked 
glycosylation.  
Polyclonal sera prepared by immunising mice with RAd-UL4 detected RAd-expressed, but not 
Merlin-expressed gpUL4. I suspected this could have been caused by lower expression levels of 
gpUL4 in the context of HCMV infection. The strong MIE promoter in AdZ often drives far 
greater HCMV gene expression compared to endogenous levels. It is also possible that gpUL4 
produced during HCMV infection undergoes distinct post-translational modifications and is not 
efficiently bound by the polyclonal sera.  
As an alternative approach to characterise expression in the context of HCMV infection, UL4 
was V5-tagged within the Merlin BAC. Using the V5 antibody, tagged gpUL4 was readily 
detected in lysates and supernatants of cells infected with the recombinant virus, confirming 
gpUL4 is a secreted HCMV protein. The migration and temporal expression pattern of 
intracellular gpUL4 were consistent with previous findings (Chang et al., 1989). Soluble gpUL4 
appeared in the extracellular media only at late times of infection. Difference in time of 
expression between the two isoforms suggests complex temporal regulation of the UL4 
promoter. Alternatively, other viral factors may inhibit secretion at earlier time-points. Soluble 
gpUL4 also migrated more diffusely, and considerably more slowly than cell-associated gpUL4. 
Interestingly, the size difference between intracellular and extracellular gpUL4 was greater 
than that observed using RAd-UL4. This adds gpUL4 to the list of HCMV glycoproteins which 
require other viral factors to undergo complete glycosylation: RL13, UL18, UL73, UL74 (Griffin 
et al., 2005, Mach et al., 2000, Stanton et al., 2010, Theiler and Compton, 2002).  
In a previous investigation into gpUL4, inhibition of N-linked glycosylation did not lead to 
detection of the 17 kDa primary polypeptide from cells infected with strain Towne (Chang et 
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al., 1989). However, but for a high molecular-weight species expressed at true-late times, 
Merlin-derived intracellular gpUL4 was almost fully sensitive to EndoH treatment. It is possible 
that inter-strain differences between Merlin and Towne are responsible for variation in glyco-
processing of gpUL4. While Chang et al. (1989) detected gpUL4 in purified virus particles; it 
was present in lower levels than other structural components. In a subsequent study by 
Varnum et al. (2004), levels of gpUL4 in the virion did not meet the qualifying threshold to be 
designated a structural protein. Here, it was shown that only minute amounts of gpUL4 were 
detected in purified Merlin virions compared to cell lysates and supernatants, suggesting low-
level contamination rather than selective incorporation. Having now been defined as a 
secreted glycoprotein, it is natural to consider the possibility gpUL4 may be acting as a 
virokine, akin to cmvIL-10 or the IL-8-like function pUL146.  
Merlin- and RAd-UL4-derived soluble gpUL4 purified on V5 antibody columns proved capable 
of inhibiting NK cell degranulation in CD107 mobilisation assays, suggesting a possible function 
as a virokine or chemokine/cytokine-binding protein receptor antagonist. The NK cell inhibiting 
function of soluble gpUL4 will be further characterised upon preparation of more concentrated 
samples. Planned experiments include screening a panel of leukocyte receptors to identify 
potential binding target(s). NK cell inhibitory function is likely specific to the secreted form of 
gpUL4 since RAd-UL4-infected cells did not inhibit NK cell activation relative to mock-infected 
cells (Dr James Davies, personal communication). 
A BLAST search of the UL4 amino acid sequence revealed homology with CD180/RP105 (amino 
acids 51-121, 30% homology, 46% similarity). CD180 is a Toll-like receptor (TLR) homologue, 
and an important negative regulator of TLR4 signalling (Divanovic et al., 2005). TLR4 forms a 
complex with MD2 at the cell surface, and binds lipopolysaccharide (LPS), a constituent of the 
outer membrane of Gram-negative bacteria. Other TLR4 targets include viral components such 
as respiratory syncytial virus (RSV) fusion proteins, vesicular stomatitis virus (VSV) glycoprotein 
G, and Ebola virus (EV) glycoprotein (Georgel et al., 2007, Kurt-Jones et al., 2000, Okumura et 
al., 2010). HCMV is also known to activate signalling through TLR4, although the precise viral 
product(s) that are recognised by TLR4 have not been identified. It has been demonstrated 
that infection of monocytes with strain Towne induces TLR4 signalling (Yew et al., 2012). 
Stimulation of the TLR4 signalling pathway with LPS led to production of inflammatory 
cytokines, and inhibited HCMV infection in foreskin fibroblasts and ectocervical tissue (Sailesh 
et al., 2007). From the above findings, it can be seen that countering TLR4 signalling may 
promote HCMV survival within host cells.  
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Preliminary experiments were performed to determine whether soluble gpUL4 is able to 
interfere with TLR4 signalling. IL-1β production was measured by enzyme-linked 
immunosorbent assay (ELISA) from THP-1 monocytes incubated with LPS or LPS and soluble 
gpUL4, and compared to that from untreated controls. Merlin- and RAd-UL4-derived soluble 
gpUL4 significantly inhibited IL-1β production in the presence of LPS (data not shown), 
suggesting function as an inhibitor of TLR4 signalling. Although promising, description of these 
results is raised tentatively and must be viewed with caution, since the amounts of soluble 
gpUL4 initially purified were insufficient for repeat of this assay. More concentrated soluble 
gpUL4 is currently being prepared in order to further investigate the effect of gpUL4 on TLR4 
signalling.  
UL4 is amongst the class of genes that contain regulatory upstream open reading frames 
(uORFs). uORFs are cis-acting elements within the 5’ leader region of some primary transcripts 
that play important roles in regulating translation of their respective main ORFs (Wethmar et 
al., 2010). uORFS are highly conserved between homologous genes; yet different uORFs are 
extremely variable in length, sequence, structural features and regulatory function. 
Bioinformatic analysis has shown that uORFs are present in diverse biological organisms such 
as fungi, viruses and mammalian cells. Although approximately half of human transcripts 
contain uORFs, this proportion is lower than might occur by random chance; furthermore 
uORF-mediated translational control has only been demonstrated for about 100 eukaryotic 
genes. Amongst these, there is a remarkable over-representation of key groups of genes 
encoding oncogenes, growth factors and cellular receptors (Morris and Geballe, 2000). The 
functional significance of uORFs in humans is reflected in the correlation between disrupting 
uORF mutations, and increased susceptibility to severe disorders such as thrombocythemia, 
cancer and Alzheimer’s disease (Medenbach et al., 2011). Viral transcripts other than UL4 that 
are known to contain functional uORFs include the human immunodeficiency virus (HIV) type 1 
mRNAs, hepatitis B virus (HBV) pregenomic RNA, and tomato golden mosaic virus AL2 and AL3 
mRNAs (Chen et al., 2005, Luukkonen et al., 1995, Shung and Sunter, 2009).  
Chang et al. (1989) first described the presence of 3 uORFs in the 5’ leader region of strain 
Towne UL4 primary transcript. Although this 5’ leader region inhibited translation of the major 
UL4 ORF in cell free assays, deletion analysis suggested none of the 3 uORFs was essential for 
this inhibition. In a series of elegant studies using intact cells and cell-free assays, it was 
subsequently demonstrated that strain Towne uORF-2 (i) is essential for inhibition of gpUL4 
translation, (ii) is translated into a polypeptide product that remains ribosome-associated, and 
(iii) causes translation inhibition by sequence-dependent ribosomal stalling (Schleiss et al., 
1991, Degnin et al., 1993, Cao and Geballe, 1995, Cao and Geballe, 1996, Alderete et al., 1999). 
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It was also shown that deletion or mutagenesis of some but not all of the 22 uORF-2 amino 
acids de-repressed gpUL4 translation. The uORF-2 sequence is well conserved amongst HCMV 
species; strains encoding non-functional uORF2 consistently express higher levels of gpUL4. 
Merlin uORF2 differs from that of Towne by a single T16I mutation. This particular mutation 
was noted in 5 other clinical isolates and is not thought to alter uORF2 function (Alderete et 
al., 1999).  
The high-degree of inter-strain conservation in the amino acid sequence of gpUL4 and its 
associated uORF-2; and potential multi-dimensional properties of soluble gpUL4 in evading the 
immune response point towards the importance of this HCMV gene product in vivo. 
 
 
 
 
238 
 
 
8- References 
 
 
 
 
239 
 
 
ABBOTTS, A. P., PRESTON, V. G., HUGHES, M., PATEL, A. H. & STOW, N. D. 2000. Interaction of 
the herpes simplex virus type 1 packaging protein UL15 with full-length and deleted 
forms of the UL28 protein. Journal of General Virology, 81, 2999-3009. 
ADAIR, R., DOUGLAS, E. R., MACLEAN, J. B., GRAHAM, S. Y., AITKEN, J. D., JAMIESON, F. E. & 
DARGAN, D. J. 2002. The products of human cytomegalovirus genes UL23, UL24, UL43 
and US22 are tegument components. Journal of General Virology, 83, 1315-1324. 
ADAIR, R., LIEBISCH, G. W. & COLBERG-POLEY, A. M. 2003. Complex alternative processing of 
human cytomegalovirus UL37 pre-mRNA. Journal of general virology, 84, 3353-3358. 
ADAM, B. L., JERVEY, T. Y., KOHLER, C. P., WRIGHT, G., NELSON, J. A. & STENBERG, R. M. 1995. 
The human cytomegalovirus UL98 gene transcription unit overlaps with the pp28 true 
late gene (UL99) and encodes a 58-kilodalton early protein. Journal of virology, 69, 
5304-5310. 
ADAMO, J. E., SCHRÖER, J. & SHENK, T. 2004. Human cytomegalovirus TRS1 protein is required 
for efficient assembly of DNA-containing capsids. Journal of virology, 78, 10221-10229. 
ADLER, B., SCRIVANO, L., RUZCICS, Z., RUPP, B., SINZGER, C. & KOSZINOWSKI, U. 2006. Role of 
human cytomegalovirus UL131A in cell type-specific virus entry and release. Journal of 
General Virology, 87, 2451-2460. 
ADLER, S. 1990. Cytomegalovirus and Child Day Care: Evidence for An Increased Infection Rate 
Among Day Care Workers. The Pediatric Infectious Disease Journal, 9, 862. 
ADLER, S. P. 1989. Cytomegalovirus and child day care. New England Journal of Medicine, 321, 
1290-1296. 
ADLISH, J. D., LAHIJANI, R. S. & JEOR, S. C. S. 1990. Identification of a putative cell receptor for 
human cytomegalovirus. Virology, 176, 337-345. 
AGGARWAL, B. B., SINGH, S., LAPUSHIN, R. & TOTPAL, K. 1995. Fas antigen signals proliferation 
of normal human diploid fibroblast and its mechanism is different from tumor necrosis 
factor receptor. FEBS letters, 364, 5-8. 
AHLQVIST, J. & MOCARSKI, E. 2011. Cytomegalovirus UL103 controls virion and dense body 
egress. Journal of virology, 85, 5125-5135. 
AHN, J. H., JANG, W. J. & HAYWARD, G. S. 1999. The human cytomegalovirus IE2 and UL112-
113 proteins accumulate in viral DNA replication compartments that initiate from the 
periphery of promyelocytic leukemia protein-associated nuclear bodies (PODs or 
ND10). Journal of virology, 73, 10458-10471. 
AHN, K., ANGULO, A., GHAZAL, P., PETERSON, P. A., YANG, Y. & FRÜH, K. 1996. Human 
cytomegalovirus inhibits antigen presentation by a sequential multistep process. 
Proceedings of the National Academy of Sciences, 93, 10990. 
AHN, K., GRUHLER, A., GALOCHA, B., JONES, T. R., WIERTZ, E. J. H. J., PLOEGH, H. L., PETERSON, 
P. A., YANG, Y. & FRÜH, K. 1997. The ER-luminal domain of the HCMV glycoprotein US6 
inhibits peptide translocation by TAP. Immunity, 6, 613-621. 
AKRIGG, A., WILKINSON, G. & ORAM, J. 1985. The structure of the major immediate early gene 
of human cytomegalovirus strain AD169. Virus Research, 2, 107-121. 
AKTER, P., CUNNINGHAM, C., MCSHARRY, B. P., DOLAN, A., ADDISON, C., DARGAN, D. J., 
HASSAN-WALKER, A. F., EMERY, V. C., GRIFFITHS, P. D. & WILKINSON, G. W. G. 2003. 
Two novel spliced genes in human cytomegalovirus. Journal of General Virology, 84, 
1117. 
AL-BARAZI, H. O. & COLBERG-POLEY, A. M. 1996. The human cytomegalovirus UL37 
immediate-early regulatory protein is an integral membrane N-glycoprotein which 
traffics through the endoplasmic reticulum and Golgi apparatus. Journal of virology, 
70, 7198-208. 
ALDERETE, J. P., JARRAHIAN, S. & GEBALLE, A. P. 1999. Translational effects of mutations and 
polymorphisms in a repressive upstream open reading frame of the human 
cytomegalovirus UL4 gene. Journal of virology, 73, 8330-8337. 
240 
 
ALFORD, C. A., STAGNO, S., PASS, R. F. & BRITT, W. J. 1990. Congenital and perinatal 
cytomegalovirus infections. Review of Infectious Diseases, 12, S745. 
ALVISI, G., RIPALTI, A., NGANKEU, A., GIANNANDREA, M., CARAFFI, S. G., DIAS, M. M. & JANS, 
D. A. 2006. Human cytomegalovirus DNA polymerase catalytic subunit pUL54 
possesses independently acting nuclear localization and ppUL44 binding motifs. 
Traffic, 7, 1322-1332. 
ANDERS, D., IRMIERE, A. & GIBSON, W. 1986. Identification and characterization of a major 
early cytomegalovirus DNA-binding protein. Journal of virology, 58, 253-262. 
ANDERS, D. G. & GIBSON, W. 1988. Location, transcript analysis, and partial nucleotide 
sequence of the cytomegalovirus gene encoding an early DNA-binding protein with 
similarities to ICP8 of herpes simplex virus type 1. Journal of virology, 62, 1364-1372. 
ANDREWES, C., BURNET, F., ENDERS, J., GARD, S., HIRST, G., KAPLAN, M. & ZHDANOV, V. 1961. 
Taxonomy of viruses infecting vertebrates: present knowledge and ignorance. 
Virology, 15, 52. 
ARLT, H., LANG, D., GEBERT, S. & STAMMINGER, T. 1994. Identification of binding sites for the 
86-kilodalton IE2 protein of human cytomegalovirus within an IE2-responsive viral 
early promoter. Journal of virology, 68, 4117-4125. 
ARNON, T. I., ACHDOUT, H., LEVI, O., MARKEL, G., SALEH, N., KATZ, G., GAZIT, R., GONEN-
GROSS, T., HANNA, J. & NAHARI, E. 2005. Inhibition of the NKp30 activating receptor 
by pp65 of human cytomegalovirus. Nature immunology, 6, 515-523. 
ARNOULT, D., BARTLE, L. M., SKALETSKAYA, A., PONCET, D., ZAMZAMI, N., PARK, P. U., 
SHARPE, J., YOULE, R. J. & GOLDMACHER, V. S. 2004. Cytomegalovirus cell death 
suppressor vMIA blocks Bax-but not Bak-mediated apoptosis by binding and 
sequestering Bax at mitochondria. Proceedings of the National Academy of Sciences of 
the United States of America, 101, 7988-7993. 
ASHIRU, O., BENNETT, N. J., BOYLE, L. H., THOMAS, M., TROWSDALE, J. & WILLS, M. R. 2009. 
NKG2D ligand MICA is retained in the cis-Golgi apparatus by human cytomegalovirus 
protein UL142. Journal of virology, 83, 12345-12354. 
ATALAY, R., ZIMMERMANN, A., WAGNER, M., BORST, E., BENZ, C., MESSERLE, M. & HENGEL, H. 
2002. Identification and expression of human cytomegalovirus transcription units 
coding for two distinct Fcγ receptor homologs. Journal of virology, 76, 8596-8608. 
AUCOIN, D. P., SMITH, G. B., MEIERING, C. D. & MOCARSKI, E. S. 2006. Betaherpesvirus-
conserved cytomegalovirus tegument protein ppUL32 (pp150) controls cytoplasmic 
events during virion maturation. Journal of virology, 80, 8199-8210. 
AWASTHI, S., ISLER, J. A. & ALWINE, J. C. 2004. Analysis of splice variants of the immediate-
early 1 region of human cytomegalovirus. Journal of virology, 78, 8191-8200. 
BAILLIE, J., SAHLENDER, D. & SINCLAIR, J. 2003. Human cytomegalovirus infection inhibits 
tumor necrosis factor alpha (TNF-α) signaling by targeting the 55-kilodalton TNF-α 
receptor. Journal of virology, 77, 7007-7016. 
BALDICK, C. & SHENK, T. 1996. Proteins associated with purified human cytomegalovirus 
particles. Journal of virology, 70, 6097-6105. 
BARRON, M. A., GAO, D., SPRINGER, K. L., PATTERSON, J. A., BRUNVAND, M. W., MCSWEENEY, 
P. A., CHANG, Z., BARÓN, A. E. & WEINBERG, A. 2009. Relationship of reconstituted 
adaptive and innate cytomegalovirus (CMV)-specific immune responses with CMV 
viremia in hematopoietic stem cell transplant recipients. Clinical infectious diseases, 
49, 1777. 
BATTISTA, M. C., BERGAMINI, G., BOCCUNI, M. C., CAMPANINI, F., RIPALTI, A. & LANDINI, M. P. 
1999. Expression and characterization of a novel structural protein of human 
cytomegalovirus, pUL25. Journal of virology, 73, 3800-3809. 
BAUMGARTNER, M., SCHNEIDER, R., AUER, B., HERZOG, H., SCHWEIGER, M. & HIRSCH-
KAUFFMANN, M. 1992. Fluorescence in situ mapping of the human nuclear NAD+ ADP-
ribosyltransferase gene (ADPRT) and two secondary sites to human chromosomal 
bands 1q42, 13q34, and 14q24. Cytogenetic and Genome Research, 61, 172-174. 
241 
 
BAXTER, M. & GIBSON, W. The putative human cytomegalovirus triplex proteins, minor capsid 
protein (mCP) and mCP-binding protein (mC-BP), form a heterotrimeric complex that 
localizes to the cell nucleus in the absence of other viral proteins. 1997. 
BECHTEL, J. T. & SHENK, T. 2002. Human cytomegalovirus UL47 tegument protein functions 
after entry and before immediate-early gene expression. Journal of virology, 76, 1043-
1050. 
BECK, S. & BARRELL, B. G. 1988. Human cytomegalovirus encodes a glycoprotein homologous 
to MHC class-I antigens. Nature, 331, 269-272. 
BEGO, M., MACIEJEWSKI, J., KHAIBOULLINA, S., PARI, G. & ST JEOR, S. 2005. Characterization of 
an antisense transcript spanning the UL81-82 locus of human cytomegalovirus. Journal 
of virology, 79, 11022. 
BEGO, M. G., KEYES, L. R., MACIEJEWSKI, J. & ST JEOR, S. C. 2011. Human cytomegalovirus 
latency-associated protein LUNA is expressed during HCMV infections in vivo. Archives 
of virology, 1-5. 
BENEDICT, C. A., BUTROVICH, K. D., LURAIN, N. S., CORBEIL, J., ROONEY, I., SCHNEIDER, P., 
TSCHOPP, J. & WARE, C. F. 1999. Cutting edge: a novel viral TNF receptor superfamily 
member in virulent strains of human cytomegalovirus. The Journal of Immunology, 
162, 6967-6970. 
BERGAMINI, G., RESCHKE, M., BATTISTA, M. C., BOCCUNI, M. C., CAMPANINI, F., RIPALTI, A. & 
LANDINI, M. P. 1998. The major open reading frame of the β2. 7 transcript of human 
cytomegalovirus: in vitro expression of a protein posttranscriptionally regulated by the 
5′ region. Journal of virology, 72, 8425-8429. 
BESOLD, K., FRANKENBERG, N., PEPPERL-KLINDWORTH, S., KUBALL, J., THEOBALD, M., HAHN, 
G. & PLACHTER, B. 2007. Processing and MHC class I presentation of human 
cytomegalovirus pp65-derived peptides persist despite gpUS2–11-mediated immune 
evasion. Journal of General Virology, 88, 1429-1439. 
BEWIG, B. & SCHMIDT, W. 2000. Accelerated titering of adenoviruses. Biotechniques, 28, 870. 
BHELLA, D., RIXON, F. J. & DARGAN, D. J. 2000. Cryomicroscopy of human cytomegalovirus 
virions reveals more densely packed genomic DNA than in herpes simplex virus type 
11. Journal of molecular biology, 295, 155-161. 
BIÈCHE, I., CHAMPÈME, M. H. & LIDEREAU, R. 1995. Loss and gain of distinct regions of 
chromosome 1q in primary breast cancer. Clinical cancer research, 1, 123-127. 
BIEGALKE, B., LESTER, E., BRANDA, A. & RANA, R. 2004. Characterization of the human 
cytomegalovirus UL34 gene. Journal of virology, 78, 9579-9583. 
BIRON, C. A., BYRON, K. S. & SULLIVAN, J. L. 1989. Severe herpesvirus infections in an 
adolescent without natural killer cells. New England Journal of Medicine, 320, 1731-
1735. 
BLANKENSHIP, C. A. & SHENK, T. 2002. Mutant human cytomegalovirus lacking the immediate-
early TRS1 coding region exhibits a late defect. Journal of virology, 76, 12290-12299. 
BOECKH, M. 2011. Complications, Diagnosis, Management, and Prevention of CMV Infections: 
Current and Future. ASH Education Program Book, 2011, 305-309. 
BOECKH, M. & GEBALLE, A. P. 2011. Cytomegalovirus: pathogen, paradigm, and puzzle. The 
Journal of clinical investigation, 121, 1673. 
BOGNER, E., RADSAK, K. & STINSKI, M. F. 1998. The gene product of human cytomegalovirus 
open reading frame UL56 binds the pac motif and has specific nuclease activity. 
Journal of virology, 72, 2259-2264. 
BOLOVAN-FRITTS, C. A., MOCARSKI, E. S. & WIEDEMAN, J. A. 1999. Peripheral blood CD14+ 
cells from healthy subjects carry a circular conformation of latent cytomegalovirus 
genome. Blood, 93, 394-398. 
BORST, E. M., WAGNER, K., BINZ, A., SODEIK, B. & MESSERLE, M. 2008. The essential human 
cytomegalovirus gene UL52 is required for cleavage-packaging of the viral genome. 
Journal of virology, 82, 2065-2078. 
242 
 
BOSHART, M., WEBER, F., JAHN, G., DORSCH-HÄSLER, K., FLECKENSTEIN, B. & SCHAFFNER, W. 
1985. A very strong enhancer is located upstream of an immediate early gene of 
human cytomegalovirus. 
BOTTINO, C., CASTRICONI, R., PENDE, D., RIVERA, P., NANNI, M., CARNEMOLLA, B., CANTONI, 
C., GRASSI, J., MARCENARO, S. & REYMOND, N. 2003. Identification of PVR (CD155) 
and Nectin-2 (CD112) as cell surface ligands for the human DNAM-1 (CD226) activating 
molecule. The Journal of experimental medicine, 198, 557-567. 
BOWMAN, J. J., LACAYO, J. C., BURBELO, P., FISCHER, E. R. & COHEN, J. I. 2011. Rhesus and 
human cytomegalovirus glycoprotein L are required for infection and cell-to-cell 
spread of virus but cannot complement each other. Journal of virology, 85, 2089-2099. 
BRADLEY, A. J., LURAIN, N. S., GHAZAL, P., TRIVEDI, U., CUNNINGHAM, C., BALUCHOVA, K., 
GATHERER, D., WILKINSON, G. W. G., DARGAN, D. J. & DAVISON, A. J. 2009. High-
throughput sequence analysis of variants of human cytomegalovirus strains Towne 
and AD169. Journal of General Virology, 90, 2375-2380. 
BRADSHAW, P. A., DURAN-GUARINO, M. R., PERKINS, S., ROWE, J. I., FERNANDEZ, J., FRY, K. E., 
REYES, G. R., YOUNG, L. & FOUNG, S. K. H. 1994. Localization of antigenic sites on 
human cytomegalovirus virion structural proteins encoded by UL48 and UL56. 
Virology, 205, 321-328. 
BRAUD, V., JONES, E. Y. & MCMICHAEL, A. 1997. The human major histocompatibility complex 
class Ib molecule HLA-E binds signal sequence-derived peptides with primary anchor 
residues at positions 2 and 9. European journal of immunology, 27, 1164-9. 
BRAUD, V. M., ALLAN, D. S., O'CALLAGHAN, C. A., SODERSTROM, K., D'ANDREA, A., OGG, G. S., 
LAZETIC, S., YOUNG, N. T., BELL, J. I., PHILLIPS, J. H., LANIER, L. L. & MCMICHAEL, A. J. 
1998. HLA-E binds to natural killer cell receptors CD94/NKG2A, B and C. Nature, 391, 
795-9. 
BRESNAHAN, W. A. & SHENK, T. 2000a. A subset of viral transcripts packaged within human 
cytomegalovirus particles. Science, 288, 2373-2376. 
BRESNAHAN, W. A. & SHENK, T. E. 2000b. UL82 virion protein activates expression of 
immediate early viral genes in human cytomegalovirus-infected cells. Proceedings of 
the National Academy of Sciences, 97, 14506. 
BRITT, B. 2007. Maturation and egress. Human herpesviruses: biology, therapy, and 
immunoprophylaxis. Cambridge University Press, Cambridge, United Kingdom. 
BRITT, W. J. & AUGER, D. 1986. Synthesis and processing of the envelope gp55-116 complex of 
human cytomegalovirus. Journal of virology, 58, 185-191. 
BRITT, W. J. & BOPPANA, S. 2004. Human cytomegalovirus virion proteins. Human 
immunology, 65, 395-402. 
BRONZINI, M., LUGANINI, A., DELL'OSTE, V., DE ANDREA, M., LANDOLFO, S. & GRIBAUDO, G. 
2012. The US16 Gene of Human Cytomegalovirus Is Required for Efficient Viral 
Infection of Endothelial and Epithelial Cells. Journal of virology, 86, 6875-6888. 
BROWN, H. L. & ABERNATHY, M. P. Cytomegalovirus infection. 1998. Elsevier, 260-266. 
BROWNE, E. P. & SHENK, T. 2003. Human cytomegalovirus UL83-coded pp65 virion protein 
inhibits antiviral gene expression in infected cells. Proceedings of the National 
Academy of Sciences, 100, 11439. 
BROWNE, E. P., WING, B., COLEMAN, D. & SHENK, T. 2001. Altered cellular mRNA levels in 
human cytomegalovirus-infected fibroblasts: viral block to the accumulation of 
antiviral mRNAs. Journal of virology, 75, 12319-12330. 
BRUNE, W. 2011. Inhibition of programmed cell death by cytomegaloviruses. Virus Research, 
157, 144-150. 
BRYANT, L., MIXON, P., DAVIDSON, M., BANNISTER, A., KOUZARIDES, T. & SINCLAIR, J. 2000. 
The human cytomegalovirus 86-kilodalton major immediate-early protein interacts 
physically and functionally with histone acetyltransferase P/CAF. Journal of virology, 
74, 7230-7237. 
243 
 
BUERGER, I., REEFSCHLAEGER, J., BENDER, W., ECKENBERG, P., POPP, A., WEBER, O., GRAEPER, 
S., KLENK, H. D., RUEBSAMEN-WAIGMANN, H. & HALLENBERGER, S. 2001. A novel 
nonnucleoside inhibitor specifically targets cytomegalovirus DNA maturation via the 
UL89 and UL56 gene products. Journal of virology, 75, 9077-9086. 
CALIENDO, A. M., GEORGE, K. S., KAO, S. Y., ALLEGA, J., TAN, B. H., LAFONTAINE, R., BUI, L. & 
RINALDO, C. R. 2000. Comparison of quantitative cytomegalovirus (CMV) PCR in 
plasma and CMV antigenemia assay: clinical utility of the prototype AMPLICOR CMV 
MONITOR test in transplant recipients. Journal of clinical microbiology, 38, 2122-2127. 
CANNON, M. J., SCHMID, D. S. & HYDE, T. B. 2010. Review of cytomegalovirus seroprevalence 
and demographic characteristics associated with infection. Reviews in medical 
virology, 20, 202-213. 
CAO, J. & GEBALLE, A. P. 1995. Translational inhibition by a human cytomegalovirus upstream 
open reading frame despite inefficient utilization of its AUG codon. Journal of virology, 
69, 1030-1036. 
CAO, J. & GEBALLE, A. P. 1996. Coding sequence-dependent ribosomal arrest at termination of 
translation. Molecular and Cellular Biology, 16, 603-608. 
CAPOSIO, P., RIERA, L., HAHN, G., LANDOLFO, S. & GRIBAUDO, G. 2004. Evidence that the 
human cytomegalovirus 46-kDa UL72 protein is not an active dUTPase but a late 
protein dispensable for replication in fibroblasts. Virology, 325, 264-276. 
CASWELL, R., BRYANT, L. & SINCLAIR, J. 1996. Human cytomegalovirus immediate-early 2 (IE2) 
protein can transactivate the human hsp70 promoter by alleviation of Dr1-mediated 
repression. Journal of virology, 70, 4028-4037. 
CASWELL, R., HAGEMEIER, C., CHIOU, C. J., HAYWARD, G., KOUZARIDES, T. & SINCLAIR, J. 1993. 
The human cytomegalovirus 86K immediate early (IE) 2 protein requires the basic 
region of the TATA-box binding protein (TBP) for binding, and interacts with TBP and 
transcription factor TFIIB via regions of IE2 required for transcriptional regulation. The 
Journal of general virology, 74, 2691. 
CERBONI, C., MOUSAVI-JAZI, M., LINDE, A., SÖDERSTRÖM, K., BRYTTING, M., WAHREN, B., 
KÄRRE, K. & CARBONE, E. 2000. Human cytomegalovirus strain-dependent changes in 
NK cell recognition of infected fibroblasts. The Journal of Immunology, 164, 4775. 
CHA, T. A., TOM, E., KEMBLE, G. W., DUKE, G. M., MOCARSKI, E. S. & SPAETE, R. R. 1996. 
Human cytomegalovirus clinical isolates carry at least 19 genes not found in laboratory 
strains. Journal of virology, 70, 78. 
CHALUPNY, N. J., REIN-WESTON, A., DOSCH, S. & COSMAN, D. 2006. Down-regulation of the 
NKG2D ligand MICA by the human cytomegalovirus glycoprotein UL142. Biochemical 
and biophysical research communications, 346, 175-181. 
CHAMPSAUR, M. & LANIER, L. L. 2010. Effect of NKG2D ligand expression on host immune 
responses. Immunological reviews, 235, 267-285. 
CHAN, G., NOGALSKI, M. T. & YUROCHKO, A. D. 2009. Activation of EGFR on monocytes is 
required for human cytomegalovirus entry and mediates cellular motility. Proceedings 
of the National Academy of Sciences, 106, 22369-22374. 
CHANG, C. P., VESOLE, D. H., NELSON, J., OLDSTONE, M. & STINSKI, M. 1989. Identification and 
expression of a human cytomegalovirus early glycoprotein. Journal of virology, 63, 
3330-3337. 
CHAUDHURI, A. R., JEOR, S. S. & MACIEJEWSKI, J. P. 1999. Apoptosis induced by human 
cytomegalovirus infection can be enhanced by cytokines to limit the spread of virus. 
Experimental hematology, 27, 1194-1203. 
CHEE, M., BANKIER, A., BECK, S., BOHNI, R., BROWN, C., CERNY, R., HORSNELL, T., HUTCHISON 
3RD, C., KOUZARIDES, T. & MARTIGNETTI, J. 1990. Analysis of the protein-coding 
content of the sequence of human cytomegalovirus strain AD169. Current topics in 
microbiology and immunology, 154, 125. 
244 
 
CHEN, A., KAO, Y. & BROWN, C. M. 2005. Translation of the first upstream ORF in the hepatitis 
B virus pregenomic RNA modulates translation at the core and polymerase initiation 
codons. Nucleic acids research, 33, 1169-1181. 
CHEN, D. H., JIANG, H., LEE, M., LIU, F. & ZHOU, Z. H. 1999. Three-dimensional visualization of 
tegument/capsid interactions in the intact human cytomegalovirus. Virology, 260, 10-
16. 
CHERRINGTON, J. M. & MOCARSKI, E. S. 1989. Human cytomegalovirus ie1 transactivates the 
alpha promoter-enhancer via an 18-base-pair repeat element. Journal of virology, 63, 
1435-1440. 
CHILD, S. J., HAKKI, M., DE NIRO, K. L. & GEBALLE, A. P. 2004. Evasion of cellular antiviral 
responses by human cytomegalovirus TRS1 and IRS1. Journal of virology, 78, 197-205. 
CHOU, S. 1986. Acquisition of donor strains of cytomegalovirus by renal-transplant recipients. 
New England Journal of Medicine, 314, 1418-1423. 
CHOU, S. 1999. Antiviral drug resistance in human cytomegalovirus. Transplant infectious 
disease, 1, 105-114. 
CHOU, S., MAROUSEK, G. I., SENTERS, A. E., DAVIS, M. G. & BIRON, K. K. 2004. Mutations in the 
human cytomegalovirus UL27 gene that confer resistance to maribavir. Journal of 
virology, 78, 7124-7130. 
CHRETIEN, J. H., MCGINNISS, C. G. & MULLER, A. 1977. Venereal causes of cytomegalovirus 
mononucleosis. JAMA: The Journal of the American Medical Association, 238, 1644-
1645. 
CINATL JR, J., CINATL, J., VOGEL, J. U., RABENAU, H., KORNHUBER, B. & DOERR, H. 1996. 
Modulatory effects of human cytomegalovirus infection on malignant properties of 
cancer cells. Intervirology, 39, 259-269. 
COBBS, C. S., HARKINS, L., SAMANTA, M., GILLESPIE, G. Y., BHARARA, S., KING, P. H., NABORS, 
L. B., COBBS, C. G. & BRITT, W. J. 2002. Human cytomegalovirus infection and 
expression in human malignant glioma. Cancer research, 62, 3347. 
COLBERG-POLEY, A. M., PATEL, M. B., EREZO, D. P. P. & SLATER, J. E. 2000. Human 
cytomegalovirus UL37 immediate-early regulatory proteins traffic through the 
secretory apparatus and to mitochondria. Journal of general virology, 81, 1779-1789. 
COMPTON, T., KURT-JONES, E. A., BOEHME, K. W., BELKO, J., LATZ, E., GOLENBOCK, D. T. & 
FINBERG, R. W. 2003. Human cytomegalovirus activates inflammatory cytokine 
responses via CD14 and Toll-like receptor 2. Journal of virology, 77, 4588-4596. 
COMPTON, T., NEPOMUCENO, R. R. & NOWLIN, D. M. 1992. Human cytomegalovirus 
penetrates host cells by pH-independent fusion at the cell surface. Virology, 191, 387-
395. 
COMPTON, T., NOWLIN, D. M. & COOPER, N. R. 1993. Initiation of human cytomegalovirus 
infection requires initial interaction with cell surface heparan sulfate. Virology, 193, 
834-841. 
COSMAN, D., FANGER, N., BORGES, L., KUBIN, M., CHIN, W., PETERSON, L. & HSU, M. L. 1997. A 
novel immunoglobulin superfamily receptor for cellular and viral MHC class I 
molecules. Immunity, 7, 273-282. 
CRANAGE, M., KOUZARIDES, T., BANKIER, A., SATCHWELL, S., WESTON, K., TOMLINSON, P., 
BARRELL, B., HART, H., BELL, S. & MINSON, A. 1986. Identification of the human 
cytomegalovirus glycoprotein B gene and induction of neutralizing antibodies via its 
expression in recombinant vaccinia virus. The EMBO journal, 5, 3057. 
CRANAGE, M. P., SMITH, G., BELL, S., HART, H., BROWN, C., BANKIER, A., TOMLINSON, P., 
BARRELL, B. & MINSON, T. 1988. Identification and expression of a human 
cytomegalovirus glycoprotein with homology to the Epstein-Barr virus BXLF2 product, 
varicella-zoster virus gpIII, and herpes simplex virus type 1 glycoprotein H. Journal of 
virology, 62, 1416-1422. 
CUNHA, B. A. 2010. Cytomegalovirus pneumonia: community-acquired pneumonia in 
immunocompetent hosts. Infectious disease clinics of North America, 24, 147-158. 
245 
 
DAL MONTE, P., PIGNATELLI, S., MACH, M. & LANDINI, M. 2001. The product of human 
cytomegalovirus UL73 is a new polymorphic structural glycoprotein (gpUL73). Journal 
of human virology, 4, 26. 
DAL MONTE, P., PIGNATELLI, S., ZINI, N., MARALDI, N., PERRET, E., PREVOST, M. & LANDINI, M. 
2002. Analysis of intracellular and intraviral localization of the human cytomegalovirus 
UL53 protein. Journal of general virology, 83, 1005-1012. 
DAS, S. & PELLETT, P. E. 2007. Members of the HCMV US12 family of predicted heptaspanning 
membrane proteins have unique intracellular distributions, including association with 
the cytoplasmic virion assembly complex. Virology, 361, 263-273. 
DAS, S., SKOMOROVSKA-PROKVOLIT, Y., WANG, F. Z. & PELLETT, P. E. 2006. Infection-
dependent nuclear localization of US17, a member of the US12 family of human 
cytomegalovirus-encoded seven-transmembrane proteins. Journal of virology, 80, 
1191-1203. 
DAS, S., VASANJI, A. & PELLETT, P. E. 2007. Three-dimensional structure of the human 
cytomegalovirus cytoplasmic virion assembly complex includes a reoriented secretory 
apparatus. Journal of virology, 81, 11861-11869. 
DAVISON, A. & BHELLA, D. 2007. Comparative genome and virion structure. Human 
herpesviruses: biology, therapy, and immunoprophylaxis. Cambridge University Press, 
Cambridge, United Kingdom. 
DAVISON, A. J. 2010. Herpesvirus systematics. Veterinary microbiology, 143, 52-69. 
DAVISON, A. J., AKTER, P., CUNNINGHAM, C., DOLAN, A., ADDISON, C., DARGAN, D. J., HASSAN-
WALKER, A. F., EMERY, V. C., GRIFFITHS, P. D. & WILKINSON, G. W. G. 2003a. 
Homology between the human cytomegalovirus RL11 gene family and human 
adenovirus E3 genes. Journal of General Virology, 84, 657. 
DAVISON, A. J., DOLAN, A., AKTER, P., ADDISON, C., DARGAN, D. J., ALCENDOR, D. J., 
MCGEOCH, D. J. & HAYWARD, G. S. 2003b. The human cytomegalovirus genome 
revisited: comparison with the chimpanzee cytomegalovirus genome. Journal of 
General Virology, 84, 17-28. 
DEGNIN, C. R., SCHLEISS, M., CAO, J. & GEBALLE, A. P. 1993. Translational inhibition mediated 
by a short upstream open reading frame in the human cytomegalovirus gpUL4 (gp48) 
transcript. Journal of virology, 67, 5514-5521. 
DEMARCHI, J. M., SCHMIDT, C. A. & KAPLAN, A. S. 1980. Patterns of transcription of human 
cytomegalovirus in permissively infected cells. Journal of virology, 35, 277-286. 
DEPTO, A. S. & STENBERG, R. M. 1992. Functional analysis of the true late human 
cytomegalovirus pp28 upstream promoter: cis-acting elements and viral trans-acting 
proteins necessary for promoter activation. Journal of virology, 66, 3241-3246. 
DHURUVASAN, K., SIVASUBRAMANIAN, G. & PELLETT, P. E. 2011. Roles of host and viral 
microRNAs in human cytomegalovirus biology. Virus Research, 157, 180-192. 
DIMITROPOULOU, P., CASWELL, R., MCSHARRY, B. P., GREAVES, R. F., SPANDIDOS, D. A., 
WILKINSON, G. W. G. & SOURVINOS, G. 2010. Differential relocation and stability of 
PML-body components during productive human cytomegalovirus infection: Detailed 
characterization by live-cell imaging. European journal of cell biology, 89, 757-768. 
DITTMER, A. & BOGNER, E. 2005. Analysis of the quaternary structure of the putative HCMV 
portal protein pUL104. Biochemistry, 44, 759-765. 
DIVANOVIC, S., TROMPETTE, A., ATABANI, S. F., MADAN, R., GOLENBOCK, D. T., VISINTIN, A., 
FINBERG, R. W., TARAKHOVSKY, A., VOGEL, S. N. & BELKAID, Y. 2005. Negative 
regulation of Toll-like receptor 4 signaling by the Toll-like receptor homolog RP105. 
Nature immunology, 6, 571-578. 
DOLAN, A., CUNNINGHAM, C., HECTOR, R. D., HASSAN-WALKER, A. F., LEE, L., ADDISON, C., 
DARGAN, D. J., MCGEOCH, D. J., GATHERER, D. & EMERY, V. C. 2004. Genetic content 
of wild-type human cytomegalovirus. Journal of General Virology, 85, 1301. 
DÖLKEN, L., PFEFFER, S. & KOSZINOWSKI, U. H. 2009. Cytomegalovirus microRNAs. Virus genes, 
38, 355-364. 
246 
 
DUCANCELLE, A., CHAMPIER, G., ALAIN, S., PETIT, F., LE PORS, M. J. S. & MAZERON, M. C. 2006. 
Short communication A novel mutation in the UL54 gene of human cytomegalovirus 
isolates that confers resistance to foscarnet. Antiviral therapy, 11, 537-540. 
DUMORTIER, J., STREBLOW, D. N., MOSES, A. V., JACOBS, J. M., KREKLYWICH, C. N., CAMP, D., 
SMITH, R. D., ORLOFF, S. L. & NELSON, J. A. 2008. Human cytomegalovirus secretome 
contains factors that induce angiogenesis and wound healing. Journal of virology, 82, 
6524-6535. 
DUNN, C., CHALUPNY, N. J., SUTHERLAND, C. L., DOSCH, S., SIVAKUMAR, P., JOHNSON, D. C. & 
COSMAN, D. 2003a. Human cytomegalovirus glycoprotein UL16 causes intracellular 
sequestration of NKG2D ligands, protecting against natural killer cell cytotoxicity. The 
Journal of experimental medicine, 197, 1427-1439. 
DUNN, W., CHOU, C., LI, H., HAI, R., PATTERSON, D., STOLC, V., ZHU, H. & LIU, F. 2003b. 
Functional profiling of a human cytomegalovirus genome. Proceedings of the National 
Academy of Sciences of the United States of America, 100, 14223. 
DUNN, W., CHOU, C., LI, H., HAI, R., PATTERSON, D., STOLC, V., ZHU, H. & LIU, F. 2003c. 
Functional profiling of a human cytomegalovirus genome. Proceedings of the National 
Academy of Sciences, 100, 14223-14228. 
DUNN, W., TRANG, P., ZHONG, Q., YANG, E., VAN BELLE, C. & LIU, F. 2005. Human 
cytomegalovirus expresses novel microRNAs during productive viral infection. Cellular 
microbiology, 7, 1684-1695. 
E. MURPHY , T. S. 2008. human cytomegalovirus Current Topics in Microbiology and 
Immunology. 
EDWARDS, R. L. 1976. Structural proteins of human cytomegalovirus. The Yale journal of 
biology and medicine, 49, 65. 
ELSING, A. & BURGERT, H. G. 1998. The adenovirus E3/10.4 K–14.5 K proteins down-modulate 
the apoptosis receptor Fas/Apo-1 by inducing its internalization. Proceedings of the 
National Academy of Sciences, 95, 10072. 
ENGEL, P., PÉREZ-CARMONA, N., ALBÀ, M. M., ROBERTSON, K., GHAZAL, P. & ANGULO, A. 
2011. Human cytomegalovirus UL7, a homologue of the SLAM-family receptor CD229, 
impairs cytokine production. Immunology and Cell Biology. 
ERTL, P. & POWELL, K. 1992. Physical and functional interaction of human cytomegalovirus 
DNA polymerase and its accessory protein (ICP36) expressed in insect cells. Journal of 
virology, 66, 4126-4133. 
FARBER, S. & WOLBACH, S. B. 1932. Intranuclear and cytoplasmic inclusions (“protozoan-like 
bodies”) in the salivary glands and other organs of infants. The American journal of 
pathology, 8, 123. 
FEHR, A. R. & YU, D. 2010. Human cytomegalovirus gene UL21a encodes a short-lived 
cytoplasmic protein and facilitates virus replication in fibroblasts. Journal of virology, 
84, 291-302. 
FEIRE, A. L., KOSS, H. & COMPTON, T. 2004. Cellular integrins function as entry receptors for 
human cytomegalovirus via a highly conserved disintegrin-like domain. Proceedings of 
the National Academy of Sciences of the United States of America, 101, 15470. 
FENG, X., SCHRÖER, J., YU, D. & SHENK, T. 2006. Human cytomegalovirus pUS24 is a virion 
protein that functions very early in the replication cycle. Journal of virology, 80, 8371-
8378. 
FIALA, M., HONESS, R., HEINER, D., HEINE JR, J., MURNANE, J., WALLACE, R. & GUZE, L. 1976. 
Cytomegalovirus proteins. I. Polypeptides of virions and dense bodies. Journal of 
virology, 19, 243-254. 
FISH, K. N., DEPTO, A. S., MOSES, A. V., BRITT, W. & NELSON, J. A. 1995. Growth kinetics of 
human cytomegalovirus are altered in monocyte-derived macrophages. Journal of 
virology, 69, 3737. 
FLECKENSTEIN, B., MÜLLER, I. & COLLINS, J. 1982. Cloning of the complete human 
cytomegalovirus genome in cosmids. Gene, 18, 39-46. 
247 
 
FORTUNATO, E. A., DELL'AQUILA, M. L. & SPECTOR, D. H. 2000. Specific chromosome 1 breaks 
induced by human cytomegalovirus. Proceedings of the National Academy of Sciences, 
97, 853. 
FORTUNATO, E. A. & SPECTOR, D. H. 2003. Viral induction of site‐specific chromosome 
damage. Reviews in medical virology, 13, 21-37. 
FOWLER, K. B., STAGNO, S., PASS, R. F., BRITT, W. J., BOLL, T. J. & ALFORD, C. A. 1992. The 
outcome of congenital cytomegalovirus infection in relation to maternal antibody 
status. New England Journal of Medicine, 326, 663-667. 
FRAILE-RAMOS, A., KLEDAL, T. N., PELCHEN-MATTHEWS, A., BOWERS, K., SCHWARTZ, T. W. & 
MARSH, M. 2001. The human cytomegalovirus US28 protein is located in endocytic 
vesicles and undergoes constitutive endocytosis and recycling. Molecular biology of 
the cell, 12, 1737-1749. 
FRAILE-RAMOS, A., PELCHEN‐MATTHEWS, A., KLEDAL, T. N., BROWNE, H., SCHWARTZ, T. W. & 
MARSH, M. 2002. Localization of HCMV UL33 and US27 in endocytic compartments 
and viral membranes. Traffic, 3, 218-232. 
FREIBERG, R. A., SPENCER, D. M., CHOATE, K. A., DUH, H. J., SCHREIBER, S. L., CRABTREE, G. R. 
& KHAVARI, P. A. 1997. Fas signal transduction triggers either proliferation or 
apoptosis in human fibroblasts. Journal of investigative dermatology, 108, 215-219. 
FURMAN, M. H., DEY, N., TORTORELLA, D. & PLOEGH, H. L. 2002. The human cytomegalovirus 
US10 gene product delays trafficking of major histocompatibility complex class I 
molecules. Journal of virology, 76, 11753-11756. 
FURNARI, B. A., POMA, E., KOWALIK, T., HUONG, S. & HUANG, E. 1993. Human 
cytomegalovirus immediate-early gene 2 protein interacts with itself and with several 
novel cellular proteins. Journal of virology, 67, 4981-4991. 
FURUKAWA, T., HORNBERGER, E., SAKUMA, S. & PLOTKIN, S. A. 1975. Demonstration of 
immunoglobulin G receptors induced by human cytomegalovirus. Journal of clinical 
microbiology, 2, 332-336. 
GANDHI, M. K. & KHANNA, R. 2004. Human cytomegalovirus: clinical aspects, immune 
regulation, and emerging treatments. The Lancet infectious diseases, 4, 725-738. 
GAO, M., BRUFATTO, N., CHEN, T., MURLEY, L. L., THALAKADA, R., DOMAGALA, M., BEATTIE, 
B., MAMELAK, D., ATHANASOPOULOS, V. & JOHNSON, D. 2005. Expression profiling of 
herpesvirus and vaccinia virus proteins using a high-throughput baculovirus screening 
system. Journal of Proteome Research, 4, 2225-2235. 
GARCIA-FUSTER, M.  ., FERRER-ALC N, M., MIRALLES, A.   GARC  A-SEVILLA, J. A. 2004. 
Deglycosylation of Fas receptor and chronic morphine treatment up-regulate high 
molecular mass Fas aggregates in the rat brain. European journal of pharmacology, 
496, 63-69. 
GATHERER, D., SEIRAFIAN, S., CUNNINGHAM, C., HOLTON, M., DARGAN, D. J., BALUCHOVA, K., 
HECTOR, R. D., GALBRAITH, J., HERZYK, P. & WILKINSON, G. W. G. 2011. High-
resolution human cytomegalovirus transcriptome. Proceedings of the National 
Academy of Sciences, 108, 19755-19760. 
GAWN, J. M. & GREAVES, R. F. 2002. Absence of IE1 p72 protein function during low-
multiplicity infection by human cytomegalovirus results in a broad block to viral 
delayed-early gene expression. Journal of virology, 76, 4441-4455. 
GEBALLE, A. P., LEACH, F. S. & MOCARSKI, E. S. 1986. Regulation of cytomegalovirus late gene 
expression: gamma genes are controlled by posttranscriptional events. Journal of 
virology, 57, 864-874. 
GEDER, K., LAUSCH, R., O'NEILL, F. & RAPP, F. 1976. Oncogenic transformation of human 
embryo lung cells by human cytomegalovirus. Science, 192, 1134-1137. 
GEORGEL, P., JIANG, Z., KUNZ, S., JANSSEN, E., MOLS, J., HOEBE, K., BAHRAM, S., OLDSTONE, 
M. & BEUTLER, B. 2007. Vesicular stomatitis virus glycoprotein G activates a specific 
antiviral Toll-like receptor 4-dependent pathway. Virology, 362, 304-313. 
248 
 
GERNA, G., SARASINI, A., PATRONE, M., PERCIVALLE, E., FIORINA, L., CAMPANINI, G., GALLINA, 
A., BALDANTI, F. & REVELLO, M. G. 2008a. Human cytomegalovirus serum neutralizing 
antibodies block virus infection of endothelial/epithelial cells, but not fibroblasts, early 
during primary infection. The Journal of general virology, 89, 853-65. 
GERNA, G., SARASINI, A., PATRONE, M., PERCIVALLE, E., FIORINA, L., CAMPANINI, G., GALLINA, 
A., BALDANTI, F. & REVELLO, M. G. 2008b. Human cytomegalovirus serum neutralizing 
antibodies block virus infection of endothelial/epithelial cells, but not fibroblasts, early 
during primary infection. Journal of general virology, 89, 853-865. 
GHAZAL, P., LUBON, H., REYNOLDS-KOHLER, C., HENNIGHAUSEN, L. & NELSON, J. A. 1990. 
Interactions between cellular regulatory proteins and a unique sequence region in the 
human cytomegalovirus major immediate-early promoter. Virology, 174, 18-25. 
GIBSON, W. 1981. Structural and nonstructural proteins of strain Colburn cytomegalovi. 
Virology, 111, 516-537. 
GIBSON, W. 1996. Structure and assembly of the virion. Intervirology, 39, 389-400. 
GIBSON, W., BAXTER, M. K. & CLOPPER, K. S. 1996a. Cytomegalovirus" missing" capsid protein 
identified as heat-aggregable product of human cytomegalovirus UL46. Journal of 
virology, 70, 7454-7461. 
GIBSON, W., CLOPPER, K. S., BRITT, W. J. & BAXTER, M. K. 1996. Human cytomegalovirus 
(HCMV) smallest capsid protein identified as product of short open reading frame 
located between HCMV UL48 and UL49. Journal of virology, 70, 5680-5683. 
GIBSON, W. & ROIZMAN, B. 1971. Compartmentalization of spermine and spermidine in the 
herpes simplex virion. Proceedings of the National Academy of Sciences, 68, 2818. 
GIESEN, K., RADSAK, K. & BOGNER, E. 2000. Targeting of the gene product encoded by ORF 
UL56 of human cytomegalovirus into viral replication centers. FEBS letters, 471, 215-
218. 
GLAß, M., BUSCHE, A., WAGNER, K., MESSERLE, M. & BORST, E. M. 2009. Conditional and 
reversible disruption of essential herpesvirus proteins. Nature methods, 6, 577-579. 
GOLDMACHER, V. 2005. Cell death suppression by cytomegaloviruses. Apoptosis, 10, 251-265. 
GOLDMACHER, V. S., BARTLE, L. M., SKALETSKAYA, A., DIONNE, C. A., KEDERSHA, N. L., VATER, 
C. A., HAN, J., LUTZ, R. J., WATANABE, S. & MCFARLAND, E. D. C. 1999. A 
cytomegalovirus-encoded mitochondria-localized inhibitor of apoptosis structurally 
unrelated to Bcl-2. Proceedings of the National Academy of Sciences, 96, 12536. 
GOLDSTEIN, L., MCDOUGALL, J., HACKMAN, R., MEYERS, J., THOMAS, E. & NOWINSKI, R. 1982. 
Monoclonal antibodies to cytomegalovirus: rapid identification of clinical isolates and 
preliminary use in diagnosis of cytomegalovirus pneumonia. Infection and immunity, 
38, 273-281. 
GONCZOL, E., ANDREWS, P. W. & PLOTKIN, S. A. 1984. Cytomegalovirus replicates in 
differentiated but not in undifferentiated human embryonal carcinoma cells. Science, 
224, 159-161. 
GOODPASTURE, E. W. & TALBOT, F. B. 1921. Concerning the nature of" protozoan-like" cells in 
certain lesions of infancy. Archives of Pediatrics and Adolescent Medicine, 21, 415. 
GOODRUM, F., REEVES, M., SINCLAIR, J., HIGH, K. & SHENK, T. 2007. Human cytomegalovirus 
sequences expressed in latently infected individuals promote a latent infection in vitro. 
Blood, 110, 937-945. 
GOODRUM, F. D., JORDAN, C. T., HIGH, K. & SHENK, T. 2002. Human cytomegalovirus gene 
expression during infection of primary hematopoietic progenitor cells: a model for 
latency. Proceedings of the National Academy of Sciences, 99, 16255. 
GRAHAM, F., SMILEY, J., RUSSELL, W. & NAIRN, R. 1977. Characteristics of a human cell line 
transformed by DNA from human adenovirus type 5. Journal of general virology, 36, 
59-72. 
GRAINGER, L., CICCHINI, L., RAK, M., PETRUCELLI, A., FITZGERALD, K. D., SEMLER, B. L. & 
GOODRUM, F. 2010. Stress-inducible alternative translation initiation of human 
cytomegalovirus latency protein pUL138. Journal of virology, 84, 9472-9486. 
249 
 
GRAZIA REVELLO, M., BALDANTI, F., PERCIVALLE, E., SARASINI, A., DE-GIULI, L., GENINI, E., 
LILLERI, D., LABÒ, N. & GERNA, G. 2001. In vitro selection of human cytomegalovirus 
variants unable to transfer virus and virus products from infected cells to 
polymorphonuclear leukocytes and to grow in endothelial cells. Journal of General 
Virology, 82, 1429. 
GREAVES, R. F. & MOCARSKI, E. S. 1998. Defective growth correlates with reduced 
accumulation of a viral DNA replication protein after low-multiplicity infection by a 
human cytomegalovirus ie1 mutant. Journal of virology, 72, 366-379. 
GREBER, U. F. & WAY, M. 2006. A superhighway to virus infection. Cell, 124, 741-754. 
GREENAWAY, P. J. & WILKINSON, G. W. G. 1987. Nucleotide sequence of the most abundantly 
transcribed early gene of human cytomegalovirus strain AD169. Virus Research, 7, 17-
31. 
GREFTE, A., HARMSEN, M. C., VAN DER GIESSEN, M., KNOLLEMA, S. & VAN SON, W. J. 1994. 
Presence of human cytomegalovirus (HCMV) immediate early mRNA but not ppUL83 
(lower matrix protein pp65) mRNA in polymorphonuclear and mononuclear leukocytes 
during active HCMV infection. The Journal of general virology, 75, 1989. 
GREIJER, A. E., DEKKERS, C. A. J. & MIDDELDORP, J. M. 2000. Human cytomegalovirus virions 
differentially incorporate viral and host cell RNA during the assembly process. Journal 
of virology, 74, 9078-9082. 
GREY, F., ANTONIEWICZ, A., ALLEN, E., SAUGSTAD, J., MCSHEA, A., CARRINGTON, J. C. & 
NELSON, J. 2005. Identification and characterization of human cytomegalovirus-
encoded microRNAs. Journal of virology, 79, 12095-12099. 
GREY, F., MEYERS, H., WHITE, E. A., SPECTOR, D. H. & NELSON, J. 2007. A human 
cytomegalovirus-encoded microRNA regulates expression of multiple viral genes 
involved in replication. PLoS pathogens, 3, e163. 
GRIFFIN, C., WANG, E. C. Y., MCSHARRY, B. P., RICKARDS, C., BROWNE, H., WILKINSON, G. W. 
G. & TOMASEC, P. 2005. Characterization of a highly glycosylated form of the human 
cytomegalovirus HLA class I homologue gpUL18. Journal of General Virology, 86, 2999-
3008. 
GRUNDY, J. E., MCKEATING, J. A. & GRIFFITHS, P. D. 1987. Cytomegalovirus strain AD169 binds 
beta 2 microglobulin in vitro after release from cells. The Journal of general virology, 
68, 777. 
GUERIN, J. L., GELFI, J., BOULLIER, S., DELVERDIER, M., BELLANGER, F. A., BERTAGNOLI, S., 
DREXLER, I., SUTTER, G. & MESSUD-PETIT, F. 2002. Myxoma virus leukemia-associated 
protein is responsible for major histocompatibility complex class I and Fas-CD95 down-
regulation and defines scrapins, a new group of surface cellular receptor abductor 
proteins. Journal of virology, 76, 2912-2923. 
GUO, Y. & HUANG, E. 1993. Characterization of a structurally tricistronic gene of human 
cytomegalovirus composed of U (s) 18, U (s) 19, and U (s) 20. Journal of virology, 67, 
2043-2054. 
HAGEMEIER, C., CASWELL, R., HAYHURST, G., SINCLAIR, J. & KOUZARIDES, T. 1994. Functional 
interaction between the HCMV IE2 transactivator and the retinoblastoma protein. The 
EMBO journal, 13, 2897. 
HAHN, G., KHAN, H., BALDANTI, F., KOSZINOWSKI, U. H., REVELLO, M. G. & GERNA, G. 2002. 
The human cytomegalovirus ribonucleotide reductase homolog UL45 is dispensable for 
growth in endothelial cells, as determined by a BAC-cloned clinical isolate of human 
cytomegalovirus with preserved wild-type characteristics. Journal of virology, 76, 9551. 
HAHN, G., REVELLO, M. G., PATRONE, M., PERCIVALLE, E., CAMPANINI, G., SARASINI, A., 
WAGNER, M., GALLINA, A., MILANESI, G. & KOSZINOWSKI, U. 2004. Human 
cytomegalovirus UL131-128 genes are indispensable for virus growth in endothelial 
cells and virus transfer to leukocytes. Journal of virology, 78, 10023-10033. 
250 
 
HANDSFIELD, H. H., CHANDLER, S. H., CAINE, V. A., MEYERS, J. D., COREY, L., MEDEIROS, E. & 
MCDOUGALL, J. K. 1985. Cytomegalovirus infection in sex partners: evidence for sexual 
transmission. Journal of Infectious Diseases, 151, 344. 
HAREL, N. Y. & ALWINE, J. C. 1998. Phosphorylation of the human cytomegalovirus 86-
kilodalton immediate-early protein IE2. Journal of virology, 72, 5481-92. 
HARKINS, L., VOLK, A. L., SAMANTA, M., MIKOLAENKO, I., BRITT, W. J., BLAND, K. I. & COBBS, C. 
S. 2002. Specific localisation of human cytomegalovirus nucleic acids and proteins in 
human colorectal cancer. The Lancet, 360, 1557-1563. 
HAYHURST, G., BRYANT, L., CASWELL, R., WALKER, S. & SINCLAIR, J. 1995. CCAAT box-
dependent activation of the TATA-less human DNA polymerase alpha promoter by the 
human cytomegalovirus 72-kilodalton major immediate-early protein. Journal of 
virology, 69, 182-188. 
HE, T. C., ZHOU, S., DA COSTA, L. T., YU, J., KINZLER, K. W. & VOGELSTEIN, B. 1998. A simplified 
system for generating recombinant adenoviruses. Proceedings of the National 
Academy of Sciences, 95, 2509-2514. 
HE, Y., XU, L. & HUANG, E. 1992. Characterization of human cytomegalovirus UL84 early gene 
and identification of its putative protein product. Journal of virology, 66, 1098-1108. 
HEGDE, N. R., TOMAZIN, R. A., WISNER, T. W., DUNN, C., BONAME, J. M., LEWINSOHN, D. M. & 
JOHNSON, D. C. 2002. Inhibition of HLA-DR assembly, transport, and loading by human 
cytomegalovirus glycoprotein US3: a novel mechanism for evading major 
histocompatibility complex class II antigen presentation. Journal of virology, 76, 10929-
10941. 
HENGEL, H., FLOHR, T., HÄMMERLING, G. J., KOSZINOWSKI, U. H. & MOMBURG, F. 1996. 
Human cytomegalovirus inhibits peptide translocation into the endoplasmic reticulum 
for MHC class I assembly. Journal of General Virology, 77, 2287-2296. 
HENGEL, H., KOOPMANN, J. O., FLOHR, T., MURANYI, W., GOULMY, E., HÄMMERLING, G. J., 
KOSZINOWSKI, U. H. & MOMBURG, F. 1997. A viral ER-resident glycoprotein 
inactivates the MHC-encoded peptide transporter. Immunity, 6, 623-632. 
HENSEL, G., MEYER, H., GÄRTNER, S., BRAND, G. & KERN, H. F. 1995. Nuclear localization of the 
human cytomegalovirus tegument protein pp150 (ppUL32). Journal of General 
Virology, 76, 1591-1601. 
HENSEL, G. M., MEYER, H. H., BUCHMANN, I., POMMEREHNE, D., SCHMOLKE, S., PLACHTER, B., 
RADSAK, K. & KERN, H. F. 1996. Intracellular localization and expression of the human 
cytomegalovirus matrix phosphoprotein pp71 (ppUL82): evidence for its translocation 
into the nucleus. Journal of general virology, 77, 3087-3097. 
HERMISTON, T. W., MALONE, C. L. & STINSKI, M. F. 1990. Human cytomegalovirus immediate-
early two protein region involved in negative regulation of the major immediate-early 
promoter. Journal of virology, 64, 3532-3536. 
HITOMI, S., KOZUKA-HATA, H., CHEN, Z., SUGANO, S., YAMAGUCHI, N. & WATANABE, S. 1997. 
Human cytomegalovirus open reading frame UL11 encodes a highly polymorphic 
protein expressed on the infected cell surface. Archives of virology, 142, 1407-1427. 
HO, M. 1990. Epidemiology of cytomegalovirus infections. Review of Infectious Diseases, 12, 
S701-S710. 
HO, M., SUWANSIRIKUL, S., DOWLING, J. N., YOUNGBLOOD, L. A. & ARMSTRONG, J. A. 1975. 
The transplanted kidney as a source of cytomegalovirus infection. New England 
Journal of Medicine, 293, 1109-1112. 
HOBOM, U., BRUNE, W., MESSERLE, M., HAHN, G. & KOSZINOWSKI, U. H. 2000. Fast screening 
procedures for random transposon libraries of cloned herpesvirus genomes: 
mutational analysis of human cytomegalovirus envelope glycoprotein genes. Journal of 
virology, 74, 7720-7729. 
HSU, C. H., CHANG, M. D. T., TAI, K. Y., YANG, Y. T., WANG, P. S., CHEN, C. J., WANG, Y. H., LEE, 
S. C., WU, C. W. & JUAN, L. J. 2004. HCMV IE2-mediated inhibition of HAT activity 
downregulates p53 function. The EMBO journal, 23, 2269-2280. 
251 
 
HUBER, M. T. & COMPTON, T. 1998. The human cytomegalovirus UL74 gene encodes the third 
component of the glycoprotein H-glycoprotein L-containing envelope complex. Journal 
of virology, 72, 8191-8197. 
HUBER, M. T. & COMPTON, T. 1999. Intracellular formation and processing of the 
heterotrimeric gH-gL-gO (gCIII) glycoprotein envelope complex of human 
cytomegalovirus. Journal of virology, 73, 3886-3892. 
HUBER, M. T., TOMAZIN, R., WISNER, T., BONAME, J. & JOHNSON, D. C. 2002. Human 
cytomegalovirus US7, US8, US9, and US10 are cytoplasmic glycoproteins, not found at 
cell surfaces, and US9 does not mediate cell-to-cell spread. Journal of virology, 76, 
5748-5758. 
HUTCHINSON, N. I. & TOCCI, M. J. 1986. Characterization of a major early gene from the 
human cytomegalovirus long inverted repeat; predicted amino acid sequence of a 30-
kDa protein encoded by the 1.2-kb mRNA. Virology, 155, 172-182. 
INABA, T., SHIMANO, H., GOTODA, T., HARADA, K., SHIMADA, M., OHSUGA, J., WATANABE, Y., 
KAWAMURA, M., YAZAKI, Y. & YAMADA, N. 1993. Expression of platelet-derived 
growth factor beta receptor on human monocyte-derived macrophages and effects of 
platelet-derived growth factor BB dimer on the cellular function. Journal of Biological 
Chemistry, 268, 24353-24360. 
IRMIERE, A. & GIBSON, W. 1983. Isolation and characterization of a noninfectious virion-like 
particle released from cells infected with human strains of cytomegalovirus. Virology, 
130, 118-133. 
ISAACSON, M., JUCKEM, L. & COMPTON, T. 2008. Virus entry and innate immune activation. 
Human Cytomegalovirus, 85-100. 
ISAACSON, M. K. & COMPTON, T. 2009. Human cytomegalovirus glycoprotein B is required for 
virus entry and cell-to-cell spread but not for virion attachment, assembly, or egress. 
Journal of virology, 83, 3891-3903. 
ISAACSON, M. K., FEIRE, A. L. & COMPTON, T. 2007. Epidermal growth factor receptor is not 
required for human cytomegalovirus entry or signaling. Journal of virology, 81, 6241-
6247. 
ISOMURA, H., STINSKI, M. F., MURATA, T., YAMASHITA, Y., KANDA, T., TOYOKUNI, S. & 
TSURUMI, T. 2011. The human cytomegalovirus gene products essential for late viral 
gene expression assemble into prereplication complexes before viral DNA replication. 
Journal of virology, 85, 6629-6644. 
IWASAKI, Y., FURUKAWA, T., PLOTKIN, S. & KOPROWSKI, H. 1973. Ultrastructural study on the 
sequence of human cytomegalovirus infection in human diploid cells. Archives of 
virology, 40, 311-324. 
JACKSON, S. E., MASON, G. M. & WILLS, M. R. 2011. Human cytomegalovirus immunity and 
immune evasion. Virus Research, 157, 151-160. 
JACOBSON, M. A. & MILLS, J. 1988. Serious Cytomegalovirus Disease in the Acquired 
Immunodeficiency Syndrome (AIDS) Clinical Findings, Diagnosis, and Treatment. 
Annals of internal medicine, 108, 585-594. 
JELASKA, A. & KORN,  . H. 1998. Anti‐fas induces apoptosis and proliferation in human dermal 
fibroblasts: Differences between foreskin and adult fibroblasts. Journal of cellular 
physiology, 175, 19-29. 
JELCIC, I., REICHEL, J., SCHLUDE, C., TREUTLER, E., SINZGER, C. & STEINLE, A. 2011. The 
Polymorphic HCMV Glycoprotein UL20 Is Targeted for Lysosomal Degradation by 
Multiple Cytoplasmic Dileucine Motifs. Traffic, 12, 1444-1456. 
JENKINS, C., ABENDROTH, A. & SLOBEDMAN, B. 2004. A novel viral transcript with homology to 
human interleukin-10 is expressed during latent human cytomegalovirus infection. 
Journal of virology, 78, 1440-1447. 
JESIONEK, A. & KIOLEMENOGLOU, B. 1904. Uber einen Befund von Protozoenartigen gebilden 
in den Organen eines heriditarluetischen Fotus. Munch Med Wochenschr, 51, 1905-
1907. 
252 
 
JONES, T. R., MUZITHRAS, V. P. & GLUZMAN, Y. 1991. Replacement mutagenesis of the human 
cytomegalovirus genome: US10 and US11 gene products are nonessential. Journal of 
virology, 65, 5860-5872. 
JONES, T. R. & SUN, L. 1997. Human cytomegalovirus US2 destabilizes major histocompatibility 
complex class I heavy chains. Journal of virology, 71, 2970. 
JONES, T. R., WIERTZ, E., SUN, L., FISH, K. N., NELSON, J. A. & PLOEGH, H. L. 1996. Human 
cytomegalovirus US3 impairs transport and maturation of major histocompatibility 
complex class I heavy chains. Proceedings of the National Academy of Sciences, 93, 
11327. 
JORDAN, M. C., ROUSSEAU, W. E., NOBLE, G. R., STEWART, J. A. & CHIN, T. D. Y. 1973. 
Association of cervical cytomegaloviruses with venereal disease. New England Journal 
of Medicine, 288, 932-934. 
JUPP, R., HOFFMANN, S., STENBERG, R., NELSON, J. & GHAZAL, P. 1993. Human 
cytomegalovirus IE86 protein interacts with promoter-bound TATA-binding protein via 
a specific region distinct from the autorepression domain. Journal of virology, 67, 
7539-7546. 
KÄGI, D., VIGNAUX, F., LEDERMANN, B., BÜRKI, K., DEPRAETERE, V., NAGATA, S., HENGARTNER, 
H. & GOLSTEIN, P. 1994. Fas and perforin pathways as major mechanisms of T cell-
mediated cytotoxicity. Science (New York, NY), 265, 528. 
KALEJTA, R. F. 2008. Tegument proteins of human cytomegalovirus. Microbiology and 
molecular biology reviews, 72, 249-265. 
KARRE, K., LJUNGGREN, H. G., PIONTEK, G. & KIESSLING, R. 1986. Selective rejection of H-2-
deficient lymphoma variants suggests alternative immune defence strategy. Nature, 
319, 675-8. 
KAYE, J., BROWNE, H., STOFFEL, M. & MINSON, T. 1992. The UL16 gene of human 
cytomegalovirus encodes a glycoprotein that is dispensable for growth in vitro. Journal 
of virology, 66, 6609-6615. 
KEAY, S. & BALDWIN, B. 1995. Update on the 92.5 kDa putative HCMV fusion receptor. 
Scandinavian journal of infectious diseases. Supplementum, 99, 32. 
KELLER, R., PEITCHEL, R., GOLDMAN, J. N. & GOLDMAN, M. 1976. An IgG-Fc receptor induced 
in cytomegalovirus-infected human fibroblasts. The Journal of Immunology, 116, 772-
777. 
KELLY, C., VAN DRIEL, R. & WILKINSON, G. W. G. 1995. Disruption of PML-associated nuclear 
bodies during human cytomegalovirus infection. Journal of General Virology, 76, 2887-
2893. 
KEMBLE, G., MCCORMICK, A., PEREIRA, L. & MOCARSKI, E. 1987. A cytomegalovirus protein 
with properties of herpes simplex virus ICP8: partial purification of the polypeptide 
and map position of the gene. Journal of virology, 61, 3143-3151. 
KEMBLE, G. W. & MOCARSKI, E. S. 1989. A host cell protein binds to a highly conserved 
sequence element (pac-2) within the cytomegalovirus a sequence. Journal of virology, 
63, 4715. 
KEPPLER, O. T., PETER, M. E., HINDERLICH, S., MOLDENHAUER, G., STEHLING, P., SCHMITZ, I., 
SCHWARTZ-ALBIEZ, R., REUTTER, W. & PAWLITA, M. 1999. Differential sialylation of 
cell surface glycoconjugates in a human B lymphoma cell line regulates susceptibility 
for CD95 (APO-1/Fas)-mediated apoptosis and for infection by a lymphotropic virus. 
Glycobiology, 9, 557-569. 
KERRY, J. A., SEHGAL, A., BARLOW, S. W., CAVANAUGH, V. J., FISH, K., NELSON, J. A. & 
STENBERG, R. M. 1995. Isolation and characterization of a low-abundance splice 
variant from the human cytomegalovirus major immediate-early gene region. Journal 
of virology, 69, 3868-3872. 
KHAN, N., COBBOLD, M., KEENAN, R. & MOSS, P. A. 2002. Comparative analysis of CD8+ T cell 
responses against human cytomegalovirus proteins pp65 and immediate early 1 shows 
253 
 
similarities in precursor frequency, oligoclonality, and phenotype. The Journal of 
infectious diseases, 185, 1025-34. 
KILPATRICK, B. A., HUANG, E. & PAGANO, J. S. 1976. Analysis of cytomegalovirus genomes with 
restriction endonucleases Hin D III and EcoR-1. Journal of virology, 18, 1095-1105. 
KIM, K., SAPIENZA, V., CARP, R. & MOON, H. 1976. Analysis of structural polypeptides of 
purified human cytomegalovirus. Journal of virology, 20, 604-611. 
KOMAZIN, G., PTAK, R. G., EMMER, B. T., TOWNSEND, L. B. & DRACH, J. C. 2003. Resistance of 
human cytomegalovirus to the benzimidazole L-ribonucleoside maribavir maps to 
UL27. Journal of virology, 77, 11499-11506. 
KOSLOWSKI, K. M., SHAVER, P. R., CASEY, J. T., WILSON, T., YAMANAKA, G., SHEAFFER, A. K., 
TENNEY, D. J. & PEDERSON, N. E. 1999. Physical and functional interactions between 
the herpes simplex virus UL15 and UL28 DNA cleavage and packaging proteins. Journal 
of virology, 73, 1704-1707. 
KOTENKO, S. V., SACCANI, S., IZOTOVA, L. S., MIROCHNITCHENKO, O. V. & PESTKA, S. 2000a. 
Human cytomegalovirus harbors its own unique IL-10 homolog (cmvIL-10). 
Proceedings of the National Academy of Sciences, 97, 1695-1700. 
KOTENKO, S. V., SACCANI, S., IZOTOVA, L. S., MIROCHNITCHENKO, O. V. & PESTKA, S. 2000b. 
Human cytomegalovirus harbors its own unique IL-10 homolog (cmvIL-10). 
Proceedings of the National Academy of Sciences, 97, 1695. 
KOUZARIDES, T., BANKIER, A. T., SATCHWELL, S. C., PREDDY, E. & BARRELL, B. G. 1988. An 
immediate early gene of human cytomegalovirus encodes a potential membrane 
glycoprotein. Virology, 165, 151-164. 
KRZYZANIAK, M., MACH, M. & BRITT, W. J. 2007. The cytoplasmic tail of glycoprotein M 
(gpUL100) expresses trafficking signals required for human cytomegalovirus assembly 
and replication. Journal of virology, 81, 10316-10328. 
KULESZA, C. A. & SHENK, T. 2004. Human cytomegalovirus 5-kilobase immediate-early RNA is a 
stable intron. Journal of virology, 78, 13182-13189. 
KURT-JONES, E. A., POPOVA, L., KWINN, L., HAYNES, L. M., JONES, L. P., TRIPP, R. A., WALSH, E. 
E., FREEMAN, M. W., GOLENBOCK, D. T. & ANDERSON, L. J. 2000. Pattern recognition 
receptors TLR4 and CD14 mediate response to respiratory syncytial virus. Nature 
immunology, 1, 398-401. 
LAHIJANI, R. S., OTTESON, E. W. & ST JEOR, S. C. 1992. A possible role for nonsense suppression 
in the synthesis of a human cytomegalovirus 58-kDa virion protein. Virology, 186, 309-
312. 
LAI, L. & BRITT, W. J. 2003. The interaction between the major capsid protein and the smallest 
capsid protein of human cytomegalovirus is dependent on two linear sequences in the 
smallest capsid protein. Journal of virology, 77, 2730-2735. 
LANDINI, M., SEVERI, B., FURLINI, G. & BADIALI DE GIORGI, L. 1987. Human cytomegalovims 
structural components: intracellular and intraviral localization of p28 and p65–69 by 
immunoelectron microscopy. Virus Research, 8, 15-23. 
LANG, D., GEBERT, S., ARLT, H. & STAMMINGER, T. 1995. Functional interaction between the 
human cytomegalovirus 86-kilodalton IE2 protein and the cellular transcription factor 
CREB. Journal of virology, 69, 6030-6037. 
LAPIERRE, L. A. & BIEGALKE, B. J. 2001. Identification of a novel transcriptional repressor 
encoded by human cytomegalovirus. Journal of virology, 75, 6062-6069. 
LAWLOR, G. & MOSS, A. C. 2010. Cytomegalovirus in inflammatory bowel disease: pathogen or 
innocent bystander? Inflammatory bowel diseases, 16, 1620-1627. 
LE, V. T. K., TRILLING, M. & HENGEL, H. 2011. The Cytomegaloviral Protein pUL138 Acts as 
Potentiator of Tumor Necrosis Factor (TNF) Receptor 1 Surface Density To Enhance 
ULb′-Encoded Modulation of TNF-α Signaling. Journal of Virology, 85, 13260-13270. 
LEATHAM, M. P., WITTE, P. & STINSKI, M. F. 1991. Alternate promoter selection within a 
human cytomegalovirus immediate-early and early transcription unit (UL119-115) 
254 
 
defines true late transcripts containing open reading frames for putative viral 
glycoproteins. Journal of virology, 65, 6144-6153. 
LEE, E., YU, D., MARTINEZ DE VELASCO, J., TESSAROLLO, L., SWING, D. A., JENKINS, N. A. & 
COPELAND, N. G. 2001. A Highly Efficient Escherichia coli-Based Chromosome 
Engineering System Adapted for Recombinogenic Targeting and Subcloning of BAC 
DNA. Genomics, 73, 56-65. 
LEGUIZAMON, G. & REECE, E. 1997. Is serologic screening of all pregnant women for 
cytomegalovirus warranted? CONTEMPORARY OB GYN, 42, 49-62. 
LEHNER, P. J., KARTTUNEN, J. T., WILKINSON, G. W. & CRESSWELL, P. 1997. The human 
cytomegalovirus US6 glycoprotein inhibits transporter associated with antigen 
processing-dependent peptide translocation. Proceedings of the National Academy of 
Sciences of the United States of America, 94, 6904-9. 
LEON, R. P., HEDLUND, T., MEECH, S. J., LI, S., SCHAACK, J., HUNGER, S. P., DUKE, R. C. & 
DEGREGORI, J. 1998. Adenoviral-mediated gene transfer in lymphocytes. Proceedings 
of the National Academy of Sciences, 95, 13159. 
LESNIEWSKI, M., DAS, S., SKOMOROVSKA-PROKVOLIT, Y., WANG, F. Z. & PELLETT, P. E. 2006. 
Primate cytomegalovirus US12 gene family: a distinct and diverse clade of seven-
transmembrane proteins. Virology, 354, 286-298. 
LI, Y., YANG, X., NGUYEN, A. H. T. & BROCKHAUSEN, I. 2007. Requirement of< i> N</i>-
glycosylation for the secretion of recombinant extracellular domain of human Fas in 
HeLa cells. The international journal of biochemistry & cell biology, 39, 1625-1636. 
LI, Y. S., RAMSAY, D. A., FAN, Y. S., ARMSTRONG, R. F. & DEL MAESTRO, R. F. 1995. Cytogenetic 
evidence that a tumor suppressor gene in the long arm of chromosome 1 contributes 
to glioma growth. Cancer genetics and cytogenetics, 84, 46-50. 
LITTLER, E., STUART, A. D. & CHEE, M. S. 1992. Human cytomegalovirus UL97 open reading 
frame encodes a protein that phosphorylates the antiviral nucleoside analogue 
ganciclovir. 
LIU, B. & STINSKI, M. F. 1992. Human cytomegalovirus contains a tegument protein that 
enhances transcription from promoters with upstream ATF and AP-1 cis-acting 
elements. Journal of virology, 66, 4434-4444. 
LIU, F. & ZHOU, Z. H. 2007. Comparative virion structures of human herpesviruses. Human 
herpesviruses: biology, therapy, and immunoprophylaxis. Cambridge University Press, 
Cambridge, United Kingdom. 
LIU, Y. & BIEGALKE, B. J. 2002. The human cytomegalovirus UL35 gene encodes two proteins 
with different functions. Journal of virology, 76, 2460-2468. 
LIU, Y., CUI, Z., ZHANG, Z., WEI, H., ZHOU, Y., WANG, M. & ZHANG, X. E. 2009. The tegument 
protein UL94 of human cytomegalovirus as a binding partner for tegument protein 
pp28 identified by intracellular imaging. Virology, 388, 68-77. 
LUKAC, D. M. & ALWINE, J. C. 1999. Effects of human cytomegalovirus major immediate-early 
proteins in controlling the cell cycle and inhibiting apoptosis: studies with ts13 cells. 
Journal of virology, 73, 2825-2831. 
LUUKKONEN, B., TAN, W. & SCHWARTZ, S. 1995. Efficiency of reinitiation of translation on 
human immunodeficiency virus type 1 mRNAs is determined by the length of the 
upstream open reading frame and by intercistronic distance. Journal of virology, 69, 
4086-4094. 
MACAGNO, A., BERNASCONI, N. L., VANZETTA, F., DANDER, E., SARASINI, A., REVELLO, M. G., 
GERNA, G., SALLUSTO, F. & LANZAVECCHIA, A. 2010. Isolation of human monoclonal 
antibodies that potently neutralize human cytomegalovirus infection by targeting 
different epitopes on the gH/gL/UL128-131A complex. Journal of virology, 84, 1005-
1013. 
MACH, M., KROPFF, B., DAL MONTE, P. & BRITT, W. 2000. Complex formation by human 
cytomegalovirus glycoproteins M (gpUL100) and N (gpUL73). Journal of virology, 74, 
11881-11892. 
255 
 
MAIDJI, E., TUGIZOV, S., ABENES, G., JONES, T. & PEREIRA, L. 1998. A novel human 
cytomegalovirus glycoprotein, gpUS9, which promotes cell-to-cell spread in polarized 
epithelial cells, colocalizes with the cytoskeletal proteins E-cadherin and F-actin. 
Journal of virology, 72, 5717-5727. 
MALONE, C. L., VESOLE, D. H. & STINSKI, M. F. 1990. Transactivation of a human 
cytomegalovirus early promoter by gene products from the immediate-early gene IE2 
and augmentation by IE1: mutational analysis of the viral proteins. Journal of virology, 
64, 1498-1506. 
MARGOLIS, M. J., PAJOVIC, S., WONG, E. L., WADE, M., JUPP, R., NELSON, J. & AZIZKHAN, J. C. 
1995. Interaction of the 72-kilodalton human cytomegalovirus IE1 gene product with 
E2F1 coincides with E2F-dependent activation of dihydrofolate reductase 
transcription. Journal of virology, 69, 7759-7767. 
MARGULIES, B. J., BROWNE, H. & GIBSON, W. 1996. Identification of the human 
cytomegalovirus G protein-coupled receptor homologue encoded by UL33 in infected 
cells and enveloped virus particles. Virology, 225, 111-125. 
MCGEOCH, D. J., DOLAN, A., DONALD, S. & RIXON, F. J. 1985. Sequence determination and 
genetic content of the short unique region in the genome of herpes simplex virus type 
1. Journal of molecular biology, 181, 1. 
MCLAREN, J. E., CALDER, C. J., MCSHARRY, B. P., SEXTON, K., SALTER, R. C., SINGH, N. N., 
WILKINSON, G. W. G., WANG, E. C. Y. & RAMJI, D. P. 2010. The TNF-Like Protein 1A–
Death Receptor 3 Pathway Promotes Macrophage Foam Cell Formation In Vitro. The 
Journal of Immunology, 184, 5827-5834. 
MCMAHON, T. P. & ANDERS, D. G. 2002. Interactions between human cytomegalovirus 
helicase-primase proteins. Virus Research, 86, 39-52. 
MCSHARRY, B., JONES, C., SKINNER, J., KIPLING, D. & WILKINSON, G. 2001. Human telomerase 
reverse transcriptase-immortalized MRC-5 and HCA2 human fibroblasts are fully 
permissive for human cytomegalovirus. Journal of General Virology, 82, 855-863. 
MCSHARRY, B. P., TOMASEC, P., NEALE, M. L. & WILKINSON, G. W. G. 2003. The most 
abundantly transcribed human cytomegalovirus gene (β2. 7) is non-essential for 
growth in vitro. Journal of General Virology, 84, 2511-2516. 
MEDENBACH, J., SEILER, M. & HENTZE, M. W. 2011. Translational control via protein-regulated 
upstream open reading frames. Cell, 145, 902-913. 
MEYERS, J. D., FLOURNOY, N. & THOMAS, E. D. 1986. Risk factors for cytomegalovirus infection 
after human marrow transplantation. Journal of Infectious Diseases, 153, 478-488. 
MICHAELIS, M., DOERR, H. W. & CINATL JR, J. 2009. The story of human cytomegalovirus and 
cancer: increasing evidence and open questions. Neoplasia (New York, NY), 11, 1. 
MICHEL, D., PAVIĆ, I., ZIMMERMANN, A., HAUPT, E., WUNDERLICH, K., HEUSCHMID, M.  
MERTENS, T. 1996. The UL97 gene product of human cytomegalovirus is an early-late 
protein with a nuclear localization but is not a nucleoside kinase. Journal of virology, 
70, 6340-6346. 
MICHELSON, S., DAL MONTE, P., ZIPETO, D., BODAGHI, B., LAURENT, L., OBERLIN, E., 
ARENZANA-SEISDEDOS, F., VIRELIZIER, J. L. & LANDINI, M. P. 1997. Modulation of 
RANTES production by human cytomegalovirus infection of fibroblasts. Journal of 
virology, 71, 6495-6500. 
MILBRADT, J., AUEROCHS, S. & MARSCHALL, M. 2007. Cytomegaloviral proteins pUL50 and 
pUL53 are associated with the nuclear lamina and interact with cellular protein kinase 
C. Journal of general virology, 88, 2642-2650. 
MILLER, D. M., CEBULLA, C. M., RAHILL, B. M. & SEDMAK, D. D. Cytomegalovirus and 
transcriptional down-regulation of major histocompatibility complex class II 
expression. 2001. Elsevier, 11-18. 
MILLER, M. S., FURLONG, W. E., PENNELL, L., GEADAH, M. & HERTEL, L. 2010. RASCAL is a new 
human cytomegalovirus-encoded protein that localizes to the nuclear lamina and in 
cytoplasmic vesicles at late times postinfection. Journal of virology, 84, 6483-6496. 
256 
 
MILNE, R., PATERSON, D. A. & BOOTH, J. C. 1998. Human cytomegalovirus glycoprotein 
H/glycoprotein L complex modulates fusion-from-without. Journal of General Virology, 
79, 855-865. 
MITCHELL, D. 2009. Human cytomegalovirus UL2829 protein is required for efficient expression 
of the viral genome, Princeton University. 
MITCHELL, D. P., SAVARYN, J. P., MOORMAN, N. J., SHENK, T. & TERHUNE, S. S. 2009. Human 
cytomegalovirus UL28 and UL29 open reading frames encode a spliced mRNA and 
stimulate accumulation of immediate-early RNAs. Journal of virology, 83, 10187-
10197. 
MOCARSKI, E. 1993. Cytomegalovirus biology and replication. The human herpesviruses. 
MOCARSKI, E. S. 2001. Cytomegaloviruses and their replication. 
MOCARSKI, E. S., KEMBLE, G. W., LYLE, J. M. & GREAVES, R. F. 1996. A deletion mutant in the 
human cytomegalovirus gene encoding IE1 (491aa) is replication defective due to a 
failure in autoregulation. Proceedings of the National Academy of Sciences, 93, 11321. 
MOCARSKI, E. S., PEREIRA, L. & MCCORMICK, A. L. 1988. Human cytomegalovirus ICP22, the 
product of the HWLF1 reading frame, is an early nuclear protein that is released from 
cells. The Journal of general virology, 69, 2613. 
MOKROS, T., REHM, A., DROESE, J., OPPERMANN, M., LIPP, M. & HÖPKEN, U. E. 2002. Surface 
expression and endocytosis of the human cytomegalovirus-encoded chemokine 
receptor US28 is regulated by agonist-independent phosphorylation. Journal of 
Biological Chemistry, 277, 45122-45128. 
MONTAG, C., WAGNER, J., GRUSKA, I. & HAGEMEIER, C. 2006. Human cytomegalovirus blocks 
tumor necrosis factor alpha-and interleukin-1β-mediated NF-κB signaling. Journal of 
virology, 80, 11686-11698. 
MONTAG, C., WAGNER, J. A., GRUSKA, I., VETTER, B., WIEBUSCH, L. & HAGEMEIER, C. 2011. 
The Latency-Associated UL138 Gene Product of Human Cytomegalovirus Sensitizes 
Cells to Tumor Necrosis Factor Alpha (TNF-α) Signaling by Upregulating TNF-α 
Receptor 1 Cell Surface Expression. Journal of virology, 85, 11409-11421. 
MOORMAN, N. J., CRISTEA, I. M., TERHUNE, S. S., ROUT, M. P., CHAIT, B. T. & SHENK, T. 2008. 
Human cytomegalovirus protein UL38 inhibits host cell stress responses by 
antagonizing the tuberous sclerosis protein complex. Cell host & microbe, 3, 253-262. 
MORRIS, D. R. & GEBALLE, A. P. 2000. Upstream open reading frames as regulators of mRNA 
translation. Molecular and Cellular Biology, 20, 8635-8642. 
MULLBERG, J., HSU, M., RAUCH, C., GERHART, M., KAYKAS, A. & COSMAN, D. 1999. The 
R27080 glycoprotein is abundantly secreted from human cytomegalovirus-infected 
fibroblasts. Journal of general virology, 80, 437-440. 
MÜLLBERG, J., HSU, M., RAUCH, C., GERHART, M., KAYKAS, A. & COSMAN, D. 1999. The 
R27080 glycoprotein is abundantly secreted from human cytomegalovirus-infected 
fibroblasts. Journal of General Virology, 80, 437-440. 
MURAKAMI, P. & MCCAMAN, M. T. 1999. Quantitation of adenovirus DNA and virus particles 
with the PicoGreen fluorescent Dye. Analytical biochemistry, 274, 283-288. 
MURPHY, E., YU, D., GRIMWOOD, J., SCHMUTZ, J., DICKSON, M., JARVIS, M. A., HAHN, G., 
NELSON, J. A., MYERS, R. M. & SHENK, T. E. 2003. Coding potential of laboratory and 
clinical strains of human cytomegalovirus. Proceedings of the National Academy of 
Sciences of the United States of America, 100, 14976. 
MURPHY, J. C., FISCHLE, W., VERDIN, E. & SINCLAIR, J. H. 2002. Control of cytomegalovirus lytic 
gene expression by histone acetylation. The EMBO journal, 21, 1112-1120. 
MYEKU, N. & FIGUEIREDO-PEREIRA, M. E. 2011. Dynamics of the Degradation of Ubiquitinated 
Proteins by Proteasomes and Autophagy ASSOCIATION WITH SEQUESTOSOME 1/p62. 
Journal of Biological Chemistry, 286, 22426-22440. 
NELMS, B. L. & LABOSKY, P. A. 2011. A predicted hairpin cluster correlates with barriers to PCR, 
sequencing and possibly BAC recombineering. Scientific reports, 1. 
257 
 
NEVELS, M., BRUNE, W. & SHENK, T. 2004. SUMOylation of the human cytomegalovirus 72-
kilodalton IE1 protein facilitates expression of the 86-kilodalton IE2 protein and 
promotes viral replication. Journal of virology, 78, 7803-7812. 
NGUYEN, N. L., LOVELAND, A. N. & GIBSON, W. 2008. Nuclear localization sequences in 
cytomegalovirus capsid assembly proteins (UL80 proteins) are required for virus 
production: inactivating NLS1, NLS2, or both affects replication to strikingly different 
extents. Journal of virology, 82, 5381-5389. 
NOGALSKI, M. T., PODDUTURI, J. P., DEMERITT, I. B., MILFORD, L. E. & YUROCHKO, A. D. 2007. 
The human cytomegalovirus virion possesses an activated casein kinase II that allows 
for the rapid phosphorylation of the inhibitor of NF-κB, IκBα. Journal of virology, 81, 
5305-5314. 
O'BRIEN, V. 1998. Viruses and apoptosis. Journal of General Virology, 79, 1833-1845. 
OGAWA-GOTO, K., TANAKA, K., GIBSON, W., MORIISHI, E., MIURA, Y., KURATA, T., IRIE, S. & 
SATA, T. 2003. Microtubule network facilitates nuclear targeting of human 
cytomegalovirus capsid. Journal of virology, 77, 8541-8547. 
OKUMURA, A., PITHA, P. M., YOSHIMURA, A. & HARTY, R. N. 2010. Interaction between Ebola 
virus glycoprotein and host toll-like receptor 4 leads to induction of proinflammatory 
cytokines and SOCS1. Journal of virology, 84, 27-33. 
PARI, G. S., KACICA, M. & ANDERS, D. 1993. Open reading frames UL44, IRS1/TRS1, and UL36-
38 are required for transient complementation of human cytomegalovirus oriLyt-
dependent DNA synthesis. Journal of virology, 67, 2575-2582. 
PARK, B., OH, H., LEE, S., SONG, Y., SHIN, J., SUNG, Y. C., HWANG, S. Y. & AHN, K. 2002. The 
MHC class I homolog of human cytomegalovirus is resistant to down-regulation 
mediated by the unique short region protein (US) 2, US3, US6, and US11 gene 
products. The Journal of Immunology, 168, 3464-3469. 
PATERSON, D. A., DYER, A. P., MILNE, R. S. B., SEVILLA-REYES, E. & GOMPELS, U. A. 2002. A role 
for human cytomegalovirus glycoprotein O (gO) in cell fusion and a new hypervariable 
locus. Virology, 293, 281-294. 
PATRONE, M., PERCIVALLE, E., SECCHI, M., FIORINA, L., PEDRALI-NOY, G., ZOPPÉ, M., 
BALDANTI, F., HAHN, G., KOSZINOWSKI, U. H. & MILANESI, G. 2003. The human 
cytomegalovirus UL45 gene product is a late, virion-associated protein and influences 
virus growth at low multiplicities of infection. Journal of general virology, 84, 3359-
3370. 
PATRONE, M., SECCHI, M., FIORINA, L., IERARDI, M., MILANESI, G. & GALLINA, A. 2005. Human 
cytomegalovirus UL130 protein promotes endothelial cell infection through a producer 
cell modification of the virion. Journal of virology, 79, 8361-8373. 
PATTERSON, C. E. & SHENK, T. 1999. Human cytomegalovirus UL36 protein is dispensable for 
viral replication in cultured cells. Journal of virology, 73, 7126-7131. 
PAWELEC, G., AKBAR, A., BEVERLEY, P., CARUSO, C., DERHOVANESSIAN, E., FÜLÖP, T., 
GRIFFITHS, P., GRUBECK-LOEBENSTEIN, B., HAMPRECHT, K. & JAHN, G. 2010. 
Immunosenescence and Cytomegalovirus: where do we stand after a decade. Immun 
Ageing, 7, 13. 
PAYA, C. V., WOLD, A. & SMITH, T. F. 1987. Detection of cytomegalovirus infections in 
specimens other than urine by the shell vial assay and conventional tube cell cultures. 
Journal of clinical microbiology, 25, 755-757. 
PENFOLD, M. E. T., DAIRAGHI, D. J., DUKE, G. M., SAEDERUP, N., MOCARSKI, E. S., KEMBLE, G. 
W.  SCHALL, T.  . 1999. Cytomegalovirus encodes a potent α chemokine. Proceedings 
of the National Academy of Sciences, 96, 9839-9844. 
PERNG, Y. C., QIAN, Z., FEHR, A. R., XUAN, B. & YU, D. 2011. The human cytomegalovirus gene 
UL79 is required for the accumulation of late viral transcripts. Journal of virology, 85, 
4841-4852. 
PETER, M., HELLBARDT, S., SCHWARTZ-ALBIEZ, R., WESTENDORP, M., WALCZAK, H., 
MOLDENHAUER, G., GRELL, M. & KRAMMER, P. 1995. Cell surface sialylation plays a 
258 
 
role in modulating sensitivity towards APO-1-mediated apoptotic cell death. Cell death 
and differentiation, 2, 163. 
PETER, M. E. & KRAMMER, P. 2003. The CD95 (APO-1/Fas) DISC and beyond. Cell Death & 
Differentiation, 10, 26-35. 
PETRUCELLI, A., RAK, M., GRAINGER, L. & GOODRUM, F. 2009. Characterization of a novel Golgi 
apparatus-localized latency determinant encoded by human cytomegalovirus. Journal 
of virology, 83, 5615-5629. 
PETRUCELLI, A., UMASHANKAR, M., ZAGALLO, P., RAK, M. & GOODRUM, F. 2012. Interactions 
between proteins encoded within the human cytomegalovirus UL133-UL138 locus. 
Journal of virology, 86, 8653-8662. 
PFEFFER, S., SEWER, A., LAGOS-QUINTANA, M., SHERIDAN, R., SANDER, C., GRÄSSER, F. A., VAN 
DYK, L. F., HO, C. K., SHUMAN, S. & CHIEN, M. 2005. Identification of microRNAs of the 
herpesvirus family. Nature methods, 2, 269-276. 
PIZZORNO, M. C., O'HARE, P., SHA, L., LAFEMINA, R. L. & HAYWARD, G. 1988. trans-activation 
and autoregulation of gene expression by the immediate-early region 2 gene products 
of human cytomegalovirus. Journal of virology, 62, 1167-1179. 
PLACHTER, B., TRAUPE, B., ALBRECHT, J. & JAHN, G. 1988. Abundant 5 kb RNA of human 
cytomegalovirus without a major translational reading frame. The Journal of general 
virology, 69, 2251. 
PLAFKER, S. M. & GIBSON, W. 1998. Cytomegalovirus assembly protein precursor and 
proteinase precursor contain two nuclear localization signals that mediate their own 
nuclear translocation and that of the major capsid protein. Journal of virology, 72, 
7722-7732. 
PLESKOFF, O., TRÉBOUTE, C. & ALIZON, M. 1998. The cytomegalovirus-encoded chemokine 
receptor US28 can enhance cell-cell fusion mediated by different viral proteins. Journal 
of virology, 72, 6389-6397. 
POMA, E. E., KOWALIK, T. F., ZHU, L., SINCLAIR, J. H. & HUANG, E. S. 1996. The human 
cytomegalovirus IE1-72 protein interacts with the cellular p107 protein and relieves 
p107-mediated transcriptional repression of an E2F-responsive promoter. Journal of 
virology, 70, 7867-7877. 
POOLE, E., DALLAS, S. R. M. G., COLSTON, J., JOSEPH, R. S. V. & SINCLAIR, J. 2011. Virally 
induced changes in cellular microRNAs maintain latency of human cytomegalovirus in 
CD34+ progenitors. Journal of General Virology, 92, 1539-1549. 
POON, A. & ROIZMAN, B. 1993. Characterization of a temperature-sensitive mutant of the 
UL15 open reading frame of herpes simplex virus 1. Journal of virology, 67, 4497-4503. 
PRICHARD, M., PENFOLD, M., DUKE, G., SPAETE, R. & KEMBLE, G. 2001. A review of genetic 
differences between limited and extensively passaged human cytomegalovirus strains. 
Reviews in medical virology, 11, 191-200. 
PRICHARD, M. N., BRITT, W. J., DAILY, S. L., HARTLINE, C. B. & KERN, E. R. 2005a. Human 
cytomegalovirus UL97 kinase is required for the normal intranuclear distribution of 
pp65 and virion morphogenesis. Journal of virology, 79, 15494-15502. 
PRICHARD, M. N., LAWLOR, H., DUKE, G. M., MO, C., WANG, Z., DIXON, M., KEMBLE, G. & 
KERN, E. R. 2005. Human cytomegalovirus uracil DNA glycosylase associates with 
ppUL44 and accelerates the accumulation of viral DNA. Virology journal, 2, 55. 
PROD'HOMME, V., SUGRUE, D. M., STANTON, R. J., NOMOTO, A., DAVIES, J., RICKARDS, C. R., 
COCHRANE, D., MOORE, M., WILKINSON, G. W. G. & TOMASEC, P. 2010. Human 
cytomegalovirus UL141 promotes efficient downregulation of the natural killer cell 
activating ligand CD112. Journal of General Virology, 91, 2034-2039. 
PROD’HOMME, V., GRIFFIN, C., AICHELER, R.  ., WANG, E. C. Y., MCSHARRY, B. P., RICKARDS, C. 
R., STANTON, R. J., BORYSIEWICZ, L. K., LÓPEZ-BOTET, M. & WILKINSON, G. W. G. 2007. 
The human cytomegalovirus MHC class I homolog UL18 inhibits LIR-1+ but activates 
LIR-1–NK cells. The Journal of Immunology, 178, 4473. 
259 
 
QIAN, Z., XUAN, B. & YU, D. 2008. The full-length protein encoded by human cytomegalovirus 
gene UL117 is required for the proper maturation of viral replication compartments. 
Journal of virology, 82, 3452-3465. 
QUINNAN JR, G. V., DELERY, M., ROOK, A. H., FREDERICK, W. R., EPSTEIN, J. A. Y. S., 
MANISCHEWITZ, J. F., JACKSON, L., RAMSEY, K. M., MITTAL, K. & PLOTKIN, S. A. 1984. 
Comparative virulence and immunogenicity of the Towne strain and a nonattenuated 
strain of cytomegalovirus. Annals of internal medicine, 101, 478-483. 
RASMUSSEN, L., MATKIN, C., SPAETE, R., PACHL, C. & MERIGAN, T. C. 1991. Antibody response 
to human cytomegalovirus glycoproteins gB and gH after natural infection in humans. 
Journal of Infectious Diseases, 164, 835-842. 
RAWLINSON, W. D. & BARRELL, B. G. 1993. Spliced transcripts of human cytomegalovirus. 
Journal of virology, 67, 5502-5513. 
RE, M. C., LANDINI, M. P., COPPOLECCHIA, P., FURLINI, G. & LA PLACA, M. 1985. A 28 000 
Molecular Weight Human Cytomegalovirus Structural Polypeptide Studied by means of 
a Specific Monoclonal Antibody. Journal of general virology, 66, 2507-2511. 
REAL, F. X., RETTIG, W. J., CHESA, P. G., MELAMED, M. R., OLD, L. J. & MENDELSOHN, J. 1986. 
Expression of epidermal growth factor receptor in human cultured cells and tissues: 
relationship to cell lineage and stage of differentiation. Cancer research, 46, 4726. 
REEVES, M., MACARY, P., LEHNER, P., SISSONS, J. & SINCLAIR, J. 2005. Latency, chromatin 
remodeling, and reactivation of human cytomegalovirus in the dendritic cells of 
healthy carriers. Proceedings of the National Academy of Sciences of the United States 
of America, 102, 4140. 
REEVES, M., MURPHY, J., GREAVES, R., FAIRLEY, J., BREHM, A. & SINCLAIR, J. 2006. 
Autorepression of the human cytomegalovirus major immediate-early 
promoter/enhancer at late times of infection is mediated by the recruitment of 
chromatin remodeling enzymes by IE86. Journal of virology, 80, 9998-10009. 
REEVES, M. B., DAVIES, A. A., MCSHARRY, B. P., WILKINSON, G. W. & SINCLAIR, J. H. 2007. 
Complex I binding by a virally encoded RNA regulates mitochondria-induced cell death. 
Science's STKE, 316, 1345. 
REEVES, M. B. & SINCLAIR, J. H. 2010. Analysis of latent viral gene expression in natural and 
experimental latency models of human cytomegalovirus and its correlation with 
histone modifications at a latent promoter. Journal of General Virology, 91, 599-604. 
REHM, A., ENGELSBERG, A., TORTORELLA, D., KÖRNER, I. J., LEHMANN, I., PLOEGH, H. L. & 
HÖPKEN, U. E. 2002. Human cytomegalovirus gene products US2 and US11 differ in 
their ability to attack major histocompatibility class I heavy chains in dendritic cells. 
Journal of virology, 76, 5043-5050. 
RIBBERT, H. 1904. Ueber protozoenartige Zellen in der Niere eines syphilitischen 
Neugeborenen und in der Parotis von Kidern. Zentralbl Allg Pathol, 15, 945-948. 
RICE, G., SCHRIER, R. D. & OLDSTONE, M. 1984. Cytomegalovirus infects human lymphocytes 
and monocytes: virus expression is restricted to immediate-early gene products. 
Proceedings of the National Academy of Sciences, 81, 6134. 
RIDDELL, S. R., WATANABE, K. S., GOODRICH, J. M., LI, C. R., AGHA, M. E. & GREENBERG, P. D. 
1992. Restoration of viral immunity in immunodeficient humans by the adoptive 
transfer of T cell clones. Science, 257, 238-241. 
ROBY, C. & GIBSON, W. 1986. Characterization of phosphoproteins and protein kinase activity 
of virions, noninfectious enveloped particles, and dense bodies of human 
cytomegalovirus. Journal of virology, 59, 714-727. 
ROIZMAN, B. 1980. GENOME VARIATION AND EVOLUTION AMONG HERPES VIRUSES*. Annals 
of the New York Academy of Sciences, 354, 472-483. 
ROMANOWSKI, M. J., GARRIDO-GUERRERO, E. & SHENK, T. 1997. pIRS1 and pTRS1 are present 
in human cytomegalovirus virions. Journal of virology, 71, 5703-5705. 
260 
 
ROMANOWSKI, M. J. & SHENK, T. 1997. Characterization of the human cytomegalovirus irs1 
and trs1 genes: a second immediate-early transcription unit within irs1 whose product 
antagonizes transcriptional activation. Journal of virology, 71, 1485-1496. 
ROWE, W., HARTLEY, J., WATERMAN, S., TURNER, H. & HUEBNER, R. 1956. Cytopathogenic 
agent resembling human salivary gland virus recovered from tissue cultures of human 
adenoids. Experimental Biology and Medicine, 92, 418. 
ROWE, W. P., HUEBNER, R. J., GILMORE, L. K., PARROTT, R. H. & WARD, T. G. Isolation of a 
cytopathogenic agent from human adenoids undergoing spontaneous degeneration in 
tissue culture. 1953. Royal Society of Medicine, 570-573. 
RYCKMAN, B. J., JARVIS, M. A., DRUMMOND, D. D., NELSON, J. A. & JOHNSON, D. C. 2006. 
Human cytomegalovirus entry into epithelial and endothelial cells depends on genes 
UL128 to UL150 and occurs by endocytosis and low-pH fusion. Journal of virology, 80, 
710-722. 
RYCKMAN, B. J., RAINISH, B. L., CHASE, M. C., BORTON, J. A., NELSON, J. A., JARVIS, M. A. & 
JOHNSON, D. C. 2008. Characterization of the human cytomegalovirus gH/gL/UL128-
131 complex that mediates entry into epithelial and endothelial cells. Journal of 
virology, 82, 60-70. 
SAILESH, H., NELL, L., REZA, Z. M. & GREGORY, S. 2007. Differential inhibition of human 
cytomegalovirus (HCMV) by toll-like receptor ligands mediated by interferon-beta in 
human foreskin fibroblasts and cervical tissue. Virology Journal, 4. 
SALSMAN, J., ZIMMERMAN, N., CHEN, T., DOMAGALA, M. & FRAPPIER, L. 2008. Genome-wide 
screen of three herpesviruses for protein subcellular localization and alteration of PML 
nuclear bodies. PLoS pathogens, 4, e1000100. 
SAMBUCETTI, L. C., CHERRINGTON, J. M., WILKINSON, G. & MOCARSKI, E. S. 1989. NF-kappa B 
activation of the cytomegalovirus enhancer is mediated by a viral transactivator and by 
T cell stimulation. The EMBO journal, 8, 4251. 
SAMPAIO, K. L., CAVIGNAC, Y., STIERHOF, Y. D. & SINZGER, C. 2005. Human cytomegalovirus 
labeled with green fluorescent protein for live analysis of intracellular particle 
movements. Journal of virology, 79, 2754-2767. 
SANCHEZ, V., ANGELETTI, P. C., ENGLER, J. & BRITT, W. 1998. Localization of human 
cytomegalovirus structural proteins to the nuclear matrix of infected human 
fibroblasts. Journal of virology, 72, 3321-3329. 
SANCHEZ, V., GREIS, K. D., SZTUL, E. & BRITT, W. J. 2000. Accumulation of virion tegument and 
envelope proteins in a stable cytoplasmic compartment during human 
cytomegalovirus replication: characterization of a potential site of virus assembly. 
Journal of virology, 74, 975-986. 
SARISKY, R. T. & HAYWARD, G. S. 1996. Evidence that the UL84 gene product of human 
cytomegalovirus is essential for promoting oriLyt-dependent DNA replication and 
formation of replication compartments in cotransfection assays. Journal of virology, 
70, 7398-7413. 
SAROV, I. & ABADY, I. 1975. The morphogenesis of human cytomegalovirus:: Isolation and 
polypeptide characterization of cytomegalovirions and dense bodies. Virology, 66, 464-
473. 
SCALZO, A. A., FORBES, C. A., SMITH, L. M. & LOH, L. C. 2009. Transcriptional analysis of human 
cytomegalovirus and rat cytomegalovirus homologues of the M73/M73. 5 spliced gene 
family. Archives of virology, 154, 65-75. 
SCHAUFLINGER, M., FISCHER, D., SCHREIBER, A., CHEVILLOTTE, M., WALTHER, P., MERTENS, T. 
& VON EINEM, J. 2011. The tegument protein UL71 of human cytomegalovirus is 
involved in late envelopment and affects multivesicular bodies. Journal of virology, 85, 
3821-3832. 
SCHIRM, J., TIMMERIJE, W., VAN DER BIJ, W., WILTERDINK, J. B., TEGZESS, A. M., VAN SON, W. 
J. & SCHRODER, F. P. 1987. Rapid detection of infectious cytomegalovirus in blood with 
the aid of monoclonal antibodies. Journal of medical virology, 23, 31-40. 
261 
 
SCHLEISS, M. R., DEGNIN, C. & GEBALLE, A. P. 1991. Translational control of human 
cytomegalovirus gp48 expression. Journal of virology, 65, 6782-6789. 
SCHMOLKE, S., DRESCHER, P., JAHN, G. & PLACHTER, B. 1995a. Nuclear targeting of the 
tegument protein pp65 (UL83) of human cytomegalovirus: an unusual bipartite nuclear 
localization signal functions with other portions of the protein to mediate its efficient 
nuclear transport. Journal of virology, 69, 1071-1078. 
SCHMOLKE, S., KERN, H. F., DRESCHER, P., JAHN, G. & PLACHTER, B. 1995b. The dominant 
phosphoprotein pp65 (UL83) of human cytomegalovirus is dispensable for growth in 
cell culture. Journal of virology, 69, 5959-5968. 
SCHOPPEL, K., SCHMIDT, C., EINSELE, H., HEBART, H. & MACH, M. 1998. Kinetics of the 
antibody response against human cytomegalovirus-specific proteins in allogeneic bone 
marrow transplant recipients. Journal of Infectious Diseases, 178, 1233-1243. 
SCULLY, A. L., SOMMER, M. H., SCHWARTZ, R. & SPECTOR, D. H. 1995. The human 
cytomegalovirus IE2 86-kilodalton protein interacts with an early gene promoter via 
site-specific DNA binding and protein-protein associations. Journal of virology, 69, 
6533-6540. 
SEIBENHENER, M. L., BABU, J. R., GEETHA, T., WONG, H. C., KRISHNA, N. R. & WOOTEN, M. W. 
2004. Sequestosome 1/p62 is a polyubiquitin chain binding protein involved in 
ubiquitin proteasome degradation. Molecular and Cellular Biology, 24, 8055-8068. 
SEVERI, B., LANDINI, M. & GOVONI, E. 1988. Human cytomegalovirus morphogenesis: an 
ultrastructural study of the late cytoplasmic phases. Archives of virology, 98, 51-64. 
SHATNYEVA, O. M., KUBARENKO, A. V., WEBER, C. E. M., PAPPA, A., SCHWARTZ-ALBIEZ, R., 
WEBER, A. N. R., KRAMMER, P. H. & LAVRIK, I. N. 2011. Modulation of the CD95-
induced apoptosis: the role of CD95 N-glycosylation. PloS one, 6, e19927. 
SHELBOURN, S., KOTHARI, S., SISSONS, J. & SINCLAIR, J. 1989. Repression of human 
cytomegalovirus gene expression asscoiated with a novel immediate early regulatory 
region binding factor. Nucleic acids research, 17, 9165-9171. 
SHEN, A., LEI, J., YANG, E., PEI, Y., CHEN, Y. C., GONG, H., XIAO, G. & LIU, F. 2011. Human 
cytomegalovirus primase UL70 specifically interacts with cellular factor Snapin. Journal 
of virology, 85, 11732-11741. 
SHIKHAGAIE, M., MERCÉ-MALDONADO, E., ISERN, E., MUNTASELL, A., ALBÀ, M. M., LÓPEZ-
BOTET, M., HENGEL, H. & ANGULO, A. 2012a. The HCMV-specific UL1 gene encodes a 
late phase glycoprotein incorporated in the virion envelope. Journal of virology. 
SHIKHAGAIE, M., MERCÉ-MALDONADO, E., ISERN, E., MUNTASELL, A., ALBÀ, M. M., LÓPEZ-
BOTET, M., HENGEL, H. & ANGULO, A. 2012b. The Human Cytomegalovirus-Specific 
UL1 Gene Encodes a Late-Phase Glycoprotein Incorporated in the Virion Envelope. 
Journal of virology, 86, 4091-4101. 
SHIN, J., PARK, B., LEE, S., KIM, Y., BIEGALKE, B. J., KANG, S. & AHN, K. 2006. A short isoform of 
human cytomegalovirus US3 functions as a dominant negative inhibitor of the full-
length form. Journal of virology, 80, 5397-5404. 
SHIRAKATA, M., TERAUCHI, M., ABLIKIM, M., IMADOME, K. I., HIRAI, K., ASO, T. & YAMANASHI, 
Y. 2002. Novel immediate-early protein IE19 of human cytomegalovirus activates the 
origin recognition complex I promoter in a cooperative manner with IE72. Journal of 
virology, 76, 3158-3167. 
SHISLER, J., YANG, C., WALTER, B., WARE, C. F. & GOODING, L. R. 1997. The adenovirus E3-10.4 
K/14.5 K complex mediates loss of cell surface Fas (CD95) and resistance to Fas-
induced apoptosis. Journal of virology, 71, 8299-8306. 
SHUNG, C. Y. & SUNTER, G. 2009. Regulation of Tomato golden mosaic virus AL2 and AL3 gene 
expression by a conserved upstream open reading frame. Virology, 383, 310-318. 
SILVA, M. C., YU, Q. C., ENQUIST, L. & SHENK, T. 2003. Human cytomegalovirus UL99-encoded 
pp28 is required for the cytoplasmic envelopment of tegument-associated capsids. 
Journal of virology, 77, 10594-10605. 
262 
 
SINCLAIR, J. 2008. Human cytomegalovirus: latency and reactivation in the myeloid lineage. 
Journal of clinical virology, 41, 180-185. 
SINCLAIR, J. 2010a. Chromatin structure regulates human cytomegalovirus gene expression 
during latency, reactivation and lytic infection. Biochimica et biophysica acta, 1799, 
286. 
SINCLAIR, J. 2010b. Chromatin structure regulates human cytomegalovirus gene expression 
during latency, reactivation and lytic infection. Biochimica et Biophysica Acta (BBA)-
Gene Regulatory Mechanisms, 1799, 286-295. 
SINCLAIR, J. & SISSONS, P. 2006. Latency and reactivation of human cytomegalovirus. Journal 
of General Virology, 87, 1763-1779. 
SINZGER, C., GREFTE, A., PLACHTER, B., GOUW, A. S. H. & JAHN, G. 1995. Fibroblasts, epithelial 
cells, endothelial cells and smooth muscle cells are major targets of human 
cytomegalovirus infection in lung and gastrointestinal tissues. Journal of General 
Virology, 76, 741. 
SINZGER, C., HAHN, G., DIGEL, M., KATONA, R., SAMPAIO, K. L., MESSERLE, M., HENGEL, H., 
KOSZINOWSKI, U., BRUNE, W. & ADLER, B. 2008. Cloning and sequencing of a highly 
productive, endotheliotropic virus strain derived from human cytomegalovirus TB40/E. 
Journal of General Virology, 89, 359-368. 
SINZGER, C., KAHL, M., LAIB, K., KLINGEL, K., RIEGER, P., PLACHTER, B. & JAHN, G. 2000. 
Tropism of human cytomegalovirus for endothelial cells is determined by a post-entry 
step dependent on efficient translocation to the nucleus. Journal of General Virology, 
81, 3021-3035. 
SINZGER, C., PLACHTER, B., GREFTE, A. & JAHN, G. 1996. Tissue macrophages are infected by 
human cytomegalovirus in vivo. Journal of Infectious Diseases, 173, 240. 
SINZGER, C., SCHMIDT, K., KNAPP, J., KAHL, M., BECK, R., WALDMAN, J., HEBART, H., EINSELE, 
H. & JAHN, G. 1999. Modification of human cytomegalovirus tropism through 
propagation in vitro is associated with changes in the viral genome. Journal of General 
Virology, 80, 2867-2877. 
SKALETSKAYA, A., BARTLE, L. M., CHITTENDEN, T., MCCORMICK, A. L., MOCARSKI, E. S. & 
GOLDMACHER, V. S. 2001. A cytomegalovirus-encoded inhibitor of apoptosis that 
suppresses caspase-8 activation. Proceedings of the National Academy of Sciences, 98, 
7829. 
SLOBEDMAN, B. & MOCARSKI, E. S. 1999. Quantitative analysis of latent human 
cytomegalovirus. Journal of virology, 73, 4806-4812. 
SMITH, A. & WEIDMAN, F. 1910. Infection of a Still-born Infant by an Amebiform Protozoan. 
Univ. of Penn. Med. Bull., 23. 
SMITH, A. & WEIDMAN, F. 1914. Further Note upon the Occurrence of Entamoeba 
Mortinatalium as a Human Parasite. Amer. J. Trop. Dis. and Prev. Med, 2, 256-259. 
SMITH, I. L., TASKINTUNA, I., RAHHAL, F. M., POWELL, H. C., AI, E., MUELLER, A. J., SPECTOR, S. 
A. & FREEMAN, W. R. 1998. Clinical failure of CMV retinitis with intravitreal cidofovir is 
associated with antiviral resistance. Archives of ophthalmology, 116, 178. 
SMITH, J. A., JAIRATH, S., CRUTE, J. J. & PARI, G. S. 1996. Characterization of the human 
cytomegalovirus UL105 gene and identification of the putative helicase protein. 
Virology, 220, 251-255. 
SMITH, J. A. & PARI, G. S. 1995. Expression of human cytomegalovirus UL36 and UL37 genes is 
required for viral DNA replication. Journal of virology, 69, 1925-1931. 
SMITH, K. O. & RASMUSSEN, L. 1963. Morphology of cytomegalovirus (salivary gland virus). 
Journal of bacteriology, 85, 1319-1325. 
SMITH, M. G. Propagation in tissue cultures of a cytopathogenic virus from human salivary 
gland virus (SGV) disease. 1956. Royal Society of Medicine, 424-430. 
SMITH, M. G. 1959. The salivary gland viruses of man and animals (cytomegalic inclusion 
disease). Prog. Med. Virol, 2, 171-202. 
263 
 
SNYDMAN, D. R., WERNER, B. G., HEINZE-LACEY, B., BERARDI, V. P., TILNEY, N. L., KIRKMAN, R. 
L., MILFORD, E. L., CHO, S. I., BUSH JR, H. L. & LEVEY, A. S. 1987. Use of 
cytomegalovirus immune globulin to prevent cytomegalovirus disease in renal-
transplant recipients. New England Journal of Medicine, 317, 1049-1054. 
SÖDERBERG-NAUCLÉR, C. 2008. HCMV microinfections in inflammatory diseases and cancer. 
Journal of clinical virology, 41, 218-223. 
SOMMER, M. H., SCULLY, A. L. & SPECTOR, D. H. 1994. Transactivation by the human 
cytomegalovirus IE2 86-kilodalton protein requires a domain that binds to both the 
TATA box-binding protein and the retinoblastoma protein. Journal of virology, 68, 
6223-6231. 
SOROCEANU, L., AKHAVAN, A. & COBBS, C. S. 2008. Platelet-derived growth factor-&agr; 
receptor activation is required for human cytomegalovirus infection. Nature, 455, 391-
395. 
SOURVINOS, G., TAVALAI, N., BERNDT, A., SPANDIDOS, D. A. & STAMMINGER, T. 2007. 
Recruitment of human cytomegalovirus immediate-early 2 protein onto parental viral 
genomes in association with ND10 in live-infected cells. Journal of virology, 81, 10123-
10136. 
SPADERNA, S., BLESSING, H., BOGNER, E., BRITT, W. & MACH, M. 2002. Identification of 
glycoprotein gpTRL10 as a structural component of human cytomegalovirus. Journal of 
virology, 76, 1450-1460. 
SPADERNA, S., KROPFF, B., KÖDEL, Y., SHEN, S., COLEY, S., LU, S., BRITT, W. & MACH, M. 2005. 
Deletion of gpUL132, a structural component of human cytomegalovirus, results in 
impaired virus replication in fibroblasts. Journal of virology, 79, 11837-11847. 
SPAETE, R. R., GEHRZ, R. C. & LANDINI, M. P. 1994. Human cytomegalovirus structural proteins. 
Journal of General Virology, 75, 3287-3308. 
SPAETE, R. R. & MOCARSKI, E. S. 1985. The alpha sequence of the cytomegalovirus genome 
functions as a cleavage/packaging signal for herpes simplex virus defective genomes. 
Journal of virology, 54, 817. 
SPAETE, R. R. & MOCARSKI, E. S. 1987. Insertion and deletion mutagenesis of the human 
cytomegalovirus genome. Proceedings of the National Academy of Sciences, 84, 7213. 
SPAETE, R. R., PEROT, K., SCOTT, P. I., NELSON, J. A., STINSKI, M. F. & PACHL, C. 1993. 
Coexpression of truncated human cytomegalovirus gH with the UL115 gene product or 
the truncated human fibroblast growth factor receptor results in transport of gH to the 
cell surface. Virology, 193, 853-861. 
SPECTOR, D. H. 1996. Activation and regulation of human cytomegalovirus early genes. 
Intervirology, 39, 361-377. 
SPEIR, E., MODALI, R., HUANG, E. S., LEON, M. B., SHAWL, F., FINKEL, T. & EPSTEIN, S. E. 1994. 
Potential role of human cytomegalovirus and p53 interaction in coronary restenosis. 
Science, 265, 391-394. 
STAGNO, S., PASS, R., DWORSKY, M. & ALFORD, C. Congenital and perinatal cytomegalovirus 
infections. 1983. 31. 
STAGNO, S., PASS, R., REYNOLDS, D., MOORE, M., NAHMIAS, A. & ALFORD, C. 1980a. 
Comparative study of diagnostic procedures for congenital cytomegalovirus infection. 
Pediatrics, 65, 251-257. 
STAGNO, S., REYNOLDS, D. W., PASS, R. F. & ALFORD, C. A. 1980b. Breast milk and the risk of 
cytomegalovirus infection. New England Journal of Medicine, 302, 1073-1076. 
STAMMINGER, T., GSTAIGER, M., WEINZIERL, K., LORZ, K., WINKLER, M. & SCHAFFNER, W. 
2002. Open reading frame UL26 of human cytomegalovirus encodes a novel tegument 
protein that contains a strong transcriptional activation domain. Journal of virology, 
76, 4836-4847. 
STANNARD, L. M. & HARDIE, D. R. 1991. An Fc receptor for human immunoglobulin G is located 
within the tegument of human cytomegalovirus. Journal of virology, 65, 3411-3415. 
264 
 
STANTON, R., WESTMORELAND, D., FOX, J. D., DAVISON, A. J. & WILKINSON, G. W. G. 2005. 
Stability of human cytomegalovirus genotypes in persistently infected renal transplant 
recipients. Journal of medical virology, 75, 42-46. 
STANTON, R. J., BALUCHOVA, K., DARGAN, D. J., CUNNINGHAM, C., SHEEHY, O., SEIRAFIAN, S., 
MCSHARRY, B. P., NEALE, M. L., DAVIES, J. A. & TOMASEC, P. 2010. Reconstruction of 
the complete human cytomegalovirus genome in a BAC reveals RL13 to be a potent 
inhibitor of replication. The Journal of clinical investigation, 120, 3191. 
STANTON, R. J., MCSHARRY, B. P., ARMSTRONG, M., TOMASEC, P. & WILKINSON, G. W. 2008a. 
Re-engineering adenovirus vector systems to enable high-throughput analyses of gene 
function. BioTechniques, 45, 659-62, 664-8. 
STANTON, R. J., MCSHARRY, B. P., ARMSTRONG, M., TOMASEC, P. & WILKINSON, G. W. G. 
2008b. Re-engineering adenovirus vector systems to enable high-throughput analyses 
of gene function. BioTechniques, 45, 659-662. 
STENBERG, R., FORTNEY, J., BARLOW, S., MAGRANE, B., NELSON, J. & GHAZAL, P. 1990. 
Promoter-specific trans activation and repression by human cytomegalovirus 
immediate-early proteins involves common and unique protein domains. Journal of 
virology, 64, 1556-1565. 
STENBERG, R. M., THOMSEN, D. R. & STINSKI, M. F. 1984. Structural analysis of the major 
immediate early gene of human cytomegalovirus. Journal of virology, 49, 190-199. 
STERN-GINOSSAR, N., ELEFANT, N., ZIMMERMANN, A., WOLF, D. G., SALEH, N., BITON, M., 
HORWITZ, E., PROKOCIMER, Z., PRICHARD, M. & HAHN, G. 2007a. Host immune 
system gene targeting by a viral miRNA. Science's STKE, 317, 376. 
STERN-GINOSSAR, N., ELEFANT, N., ZIMMERMANN, A., WOLF, D. G., SALEH, N., BITON, M., 
HORWITZ, E., PROKOCIMER, Z., PRICHARD, M. & HAHN, G. 2007b. Host immune 
system gene targeting by a viral miRNA. Science, 317, 376. 
STERN-GINOSSAR, N., SALEH, N., GOLDBERG, M. D., PRICHARD, M., WOLF, D. G. & 
MANDELBOIM, O. 2009. Analysis of human cytomegalovirus-encoded microRNA 
activity during infection. Journal of virology, 83, 10684-10693. 
STERN, H. & FRIEDMANN, I. 1960. Intranuclear formation of cytomegalic inclusion disease 
virus. 
STEVEN, A. & SPEAR, P. 1997. Herpesvirus capsid assembly and envelopment. Structural 
biology of viruses. Oxford University Press, New York, NY, 312-351. 
STINSKI, M. 1983. Molecular biology of cytomegaloviruses. The herpesviruses, 2, 67-113. 
STINSKI, M. & MEIER, J. 2007. Immediate–early viral gene regulation and function. Human 
Herpesviruses 
Biology, Therapy, and Immunoprophylaxis. Cambridge: Cambridge University Press. 
STINSKI, M. F. 1977. Synthesis of proteins and glycoproteins in cells infected with human 
cytomegalovirus. Journal of virology, 23, 751-767. 
STIRK, P. & GRIFFITHS, P. 1987. Use of monoclonal antibodies for the diagnosis of 
cytomegalovirus infection by the detection of early antigen fluorescent foci (DEAFF) in 
cell culture. Journal of medical virology, 21, 329-337. 
STRANG, B. L., BOULANT, S., CHANG, L., KNIPE, D. M., KIRCHHAUSEN, T. & COEN, D. M. 2012. 
Human cytomegalovirus UL44 concentrates at the periphery of replication 
compartments, the site of viral DNA synthesis. Journal of virology, 86, 2089-2095. 
SU, Y., TESTAVERDE, J. R., DAVIS, C. N., HAYAJNEH, W. A., ADAIR, R. & COLBERG-POLEY, A. M. 
2003. Human cytomegalovirus UL37 immediate early target minigene RNAs are 
accurately spliced and polyadenylated. Journal of general virology, 84, 29-39. 
SYLWESTER, A. W., MITCHELL, B. L., EDGAR, J. B., TAORMINA, C., PELTE, C., RUCHTI, F., SLEATH, 
P. R., GRABSTEIN, K. H., HOSKEN, N. A. & KERN, F. 2005. Broadly targeted human 
cytomegalovirus-specific CD4+ and CD8+ T cells dominate the memory compartments 
of exposed subjects. The Journal of experimental medicine, 202, 673-685. 
TAKEUCHI, O. & AKIRA, S. 2009. Innate immunity to virus infection. Immunological reviews, 
227, 75-86. 
265 
 
TALBOT, P. & ALMEIDA, J. D. 1977. Human cytomegalovirus: purification of enveloped virions 
and dense bodies. Journal of General Virology, 36, 345. 
TAMASHIRO, J. C. & SPECTOR, D. H. 1986. Terminal structure and heterogeneity in human 
cytomegalovirus strain AD169. Journal of virology, 59, 591. 
TANAKA, K., ZOU, J. P., TAKEDA, K., FERRANS, V. J., SANDFORD, G. R., JOHNSON, T. M., FINKEL, 
T. & EPSTEIN, S. E. 1999. Effects of human cytomegalovirus immediate-early proteins 
on p53-mediated apoptosis in coronary artery smooth muscle cells. Circulation, 99, 
1656-1659. 
TANDON, R. & MOCARSKI, E. S. 2008. Control of cytoplasmic maturation events by 
cytomegalovirus tegument protein pp150. Journal of virology, 82, 9433-9444. 
TAVALAI, N., PAPIOR, P., RECHTER, S., LEIS, M. & STAMMINGER, T. 2006. Evidence for a role of 
the cellular ND10 protein PML in mediating intrinsic immunity against human 
cytomegalovirus infections. Journal of virology, 80, 8006-8018. 
TAYLOR-WIEDEMAN, J., SISSONS, J., BORYSIEWICZ, L. K. & SINCLAIR, J. 1991. Monocytes are a 
major site of persistence of human cytomegalovirus in peripheral blood mononuclear 
cells. The Journal of general virology, 72, 2059. 
TAYLOR-WIEDEMAN, J., SISSONS, P. & SINCLAIR, J. 1994. Induction of endogenous human 
cytomegalovirus gene expression after differentiation of monocytes from healthy 
carriers. Journal of virology, 68, 1597-1604. 
TENNEY, D. J., SANTOMENNA, L. D., GOUDIE, K. B. & COLBERG-POLEY, A. M. 1993. The human 
cytomegalovirus US3 immediate-early protein lacking the putative transmembrane 
domain regulates gene expression. Nucleic acids research, 21, 2931-2937. 
TEPPER, C. G., SELDIN, M. F. & MUDRYJ, M. 2000. Fas-mediated apoptosis of proliferating, 
transiently growth-arrested, and senescent normal human fibroblasts. Experimental 
cell research, 260, 9-19. 
TERAUCHI, M., KOI, H., HAYANO, C., TOYAMA-SORIMACHI, N., KARASUYAMA, H., YAMANASHI, 
Y., ASO, T. & SHIRAKATA, M. 2003. Placental extravillous cytotrophoblasts persistently 
express class I major histocompatibility complex molecules after human 
cytomegalovirus infection. Journal of virology, 77, 8187-8195. 
TERHUNE, S., TORIGOI, E., MOORMAN, N., SILVA, M., QIAN, Z., SHENK, T. & YU, D. 2007. 
Human cytomegalovirus UL38 protein blocks apoptosis. Journal of virology, 81, 3109-
3123. 
TERHUNE, S. S., SCHRÖER, J. & SHENK, T. 2004. RNAs are packaged into human 
cytomegalovirus virions in proportion to their intracellular concentration. Journal of 
virology, 78, 10390-10398. 
THEILER, R. N. & COMPTON, T. 2002. Distinct glycoprotein O complexes arise in a post-Golgi 
compartment of cytomegalovirus-infected cells. Journal of virology, 76, 2890-2898. 
THOMA, C., BORST, E., MESSERLE, M., RIEGER, M., HWANG, J. S. & BOGNER, E. 2006. 
Identification of the interaction domain of the small terminase subunit pUL89 with the 
large subunit pUL56 of human cytomegalovirus. Biochemistry, 45, 8855-8863. 
THOMSEN, D. R., STENBERG, R. M., GOINS, W. F. & STINSKI, M. F. 1984. Promoter-regulatory 
region of the major immediate early gene of human cytomegalovirus. Proceedings of 
the National Academy of Sciences, 81, 659. 
TOLLEFSON, A. E., HERMISTON, T. W., LICHTENSTEIN, D. L., COLLE, C. F., TRIPP, R. A., 
DIMITROV, T., TOTH, K., WELLS, C. E., DOHERTY, P. C. & WOLD, W. S. M. 1998. Forced 
degradation of Fas inhibits apoptosis in adenovirus-infected cells. Nature, 392, 726-
730. 
TOMASEC, P., BRAUD, V. M., RICKARDS, C., POWELL, M. B., MCSHARRY, B. P., GADOLA, S., 
CERUNDOLO, V., BORYSIEWICZ, L. K., MCMICHAEL, A. J. & WILKINSON, G. W. G. 2000. 
Surface expression of HLA-E, an inhibitor of natural killer cells, enhanced by human 
cytomegalovirus gpUL40. Science, 287, 1031. 
TOMASEC, P., WANG, E. C. Y., DAVISON, A. J., VOJTESEK, B., ARMSTRONG, M., GRIFFIN, C., 
MCSHARRY, B. P., MORRIS, R. J., LLEWELLYN-LACEY, S. & RICKARDS, C. 2005. 
266 
 
Downregulation of natural killer cell–activating ligand CD155 by human 
cytomegalovirus UL141. Nature immunology, 6, 181-188. 
TOMAZIN, R., BONAME, J., HEGDE, N. R., LEWINSOHN, D. M., ALTSCHULER, Y., JONES, T. R., 
CRESSWELL, P., NELSON, J. A., RIDDELL, S. R. & JOHNSON, D. C. 1999. Cytomegalovirus 
US2 destroys two components of the MHC class II pathway, preventing recognition by 
CD4+ T cells. Nature medicine, 5, 1039-1043. 
TOWLER, J. C., EBRAHIMI, B., LANE, B., DAVISON, A. J. & DARGAN, D. J. 2012. Human 
cytomegalovirus transcriptome activity differs during replication in human fibroblast, 
epithelial and astrocyte cell lines. Journal of General Virology. 
VAN DE BERG, P. J. E. J., VAN STIJN, A., TEN BERGE, I. J. M. & VAN LIER, R. A. W. 2008. A 
fingerprint left by cytomegalovirus infection in the human T cell compartment. Journal 
of clinical virology, 41, 213-217. 
VAN DER BIJ, W., SCHIRM, J., TORENSMA, R., VAN SON, W. & TEGZESS, A. 1988a. Comparison 
between viremia and antigenemia for detection of cytomegalovirus in blood. Journal 
of clinical microbiology, 26, 2531-2535. 
VAN DER BIJ, W., TORENSMA, R., VAN SON, W. J., ANEMA, J., SCHIRM, J. & TEGZESS, A. M. 
1988b. Rapid immunodiagnosis of active cytomegalovirus infection by monoclonal 
antibody staining of blood leucocytes. Journal of medical virology, 25, 179-188. 
VANARSDALL, A. L. & JOHNSON, D. C. 2012. Human cytomegalovirus entry into cells. Current 
Opinion in Virology. 
VARNUM, S. M., STREBLOW, D. N., MONROE, M. E., SMITH, P., AUBERRY, K. J., PASA-TOLIC, L., 
WANG, D., CAMP, D. G., RODLAND, K. & WILEY, S. 2004. Identification of proteins in 
human cytomegalovirus (HCMV) particles: the HCMV proteome. Journal of virology, 
78, 10960. 
VERSTREPEN, L., VERHELST, K., CARPENTIER, I. & BEYAERT, R. 2011. TAX1BP1, a ubiquitin-
binding adaptor protein in innate immunity and beyond. Trends in biochemical 
sciences, 36, 347-354. 
VIVIER, E., RAULET, D. H., MORETTA, A., CALIGIURI, M. A., ZITVOGEL, L., LANIER, L. L., 
YOKOYAMA, W. M. & UGOLINI, S. 2011. Innate or adaptive immunity? The example of 
natural killer cells. Science, 331, 44-49. 
WAGNER, S., ARNOLD, F., WU, Z., SCHUBERT, A., WALLISER, C., TADAGAKI, K., JOCKERS, R., 
MERTENS, T. & MICHEL, D. 2012. The 7-transmembrane protein homologue UL78 of 
the human cytomegalovirus forms oligomers and traffics between the plasma 
membrane and different intracellular compartments. Archives of virology, 1-15. 
WALDMAN, W. J., ROBERTS, W., DAVIS, D., WILLIAMS, M., SEDMAK, D. & STEPHENS, R. 1991. 
Preservation of natural endothelial cytopathogenicity of cytomegalovirus by 
propagation in endothelial cells. Archives of virology, 117, 143-164. 
WANG, D., BRESNAHAN, W. & SHENK, T. 2004. Human cytomegalovirus encodes a highly 
specific RANTES decoy receptor. Proceedings of the National Academy of Sciences of 
the United States of America, 101, 16642-16647. 
WANG, D. & SHENK, T. 2005. Human cytomegalovirus virion protein complex required for 
epithelial and endothelial cell tropism. Proceedings of the National Academy of 
Sciences of the United States of America, 102, 18153-18158. 
WANG, E. C. Y., MCSHARRY, B., RETIERE, C., TOMASEC, P., WILLIAMS, S., BORYSIEWICZ, L. K., 
BRAUD, V. M. & WILKINSON, G. W. G. 2002. UL40-mediated NK evasion during 
productive infection with human cytomegalovirus. Proceedings of the National 
Academy of Sciences, 99, 7570. 
WANG, S. K., DUH, C. Y. & CHANG, T. T. 2000. Cloning and identification of regulatory gene 
UL76 of human cytomegalovirus. Journal of general virology, 81, 2407-2416. 
WANG, X., HUONG, S. M., CHIU, M. L., RAAB-TRAUB, N. & HUANG, E. S. 2003. Epidermal 
growth factor receptor is a cellular receptor for human cytomegalovirus. Nature, 424, 
456-461. 
267 
 
WANG, Z. G., RUGGERO, D., RONCHETTI, S., ZHONG, S., GABOLI, M., RIVI, R. & PANDOLFI, P. P. 
1998. PML is essential for multiple apoptotic pathways. Nature genetics, 20, 266-272. 
WARMING, S., COSTANTINO, N., JENKINS, N. A. & COPELAND, N. G. 2005. Simple and highly 
efficient BAC recombineering using galK selection. Nucleic acids research, 33, e36-e36. 
WATHEN, M. W. & STINSKI, M. F. 1982. Temporal patterns of human cytomegalovirus 
transcription: mapping the viral RNAs synthesized at immediate early, early, and late 
times after infection. Journal of virology, 41, 462-477. 
WEBER, B., BARGANE FALL, E. H. M., BERGER, A. & DOERR, H. W. 1999. Screening of blood 
donors for human cytomegalovirus (HCMV) IgG antibody with an enzyme 
immunoassay using recombinant antigens. Journal of clinical virology, 14, 173-181. 
WEI, X., DECKER, J. M., WANG, S., HUI, H., KAPPES, J. C., WU, X., SALAZAR-GONZALEZ, J. F., 
SALAZAR, M. G., KILBY, J. M. & SAAG, M. S. 2003. Antibody neutralization and escape 
by HIV-1. Nature, 422, 307-312. 
WEILAND, K. L., OIEN, N. L., HOMA, F. & WATHEN, M. W. 1994. Functional analysis of human 
cytomegalovirus polymerase accessory protein. Virus research, 34, 191-206. 
WELLER, T. H. 1971. The cytomegaloviruses: ubiquitous agents with protean clinical 
manifestations. New England Journal of Medicine, 285, 203-214. 
WELLER, T. H., HANSHAW, J. B. & SCOTT, D. 1960. Serologic Differentiation of Viruses 
responsible for Cytomegalic Inclusion Disease. Virology, 12, 130-32. 
WELLER, T. H., HANSHAW, J. B. & SCOTT, D. M. E. 1962. Virologic and clinical observations on 
cytomegalic inclusion disease. New England Journal of Medicine, 266, 1233-1244. 
WELLER, T. H., MACAULEY, J., CRAIG, J. & WIRTH, P. Isolation of intranuclear inclusion 
producing agents from infants with illnesses resembling cytomegalic inclusion disease. 
1957. Royal Society of Medicine, 4-12. 
WELLS, D. E., VUGLER, L. G. & BRITT, W. J. 1990. Structural and immunological characterization 
of human cytomegalovirus gp55-116 (gB) expressed in insect cells. Journal of general 
virology, 71, 873-880. 
WELTE, S. A., SINZGER, C., LUTZ, S. Z., SINGH‐ ASU A, H., SAMPAIO, K. L., EKNIGK, U., 
RAMMENSEE, H. G. & STEINLE, A. 2002. Selective intracellular retention of virally 
induced NKG2D ligands by the human cytomegalovirus UL16 glycoprotein. European 
journal of immunology, 33, 194-203. 
WESTON, K. 1988. An enhancer element in the short unique region of human cytomegalovirus 
regulates the production of a group of abundant immediate early transcripts. Virology, 
162, 406-416. 
WESTSTRATE, M., GEELEN, J. & VAN DER NOORDAA, J. 1980. Human cytomegalovirus DNA: 
physical maps for the restriction endonucleases BglII, HindIII and XbaI. Journal of 
General Virology, 49, 1-21. 
WETHMAR, K., SMINK, J. J. & LEUTZ, A. 2010. Upstream open reading frames: molecular 
switches in (patho) physiology. Bioessays, 32, 885-893. 
WHITE, C. A., STOW, N. D., PATEL, A. H., HUGHES, M. & PRESTON, V. G. 2003. Herpes simplex 
virus type 1 portal protein UL6 interacts with the putative terminase subunits UL15 
and UL28. Journal of virology, 77, 6351-6358. 
WHITE, E. & SPECTOR, D. 2007. Early viral gene expression and function. Human herpesviruses: 
biology, therapy, and immunoprophylaxis. Cambridge University Press, Cambridge, 
United Kingdom. 
WHITE, E. A., CLARK, C. L., SANCHEZ, V. & SPECTOR, D. H. 2004. Small internal deletions in the 
human cytomegalovirus IE2 gene result in nonviable recombinant viruses with 
differential defects in viral gene expression. Journal of virology, 78, 1817-1830. 
WIERTZ, E., JONES, T. R., SUN, L., BOGYO, M., GEUZE, H. J. & PLOEGH, H. L. 1996a. The human 
cytomegalovirus US11 gene product dislocates MHC class I heavy chains from the 
endoplasmic reticulum to the cytosol. Cell, 84, 769-780. 
268 
 
WIERTZ, E., TORTORELLA, D., BOGYO, M., YU, J., MOTHES, W., JONES, T. R., RAPOPORT, T. A. & 
PLOEGH, H. L. 1996b. Sec61-mediated transfer of a membrane protein from the 
endoplasmic reticulum to the proteasome for destruction. Nature, 384, 432-438. 
WILKINSON, G., AKRIGG, A. & GREENAWAY, P. 1984. Transcription of the immediate early 
genes of human cytomegalovirus strain AD169. Virus Research, 1, 101-116. 
WILKINSON, G., KELLY, C., SINCLAIR, J. H. & RICKARDS, C. 1998. Disruption of PML-associated 
nuclear bodies mediated by the human cytomegalovirus major immediate early gene 
product. Journal of General Virology, 79, 1233-1245. 
WILKINSON, G. W. G. & AKRIGG, A. 1992. Constitutive and enhanced expression from the CMV 
major IE promoter in a defective adenovirus vector. Nucleic acids research, 20, 2233-
2239. 
WILKINSON, G. W. G., TOMASEC, P., STANTON, R. J., ARMSTRONG, M., PROD'HOMME, V., 
AICHELER, R., MCSHARRY, B. P., RICKARDS, C. R., COCHRANE, D. & LLEWELLYN-LACEY, 
S. 2008. Modulation of natural killer cells by human cytomegalovirus. Journal of clinical 
virology, 41, 206-212. 
WILLCOX, B. E., THOMAS, L. M. & BJORKMAN, P. J. 2003. Crystal structure of HLA-A2 bound to 
LIR-1, a host and viral major histocompatibility complex receptor. Nature immunology, 
4, 913-919. 
WILLE, P. T., KNOCHE, A. J., NELSON, J. A., JARVIS, M. A. & JOHNSON, D. C. 2010. A human 
cytomegalovirus gO-null mutant fails to incorporate gH/gL into the virion envelope and 
is unable to enter fibroblasts and epithelial and endothelial cells. Journal of virology, 
84, 2585-2596. 
WILLS, M. R., ASHIRU, O., REEVES, M. B., OKECHA, G., TROWSDALE, J., TOMASEC, P., 
WILKINSON, G. W. G., SINCLAIR, J. & SISSONS, J. 2005a. Human cytomegalovirus 
encodes an MHC class I-like molecule (UL142) that functions to inhibit NK cell lysis. The 
Journal of Immunology, 175, 7457. 
WILLS, M. R., ASHIRU, O., REEVES, M. B., OKECHA, G., TROWSDALE, J., TOMASEC, P., 
WILKINSON, G. W. G., SINCLAIR, J. & SISSONS, J. G. P. 2005b. Human cytomegalovirus 
encodes an MHC class I-like molecule (UL142) that functions to inhibit NK cell lysis. The 
Journal of Immunology, 175, 7457-7465. 
WILLS, M. R., CARMICHAEL, A. J., MYNARD, K., JIN, X., WEEKES, M. P., PLACHTER, B. & SISSONS, 
J. 1996. The human cytotoxic T-lymphocyte (CTL) response to cytomegalovirus is 
dominated by structural protein pp65: frequency, specificity, and T-cell receptor usage 
of pp65-specific CTL. Journal of virology, 70, 7569-7579. 
WILLS, M. R., CARMICHAEL, A. J., WEEKES, M. P., MYNARD, K., OKECHA, G., HICKS, R. & 
SISSONS, J. 1999. Human virus-specific CD8+ CTL clones revert from CD45ROhigh to 
CD45RAhigh in vivo: CD45RAhighCD8+ T cells comprise both naive and memory cells. 
The Journal of Immunology, 162, 7080. 
WING, B. A., LEE, G. & HUANG, E. S. 1996. The human cytomegalovirus UL94 open reading 
frame encodes a conserved herpesvirus capsid/tegument-associated virion protein 
that is expressed with true late kinetics. Journal of virology, 70, 3339-3345. 
WINKLER, M., RICE, S. A. & STAMMINGER, T. 1994. UL69 of human cytomegalovirus, an open 
reading frame with homology to ICP27 of herpes simplex virus, encodes a 
transactivator of gene expression. Journal of virology, 68, 3943-3954. 
WINKLER, M. & STAMMINGER, T. 1996. A specific subform of the human cytomegalovirus 
transactivator protein pUL69 is contained within the tegument of virus particles. 
Journal of virology, 70, 8984-8987. 
WOLF, D. G., COURCELLE, C. T., PRICHARD, M. N. & MOCARSKI, E. S. 2001. Distinct and 
separate roles for herpesvirus-conserved UL97 kinase in cytomegalovirus DNA 
synthesis and encapsidation. Proceedings of the National Academy of Sciences, 98, 
1895-1900. 
WOMACK, A. & SHENK, T. 2010. Human cytomegalovirus tegument protein pUL71 is required 
for efficient virion egress. MBio, 1. 
269 
 
WOOD, L. J., BAXTER, M. K., PLAFKER, S. M. & GIBSON, W. 1997. Human cytomegalovirus 
capsid assembly protein precursor (pUL80. 5) interacts with itself and with the major 
capsid protein (pUL86) through two different domains. Journal of virology, 71, 179-
190. 
WOODHALL, D. L., GROVES, I. J., REEVES, M. B., WILKINSON, G. & SINCLAIR, J. H. 2006. Human 
Daxx-mediated repression of human cytomegalovirus gene expression correlates with 
a repressive chromatin structure around the major immediate early promoter. The 
Journal of biological chemistry, 281, 37652-60. 
WRIGHT, D. A. & SPECTOR, D. H. 1989. Posttranscriptional regulation of a class of human 
cytomegalovirus phosphoproteins encoded by an early transcription unit. Journal of 
virology, 63, 3117-3127. 
WRIGHT, J. F., KUROSKY, A., PRYZDIAL, E. & WASI, S. 1995. Host cellular annexin II is associated 
with cytomegalovirus particles isolated from cultured human fibroblasts. Journal of 
virology, 69, 4784-4791. 
WRIGHT JR, H. T., GOODHEART, C. R. & LIELAUSIS, A. 1964. Human cytomegalovirus. 
Morphology by negative staining. Virology, 23, 419-424. 
WYATT, J. P., SAXTON, J., LEE, R. & PINKERTON, H. 1950. Generalized cytomegalic inclusion 
disease. Journal of Pediatrics, 36, 271-94. 
YAMAMOTO, T., SUZUKI, S., RADSAK, K. & HIRAI, K. 1998. The UL112/113 gene products of 
human cytomegalovirus which colocalize with viral DNA in infected cell nuclei are 
related to efficient viral DNA replication. Virus research, 56, 107-14. 
YAMASHITA, Y., SHIMOKATA, K., MIZUNO, S., YAMAGUCHI, H. & NISHIYAMA, Y. 1993. Down-
regulation of the surface expression of class I MHC antigens by human 
cytomegalovirus. Virology, 193, 727-736. 
YEAGER, A. S., CARL GRUMET, F., HAFLEIGH, E. B., ARVIN, A. M., BRADLEY, J. S. & PROBER, C. G. 
1981. Prevention of transfusion-acquired cytomegalovirus infections in newborn 
infants. The Journal of Pediatrics, 98, 281-287. 
YEW, K. H., CARPENTER, C., DUNCAN, R. S. & HARRISON, C. J. 2012. Human Cytomegalovirus 
Induces TLR4 Signaling Components in Monocytes Altering TIRAP, TRAM and 
Downstream Interferon-Beta and TNF-Alpha Expression. PloS one, 7, e44500. 
YU, D., ELLIS, H. M., LEE, E. C., JENKINS, N. A. & COPELAND, N. G. 2000. An efficient 
recombination system for chromosome engineering in Escherichia coli. Proceedings of 
the National Academy of Sciences, 97, 5978-5983. 
YU, X. K., O'CONNOR, C. M., ATANASOV, I., DAMANIA, B., KEDES, D. H. & ZHOU, Z. H. 2003. 
Three-dimensional structures of the A, B, and C capsids of rhesus monkey 
rhadinovirus: insights into gammaherpesvirus capsid assembly, maturation, and DNA 
packaging. Journal of virology, 77, 13182-13193. 
YUROCHKO, A. D., HWANG, E., RASMUSSEN, L., KEAY, S., PEREIRA, L. & HUANG, E. 1997. The 
human cytomegalovirus UL55 (gB) and UL75 (gH) glycoprotein ligands initiate the rapid 
activation of Sp1 and NF-kappaB during infection. Journal of virology, 71, 5051-5059. 
ZAIA, J., GALLEZ-HAWKINS, G., CHURCHILL, M., MORTON-BLACKSHERE, A., PANDE, H., ADLER, 
S., SCHMIDT, G. & FORMAN, S. 1990. Comparative analysis of human cytomegalovirus 
a-sequence in multiple clinical isolates by using polymerase chain reaction and 
restriction fragment length polymorphism assays. Journal of clinical microbiology, 28, 
2602. 
ZHANG, G., RAGHAVAN, B., KOTUR, M., CHEATHAM, J., SEDMAK, D., COOK, C., WALDMAN, J. & 
TRGOVCICH, J. 2007. Antisense transcription in the human cytomegalovirus 
transcriptome. Journal of virology, 81, 11267. 
ZHOU, Z. H., CHEN, D. H., JAKANA, J., RIXON, F. J. & CHIU, W. 1999. Visualization of tegument-
capsid interactions and DNA in intact herpes simplex virus type 1 virions. Journal of 
virology, 73, 3210-3218. 
270 
 
ZHU, H., CONG, J. P., MAMTORA, G., GINGERAS, T. & SHENK, T. 1998. Cellular gene expression 
altered by human cytomegalovirus: global monitoring with oligonucleotide arrays. 
Proceedings of the National Academy of Sciences, 95, 14470. 
ZHU, H., CONG, J. P. & SHENK, T. 1997. Use of differential display analysis to assess the effect 
of human cytomegalovirus infection on the accumulation of cellular RNAs: induction of 
interferon-responsive RNAs. Proceedings of the National Academy of Sciences, 94, 
13985. 
ZHU, H., SHEN, Y. & SHENK, T. 1995. Human cytomegalovirus IE1 and IE2 proteins block 
apoptosis. Journal of virology, 69, 7960-7970. 
 
271 
 
 
 
9- Appendix 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
i 
 
 
Appendix I 
Chapter 2: Sample PCR reaction mixtures and programs 
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 Sample PCR reaction mixture  
 
PCR kit 
Phusion® High-Fidelity DNA Polymerase 
(M0530L, New England Biolabs) 
Expand High fidelity (HIFI, 11732 
641001, Roche)/Taq polymerase 
 Volume (µl) Volume (µl) 
Water 33.5 38.5 
Buffer 10 (5x buffer) 5 (10x buffer) 
DNA 1 1 
Primers (F+R) 2.5 of 100 µM each 2.5 of 100 µM each 
dNTPs 1 1 
DMSO 1.5 1.5 
Enzyme 0.5 0.5 
Total volume 50 50 
 
      
 
      Standard Phusion PCR program  
Step Temperature (⁰C) Time (seconds) cycles 
Initial denaturation 98 30 1 
Denaturation 
Annealing 
Extension 
98 
56 
72 
12 
30 
60/kb 
 
25-35 
Final extension 72 700 1 
Hold 4 - - 
 
 
 
 
     
 
 
 
 
iii 
 
 
 
 
     Standard HIFI or Taq DNA polymerase PCR program 
Step Temperature (⁰C) Time (seconds) cycles 
Initial denaturation 94 120 1 
Denaturation 
Annealing 
Extension 
94 
56 
72 
15 
30 
60/kb 
 
25-35 
Final extension 72 720 1 
Hold 4 - - 
 
 
   
   PCR program used to amplify selection cassette from AdZ using HIFI 
Step Temperature (⁰C) Time (seconds) cycles 
Initial denaturation 94 120 1 
Denaturation 
Annealing 
Extension 
94 
56 
72 
30 
30 
270 
 
9 
Denaturation 
Annealing 
Extension 
94 
56 
72 
30 
30 
270                
  (+20 per successive cycle) 
 
24 
Final extension 72 420 1 
Hold 4 - - 
 
 
 
 
 
 
 
 
 
iv 
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Chapter 2: Primer and oligonucleotide sequences 
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First round primers used to amplify Merlin genes  
 
F R 
RL8A 
AAGACACCGGGACCGATCCAGCCTGGATCC
TTTTCCTTTCTTCTCCGTTTCTCC 
GAGCGGGTTAGGGATTGGCTTACCAGCGCTG
CTAAAAACAGCGGACAGTCC 
RL9A 
AAGACACCGGGACCGATCCAGCCTGGATCC
CGCGCCGCCGGTCCCCC 
GAGCGGGTTAGGGATTGGCTTACCAGCGCTG
AGAAACAGCACGTAGGTCAGG 
UL7/8 
ACACCGGGACCGATCCAGCCTGGATCCACG
TGGTAAATAAATCATGG 
GAGCGGGTTAGGGATTGGCTTACCAGCGCTC
AGTTCCGTGTCTGTCATAAACA 
UL36 
GACACCGGGACCGATCCAGCCTGGATCCGC
GAAGGTAGAGGAGTCCGTCATGGA 
GTTGTTCATGTAGGCGTGTGGCGGAGCGGGT
TAGGGATTGGCTTACCAGCGCT 
UL50 
AAGACACCGGGACCGATCCAGCCTGGATCC
TCGGCGGTGGCGTCGGTGCG 
GAGCGGGTTAGGGATTGGCTTACCAGCGCTG
TCGCGGTGTGCGGAGCGTG 
UL69 
AAGACACCGGGACCGATCCAGCCTGGATCC
GCGACGGCGGCCATGGAGCT 
GAGCGGGTTAGGGATTGGCTTACCAGCGCTG
TCATCCATATCATCGCTGTAACAC 
UL73 
AAGACACCGGGACCGATCCAGCCTGGATCC
TCGTGGCGGTGGTGTGATGG 
GAGCGGGTTAGGGATTGGCTTACCAGCGCTA
TAGCCTTTGGTGGTGGTCG 
UL77  
AAGACACCGGGACCGATCCAGCCTGGATCC
GTTCTGGACTATCTGGGACG 
GAGCGGGTTAGGGATTGGCTTACCAGCGCTC
AACACCGCCACGCTCGGA 
UL82  
AAGACACCGGGACCGATCCAGCCTGGATCC
CTGACCCTCCCCCCATCCC 
GAGCGGGTTAGGGATTGGCTTACCAGCGCTG
ATGCGGGGTCGACTGCGTG 
UL83  
AAGACACCGGGACCGATCCAGCCTGGATCC
GCCGCTCAGTCGCCTACAC 
GAGCGGGTTAGGGATTGGCTTACCAGCGCTA
CCTCGGTGCTTTTTGGGC 
UL84  
AAGACACCGGGACCGATCCAGCCTGGATCC
GCCCTCTCGCGCCCGCAG 
GAGCGGGTTAGGGATTGGCTTACCAGCGCTG
AGATCGCCGCAGACCATG 
UL85  
AAGACACCGGGACCGATCCAGCCTGGATCC
TCTCCGCTTCTCCTCCGTC 
GAGCGGGTTAGGGATTGGCTTACCAGCGCTG
CCTTTAAATATGCAGGTCGCGG 
UL93  
AAGACACCGGGACCGATCCAGCCTGGATCC
TTCCGAATATGGAAACGCACC 
GAGCGGGTTAGGGATTGGCTTACCAGCGCTA
AGATCGTCGAACGGCAAGC 
UL95  
AAGACACCGGGACCGATCCAGCCTGGATCC
GAATCTCCGCGCAACATGATG 
GAGCGGGTTAGGGATTGGCTTACCAGCGCTT
AGATTCAACGTGATGAGACCCG 
UL128  
AAGACACCGGGACCGATCCAGCCTGGATCC
CGCGCGTCATGAGTCCCA 
GAGCGGGTTAGGGATTGGCTTACCAGCGCTA
TAGGGAACGCTGCCAGCGG 
UL130  
AAGACACCGGGACCGATCCAGCCTGGATCC
GCCTGCGTCACGGGAAATAA 
GAGCGGGTTAGGGATTGGCTTACCAGCGCTA
ACGATGAGATTGGGATGGGTG 
UL132  
AAGACACCGGGACCGATCCAGCCTGGATCC
ATCCACGTCGCCACGTCTCG 
GAGCGGGTTAGGGATTGGCTTACCAGCGCTG
TCGTACTCGGGATCTCTGAGCG 
UL148  
AAGACACCGGGACCGATCCAGCCTGGATCC
TTCCTAACCCGCGCAGCATG 
GAGCGGGTTAGGGATTGGCTTACCAGCGCTC
CGACGCCGCGACACCAGGT 
UL147A  
AAGACACCGGGACCGATCCAGCCTGGATCC
GACTGCGCTGGTGATCATGTC 
GAGCGGGTTAGGGATTGGCTTACCAGCGCTG
ATCACACAAGTGACGAGGAGCG 
UL147  
AAGACACCGGGACCGATCCAGCCTGGATCC
GCAGAAAATATCATGTTTTCAATATGTTGC 
GAGCGGGTTAGGGATTGGCTTACCAGCGCTC
CAGCGCAGTCTAAAGTAGTGGTAA 
UL146  
AAGACACCGGGACCGATCCAGCCTGGATCC
CCGGATATTACGAATTATTGGTAGTGAC 
GAGCGGGTTAGGGATTGGCTTACCAGCGCTTT
CCTTCAGACCTACTAGGGTTACAG 
UL145  
AAGACACCGGGACCGATCCAGCCTGGATCC
GTCACTCTTTCTTGTTGCCTTCG 
GAGCGGGTTAGGGATTGGCTTACCAGCGCTA
TCTTCACTTCCACCCATCGGG 
UL144  
AAGACACCGGGACCGATCCAGCCTGGATCC
TCTTCCGGTAGGAGGCATGAAG 
GAGCGGGTTAGGGATTGGCTTACCAGCGCTC
AGGGTGCGGTAGAAAATTTTGC 
vi 
 
 
 
 
 
Second round primers for amplifying Merlin genes 
F 
AACCGTCAGATCGCCTGGAGACGCCATCCACGCTGTTTTGACCTCCATAGAAGACACCGGGACCGATCC
AGCCTGGATCC 
R 
GGCGTGACACGTTTATTGAGTAGGATTACAGAGTATAACATAGAGTATAATATAGAGTATACAATAGT
GACGTGGGATCC 
 
 
 
 
 
 
 
 
 
UL142  
AAGACACCGGGACCGATCCAGCCTGGATCC
GCAGTGTGTGAAATGTGAATAGTGTG 
GAGCGGGTTAGGGATTGGCTTACCAGCGCTC
TGACCGCGCCATACTTCGT 
UL140  
AAGACACCGGGACCGATCCAGCCTGGATCC
CTCTTCAGACTTGTCATGACCCC 
GAGCGGGTTAGGGATTGGCTTACCAGCGCTC
AGGGTCTGATGAAGCTGCCAA 
UL139  
AAGACACCGGGACCGATCCAGCCTGGATCC
CGACAAAGGGGTTCGTATATCAAT 
GAGCGGGTTAGGGATTGGCTTACCAGCGCTC
CGAGGCGGAGGTGGAAATG 
UL138  
AAGACACCGGGACCGATCCAGCCTGGATCC
GACAGAGGACGGTCACCATGG 
GAGCGGGTTAGGGATTGGCTTACCAGCGCTC
GTGTATTCTTGATGATAATGTACCATGG 
UL148A  
AAGACACCGGGACCGATCCAGCCTGGATCC
CGTCGGCGGCGATAGCCATG 
GAGCGGGTTAGGGATTGGCTTACCAGCGCTG
TAACACTCGTCCGACACTTCCAC 
UL148B  
AAGACACCGGGACCGATCCAGCCTGGATCC
GGGAGCGAACGGGATGGC 
GAGCGGGTTAGGGATTGGCTTACCAGCGCTA
AGTCGCGTGTGGTAGATCTCCT 
UL148C  
AAGACACCGGGACCGATCCAGCCTGGATCC
CCTTCTCCGCGAGCAAATGTT 
GAGCGGGTTAGGGATTGGCTTACCAGCGCTG
GGGAAGGCTGTAAGCACGG 
UL148D  
AAGACACCGGGACCGATCCAGCCTGGATCC
GAGGAGTCGCGGCATGACG 
GAGCGGGTTAGGGATTGGCTTACCAGCGCTG
CCGCTGCCGCTCCC 
US23 
AAGACACCGGGACCGATCCAGCCTGGATCC
CCTCTTTTGACATGTGGCGTACA 
GAGCGGGTTAGGGATTGGCTTACCAGCGCT 
CACAAAGTGCTCCCGAAAATCGA 
US24 
AAGACACCGGGACCGATCCAGCCTGGATCC
GCTGAGAGTGTCGCGCAATGATGGAT 
GAGCGGGTTAGGGATTGGCTTACCAGCGCT 
AATCTGGATGTACTCGCGCACACCCG 
US33A 
AAGACACCGGGACCGATCCAGCCTGGATCC
GGCGCAAAAGCACCATGAGC 
GAGCGGGTTAGGGATTGGCTTACCAGCGCTG
GACCGCGGCACGTAAAACG 
vii 
 
 
 
 
Adz sequencing primers 
From MIE Promoter AATGTCGTAACAACTCCG  
From MIE PolyA ACCTGATGGTGATAAGAAG 
 
 
 
 
 
Ad recombinant internal primers: where sequencing from MIE promoter and MIE polyA 
was insufficient to cover the full length of the insert, internal primers were designed) 
US23F1 CCACAGACGCCGTTTGCTAC 
US23F2 CTACGAACACGGTCTGCGGC 
UL36F1 CCGTCTGTTCGCAAGGTAAGC 
UL36F2 CGCCTTCTGGACCCACAACAC 
UL36F3 TGACGAGGATGACGACGACG 
UL69F1 CTTCTCACCCCTCCTCAGCC 
UL69F2 TATCTGGAGACGGTGGGCGG 
US24F1 CACTCTGCGGAGAATGACGG 
 
 
 
Sequencing primers for modified Merlin BACs: 
UL4-tags-seq-F GTATGGAATAACGAATCTCACG 
UL4-tags-seq-R GAAACGCAAACCGACCAAC 
UL74A-V5seq-F TCCGTCTGCCTTGTGGTTTG 
UL74A-V5seq-R TCTACGCGCTATCGGCCATC 
UL150A-V5seq-F  CGTCGGCTTCCAGCTTGTCT 
UL150A-V5seq-R CTCAGCGGTCGCCCTATCAC 
 
 
 
 
viii 
 
 
 
Amplifying selection cassette for insertion into Merlin BAC: (insert target 
sequence): 
UL4-L  
AACAGCGGAAAGTATTATTTCAAACGAGAAGATGTGAATTCCACCTTTTATTACTCTTGTTA
CAACCTGACCGTGACCCCTGTGACGGAAGATCACTTCG 
UL4-R 
CGTAGGGACGCTTAACATTTCAAAAGCAACGTAAACACAATAGCTACAGCCACGCGGCTCT
GTGGAACTTTACATGCGTCTGAGGTTCTTATGGCTCTTG 
UL74A-L 
CTAGTCTCCCGCACCTTGGCTGTGTACCGAGCTTGTATACAGGGCCCGATATGTAACCAAAC
CCACAACAGTACCTCGCCTGTGACGGAAGATCACTTCG 
UL74A-R 
GGGCACTCTTGCTCATTGTAATAAAGTACACGCCACACGGTGTGATGATACTATATGCGTG
AGGTTTGTGCGTCTTTATCTGAGGTTCTTATGGCTCTTG 
UL150A-L 
TTCTCTCGTGGAGGCGACGGCGAATGCAGCAGACGGTGTTCGATGGAGATGGCGTGCGAG
GAAGAAAGCGCCGTGTTGCCTGTGACGGAAGATCACTTCG 
UL150A-R 
GACAAGCACAAGTGGACACCGCCATCTGCCACCACACATGGCCCATGTGCTCCGACGTCCC
GCATCCAACGTCGTCTGCCTGAGGTTCTTATGGCTCTTG 
 
 
 
Oligonucleotides to replace selection cassette from Merlin BAC with C-
terminal V5 tag: 
UL4-V5-F 
AGATGTGAATTCCACCTTTTATTACTCTTGTTACAACCTGACCGTGACCAGCGCTGGTAA
GCCAATCCCTAACCCGCTCCTAGGTCTTGATTCTACGTAA 
UL4-V5-R 
GTAAACACAATAGCTACAGCCACGCGGCTCTGTGGAACTTTACATGCGTTTACGTAGAA
TCAAGACCTAGGAGCGGGTTAGGGATTGGCTTACCAGCGCT 
UL74A-V5-F 
AGCTTGTATACAGGGCCCGATATGTAACCAAACCCACAACAGTACCTCGAGCGCTGGT
AAGCCAATCCCTAACCCGCTCCTAGGTCTTGATTCTACGTAA 
UL74A-V5-R 
CGCCACACGGTGTGATGATACTATATGCGTGAGGTTTGTGCGTCTTTATTTACGTAGAA
TCAAGACCTAGGAGCGGGTTAGGGATTGGCTTACCAGCGCT 
UL150A-V5-F 
CAGACGGTGTTCGATGGAGATGGCGTGCGAGGAAGAAAGCGCCGTGTTGAGCGCTGG
TAAGCCAATCCCTAACCCGCTCCTAGGTCTTGATTCTACGTAA 
UL150A-V5-R 
ACCACACATGGCCCATGTGCTCCGACGTCCCGCATCCAACGTCGTCTGCTTACGTAGAA
TCAAGACCTAGGAGCGGGTTAGGGATTGGCTTACCAGCGCT 
 
 
 
 
 
 
 
 
  
ix 
 
 
Appendix III 
Chapter 3: Immunofluorescence images lacking DAPI and/or 
Phalloidin co-staining 
 
  
 
 
 
 
 
 
 
 
RL5A Mock RL10 RL11 RL12 
UL1 RL13 UL2 UL4 UL5 
UL7 UL6 UL8 UL9 UL11 
UL15A UL13 UL16 UL17 UL18 
x
UL20 UL19 UL21A UL22A UL23 
UL25 UL24 UL27 UL28/29 UL31 
UL34 UL32 UL35 UL36 UL37 
UL40 UL38 UL41A UL42 UL43 
xi
UL45 UL44 UL46 UL48 UL54 
UL57 UL55 UL71 UL74 UL84 
UL87 UL84 UL91 UL92 UL93 
UL102 UL96 UL104 UL105 UL116 
xii
UL121 UL119 UL124 UL128 UL130 
UL132 UL131A UL133 UL136 UL138 
UL140 UL139 UL144 UL145 UL147 
UL148A UL148 UL148B UL148C UL148D 
xiii
IRS1 UL150 TRS1 
xiv
xv 
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Reconstruction of the complete human 
cytomegalovirus genome in a BAC reveals 
RL13 to be a potent inhibitor of replication
Richard J. Stanton,1 Katarina Baluchova,2 Derrick J. Dargan,2 Charles Cunningham,2 Orla Sheehy,2 
Sepehr Seirafian,1 Brian P. McSharry,1 M. Lynne Neale,1 James A. Davies,1 Peter Tomasec,1  
Andrew J. Davison,2 and Gavin W.G. Wilkinson1
1Section of Medical Microbiology, Tenovus Building, School of Medicine, Cardiff University, Cardiff, United Kingdom. 2MRC Virology Unit,  
Institute of Virology, University of Glasgow, Church Street, Glasgow, United Kingdom.
Human	cytomegalovirus	(HCMV)	in	clinical	material	cannot	replicate	efficiently	in	vitro	until	it	has	adapted	
by	mutation.	Consequently,	wild-type	HCMV	differ	fundamentally	from	the	passaged	strains	used	for	research.	
To	generate	a	genetically	intact	source	of	HCMV,	we	cloned	strain	Merlin	into	a	self-excising	BAC.	The	Merlin	
BAC	clone	had	mutations	in	the	RL13	gene	and	UL128	locus	that	were	acquired	during	limited	replication	in	
vitro	prior	to	cloning.	The	complete	wild-type	HCMV	gene	complement	was	reconstructed	by	reference	to	
the	original	clinical	sample.	Characterization	of	viruses	generated	from	repaired	BACs	revealed	that	RL13	
efficiently	repressed	HCMV	replication	in	multiple	cell	types;	moreover,	RL13	mutants	rapidly	and	repro-
ducibly	emerged	in	transfectants.	Virus	also	acquired	mutations	in	genes	UL128,	UL130,	or	UL131A,	which	
inhibited	virus	growth	specifically	in	fibroblast	cells	in	wild-type	form.	We	further	report	that	RL13	encodes	
a	highly	glycosylated	virion	envelope	protein	and	thus	has	the	potential	to	modulate	tropism.	To	overcome	
rapid	emergence	of	mutations	in	genetically	intact	HCMV,	we	developed	a	system	in	which	RL13	and	UL131A	
were	conditionally	repressed	during	virus	propagation.	This	technological	advance	now	permits	studies	to	be	
undertaken	with	a	clonal,	characterized	HCMV	strain	containing	the	complete	wild-type	gene	complement	
and	promises	to	enhance	the	clinical	relevance	of	fundamental	research	on	HCMV.
Introduction
Human cytomegalovirus (HCMV) is a clinically important her-
pesvirus that  is ubiquitous  in human populations worldwide 
(1). Primary infection is followed by lifelong persistence, during 
which virus reactivation must be constrained continuously by host 
immune surveillance. Myeloid cell progenitors are a recognized 
site of latency, with infectious virus being produced following dif-
ferentiation into macrophages or dendritic cells. Severe disease 
is most commonly observed when immunity is compromised by 
infection (e.g., HIV/AIDS) or immunosuppressive therapy (e.g., in 
transplant recipients). HCMV is also the leading viral cause of con-
genital disability and malformation, which was the primary basis 
for it being designated a highest priority level vaccine target by 
the US Institute of Medicine (2). HCMV disease can manifest as 
a wide range of clinical conditions (e.g., pneumonia, colitis, reti-
nitis, hepatitis, arteriosclerosis, or systemic infection), reflecting 
the capacity of the virus to infect a wide range of cell types in vivo 
(3–7). Despite this wide tropism in vivo, only fibroblasts support 
the efficient growth of cultured strains in vitro.
Appreciation of HCMV pathogenesis is heavily dependent on 
research performed using the high-passage strains AD169 and 
Towne. However, these strains are known to have both lost viru-
lence and experienced substantial alterations in their genomes dur-
ing passage in cell culture (8–10). The HCMV genome may be repre-
sented as ab-UL-b′a′c′-US-ca, where UL and US denote long and short 
unique regions and ba/b′a′ and ca/c′a′ indicate inverted repeats 
flanking the unique regions. AD169 and Towne have acquired large 
deletions (15 kb and 13 kb, respectively) in the UL/b′ region in addi-
tion to defects elsewhere in genes that are dispensable for growth 
in fibroblasts (11–18). The UL/b′ region encodes a viral CXCL che-
mokine (gene UL146; ref. 19), a tumor necrosis factor receptor 
homolog (gene UL144; ref. 20), natural killer cell evasion functions 
(genes UL141 and UL142; refs. 21–23), a regulator of latency (gene 
UL138; refs. 24, 25), and several other uncharacterized functions. 
Therefore, the UL/b′ region is likely to contribute to virulence via 
several pathways. Spontaneous defects clearly arise elsewhere in the 
HCMV genome, yet their significance is only occasionally defined 
functionally (13, 18, 26, 27). Indeed, whole-genome sequencing of 
multiple clinical strains following growth in vitro reveals that clini-
cal HCMV genomes invariably mutate whether passaged in fibro-
blasts, epithelial cells, or endothelial cells (28).
There is a need to develop and characterize low-passage HCMV 
strains for experimental applications. However, the generation of 
laboratory strains of WT HCMV is problematic not only because 
clinical samples often contain multiple strains (27, 29–36), but 
especially because genetic adaptations occur even during the early 
stages of passage in cell culture. Thus, most strains passaged in 
fibroblasts are mutated in 1 of 3 adjacent genes (UL128, UL130, 
and UL131A; collectively termed the UL128 locus, UL128L) whose 
products form a complex bound to glycoproteins gH and gL in 
the virion envelope (37–43). These mutations inhibit formation 
of the complex and thereby render the virus incapable of infecting 
epithelial, endothelial, and certain myeloid cell types (12, 44–48).
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Figure 1
Steps in the construction of pAL1111. The approximate location of the insertion site of the BAC vector between US28 and US29 in the 
US region of the HCMV genome is shown at the top. The designations of BACs (pAL series) and viruses (RCMV series) are shown on the 
right. Boxes indicate protein-coding regions (labeled), and circles denote loxP sites (L). The BAC box represents pBeloBAC11, the eGFP/
Puro box represents a cassette expressing eGFP and a puromycin resistance protein, and the Cre box represents a Cre recombinase gene 
containing a synthetic intron.
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The genomes of several HCMV strains have been captured as BACs, 
including a number based on low-passage viruses, and these are 
proving to be an invaluable resource for research (49–54). However, 
none contains the full complement of HCMV genes, both because of 
mutations that occurred in cell culture prior to being cloned and, in 
most cases, because sequences were deleted in order to accommodate 
the BAC vector. In addition, the original clinical material is not avail-
able for most of these strains, thus preventing the sequences of the 
cloned genomes being verified against those of unpassaged virus. To 
provide a reliable source of HCMV gene sequences and a reproduc-
ible source of genetically intact, clonal virus for pathogenesis studies, 
we sought to produce an infectious BAC containing the complete 
HCMV gene complement. HCMV strain Merlin (ATCC VR-1590) 
was selected because it is designated the reference HCMV genome 
sequence by the National Center for Biotechnology Information 
(GenBank AY446894; RefSeq NC_006273) and the original clini-
cal sample is available for comparison. Merlin was derived from the 
urine of a congenitally infected infant and sequenced after 3 passages 
(p3) in human fibroblasts (27).
Our study commenced with the construction of a BAC clone con-
taining the complete genome of strain Merlin (p5). DNA sequenc-
ing led to the identification of disabling mutations in genes RL13 
and UL128, which were repaired first singly and then in combina-
tion to produce BACs containing a complete WT gene comple-
ment. Experiments conducted with viruses derived from the BACs 
revealed that RL13 expression severely impairs HCMV replication 
in fibroblast and epithelial cell cultures. Thus, when viruses gener-
ated from BACs containing the WT RL13 gene were passaged in 
vitro, further mutants emerged rapidly, producing a phenotypically 
altered virus with enhanced growth properties. Although RL13 is 
known to be a member of a restricted set of HCMV hypervariable 
genes (27), its expression had not, to our knowledge, previously 
been characterized. Use of the BACs showed that RL13 encodes a 
highly glycosylated protein located in the virion envelope. Since 
virus generated from the WT BAC was susceptible to mutation, cell 
lines were constructed in which expression of RL13 and UL131A 
could be modulated. For what we believe is the first time, these cell 
lines permit experiments to be undertaken using a characterized 
HCMV strain containing the complete WT gene complement.
Results
Cloning the HCMV strain Merlin genome. We aimed to clone the com-
plete HCMV strain Merlin genome by inserting a BAC vector into 
a noncoding region between virus genes US28 and US29. Pre-
liminary studies (data not shown) indicated that straightforward 
insertion of the BAC-targeting vector into the HCMV genome 
by homologous recombination during virus growth in primary 
human fetal foreskin fibroblasts (HFFFs) was associated with 
compensating deletions in virus sequences, presumably due to 
genome size constraints operating during virus DNA packaging. 
The BAC-targeting vector was therefore redesigned to replace the 
region of the HCMV genome containing US29–US34 (Figure 1). 
BAC vector DNA was transfected into HFFFs, which were super-
infected with HCMV strain Merlin (p5), and puromycin selection 
was used to enrich for recombinants. Circular DNA was extracted 
and electroporated into E. coli. A total of 22 clones were analyzed 
by restriction endonuclease digestion (data not shown), and all 
contained the HCMV genome minus US29–US34. Since both UL 
and US may be present in either orientation in an HCMV genome, 
a linear molecule will be one of 4 isomers and a circular molecule 
one of 2. Restriction endonuclease profiles corresponding to both 
circular conformations were detected among the BAC clones (data 
not shown). A single clone (pAL1031; Figure 1) of the 12 clones 
with UL and US present in the standard arrangement was selected 
for further analysis.
Recombineering (55, 56) was used to insert the US29–US34 
region into pAL1031, thus generating pAL1040, which contains 
the  entire Merlin genome  (Figure 1). Cre/lox  technology has 
been deployed previously to promote excision of prokaryotic vec-
tor sequences (also located between US28 and US29) from an 
AD169 BAC following transfection into HFFFs (53). We adopted 
this strategy to produce a self-excising Merlin BAC by 2 rounds 
of recombineering, in which the enhanced GFP (eGFP)/Puro cas-
sette in pAL1040 was replaced by a gene encoding Cre recombi-
nase, thus generating pAL1053 (Figure 1). The version of Cre used 
contained a synthetic intron to prevent its expression in E. coli (57, 
58). Following transfection into HFFFs however, Cre recombinase 
was expressed and mediated removal of the BAC vector by recom-
bination between loxP sites engineered at the junctions with the 
virus genome. Thus, the only exogenous sequences remaining in 
virus generated from pAL1053 and subsequent BACs were those 
of single loxP and NheI sites (40 bp in total) located between US28 
and US29 (Figure 1).
Sequence of BAC pAL1053. Sequencing of the entire HCMV com-
ponent of pAL1053 confirmed that the whole Merlin genome had 
been captured and that a single a/a′ sequence was present between 
Table 1
Sequence differences between Merlin (NC_006273) and the HCMV genome in pAL1053
Position	 Change	(NC_006273	→	pAL1053)	 Coding	region	affected	 Coding	effect
11363 CAAAAAAAC → CAAAAAAAAC RL13 ƒ
40231 TTGGAGG → TTGCAGG UL32 None
48828 GGCGAAC → GGCAAAC UL36 R → C
49054 CATGATC → CATCATC UL36 I → M
49203 GACGGTA → GACAGTA UL36 R → C
49791 AGGGGTG → AGGAGTG UL36 P → S
49792 GGGGTGC → GGGCTGC UL36 H → Q
194592–194643 (1025–1076) ACACCCCCCGTCCCCGCACACCCCCCGTCCCCGCACACCCCCCGTCCCCG → G None (b/b′) None
195063 (605) GGACCGC → GGAGCGC None (b/b′) None
194781 CCGTAGA → CCGCAGA None (b′ only) None
Nt positions are given with respect to NC_006273. ƒ, frameshift. Altered bases underlined.
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the b and c, and b′ and c′, sequences. As in Merlin (p3), pAL1053 
contained a G to A (G → A) substitution at nt 176311 that intro-
duces an in-frame stop codon and would lead to premature termi-
nation of the UL128 protein. pAL1053 differed from Merlin (p3) 
at a total of 12 locations (Table 1). These included 5 substitutions 
clustered in UL36. The sequences of PCR products amplified from 
the original clinical material, Merlin (p3), the earliest BAC precur-
sor of pAL1053 (pAL1031), and 10 additional Merlin BACs from 
the same stage as pAL1031 showed that these mutations were pres-
ent only in pAL1031, whereas the sequences from all other sources 
were identical to that of the Merlin (p3) sequence. Thus, the differ-
ences in UL36 were atypical and limited to the Merlin genome that 
was captured in pAL1031. The UL36 mutations in pAL1053 were 
repaired by recombineering to match the Merlin (p3) sequence, 
thus generating pAL1111 (Figure 1).
The most significant additional difference between Merlin (p3) 
and pAL1053 (and hence pAL1111) was a frameshift in RL13 at 
nt 11363 caused by a single nt insertion (Table 1; also see below). 
The remaining differences had no apparent effect on protein-cod-
ing potential. A synonymous substitution in gene UL32 was found 
retrospectively to represent a single nt polymorphism in the Mer-
lin (p3) genome. Three alterations were noted in the b/b′ inverted 
repeat sequence. Two of these were substitutions, one being pres-
ent in both b and b′ and the other in b′ alone. The other was a 
51-bp deletion due to natural length variation in a tandem repeat 
sequence in both b and b′. The b/b′ sequence is the region of the 
HCMV genome that is most prone to variation in HCMV (18, 59)
Mutations in RL13. To investigate the origin of the frameshift 
mutation in the RL13 coding region (nt 11189–12070), this locus 
was sequenced  in 10 additional BACs from the same stage as 
pAL1031. Surprisingly, all were found to contain disruptive muta-
tions, and 4 different classes (classes 1–4) of mutant were identi-
fied, each of which is predicted to express a truncated RL13 protein 
(Figure 2). To determine whether RL13 was mutated in the virus 
stock used to generate pAL1031, the coding region was amplified 
by PCR from Merlin (p5) and 15 clones were sequenced (Figure 2). 
Mutations that were detected in single clones, except where they 
corresponded to mutations in the BACs, could have arisen by PCR 
error and were excluded from the analysis. The PCR clones identi-
fied mutations that corresponded to 3 of the 4 mutant groups 
Figure 2
Alignment of amino acid sequences potentially encoded by mutated versions of RL13 in pAL1031 and 10 other BACs from this stage, and PCR 
clones from Merlin (p5). Shading indicates identity to the WT Merlin sequence (NC_006273). Numbers in parentheses indicate the number of 
clones containing the relevant mutation. Nt mutations were as follows (numbering relative to strain Merlin sequence, NC_006273): mutant 1, 
C → T (nt 11573; premature stop codon); mutant 2, G → T (nt 11534; premature stop codon); mutant 3, C → T (nt 11531; premature stop codon); 
mutant 4 (which includes pAL1031), extra A (nt 11363; frameshift); mutant 5, G → C (nt 11563, W → C); mutant 6, deletion of nt 11276–11860; 
mutant 7, G → A (nt 11191, M → I, altered start codon; the protein is depicted as starting from next in-frame M).
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(groups 1, 2, and 4) in BACs, plus 3 additional groups (classes 5–7). 
None of the BAC or PCR clones yielded a sequence representing 
the WT RL13 coding region.
The finding that all genomes in Merlin (p5) and BACs derived 
from Merlin at the pAL1031 stage were mutated in RL13 raised the 
question of at which stage these mutations had arisen. The original 
Merlin sequence was determined from bacteriophage M13 clones 
derived from Merlin (p3). Retrospective analysis of the sequence 
database revealed that, although the RL13 consensus was WT, all 
individual M13 clones were mutated at various different positions 
(Table 2). Moreover, an analysis of individual PCR clones produced 
from Merlin (p3) was also consistent with this virus stock com-
prising a mixture of RL13 mutants (Table 2). Thus, 18/22 PCR 
clones exhibited substitutions that were also detected in the M13 
clones. Each of the remaining 4/22 PCR clones contained unique 
mutations in RL13 (data not shown), though it is not possible to 
exclude the possibility that these resulted from PCR errors.
To investigate whether the mutants detected in Merlin (p3 and 
p5) were present in the clinical sample or whether they originated 
during cell culture, 10 PCR clones of RL13 were generated from the 
original clinical sample, using the same primers and conditions as 
were used for Merlin (p5). Nine clones were WT in sequence, and 
one clone contained a single synonymous substitution (A → G at 
nt 11959). This substitution was not detected in any versions of 
Merlin from passage in cell culture and thus most probably result-
ed from a PCR error. These data indicated that RL13 was predom-
inantly WT in the clinical sample and are consistent with RL13 
mutants having arisen and been selected during cell culture.
Growth properties of virus generated from the Merlin BAC. Virus 
(RCMV1111) was readily recovered from HFFFs transfected with 
pAL1111 (Figure 1) and exhibited a restriction endonuclease pro-
file identical to that of Merlin (p5) (Figure 3A). A pattern diagnos-
tic of the presence of all 4 genome isoforms was distinguishable in 
the linear RCMV1111 genome. Infections of HFFFs at low MOI 
(0.01 PFU/cell) demonstrated that RCMV1111 grew with kinetics 
comparable to those of Merlin (p5) (Figure 3B).
In generating RCMV1111, the BAC vector was excised from 
the genome to leave only a residual sequence of 40 bp between 
US28 and US29. Intracellular FACS indicated that RCMV1111 
expressed the US28 protein during the course of productive infec-
tion at an abundance comparable with Merlin (p5) (Figure 3C). 
Since an antibody was not available for the US29 protein, US29 
transcript levels expressed by RCMV1111 and Merlin (p5) were 
measured by quantitative RT-PCR (QRT-PCR) (Figure 3D), using 
UL123 (IE1) as a standard, and were comparable. Thus, the resid-
ual 40 bp in RCMV1111 had no discernible effect on expression 
of the adjacent US28 and US29 genes.
Expression of eGFP by virus generated from the Merlin BAC. To facili-
tate the characterization of viruses generated from Merlin BACs, 
an IRES-eGFP expression cassette was  inserted  into pAL1111 
immediately downstream from UL122 (IE2), so that expression 
was under the control of the major IE promoter (60), generating 
pAL1158. In the resulting virus (RCMV1158), eGFP was expressed 
with IE kinetics (data not shown). In growth studies performed at 
low MOI (0.01 PFU/cell) in HFFFs, RCMV1158 exhibited a small 
but consistent reduction in levels of virus production (2-fold) at 12 
days post-infection (PI) (Figure 3E).
Repair of RL13 or UL128 results in growth defects in fibroblasts. In 
order to reconstitute the complete HCMV gene complement, 
the lesions in UL128 and RL13 in pAL1111 were repaired seam-
lessly by recombineering, both singly and in combination, cul-
minating in a set of 4 BACs (pAL1111, pAL1119, pAL1120, and 
pAL1128; Table 3). The complete sequence of the fully repaired 
BAC (pAL1128) was verified by Solexa sequencing. A correspond-
ing set of eGFP-tagged BACs was also constructed (pAL1158, 
pAL1159, pAL1160, and pAL1161; Table 3).
To assess the efficiency of virus spread from cell to cell, the 4 
eGFP-tagged BACs were  transfected  individually  into HFFFs, 
the cells were overlaid, and then plaque areas were measured at 
3 weeks post-transfection (PT) (Figure 4 and Figure 5A). Compa-
rable results were obtained using the BACs lacking the eGFP tag 
(data not shown). Viruses with either RL13 (RCMV1159) or UL128 
(RCMV1160) repaired produced much smaller plaques than the 
double mutant (RCMV1158). Furthermore, the virus (RCMV1161) 
with both genes repaired produced even smaller plaques. RL13 and 
UL128 thus act independently to restrict either cell-to-cell trans-
mission or virus production in fibroblast cultures.
To investigate further, HFFFs transfected with the eGFP-tagged 
BACs without overlay were monitored over time. Plaques formed 
initially by viruses with UL128, RL13, or both genes repaired 
(RCMV1159, RCMV1160, and RCMV1161) were subsequently 
outgrown by uninfected cells. To encourage virus dissemina-
tion, cells transfected with pAL1159, pAL1160, or pAL1161 were 
trypsinized at 7-day intervals and reseeded in the same flask with-
out the addition or removal of cells. The eGFP reporter gene was 
used to identify infected cells (Figure 5B), and cell-free virus levels 
were measured by titration (Figure 5C). The rates of virus spread 
through  the monolayer  (Figure 5B) were  consistent with  the 
Table 2
Sequence differences between RL13 in WT Merlin (NC_006273) and subpopulations of Merlin (p3) represented in bacteriophage M13  
or PCR clones
Position	 Mutation	(NC_006273	→	clone)	 Residue	 Coding	effect	 No.	of	M13	clones	 No.	of	PCR	clones
11191 CATGCAC → CATACAC 1 M → I 1/6 0/22
11537 GAAGTGA → GAAATGA 117 V → M 4/8 11/22
11563 ATGGAAT → ATGCAAT 125 W → C 2/8 1/22
11563 ATGGAAT → ATGCAAT 125 W → C 2/8 4/22
11900 ATTGAAA → ATTCAAA 238 E → Q 2/8 4/22
11884 AATCGGG → AATTGGG 232 None 1/8 2/22
11964 TATCGGT → TATAGGT 259 S → X 1/8 2/22
Nt positions are given with respect to NC_006273. X, termination codon. Altered bases underlined.
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relative plaque sizes (Figure 5A), with slowest growth occurring 
when RL13 and UL128 were both repaired (Figure 5, A–C). Repair-
ing either RL13 or UL128 also gave a clear reduction in the levels of 
infectious virus released into the supernatant (Figure 5C). Repair-
ing both genes delayed dissemination of the infection through the 
monolayer, but substantial and increasing amounts of infectious 
virus were released by 5–7 weeks PT (Figure 5C).
In titrations conducted to generate Figure 5C, the plaque sizes 
were largely in accord with those reported in Figure 5A. How-
ever, some plaques from the repaired viruses were substantially 
larger than the majority. Plaque sizes were measured at the earli-
est time point possible: 2 weeks PT for RCMV1158, 3 weeks PT 
for RCMV1159 and RCMV1160, and 4 weeks PT for RCMV1161 
(Figure 5D). Two clearly distinct plaque sizes were evident for 
RCMV1159. The 3 larger plaques were expanded individually in 
HFFFs, and RL13 was amplified by PCR and sequenced. Each virus 
contained the same 2 mutations in RL13, specifically C → A at nt 
11286 (resulting in S → Y) and C → G at nt 11436 (resulting in the 
introduction of an in-frame stop codon). Sequencing of viruses 
derived from the 3 largest RCMV1161 plaques did not reveal any 
mutations in RL13 or UL128L.
Repairing RL13 results in growth defects in epithelial cells. Restoration 
of RL13 independently of UL128 suppressed virus replication in 
fibroblasts, with approximately 10% of virus having remutated in 
Figure 3
Properties of Merlin BAC–derived virus RCMV1111. (A) Restriction endonuclease profiles of DNA extracted from Merlin (p5), RCMV1111 (the 
virus derived from pAL1111), and pAL1111. Markers (kb) are shown. (B) Virus titers released into the medium following infection of HFFFs at 
an MOI of 0.01 PFU/cell. Error bars show mean ± SD; results are representative of 2 experiments. (C) Intracellular FACS staining for the US28 
protein in cells at various times PI with either Merlin (p5) or RCMV1111. Controls in the form of samples stained with IgG are shown. (D) Copy 
numbers of US29 transcripts relative to UL123 (IE1) transcripts at various times PI with Merlin (p5) or RCMV1111. Figures were averaged from 
3 experiments; error bars show mean ± SD. (E) Virus titers released into the medium following infection of HFFFs at an MOI of 0.01 PFU/ml with 
RCMV1158 or RCMV1111. Error bars show mean ± SD; results are representative of 2 experiments.
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RL13 by 3 weeks PT (see above; Figure 5D). To determine whether 
this effect was limited to fibroblasts or whether RL13 may be advan-
tageous in other cell types (as is the case for UL128L), retinal pig-
mented epithelial cells (ARPE-19s) were transfected with pAL1160 
or pAL1161 (Table 3) and the size of plaques was measured (Figure 
6A). At all time points measured, plaques from the virus lacking 
RL13 (pAL1160) were larger than those from the virus in which 
RL13 had been repaired (pAL1161). Therefore, RL13 conferred a 
growth restriction in epithelial cells as well as fibroblasts. In con-
trast, UL128L is known to confer a restriction only in fibroblasts.
Cell cultures transfected with the eGFP-tagged BACs were moni-
tored simultaneously for the number of infected cells (Figure 6B) 
and amount of infectious virus released into the supernatant (Fig-
ure 6C). The lack of growth of UL128 mutants (RCMV1158 and 
RCMV1159) in ARPE-19s (data not shown) was consistent with 
previous observations that UL128L is essential for epithelial cell 
tropism. As was the case with HFFFs, plaques generated by viruses 
in which UL128 was repaired (RCMV1160 and RCMV1161) were 
eventually overgrown by uninfected cells, and virus dissemination 
required periodic reseeding of the monolayer. Both RCMV1160 
and RCMV1161 grew much more slowly in ARPE-19s than HFFFs, 
and, unlike HFFFs, ARPE-19s did not attain complete infection 
(Figure 6B),  instead reaching a plateau and forming a chronic 
infection. The virus in which both UL128 and RL13 were repaired 
(RCMV1161) grew much more slowly than RCMV1160 and formed 
a chronic infection in which a much lower proportion of cells was 
infected (approximately 15% for RCMV1161 compared with 35% 
for RCMV1160). RCMV1161 also produced lower levels of cell-free 
virus than RCMV1160 (Figure 6C). This effect was only partially 
attributable to the lower numbers of infected cells, since RCMV1161 
infected about half the number of cells as did RCMV1160 and yet 
produced over 10-fold less cell-free virus. Comparable results were 
obtained using viruses lacking the eGFP marker. Thus, repairing 
RL13 results in slower cell-to-cell spread and reduced levels of cell-
free virus from epithelial cells as well as fibroblasts.
Rapid generation and selection of RL13 and UL128L mutants in fibro-
blasts. To generate working stocks of BAC-derived viruses in HFFFs, 
the cells in a 25-cm2 flask were transfected with BAC DNA and 
reseeded periodically until 100% were infected. Cell-free virus was 
transferred to a single 150 cm2 flask and then to five 150 cm2 flasks, 
and virus stocks (p3) were prepared. To test the genetic integrity of 
the virus, 10 PCR clones each of RL13 and UL128L were sequenced. 
Differences from the original sequences were excluded as proba-
ble PCR errors if they were detected in single clones. An analysis 
of 13 virus stocks (Table 4), each derived independently from BAC 
DNA, found that (a) when only RL13 was repaired, it mutated in all 
stocks (stocks 1–4); (b) when only UL128 was repaired, the UL128 
locus mutated in 2 of 3 HFFF derived stocks (stocks 5, 6), whereas 
it remained intact in epithelial derived stocks (stocks 8, 9; a synony-
mous substitution was detected in one instance); and (c) when both 
RL13 and UL128 were repaired, RL13 mutated in 1 stock (stock 
11), whereas the UL128 locus appeared to remain intact. When the 
stock (stock 11) containing an RL13+UL128+ virus that harbored a 
frameshift in RL13 in 20% of genomes was passaged a fourth time, 
the RL13 mutation was then observed in 100% of clones, along with 
a deletion compromising both UL128 and UL130 in the UL128 
locus. Thus, both RL13 and the UL128 locus remutated in fibro-
blasts, with the former tending to mutate more rapidly.
RL13 encodes a virion envelope protein. Since RL13 has not previously 
been characterized, it was important to establish and investigate its 
expression. RL13 was therefore tagged with a sequence encoding a 
C-terminal V5 epitope and inserted into a recombinant adenovirus 
(RAd) vector. The V5 epitope was also fused to RL13 within the 
strain Merlin BACs, in both a UL128– (RCMV1279) and a UL128+ 
(RCMV1280) background (Table 3). The primary translation prod-
uct of RL13 is predicted to be a 35-kDa protein containing a signal 
sequence, a transmembrane domain, 7 potential N-linked glyco-
sylation sites, and 26 potential O-linked glycosylation sites. When 
RL13V5 was expressed in isolation using the RAd vector, 80-kDa 
and 55-kDa proteins were detected (Figure 7A), whereas 100-kDa 
and 55-kDa species were detected in cells infected with RCMV1279 
(RL13V5+UL128–; Figure 7B). The 55-kDa proteins were suscep-
tible to EndoH digestion, indicative of them being an ER-retained 
immature form, whereas the 80- and 100-kDa proteins were resis-
Table 3
WT (+), mutated (–) status of RL13 and UL128 in Merlin BACs
BAC	 Derived	virus	 RL13	 UL128
BACs	containing	no	tags
pAL1111 RCMV1111 – –
pAL1119 RCMV1119 + –
pAL1120 RCMV1120 – +
pAL1128 RCMV1128 + +
BACs	tagged	with	eGFP
pAL1158 RCMV1158 – –
pAL1159 RCMV1159 + –
pAL1160 RCMV1160 – +
pAL1161 RCMV1161 + +
BACs	containing	RL13	tagged	with	a	V5	epitope
pAL1279 RCMV1279 + –
pAL1280 RCMV1280 + +
BACs	tagged	with	eGFP,	tet	Operators	before	RL13/UL128L
pAL1393 RCMV1393 – + (tetO)
pAL1448 RCMV1448 + (tetO) –
pAL1498 RCMV1498 + (tetO) + (tetO)
Figure 4
Growth of BAC-derived viruses in HFFFs. Images show eGFP 
expressed by plaques formed in HFFFs 3 weeks PT with BAC DNA as 
indicated. Scale bars: 100 μm.
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tant to EndoH digestion and are thus presumably fully mature. 
PNGaseF digestion reduced the 55-kDa proteins to 35 kDa and, in 
addition, reduced the 80- and 100-kDa proteins to 57 and 65 kDa, 
respectively. Since neither enzyme was able to reduce the 80- and 
100-kDa proteins to 35 kDa, it is likely that mature gpRL13 con-
tains O-linked, as well as N-linked, sugars. Identical results were 
obtained with cells infected with RCMV1280 (RL13V5+UL128+), 
and no bands were seen using lysates from RL13– virus (data not 
shown). The observation that gpRL13 appears to be more exten-
sively glycosylated in the context of HCMV infection than when 
expressed in isolation is consistent with previous observations on 
CD155 and gpUL18, to the effect that HCMV infection alters nor-
mal cellular glycosylation processes (22, 61).
The V5 epitope was also used to track gpRL13 expression by 
immunofluorescence. When RL13V5 was expressed using the 
RAd vector, gpRL13 trafficked to discrete cytoplasmic vesicles, a 
proportion of which could be stained with the early endosomal 
marker Rab5A (Figure 7C). This observation is consistent with 
much of the protein having transited the Golgi apparatus. In the 
context of a productive HCMV infection, the intracellular distri-
bution of gpRL13 was different. The protein localized to the cyto-
plasmic site of virion assembly and colocalized in both HFFFs and 
ARPE-19s with a marker for the trans-Golgi network (TGN46) 
and pp28 (an outer tegument protein encoded by gene UL99 that 
interacts with the envelope and is acquired by the virion in the 
cytoplasm; Figure 7D) and gH (a virion envelope glycoprotein 
encoded by gene UL75; Figure 7E).
The finding that gpRL13 is a glycoprotein that tracks to the site 
of virion assembly raised the possibility that it might be a virion 
surface envelope protein. Growth of RL13+ HCMV in vitro is inef-
ficient, and spontaneous mutants will arise and be rapidly selected 
(see above). Nevertheless, we found that limited, short-term growth 
of RL13+ virus could be fostered by sequential reseeding of cultures 
(Figure 5), and the antibody to a C-terminal tag would preferen-
tially recognize full-length, nonmutated gpRL13 even if a propor-
tion of mutants had arisen during passage. In virions purified from 
such cultures, only the 100-kDa mature, Endo H–resistant form of 
gpRL13 was detected. In virion fractionation studies, this protein 
copurified with glycoprotein B (gB; the product of gene UL55) in 
the soluble envelope fraction, rather than with pp65 (the product 
of gene UL83) in the tegument (Figure 8A). The V5 epitope is pre-
dicted to be located topologically on the inner side of the envelope, 
and this orientation was supported by immunoelectron microsco-
py, in which gold-labeled secondary antibody exhibited extensive 
labeling around the inner surface of the envelope (Figure 8B).
Conditional expression of RL13 and UL128L. The BAC pAL1111 
(RL13–UL128–) has utility as a reproducible source of fully char-
acterized, clonal HCMV that exhibits good genetic stability and 
rapid growth to high titers in fibroblasts. We also show above 
that short-term experiments can be performed using the Mer-
lin BAC in which RL13 and UL128 are repaired. The major phe-
notypic impact these genes have on HCMV biology emphasized 
the need to work with WT virus. However, the rapid emergence 
of mutants at these loci during amplification from Merlin BAC 
Figure 5
Growth of BAC-derived viruses in HFFFs. (A) Areas of individual plaques at 3 weeks PT, with cells overlaid to prevent cell-free spread of virus. 
(B) Kinetics of infection measured by FACS analysis. (C) Kinetics of infectious virus release into the medium of the cultures in B, with error bars 
showing mean ± SD. (D) Area of plaques generated by virus harvested from the media in C, with each sample derived from the earliest time 
point at which more than 10 plaques were visible.
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transfections meant virus stocks were inevitably contaminated 
with mutants. In order to enable studies with phenotypically WT 
virus, we sought to suppress expression of RL13 and the UL128 
locus during virus expansion following Merlin BAC transfec-
tion. To achieve this, hTERT-immortalized HFFFs were trans-
duced with a retrovirus encoding the tet repressor containing a 
C-terminal nuclear localization signal (NLS) and tet operators 
were inserted upstream of the translation initiation codon of the 
gene to be modulated (62, 63). In HFFF-tet cells, the tet repressor 
binds to the tet operators and prevents transcription of the tar-
get gene, whereas transcription proceeds as normal in parental 
HFFFs. When tested with a RAd-expressing tet-regulated GFP, 
expression levels in HFFF-tet cells were reduced 180-fold relative 
to parental HFFFs, showing little more fluorescence than cells 
infected with an empty vector control (Figure 9A).
The transcriptional initiation sites for RL13 are located approxi-
mately 30- and 110-bp upstream from the translational initiation 
codon (K. Baluchova, unpublished observations). Transcription 
of UL128 starts within the UL130 coding region, and an mRNA 
initiating approximately 10 bp upstream of UL131A potentially 
encodes both the UL131A and UL130 proteins (26, 43). tet opera-
tors were inserted in various locations upstream from the RL13 
or UL131A coding regions, and their capacity to selectively pro-
mote replication of RL13+ or UL128+ viruses in HFFF-tet cells 
was tested empirically. The optimal location for the tet opera-
tors was determined to be a single tet operator 19 bp upstream of 
RL13 (pAL1448) and 2 tet operators 33 bp upstream of UL131A 
(pAL1393; Table 3). Plaque formation was  inhibited approxi-
mately 10-fold in HFFF cells by the presence of an intact UL128 
locus, and this inhibition was relieved by infection of HFFF-tet 
cells with a tet-controlled UL131A virus, RCMV1393 (Figure 9, B 
and C). Similarly, plaque formation was inhibited approximately 
10-fold in HFFF cells by the presence of an intact RL13, and this 
inhibition was relieved by infection of HFFF-tet cells with a tet-
controlled RL13 virus, RCMV1448 (Figure 9, D and E). Titers of 
tet-controlled viruses obtained from HFFF-tet cells were increased 
18- to 32-fold relative to the non-tet–controlled viruses (Figure 
9F). In addition, sequencing of 10 PCR clones of UL128L and 
RL13 from RCMV1393 and RCMV1448, respectively, showed all 
contained the WT sequence. Following passage in HFFFs with 
this RCMV1393 stock, virus was able to infect ARPE19 cells and 
produced plaques of a size equivalent to the non–tet-controlled 
parental virus RCMV1160 (Figure 9G). Finally, having verified that 
both RL13 and UL131A could be independently tet-controlled, a 
virus was constructed in which both genes contained tet opera-
tors upstream of their ATG codons. Like the previous constructs, 
plaque formation was inhibited in HFFF cells by the presence of 
an intact RL13 and UL128 locus, and this repression was relieved 
by infection of HFFF-tet cells with a virus in which both RL13 and 
UL128 were tet-controlled (RCMV1498) (Figure 10, A and B).
Thus, repression of RL13 and UL131A in HFFF-tet cells demon-
strably provides a means to amplify Merlin virions containing 
intact versions of RL13 and the UL128 locus. Two options are 
available to produce phenotypically WT HCMV from these viruses: 
either transcriptional repression can be released by the addition of 
doxycycline to infected HFFF-tet cells or, as demonstrated above, 
a final replication cycle can be performed in HFFFs.
Discussion
Diagnostic laboratories have long recognized that HCMV strains 
in clinical samples do not adapt readily to cell culture. Our con-
struction of what we believe is the first BAC containing a complete, 
characterized copy of a genetically intact HCMV genome provides 
an explanation for this phenomenon in showing that adaptation 
is dependent on 2 independent mutations, one in the UL128 locus 
(previously recognized; ref. 26) and one in RL13 (identified in the 
present study). To date, HCMV research has by necessity used virus-
es that, to varying degrees, are compromised genetically. Although 
laboratory-adapted viruses have proved invaluable, there is a clear 
need to develop systems that represent the WT virus responsi-
ble for clinical disease. To this end, the Merlin genome (p5) was 
cloned using BAC technology, and the sequence of an initial BAC 
(pAL1053) was compared with that of the parental strain. Spe-
cific issues relating to tissue culture adaptation were clarified and 
resolved using sequence data derived directly from the original clin-
Figure 6
Growth of BAC-derived viruses in ARPE-19s. (A) Size of plaques at 2, 
3, or 4 weeks PT, with cells overlaid to prevent cell-free spread of virus. 
(B) Kinetics of infection following transfection of BACs into ARPE-19s 
without overlay, measured by FACS analysis of eGFP. (C) Kinetics of 
infectious virus release into the medium of the cultures in B, with error 
bars showing mean ± SD.
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ical sample that gave rise to Merlin. Mutations that affected HCMV 
coding regions were sequentially repaired by recombineering, so 
that the only relic in virus recovered from BACs by DNA transfec-
tion was a 40-bp sequence containing a loxP and an NheI site locat-
ed between the US28 and US29 coding regions. The presence of this 
sequence did not affect expression of the flanking genes.
The high level of sequence identity between pAL1053 and strain 
Merlin (p3) demonstrated that the HCMV genome had suffered 
minimal perturbation during BAC cloning. In pAL1053, nonsyn-
onymous mutations in protein-coding regions were identified in 
UL36, UL128, and RL13. The differences in UL36 were specific 
to pAL1053 and its predecessor, pAL1031, and were presumably 
derived from a small proportion of mutants that arose in cell cul-
ture. HCMV and rhesus cytomegalovirus strains have previously 
been found to have acquired inactivating mutations in UL36 fol-
lowing passage in vitro, implying that there may be some selective 
pressure for such mutants (14, 64). Following repair of UL36, the 
resulting BAC (pAL1111) provided a reproducible source of clonal 
HCMV strain Merlin (RCMV1111; RL13–UL128–; Table 3), whose 
growth properties were indistinguishable from the parental virus. 
BACs in which either RL13, UL128, or both genes were repaired 
were generated from pAL1111 and supplemented by a correspond-
ing series of BACs containing an eGFP marker. pAL1128 and 
pAL1161 contain the complete HCMV gene complement and, for 
what we believe is the first time, enabled experiments to be under-
taken with a clonal population of effectively WT virus. Although 
RCMV1111 and its eGFP-expressing counterpart (RCMV1158) 
were stable during limited culture and suitable for generation of 
high-titer virus stocks, repair of UL128 or RL13 (or both) severe-
ly impaired HCMV growth in HFFFs, and propagation of these 
viruses was associated with rapid selection of further mutants at 
these loci. Therefore, we developed the HFFF-tet cell line, which 
allowed RL13 or UL131A to be repressed during recovery of virus 
from the BAC, thus providing a stable platform for experimenta-
tion on genetically intact HCMV.
Although HCMV replication has been described in a wide range 
of cell types, efficient virus production in vitro has been achieved 
only using viruses adapted to growth in fibroblasts. Indeed, exist-
ing cell-culture systems appear to be essentially incompatible 
with efficient propagation of WT HCMV. HCMV is not excep-
tional in this regard. Of the 8 known human herpesviruses, only 
WT herpes simplex virus types 1 and 2 (HSV-1 and HSV-2) can be 
propagated readily to high titer in cell culture. Nonetheless, very 
high HCMV virus loads are often detected in urine samples from 
congenitally infected neonates (as was the case for the sample 
from which Merlin was isolated), and this indicates that condi-
tions exist in vivo that are compatible with efficient replication 
of WT HCMV. It is possible that RL13 regulates a switch to pro-
ductive HCMV replication in vivo.
The UL128 locus is essential for the efficient infection of epi-
thelial and endothelial cells by HCMV (37–43) but is detrimental 
to growth in fibroblasts. Consequently, mutants in this locus are 
selected when clinical isolates are passaged in fibroblasts (12, 26, 
27, 44, 45, 47, 48). Merlin was originally selected for detailed inves-
tigation from a series of clinical isolates partly on the basis of its 
excellent growth properties in fibroblasts. However, this process 
favored the selection of a UL128 mutant, which emerged during p1 
(26). When the lesion was repaired in the BACs, alternative defects 
in the UL128 locus emerged by p3–p4. In other studies monitoring 
endothelial cell tropism in clinical isolates, loss of phenotype has 
been reported in fibroblasts after p20 (44), p22 (45), or p15–p20 
(28). Such studies defined a virus “passage” as corresponding to 
Table 4
RL13 and UL128L mutations detected by PCR in BAC-derived viruses at p3
Stock	 RL13	mutations	 UL128L	mutations
	 Mutation	 Position	 Affected	clones	(%)	 Effect	 Mutation	 Position	 Affected	clones	(%)	 Effect
RL13+UL128–	BAC	transfected	into	HFFFs
1 ^A 11363 33 ƒ    
1 G → T 11901 40 E → X    
2 ΔA 11363 30 ƒ    
3 ^A 11363 50 ƒ    
4 A → G 11297 20 S → G    
4 C → T 11427 20 A → V    
4 A → G 11956 20 I → M    
RL13–UL128+	BAC	transfected	into	HFFFs
5     C → T 176229 14 R → Q
5     T → C 176845 14 I → V
5     CAAGA → TCTTG 176915-9 21 FL → SA
6     ΔT 176456 30 None (intron)
7     None  100 None
RL13–UL128+	BAC	transfected	into	ARPE-19s
8     None  100 None
9     A → G 176917 20 None
RL13+UL128+	transfected	into	HFFFs
10 None  100  ΔT 176456 50 None (intron)
11 ^A 11363 20 ƒ None  100 None
12 None  100  ΔT 176456 30 None (intron)
13 None  100  ΔT 176456 30 None (intron)
Each row represents an individual virus stock. Nt positions are given with respect to NC_006273. +, WT gene; –, mutated gene; ^, inserted nt; Δ, deleted nt.
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each serial subculture (usually weekly) of an infected cell monolayer. 
However, in the present study, virus passage involved destruction 
of the entire cell monolayer following infection with cell-free virus, 
a process that normally involves many more cycles of virus replica-
tion. Also, given that viruses mutated in the UL128 locus released 
higher amounts of virus into the medium, our use of cell-free virus 
may have further encouraged the selection of mutants.
The identification of an RL13 mutation in pAL1053 was unex-
pected because the genome sequence of Merlin (p3) indicated 
that this coding region was intact (27). It led to the discovery that 
low-passage Merlin stocks actually consisted of mixtures of vari-
ous different RL13 mutants. This finding brings a resolution with 
observations that almost all HCMV strains and BACs are overtly 
mutated in RL13 (27). Parallels exist between RL13 and the UL128 
locus in the fact that mutations arise in both genes during adapta-
tion to culture in fibroblasts. However, it is clear that RL13 and 
the UL128 locus can function independently because either gene 
in intact form was capable of suppressing virus replication, and 
Figure 7
Characterization of gpRL13. (A 
and B) Western blot performed on 
RL13V5, showing the sizes of the 
proteins in native form or following 
digestion with EndoH or PNGaseF. 
RL13V5 was either expressed in 
isolation from a RAd (A) or from its 
native position in RCMV1279 (B). 
(C) Immunofluorescence performed 
for the indicated antigens on HFFFs 
infected with the RAd express-
ing RL13V5 (×640 magnification). 
(D and E) Immunofluorescence 
performed for the indicated anti-
gens either on HFFFs infected with 
RCMV1279 or on ARPE-19s infect-
ed with RCMV1280. Original magni-
fication, ×640.
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repair of both had an additive effect. The RL13 phenotype was also 
shown to be distinct from that of the UL128 locus, since RL13 sup-
pressed HCMV replication in both fibroblasts and epithelial cells, 
whereas the UL128 locus was not only stable, but promoted infec-
tion, in epithelial cells. Nevertheless, the finding that gpRL13 is 
present in the virion indicates that it may have a role in modifying 
tropism (similar to the UL128 locus) or in modulating cell signal-
ing during virus entry (as proposed for gB).
The apparent ease with which RL13 mutants were selected in 
cell culture raised the possibility that they preexisted in the clinical 
sample, perhaps reflecting the potential for an expanded cell tro-
pism in vivo. This possibility is technically challenging to disprove, 
since such mutants might be present in very low proportions. 
However, we were unable to detect the existence of RL13 mutants 
in the primary clinical sample from which Merlin was derived. It 
was estimated that approximately 106 particles were used in the 
initial infection of a 25-cm2 flask to isolate Merlin, and this would 
have resulted in most cells receiving a particle. Nonetheless, pas-
sage 1 of Merlin took 4 weeks to complete. The mutation rate of 
DNA viruses is relatively low and has been calculated at 0.003 per 
genome replication for HSV-1 (65). If this value holds for HCMV, 
mutants  in  the UL128  locus and/or RL13 would be expected 
to arise during p1. This mutation rate operating on 106 viruses 
would result in a total of 3,000 mutations per genome replication. 
Since RL13 accounts for 879/235,646 bp in strain Merlin genome, 
approximately 11 mutations would be in RL13. The acquisition 
of mutations in both RL13 and UL128 could have resulted either 
from sequential mutations in the same template or as a result of 
recombination between independent mutants. Despite the coun-
terintuitive nature of such rapid selection events in a herpesvirus, 
mutations in RL13 and the UL128 locus were also identified at p3 
following transfection of the repaired BACs into HFFFs, and these 
were clearly generated de novo. Interestingly, mutants emerged in 
RL13 more rapidly than in the UL128 locus. Some data also indi-
cated that RL13 may mutate more rapidly in the context of UL128 
mutated viruses; however,  this may  simply  reflect  the  slower 
growth of the WT virus.
In support of our conclusions concerning the instability of RL13 
in cell culture, a collaborative study has shown that RL13 mutants 
were invariably selected in fibroblasts, epithelial, and endothelial 
cells during sequential passage of HCMV strains from clinical 
samples (28). Also, in most existing HCMV BACs (including FIX, 
Ph, Towne, Toledo, and AD169), RL13 is mutated overtly by dele-
tions, frameshifts, or substitutions that introduce premature ter-
mination codons (27), and that derived from strain TB40/E (54) 
contains a unique substitution that greatly reduces the prediction 
of a signal peptide for gpRL13 (A.J. Davison, unpublished observa-
tions). Relating to this, we note that on 2 occasions, viruses derived 
from Merlin BACs replicated relatively efficiently in fibroblasts 
and yet retained an intact RL13 (RCMV1159 [data not shown] 
and a proportion of RCMV1161; see Figure 5D). This suggests that 
another HCMV gene may be required for RL13 function and that 
this gene is less prone to mutation than RL13.
HCMV exhibits the highest degree of intrastrain sequence varia-
tion of any human herpesvirus, and RL13 is a member of a small 
group of genes that exhibit the greatest variation (27). Also among 
this group are genes UL146 (27, 35, 36, 66–68) and UL74 (gO) (27, 
35, 69–71), which are well characterized because of their utility in 
genotyping clinical isolates. The selection pressures responsible 
for generating such degrees of divergence are not fully understood, 
but their origins, and perhaps the era in which they have operated, 
appears to be ancient (66). Despite remarkable sequence variation 
among HCMV strains, UL146 and UL74 are stable within indi-
vidual patients, and identical UL146 sequences have been detected 
in geographically distant individuals (35, 66). RL13 is one of 14 
members of the RL11 gene family, which is believed to have arisen 
through gene duplication and then diverged during the evolution 
of the primate cytomegaloviruses (72). Several other members of 
this family are also hypervariable. As a virion envelope protein, 
gpRL13 may be a prime target for neutralizing antibody, and it is 
possible that selection is exerted on it in vivo to drive escape from 
the humoral immune response. In support of this, when CD4+ 
T cell responses to HCMV were measured, RL13 was one of the top 
5 most immunogenic HCMV ORFs (73). It would be interesting to 
determine whether RL13 is now stable or whether the mechanism 
driving its genetic variation remains operational.
The question arises of why RL13 is detrimental to virus replica-
tion in both epithelial and fibroblast cells in culture. The virion 
components encoded by the UL128 locus are clearly also detrimen-
tal in fibroblasts, yet they are essential for infection of other cell 
types. Since gpRL13 is also present in the virion, it may likewise 
modify tropism in some way that has not yet been recapitulated 
in vitro. Recent studies have suggested that HCMV is capable in 
vivo of establishing persistent, low-level infections that are cor-
Figure 8
Localization of RL13 in the virion. (A) Western blot per-
formed on purified virions from virus expressing a trun-
cated gpRL13 (RCMV1111, RL13–) or full-length RL13 
with a C-terminal epitope tag, gpRL13V5 (RCMV1279, 
RL13+). Complete virions (V), envelope fraction (E), 
and tegument/capsid fraction (T) were probed for 
the antigens indicated. (B) Immunogold EM staining 
for RL13V5 in purified RCMV1279 virions. Original 
magnification, ×40,000.
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Figure 9
Repression of UL128L and RL13 by 
BAC-derived viruses in HFFF-tet cells. 
(A) FACS analysis of parental HFFFs 
or HFFF-tet cells, infected with empty 
control adenovirus (RAd-Ctrl) or RAd-
expressing eGFP (RAd-GFP). RAd-
GFP expresses GFP from the HCMV 
MIE promoter, containing 2 tet opera-
tors 10 bp downstream of the TATA 
box. (B–E) Plaque sizes of viruses 
generated at 2 weeks PT in HFFFs (B 
and D) or HFFF-tet cells (C and E), with 
cells overlaid to prevent cell-free spread 
of virus, showing (B and C) repression 
of UL128L in RCMV1393 and (D and 
E) repression of RL13 in RCMV1448. 
(F) Titers of virus stocks obtained from 
HFFF-tet cells infected with viruses in 
which RL13 and UL131A were tet con-
trolled (RCMV1448 and RCMV1393, 
respectively) or the parental viruses 
in which RL13 and UL131A were 
not tet controlled (RCMV1159 and 
RCMV1160, respectively). (G) Plaque 
size of parental virus (RCMV1160) or 
virus in which UL131A was tet con-
trolled (RCMV1393) in ARPE19 cells, 
3 weeks PT.
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related with the presence of glioblastomas (74–76). Alternatively, 
therefore, RL13 may act as a regulator, promoting persistence of 
HCMV by suppressing the switch to full lytic infection until virus 
dissemination is required. Clearly there are situations in vivo, as 
illustrated by UL138 (which promotes latency by suppressing lytic 
infection in CD34+ myeloid progenitors), where it can be beneficial 
for the virus to restrict or limit productive infection.
Consideration has been given to using live HCMV as a vacci-
nation agent, vaccine carrier, and vector for gene therapy. Such 
studies are being developed with strains adapted to cell culture 
that have lost RL13 function. When the low passage HCMV strain 
Toledo was evaluated in human virus challenge, mild to severe 
disease was induced in immunocompetent individuals (both sero-
negative and seropositive) receiving doses ranging between 10 
and 1,000 PFU (9). Indeed, the capacity of this strain to induce 
clinical disease was impressive. However, Toledo is known to have 
a large, in-frame deletion in RL13 and an ablation of UL128 (27). 
The absence of RL13 function as a repressor of HCMV replication 
could potentially have enhanced the efficiency of Toledo replica-
tion, dissemination, and pathogenesis during an acute infection. 
In addition to demonstrating that RL13 is incompatible with effi-
cient virus replication in vitro, we have now provided a method 
for conditional expression of RL13 and UL131A in the context 
of productive virus infection in HFFFs. The system that we have 
developed will facilitate HCMV studies with virus fully represent-
ing the clinical agent.
Methods
All studies in human and animal cells were approved by Bro Taf Local 
Research Ethics Committee, Cardiff, United Kingdom.
Cells and viruses. HFFFs and ARPE-19s (77) were grown in DMEM (Gibco; 
Invitrogen) containing 10% FCS (Gibco; Invitrogen) at 37°C in 5% CO2. 
HCMV strain Merlin (p5) (27) was utilized to generate BACs as described 
below. Infections were performed as described previously (78), and viruses 
were titrated in triplicate by plaque assay for 14 days on HFFFs using a 1% 
Avicel overlay (79). Cultures that exhibited small plaques at 14 days PT 
were incubated for a further 14 days and recounted. Plaques were visual-
ized using an ORCA-ER camera mounted on a Leica DMIRBE microscope, 
and sizes were computed using Openlab 3 software (Improvision).
PCR. Three DNA polymerases were used in PCR reactions according to 
the manufacturers’ protocols: Phusion (NEB) for fragments greater than 
4 kb; Advantage 2 (Clontech) for amplification directly from virus stocks 
or cultures; and Expand Hi-Fi (Roche) for all other experiments. Oligo-
nucleotide primers were purchased from Sigma-Aldrich at desalted purity. 
RL13 and the UL128 locus were amplified for sequencing using primers 
RL13F (ATCCTGAACATGAAGACTGACGTT) and RL13R (GAATAAACA-
CACCCAAACATTAATGAC), and UL128F (CAGAAACTCACATCGGCGA-
CA) and UL131AR (CCATCACCTCGCCTATACTATGTG), respectively.
Isolation, transformation, and transfection of DNA. Minipreps of plasmids 
or BACs were produced as described previously (62). Maxipreps were pro-
duced using NucleoBond BAC100 kits (Machery Nagel) from 500 ml over-
night bacterial cultures. BAC DNA transfections (2 μg) of HFFFs (106 cells) 
were performed using a basic fibroblast kit and a Nucleofector (Amaxa) 
according to the manufacturer’s protocol. Transfections into ARPE-19s 
were performed in 25-cm2 flasks using effectene (QIAGEN) according to 
the manufacturer’s protocol for 60-mm dishes.
Transformation of E. coli was performed by electroporation at 2.5 kV using 
2-mm cuvettes and a Micropulser (Bio-Rad). When PCR products were 
cloned for sequencing, DNA was purified from agarose gels using a GFX 
PCR DNA and Gel Band Purification kit (GE Healthcare) and cloned into 
pCR4-TOPO (Invitrogen) according to the manufacturer’s instructions.
Construction of the BAC-targeting vector.  The  BAC-targeting  vector 
(pAL1026; Figure 1) used to capture the Merlin genome contained mark-
ers for eGFP and puromycin resistance (eGFP/Puro) and homology arms 
matching HCMV genes US28 and US34A (817 and 888 bp, respectively), 
a chloramphenicol resistance gene (cat), genes sopA, sopB, and sopC, which 
ensure active partitioning during cell division, and gene repE, which medi-
ates assembly of the replication complex in E. coli at Ori2. Each homology 
arm was flanked by a loxP site, and a unique NheI restriction site was posi-
tioned between them.
To generate pAL1026, pBeloBAC11 (New England Biolabs; GenBank 
U51113; ref. 80) was digested with HpaI and ApaLI, blunt-ended with Kle-
now DNA polymerase, and religated to remove the existing cos and loxP 
sites, thus generating pAL767. Homology arms matching genes US28 and 
US34 were amplified from Merlin DNA using primers US28F (GGCC-
GCTAGCTGGCGACGTCGGATTCAATG; NheI site underlined), US28R 
(GGCCGGATCCATAACTTCGTATAATGTATGCTATACGAAGT-
TATAGCGCTTTTTTATTACGGTATAAT; BamHI site underlined, loxP 
site shown in bold), and US34F (GGCCGCATGCATAACTTCGTATAG-
CATACATTATACGAAGTTATGACCAGTGGTGGCGGGGAAT; SphI 
site underlined, loxP site shown in bold) and US34R (GGCCGCTAGC-
GGGACTTTCATCCTGCATTA; NheI site underlined), respectively. The 
2 PCR products were digested with NheI, ligated together, digested with 
SphI and BamHI, and inserted into pAL767, thus generating pAL799. A 
linker containing a PacI site was inserted into the BamHI site, and then 
an expression cassette encoding eGFP/Puro (under the control of an SV40 
promoter and linked by an internal ribosome entry site [IRES]) was insert-
ed into pAL799, thus generating pAL815. The eGFP/Puro expression cas-
sette was derived from the BAC-targeting vector YD-C19 (a gift from D. Yu; 
ref. 53) by amplification using primers eGFP-PuroF (GGCCTTAATTA-
ACAATTCGGCGCAGCACCA; PacI site underlined) and eGFP-PuroR 
(GGCCTTAATTAAGATCCAGACATGATAAGATACATTGATG; PacI site 
Figure 10
Simultaneous repression of UL128L and UL13 by BAC-
derived viruses in HFFF-tet cells. Plaque sizes of virus-
es generated at 3 weeks PT in HFFFs (A) or HFFF-tet 
(B) cells, with cells overlaid to prevent cell-free spread 
of virus. Data points represent individual plaque sizes 
recorded for each mutant.
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underlined). The amplified fragment was digested with PacI and inserted 
into PacI-digested pAL815, thus generating pAL1026.
Construction of a Merlin BAC. 1 μg pAL1026 was linearized by NheI diges-
tion and transfected using Effectene (QIAGEN) into 5 × 105 HFFFs. Cells 
were infected at 24 hours PT with Merlin (p5) at an MOI of 10, and recombi-
nants were enriched by selection with puromycin (2.5 μg/ml) and detected 
by visualizing eGFP. When a significant proportion of cells exhibited eGFP 
expression, circular DNA was extracted using Hirt extraction (53, 81) and 
transfected into E. coli. Selection with chloramphenicol allowed the identi-
fication of BAC colonies, from among which pAL1031 (Figure 1) was ana-
lyzed in detail and repaired by recombineering.
Repairing of Merlin BACs. Recombineering was performed in E. coli SW102 
using lacZ/ampr/sacB (62) and galK selection cassettes (82) as previously 
described. The sequences of the primers used are listed in Supplemen-
tal Table 1  (supplemental material  available online with  this article; 
doi:10.1172/JCI42955DS1). All constructs were verified by sequencing 
modified regions and by restriction digest at each step. To enable the 
Merlin UL29–UL34  sequence  to  be  reintroduced  into  pAL1031,  the 
lacZ/ampr/sacB cassette was amplified and inserted between the loxP site 
and US34A using  primers  SacBF-LoxPHom  and  SacBR-US34AHom 
to generate pAL1033 (Figure 1). To generate the insert, 2 PCR products 
were produced, digested with NheI, and ligated together. A 482-bp region 
encompassing the loxP site adjacent to US34 in pAL1026 was amplified 
using primers LoxP-R (GGCCGCTAGCATAACTTCGTATAATGTATGC-
TATACGAAGTTATGCATGCAAGCTTGAGTATTC; NheI site underlined) 
and Chlor-F (GGCCAGATCTGTCGGCAGAATGCTTAATGAA; BglII site 
underlined). A 5.2-kb region of the Merlin genome spanning genes US29 
to US34A was also amplified using primers US29F (GGCCGCTAGC-
ACCTCGGCCTTTTCATACAA; NheI site underlined) and US34AR (GGC-
CAGATCTGGGACTTTCATCCTGCATTA; BglII site underlined). Each 
amplicon was cloned into pCR2.1-TOPO (Invitrogen) for sequencing. A 
clone of each amplicon in which the sequence was correct was digested 
with BglII/NheI. The fragments were ligated together and recombineered 
into pAL1033, thus replacing the lacZ/ampr/sacB cassette by US29–US34A 
and generating pAL1040 (Figure 1).
The eGFP/Puro cassette in pAL1040 was replaced by a Cre recombinase 
gene under the control of an SV40 promoter and containing a synthetic 
intron (57) so that the protein would be expressed in mammalian cells but 
not E. coli. The lacZ/ampr/sacB cassette was amplified using primers SacBF-
GFPPuroHom and SacBR-GFPPuroHom and inserted into pAL1040, thus 
generating pAL1047 (Figure 1). The Cre recombinase expression cassette 
was amplified from YD-C66 (a gift from D. Yu; ref. 53), using primers 
CreF-SV40Hom and CreR-BACHom, and recombineered in place of the 
lacZ/ampr/sacB cassette, thus generating pAL1053 (Figure 1).
The sequence of pAL1053 was determined (see below) and indicated 
the presence of several differences from that of WT Merlin (see Results). 
Redundant sequences containing residual lacZ sequences were deleted 
by replacement with a galK selectable marker, which was amplified using 
primers GalKF-CreHom and GalKR-SopCHom. The galK marker was then 
removed using the primer RemoveGalKBAC, thus generating pAL1090 
(Figure 1). To repair the lesions in gene UL36, the lacZ/ampr/sacB cassette 
was amplified using primers SacBF-UL36Hom and SacBR-UL36Hom and 
inserted in place of UL36. UL36 was then amplified from Merlin DNA 
using primers UL36F and UL36R and recombineered in place of the lacZ/
ampr/sacB cassette, thus generating pAL1111 (Figure 1). Additional BACs 
were generated by repairing either and then both of the UL128 and RL13 
mutations by the same technique. In each case, the lacZ/ampr/sacB cassette 
was amplified using primers flanking the mutation (SacBF-UL128Hom 
and SacBR-UL128Hom or SacBF-RL13Hom and SacBR-RL13Hom) and 
recombineered  into  the  relevant BAC, and the selectable marker was 
excised and the mutation repaired by recombination with oligonucleotide 
UL128Rep or RL13Rep.
To insert an IRES-eGFP expression cassette immediately downstream 
from gene UL122 (IE2) into each of the 4 BACs described above, the lacZ/
ampr/sacB cassette was amplified using primers SacBF-IE2Hom and SacBR-
IE2Hom. In the resulting BACs, the lacZ/ampr/sacB cassette was replaced 
by an IRES-eGFP cassette amplified from pIRES2-GFP (Clontech) using 
primers IRESF-IE2Hom and GFPR-IE2Hom.
DNA sequencing. All PCR products in directly cloned or recombineered 
form were verified by sequencing using a BigDye 3.1 kit (ABI) and stan-
dard techniques, except that the number of cycles during sequencing was 
increased from 25 to 100. Reactions were purified using Dye Terminator 
Removal Columns (EdgeBio) and analyzed on an ABI Prism 3130xl Genetic 
Analyzer (Applied Biosystems).
Two BACs were sequenced using published approaches (59). The com-
plete HCMV component of pAL1053 was determined via standard Staden 
sequencing of a set of overlapping PCR products, and that of pAL1128 in 
its entirety was determined using data from an Illumina Genome Analyzer 
(The GenePool, University of Edinburgh). The sequence of pAL1128 was 
deposited in GenBank as accession GU179001. All nts in the text are speci-
fied relative to Merlin (NC_006273).
QRT-PCR. QRT-PCR was performed to analyze the expression levels of 
gene US29 in infected cells. The cells were trypsinized and washed once 
in PBS, and whole-cell RNA was extracted using an RNEasy Mini Kit 
(QIAGEN) and DNAse-treated using Turbo DNA-free (Ambion). US29 
transcripts were amplified using primers US29F (GACATCGGTGACA-
CAGCTTCA) and US29R (CTTGGCCTTCAGAGACCGC), and UL123 
(IE1) transcripts were amplified using primers IE1F (AGGAAGAAAGT-
GAACAGAGTGATGA) and IE1R (TTCCTCAGCACCATCCTCCT). For 
RT-PCR with real-time detection, an iScript One-Step RT-PCR kit with 
SYBR Green (Bio-Rad) was employed according to manufacturer’s instruc-
tions, and samples were analyzed on an iCycler (Bio-Rad). Serial dilutions 
of a Merlin BAC (pAL1053; see below) were used to establish a calibration 
curve. Since transcripts antisense to US29 have been reported (83), the 
sense transcript was amplified specifically using the reverse primers (100 
pmol) with 100 ng RNA in a reverse transcription step at 50°C for 10 min-
utes, followed by inactivating reverse transcriptase at 95°C for 5 minutes. 
The forward primer was then added, and the samples were cycled 40 times 
through 95°C for 10 seconds, 60°C 30 seconds, and 83°C for 10 seconds, 
with data being collected following the final step of each cycle. Melt curve 
analysis was performed following the 40 cycles, and amplification of a 
product of the correct size was confirmed by agarose gel electrophoresis. 
Samples were analyzed in triplicate, and the results were averaged. Samples 
from uninfected cells and infected cells processed without conducting the 
reverse transcriptase step were uniformly negative.
Flow cytometry. A Cytofix/Cytoperm plus kit (BD) was used for intracellular 
staining of the US28 protein, and the Tub-45 antibody (a gift from U. Höp-
ken; ref. 84) was used (1:5) in combination with goat anti-mouse Alexa 
Fluor 488 (1:200) for detection (Invitrogen). HCMV infection was moni-
tored directly by eGFP expression or indirectly by downregulation of MHC 
class I from the cell surface using antibody W6/32 (1:100) followed by goat 
anti-mouse Alexa Fluor 647 (1:200) (Invitrogen). Samples were measured on 
a FACSCalibur (BD), and data were analyzed in FlowJo (Treestar).
Generation of the HFFF-tet cell line. The coding region of the tet repres-
sor was amplified using primers tetR-F (GGCCGGATCCCTATAGGGC-
GAATTGATATGTCTA; BamHI site underlined, initiation codon in bold) 
and tetR-R (GGCCGAATTCTTATACCTTTCTCTTCTTTTTTGGATCA-
GACCCACTTTCACATTTAAGTTG; EcoRI site underlined, NLS shown 
in bold) and cloned into the BamHI/EcoRI sites of the retrovirus vector 
pMXs-IP (85). Retrovirus stocks were produced by transfecting 293Phoenix 
technical advance
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packaging cells (86) using Effectene (QIAGEN) according to manufactur-
er’s instructions and harvesting the supernatant 48 hours PT. Retrovirus 
was bound to culture dishes with Retronectin (Clontech) and used to 
infect hTERT-immortalized HFFFs. The cells were selected in puromycin 
(1 μg/ml) at 48 hours PI.
Inserting tet operators into BACs. tet operators were inserted by recombineer-
ing. To insert 1 tet operator 19 bp upstream of the RL13 coding region, 
the lacZ/ampr/sacB cassette was amplified with primers SacBF-RL13-2 and 
SacBR-RL13-2 and inserted into the BAC and then removed with oligo-
nucleotide tetO-RL13, leaving behind 1 tet operator. To insert 2 tet oper-
ators 33 bp upstream of the UL131A coding region, the lacZ/ampr/sacB 
cassette was amplified with primers SacBF-UL131A and SacBR-UL131A 
and inserted into the BAC and then removed with oligonucleotide tetO-
UL131A, leaving behind 2 tet operators.
Tagging RL13 in BACs with a V5 epitope. A sequence encoding a V5 epitope 
was fused to the C terminus of gpRL13 by recombineering. The lacZ/ampr/
sacB cassette was amplified with primers SacBF-RL13Hom and SacBR-
RL13Hom and inserted after the RL13 ORF within the BAC; then the cas-
sette was removed using overlapping oligos V5-RL13-F and V5-RL13-R, 
which fused the coding sequence for a V5 tag to the end of gene RL13.
Generating replication-deficient RAd vectors. RL13 was cloned by recom-
bineering into a RAd using the AdZ system as described previously (62), 
using primers RL13F and RL13R, so that the gpRL13 was tagged with a 
C-terminal V5 epitope. Virus was recovered from the vector by transfection 
into 293TREx cells and titrated as described previously (62). Empty vector 
control (RAd-Ctrl) and RAd-GFP, which expresses eGFP from a version of 
the HCMV MIE promoter that contains 2 tet operators 10 bp downstream 
from the TATA box, have been described previously (62).
Protein predictions. N- and O-linked glycosylation sites were predicted 
using NetNGlyc 1.0 and NetOGlyc 3.1 (87). Signal sequences and trans-
membrane domains were predicted using SignalP 3.0 (88) and TMHMM 
2.0 (http://www.cbs.dtu.dk/services/).
Purification of HCMV virions. HCMV particles in cell supernatants were 
separated into virion, dense body, and noninfectious enveloped particle 
(NIEP) fractions by positive density/negative viscosity gradient centrifuga-
tion as described previously (89). Particle concentrations in the prepara-
tions were estimated by counting negatively stained samples by EM in rela-
tion to a standard concentration of latex beads. To separate virion envelope 
proteins from capsid and tegument proteins, 108 particles were mixed 1:1 
with envelope stripping buffer (2% Nonidet-P40 in PBS) and incubated for 
15 minutes at 4°C. Particles were pelleted (12,000 g for 5 minutes at 4°C), 
and the soluble envelope fraction was harvested. The insoluble capsid/teg-
ument material was washed twice with envelope-stripping buffer and once 
in PBS before being solubilized in SDS-PAGE sample buffer.
SDS-PAGE and Western immunoblotting. Protein samples were separated by 
SDS-PAGE using 4%–12% Bis-Tris NuPAGE protein gels (Invitrogen) accord-
ing to the manufacturer’s instructions, then transferred to nitrocellulose by 
semi-dry transfer. Membranes were blocked overnight in blocking buffer (3% 
BSA in PBS containing 0.1% Tween 20 [PBST]) and then incubated with pri-
mary antibody for 1 hour. Following 3 washes in PBST, secondary antibody 
was incubated for 1 hour and washed 3 times. Bound antibody was detected 
using ECL–Western blotting detection system (RPN 2132; Amersham) and 
exposure to film. Primary antibodies were chicken anti-V5 (9113; Abcam), 
mouse anti-gB (CMV-023-40154; Capricorn), and mouse anti-pp65 (CMV-
018-48151; Capricorn). Secondary antibodies were goat anti–chicken-HRP 
(6877; Abcam) and goat anti–mouse-HRP (170-6516; Bio-Rad).
Glycosidase treatment. Samples were treated with PNGase F (P0705S; New 
England BioLabs) or ENDO H (P0703S; New England BioLabs) according 
to the manufacturer’s instructions. Briefly, the samples were denatured 
in glycoprotein-denaturing buffer at 100°C for 10 minutes and cooled to 
0°C for 5 minutes. The samples were then digested overnight at 37°C with 
PNGase F or ENDO H before being analyzed by Western immunoblotting.
Immunogold electron microscopy. Purified virions were air-dried to the 
surface of Formvar-coated EM grids. The grids were treated with chicken 
anti-V5 antibody (9113) for 4 hours at room temperature, washed 3 times 
with PBS, and incubated with goat anti-chicken antibody (39604; Abcam) 
conjugated to 6-nm gold particles for 1 hour at room temperature. After 
further washing in PBS, the grids were negatively stained with phospho-
tungstic acid and subjected to EM.
Immunofluorescence. Cells were plated on glass coverslips and infected 
with HCMV. At 7 days PI, the cells were fixed in 4% paraformaldehyde, 
permeabilized with 0.5% NP-40, and incubated with primary antibody for 
1 hour at 37°C. Following washing, secondary antibodies were incubated 
for 1 hour at 37°C, washed again, and mounted. Primary antibodies were 
chicken anti-V5 (9113; Abcam), sheep anti-human TGN46 (AHP500; Sero-
tec), mouse MAb anti-pp28 (6502; Abcam), and mouse anti-gH (2470-5437; 
Biogenesis). Secondary antibodies were donkey anti-chicken Cy3 (AP194C; 
Millipore), donkey anti-sheep IgG–Alexa Fluor 633 (A21100; Invitrogen), 
and donkey anti-mouse IgG–Alexa Fluor 488 (A-2102; Invitrogen). The 
intracellular locations of antibody-tagged proteins were examined under 
laser illumination in a Zeiss LMS 510 confocal microscope, and images 
were captured using LMS software.
Statistics. Means ± SD were calculated using GraphPad Prims software.
Acknowledgments
This work was supported by the Wellcome Trust, the United King-
dom Medical Research Council (MRC), and the Biotechnology 
and Biological Sciences Research Council (BBSRC). The authors 
thank Sian Llewellyn-Lacey and Carole Rickards for tissue culture 
support; Brent Ryckman for helpful discussions; Neal Copeland, 
Dong Yu, and Uta Höpken for reagents; Richard Darley and Phil-
lip Taylor for reagents and advice regarding retrovirus generation; 
and Jim Aitken for performing the EM.
Received for publication March 12, 2010, and accepted in revised 
form June 23, 2010.
Address correspondence to: Richard Stanton, Section of Medical 
Microbiology, Department of Infection, Immunity and Biochemis-
try, School of Medicine, Cardiff University, Tenovus Building, Heath 
Park, Cardiff CF14 4XN, United Kingdom. Phone: 44.0.29.20687319; 
Fax: 44.0.29.20742161; E-mail: StantonRJ@cf.ac.uk.
  1. Mocarski ES. Cytomegaloviruses. In: Fields BN, 
Knipe DM, Howley PM, eds. Fields Virology. 5th 
ed. Philadelphia, Pennsylvania, USA: Lippincott–
Raven; 2006:2447–2492.
  2. Stratton KR, Durch JS, Lawrence RS. Vaccines for the 
21st Century: A Tool for Decisionmaking. Washington, 
DC, USA: National Academies Press; 2000.
  3. Sinzger C, Grefte A, Plachter B, Gouw AS, The TH, 
Jahn G. Fibroblasts, epithelial cells, endothelial cells 
and smooth muscle cells are major targets of human 
cytomegalovirus infection in lung and gastrointes-
tinal tissues. J Gen Virol. 1995;76(pt 4):741–750.
  4. Sinzger C, Plachter B, Grefte A, The TH, Jahn G. Tis-
sue macrophages are infected by human cytomega-
lovirus in vivo. J Infect Dis. 1996;173(1):240–245.
  5. Bissinger  AL,  Sinzger C,  Kaiserling  E,  Jahn G. 
Human cytomegalovirus as a direct pathogen: cor-
relation of multiorgan involvement and cell distri-
bution with clinical and pathological findings in 
a case of congenital inclusion disease. J Med Virol. 
2002;67(2):200–206.
  6. Kahl  M,  Siegel-Axel  D,  Stenglein  S,  Jahn  G, 
Sinzger C. Efficient lytic infection of human arte-
rial endothelial cells by human cytomegalovirus 
strains. J Virol. 2000;74(16):7628–7635.
  7. Riegler S, Hebart H, Einsele H, Brossart P, Jahn G, 
Sinzger C. Monocyte-derived dendritic cells are per-
missive to the complete replicative cycle of human 
cytomegalovirus. J Gen Virol. 2000;81(pt 2):393–399.
  8. Quinnan GV Jr, et al. Comparative virulence and 
technical advance
	 The	Journal	of	Clinical	Investigation      http://www.jci.org      Volume 120      Number 9      September 2010  3207
immunogenicity of the Towne strain and a nonat-
tenuated strain of cytomegalovirus. Ann Intern Med. 
1984;101(4):478–483.
  9. Plotkin SA, Starr SE, Friedman HM, Gonczol E, 
Weibel RE. Protective effects of Towne cytomega-
lovirus  vaccine  against  low-passage  cytomega-
lovirus administered as a challenge.  J Infect Dis. 
1989;159(5):860–865.
  10. Elek SD, Stern H. Development of a vaccine against 
mental  retardation  caused by  cytomegalovirus 
infection in utero. Lancet. 1974;1(7845):1–5.
  11. Cha TA, Tom E, Kemble GW, Duke GM, Mocarski 
ES, Spaete RR. Human cytomegalovirus clinical 
isolates carry at least 19 genes not found in labora-
tory strains. J Virol. 1996;70(1):78–83.
  12. Prichard MN, Penfold ME, Duke GM, Spaete RR, 
Kemble GW. A review of genetic differences between 
limited and extensively passaged human cytomega-
lovirus strains. Rev Med Virol. 2001;11(3):191–200.
  13. Davison AJ,  et  al. The human cytomegalovirus 
genome revisited: comparison with the chimpan-
zee  cytomegalovirus genome.  J Gen Virol.  2003; 
84(pt 1):17–28.
  14. Skaletskaya A, Bartle LM, Chittenden T, McCor-
mick AL, Mocarski ES, Goldmacher VS. A cyto-
megalovirus-encoded inhibitor of apoptosis that 
suppresses caspase-8 activation. Proc Natl Acad Sci 
U S A. 2001;98(14):7829–7834.
  15. Dargan DJ, Jamieson FE, MacLean J, Dolan A, Addi-
son C, McGeoch DJ. The published DNA sequence 
of human cytomegalovirus strain AD169 lacks 929 
base pairs affecting genes UL42 and UL43. J Virol. 
1997;71(12):9833–9836.
  16. Mocarski ES, Prichard MN, Tan CS, Brown JM. 
Reassessing the organization of the UL42-UL43 
region of the human cytomegalovirus strain AD169 
genome. Virology. 1997;239(1):169–175.
  17. Brown JM, Kaneshima H, Mocarski ES. Dramatic 
interstrain differences in the replication of human 
cytomegalovirus  in  SCID-hu mice.  J Infect Dis. 
1995;171(6):1599–1603.
  18. Bradley  AJ,  et  al.  High-throughput  sequence 
analysis of  variants of human cytomegalovirus 
strains  Towne  and  AD169.  J Gen Virol.  2009; 
90(pt 10):2375–2380.
  19. Penfold ME,  et  al.  Cytomegalovirus  encodes  a 
potent alpha chemokine. Proc Natl Acad Sci U S A. 
1999;96(17):9839–9844.
 20. Benedict CA, et al. Cutting edge: a novel viral TNF 
receptor superfamily member in virulent strains 
of  human  cytomegalovirus.  J Immunol.  1999; 
162(12):6967–6970.
  21. Wills MR, et al. Human cytomegalovirus encodes 
an MHC class I-like molecule (UL142) that func-
tions  to  inhibit NK cell  lysis.  J Immunol.  2005; 
175(11):7457–7465.
  22. Tomasec P, et al. Downregulation of natural killer 
cell-activating ligand CD155 by human cytomega-
lovirus UL141. Nat Immunol. 2005;6(2):181–188.
  23. Cerboni C, et al. Human cytomegalovirus strain-
dependent changes in NK cell recognition of infect-
ed fibroblasts. J Immunol. 2000;164(9):4775–4782.
  24. Goodrum F, Reeves M, Sinclair J, High K, Shenk 
T. Human cytomegalovirus sequences expressed in 
latently infected individuals promote a latent infec-
tion in vitro. Blood. 2007;110(3):937–945.
  25. Petrucelli A, Rak M, Grainger L, Goodrum F. Char-
acterization of a novel Golgi apparatus-localized 
latency determinant encoded by human cytomega-
lovirus. J Virol. 2009;83(11):5615–5629.
  26. Akter P, et al. Two novel spliced genes in human cyto-
megalovirus. J Gen Virol. 2003;84(pt 5):1117–1122.
  27. Dolan  A,  et  al.  Genetic  content  of  wild-type 
human  cytomegalovirus.  J Gen Virol.  2004; 
85(pt 5):1301–1312.
  28. Dargan DJ, et al. Sequential mutations associated 
with adaptation of human cytomegalovirus to growth 
in cell culture. J Gen Virol. 2010;91(pt 6):1535–1546.
  29. Chandler SH, Handsfield HH, McDougall JK. Iso-
lation of multiple strains of cytomegalovirus from 
women attending a clinic for sexually transmitted 
disease. J Infect Dis. 1987;155(4):655–660.
  30. Collier AC, Chandler SH, Handsfield HH, Corey L, 
McDougall JK. Identification of multiple strains 
of cytomegalovirus in homosexual men. J Infect Dis. 
1989;159(1):123–126.
  31. Spector SA, Hirata KK, Newman TR. Identification 
of multiple cytomegalovirus strains in homosexual 
men with acquired immunodeficiency syndrome. 
J Infect Dis. 1984;150(6):953–956.
  32. Baldanti F, et al. Coinfection of the immunocom-
promised but not  the  immunocompetent host 
by multiple human cytomegalovirus strains. Arch 
Virol. 1998;143(9):1701–1709.
  33. Chou  SW.  Reactivation  and  recombination  of 
multiple cytomegalovirus strains from individual 
organ donors. J Infect Dis. 1989;160(1):11–15.
  34. Drew WL, Sweet ES, Miner RC, Mocarski ES. Mul-
tiple infections by cytomegalovirus in patients with 
acquired immunodeficiency syndrome: documen-
tation by Southern blot hybridization. J Infect Dis. 
1984;150(6):952–953.
  35. Stanton R, Westmoreland D, Fox JD, Davison AJ, 
Wilkinson GW. Stability of human cytomegalovi-
rus genotypes in persistently infected renal trans-
plant recipients. J Med Virol. 2005;75(1):42–46.
  36. Hassan-Walker AF, Okwuadi S, Lee L, Griffiths 
PD, Emery VC. Sequence variability of the alpha-
chemokine UL146 from clinical strains of human 
cytomegalovirus. J Med Virol. 2004;74(4):573–579.
  37. Adler B, Scrivano L, Ruzcics Z, Rupp B, Sinzger C, 
Koszinowski U. Role of human cytomegalovirus 
UL131A in cell type-specific virus entry and release. 
J Gen Virol. 2006;87(pt 9):2451–2460.
  38. Hahn G, et al. Human cytomegalovirus UL131-
128 genes are indispensable for virus growth in 
endothelial cells and virus transfer to leukocytes. 
J Virol. 2004;78(18):10023–10033.
  39. Patrone M, Secchi M, Bonaparte E, Milanesi G, 
Gallina A. Cytomegalovirus UL131-128 products 
promote gB conformational  transition and gB-
gH interaction during entry into endothelial cells. 
J Virol. 2007;81(20):11479–11488.
  40. Ryckman BJ, Chase MC, Johnson DC. HCMV gH/
gL/UL128-131 interferes with virus entry into epi-
thelial cells: Evidence for cell type-specific receptors. 
Proc Natl Acad Sci U S A. 2008;105(37):14118–14123. 
  41. Ryckman BJ, Jarvis MA, Drummond DD, Nelson 
JA, Johnson DC. Human cytomegalovirus entry 
into epithelial and endothelial cells depends on 
genes UL128 to UL150 and occurs by endocytosis 
and low-pH fusion. J Virol. 2006;80(2):710–722.
  42. Ryckman BJ, et al. Characterization of the human 
cytomegalovirus gH/gL/UL128-131 complex that 
mediates entry into epithelial and endothelial cells. 
J Virol. 2008;82(1):60–70.
  43. Wang D, Shenk T. Human cytomegalovirus UL131 
open reading frame is required for epithelial cell 
tropism. J Virol. 2005;79(16):10330–10338.
  44. Waldman WJ, Roberts WH, Davis DH, Williams 
MV, Sedmak DD, Stephens RE. Preservation of 
natural endothelial cytopathogenicity of cytomeg-
alovirus by propagation in endothelial cells. Arch 
Virol. 1991;117(3–4):143–164.
  45. Sinzger C, et al. Modification of human cytomega-
lovirus tropism through propagation in vitro is 
associated with changes in the viral genome. J Gen 
Virol. 1999;80(pt 11):2867–2877.
  46. Sinzger C, Knapp J, Plachter B, Schmidt K, Jahn 
G. Quantification of replication of clinical cyto-
megalovirus isolates in cultured endothelial cells 
and fibroblasts by a focus expansion assay. J Virol 
Methods. 1997;63(1–2):103–112.
  47. MacCormac LP, Grundy JE. Two clinical isolates 
and the Toledo strain of cytomegalovirus contain 
endothelial cell tropic variants that are not present 
in the AD169, Towne, or Davis strains. J Med Virol. 
1999;57(3):298–307.
  48. Grazia Revello M, et al. In vitro selection of human 
cytomegalovirus variants unable to transfer virus 
and virus products from infected cells to polymor-
phonuclear leukocytes and to grow in endothelial 
cells. J Gen Virol. 2001;82(pt 6):1429–1438.
  49. Marchini A, Liu H, Zhu H. Human cytomegalovi-
rus with IE-2 (UL122) deleted fails to express early 
lytic genes. J Virol. 2001;75(4):1870–1878.
  50. Murphy E, et al. Coding potential of laboratory 
and clinical strains of human cytomegalovirus. Proc 
Natl Acad Sci U S A. 2003;100(25):14976–14981.
  51. Hahn G, Rose D, Wagner M, Rhiel S, McVoy MA. 
Cloning of the genomes of human cytomegalovirus 
strains Toledo, TownevarRIT3, and Towne long as 
BACs and site-directed mutagenesis using a PCR-
based technique. Virology. 2003;307(1):164–177.
  52. Borst EM, Hahn G, Koszinowski UH, Messerle M. 
Cloning of the human cytomegalovirus (HCMV) 
genome as an infectious bacterial artificial chro-
mosome in Escherichia coli: a new approach for 
construction  of HCMV mutants.  J Virol.  1999; 
73(10):8320–8329.
  53. Yu D, Smith GA, Enquist LW, Shenk T. Construc-
tion of a self-excisable bacterial artificial chromo-
some  containing  the  human  cytomegalovirus 
genome  and mutagenesis  of  the  diploid TRL/
IRL13 gene. J Virol. 2002;76(5):2316–2328.
  54. Sinzger C, et al. Cloning and sequencing of a highly 
productive, endotheliotropic virus strain derived 
from human cytomegalovirus TB40/E. J Gen Virol. 
2008;89(pt 2):359–368.
  55. Copeland NG,  Jenkins NA, Court DL. Recom-
bineering: a powerful new tool for mouse function-
al genomics. Nat Rev Genet. 2001;2(10):769–779.
  56. Court DL, Sawitzke  JA, Thomason LC. Genetic 
engineering using homologous  recombination. 
Annu Rev Genet. 2002;36:361–388.
  57. Smith GA, Enquist LW. A self-recombining bacte-
rial artificial chromosome and its application for 
analysis of herpesvirus pathogenesis. Proc Natl Acad 
Sci U S A. 2000;97(9):4873–4878.
  58. Hobom  U,  Brune  W,  Messerle  M,  Hahn  G, 
Koszinowski UH. Fast screening procedures for 
random transposon libraries of cloned herpesvirus 
genomes: mutational analysis of human cytomega-
lovirus envelope glycoprotein genes. J Virol. 2000; 
74(17):7720–7729.
  59. Cunningham  C,  et  al.  Sequences  of  complete 
human cytomegalovirus genomes from infected cell 
cultures and clinical specimens. J Gen Virol. 2010; 
91(pt 3):605–615.
  60. Sanchez V, Clark CL, Yen JY, Dwarakanath R, Spec-
tor DH. Viable human cytomegalovirus recombi-
nant virus with an internal deletion of the IE2 86 
gene affects late stages of viral replication. J Virol. 
2002;76(6):2973–2989.
  61. Griffin C, et al. Characterization of a highly gly-
cosylated  form of  the human  cytomegalovirus 
HLA class I homologue gpUL18. J Gen Virol. 2005; 
86(pt 11):2999–3008.
  62. Stanton RJ, McSharry BP, Armstrong M, Tomasec 
P, Wilkinson GW. Re–engineering adenovirus vector 
systems to enable high–throughput analyses of gene 
function. Biotechniques. 2008;45(6):659–662, 664–668.
  63. Yao F, Svensjo T, Winkler T, Lu M, Eriksson C, 
Eriksson E. Tetracycline  repressor,  tetR,  rather 
than the tetR-mammalian cell transcription fac-
tor  fusion derivatives,  regulates  inducible gene 
expression  in mammalian cells. Hum Gene Ther. 
1998;9(13):1939–1950.
  64. Lilja AE, Shenk T. Efficient  replication of  rhe-
sus cytomegalovirus variants in multiple rhesus 
and human cell  types. Proc Natl Acad Sci U S A. 
2008;105(50):19950–19955.
  65. Drake JW, Hwang CB. On the mutation rate of herpes 
simplex virus type 1. Genetics. 2005;170(2):969–970.
technical advance
3208	 The	Journal	of	Clinical	Investigation      http://www.jci.org      Volume 120      Number 9      September 2010
  66. Bradley AJ, et al. Genotypic analysis of two hyper-
variable human cytomegalovirus genes. J Med Virol. 
2008;80(9):1615–1623.
  67. Lurain NS, et al. Analysis of the human cytomegalo-
virus genomic region from UL146 through UL147A 
reveals sequence hypervariability, genotypic stability, 
and overlapping transcripts. Virol J. 2006;3:4.
  68. He R, et al. Sequence variability of human cytomeg-
alovirus UL146 and UL147 genes in low-passage 
clinical isolates. Intervirology. 2006;49(4):215–223.
  69. Mattick C, et al. Linkage of human cytomegalovi-
rus glycoprotein gO variant groups identified from 
worldwide clinical isolates with gN genotypes, impli-
cations for disease associations and evidence for 
N-terminal sites of positive selection. Virology. 2004; 
318(2):582–597.
  70. Rasmussen L, Geissler A, Cowan C, Chase A, Winters 
M. The genes encoding the gCIII complex of human 
cytomegalovirus exist in highly diverse combinations 
in clinical isolates. J Virol. 2002;76(21):10841–10848.
  71. Rasmussen L, Geissler A, Winters M. Inter- and 
intragenic  variations  complicate  the molecular 
epidemiology of human cytomegalovirus. J Infect 
Dis. 2003;187(5):809–819.
  72. Davison AJ, et al. Homology between the human cyto-
megalovirus RL11 gene family and human adenovirus 
E3 genes. J Gen Virol. 2003;84(pt 3):657–663.
  73. Sylwester  AW,  et  al.  Broadly  targeted  human 
cytomegalovirus-specific CD4+ and CD8+ T cells 
dominate the memory compartments of exposed 
subjects. J Exp Med. 2005;202(5):673–685.
  74. Cobbs CS, et al. Human cytomegalovirus infection 
and expression in human malignant glioma. Cancer 
Res. 2002;62(12):3347–3350.
  75. Luo MH, Fortunato EA. Long-term infection and 
shedding of human cytomegalovirus in T98G glio-
blastoma cells. J Virol. 2007;81(19):10424–10436.
  76. Mitchell DA, et al. Sensitive detection of human 
cytomegalovirus in tumors and peripheral blood of 
patients diagnosed with glioblastoma. Neuro Oncol. 
2008;10(1):10–18.
  77. Dunn KC, Aotaki-Keen AE, Putkey FR, Hjelmeland 
LM. ARPE-19, a human retinal pigment epithelial cell 
line with differentiated properties. Exp Eye Res. 1996; 
62(2):155–169.
  78. Stanton RJ, McSharry  BP,  Rickards CR, Wang 
EC, Tomasec P, Wilkinson GW. Cytomegalovirus 
destruction of focal adhesions revealed in a high 
throughput Western blot analysis of cellular pro-
tein expression. J Virol. 2007;81(15):7860–7872.
  79. Matrosovich M, Matrosovich T, Garten W, Klenk 
HD. New low-viscosity overlay medium for viral 
plaque assays. Virol J. 2006;3:63.
  80. Shizuya H, et al. Cloning and stable maintenance 
of 300-kilobase-pair  fragments of human DNA 
in Escherichia coli using an F-factor-based vector. 
Proc Natl Acad Sci U S A. 1992;89(18):8794–8797.
  81. Hirt  B.  Selective  extraction  of  polyoma  DNA 
from infected mouse cell cultures. J Mol Biol. 1967; 
26(2):365–369.
  82. Warming S, Costantino N, Court DL, Jenkins NA, 
Copeland NG. Simple and highly efficient BAC 
recombineering using galK selection. Nucleic Acids 
Res. 2005;33(4):e36.
  83. Grey F, et al. Identification and characterization 
of human cytomegalovirus-encoded microRNAs. 
J Virol. 2005;79(18):12095–12099.
 84. Mokros T, Rehm A, Droese J, Oppermann M, Lipp 
M, Hopken UE.  Surface  expression  and  endo-
cytosis of the human cytomegalovirus-encoded 
chemokine  receptor US28  is  regulated by ago-
nist-independent phosphorylation.  J Biol Chem. 
2002;277(47):45122–45128.
  85. Kitamura T, et al. Retrovirus-mediated gene transfer 
and expression cloning: powerful tools in function-
al genomics. Exp Hematol. 2003;31(11):1007–1014.
  86. Kinsella TM, Nolan GP. Episomal vectors rapidly 
and stably produce high-titer recombinant retrovi-
rus. Hum Gene Ther. 1996;7(12):1405–1413.
  87. Julenius K, Molgaard A, Gupta R, Brunak S. Predic-
tion, conservation analysis, and structural charac-
terization of mammalian mucin-type O-glycosyl-
ation sites. Glycobiology. 2005;15(2):153–164.
  88. Emanuelsson O, Brunak S, von Heijne G, Nielsen H. 
Locating proteins in the cell using TargetP, SignalP 
and related tools. Nat Protoc. 2007;2(4):953–971.
  89. Irmiere A, Gibson W. Isolation and characterization 
of a noninfectious virion-like particle released from 
cells infected with human strains of cytomegalovi-
rus. Virology. 1983;130(1):118–133.
High-resolution human cytomegalovirus transcriptome
Derek Gatherera, Sepehr Seiraﬁanb, Charles Cunninghama, Mary Holtona, Derrick J. Dargana, Katarina Baluchovaa,1,
Ralph D. Hectora,2, Julie Galbraithc, Pawel Herzykc, Gavin W. G. Wilkinsonb, and Andrew J. Davisona,3
aMedical Research Council–University of Glasgow Centre for Virus Research, Glasgow G11 5JR, United Kingdom; bSchool of Medicine, Cardiff University,
Cardiff CF14 4XN, United Kingdom; and cSir Henry Wellcome Functional Genomics Facility, Institute of Molecular, Cell and Systems Biology, College of
Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow G12 8QQ, United Kingdom
Edited by Elliott Kieff, Harvard Medical School and Brigham and Women’s Hospital, Boston, MA, and approved October 27, 2011 (received for review
September 26, 2011)
Deep sequencing was used to bring high resolution to the human
cytomegalovirus (HCMV) transcriptome at the stage when in-
fectious virion production is under way, and major ﬁndings were
conﬁrmed by extensive experimentation using conventional tech-
niques. The majority (65.1%) of polyadenylated viral RNA tran-
scription is committed to producing four noncoding transcripts
(RNA2.7, RNA1.2, RNA4.9, and RNA5.0) that do not substantially
overlap designated protein-coding regions. Additional noncoding
RNAs that are transcribed antisense to protein-coding regions map
throughout the genome and account for 8.7% of transcription
from these regions. RNA splicing is more common than recognized
previously, which was evidenced by the identiﬁcation of 229
potential donor and 132 acceptor sites, and it affects 58 protein-
coding genes. The great majority (94) of 96 splice junctions most
abundantly represented in the deep-sequencing data was con-
ﬁrmed by RT-PCR or RACE or supported by involvement in
alternative splicing. Alternative splicing is frequent and particu-
larly evident in four genes (RL8A, UL74A, UL124, and UL150A) that
are transcribed by splicing from any one of many upstream exons.
The analysis also resulted in the annotation of four previously
unrecognized protein-coding regions (RL8A, RL9A, UL150A, and
US33A), and expression of the UL150A protein was shown in the
context of HCMV infection. The overall conclusion, that HCMV
transcription is complex and multifaceted, has implications for
the potential sophistication of virus functionality during infection.
The study also illustrates the key contribution that deep sequenc-
ing can make to the genomics of nuclear DNA viruses.
The genetic repertoire of human cytomegalovirus (HCMV;species Human herpesvirus 5) is incompletely understood.
Most bioinformatic investigations have focused on identifying
open reading frames (ORFs) that are conserved in other
organisms or that exhibit pattern-based similarities (e.g., in nu-
cleotide or codon bias) to recognized protein-coding regions
(CRs) (1). Our current map of the wild-type HCMV genome,
based on strain Merlin, contains 166 protein-coding genes (2–5).
It is entirely possible that additional, small protein-coding genes
will be found. Candidates involve ORFs that overlap recognized
CRs and for which there is some evidence for expression (6),
ORFs highlighted in pattern-based bioinformatic (7) or proteomic
analyses (8), and ORFs whose expression is presently unsuspected.
Recognition of many protein-coding genes has been supple-
mented by information on protein expression and function.
However, HCMV also speciﬁes polyadenylated (polyA) tran-
scripts that, because they lack sizeable, conserved ORFs, appear
unlikely to function via translation. One class consists of non-
coding, nonoverlapping transcripts (NNTs) that do not sub-
stantially overlap the designated CRs of other genes. These
include an abundant 2.7-kb RNA (β2.7 or RNA2.7) (9), a 1.1-kb
spliced RNA and associated 5-kb stable intron (RNA5.0) (10,
11), and a 1.2-kb RNA (RNA1.2) (12). RNA2.7 functions in
inhibiting apoptosis (13), the RNA5.0 homolog in murine cyto-
megalovirus is involved in virulence (14), and the role of RNA1.2
is unknown. Antisense transcripts (ASTs) form a second class of
noncoding RNA, and are transcribed antisense to CRs (15, 16).
In addition, HCMV speciﬁes several small, nonpolyA RNAs that
may have regulatory roles, including microRNAs (miRNAs) (17)
processed from longer transcripts and RNAs associated with the
origin of DNA replication (18).
To extend the understanding of HCMV genome expression,
we used deep sequencing to study viral transcription in human
ﬁbroblasts. The focus was on identifying previously unrecognized
protein-coding or noncoding polyA RNAs, and on determining
the extent of RNA splicing.
Results
Transcription Proﬁles. Whole-cell RNA was isolated from human
ﬁbroblasts infected with HCMV strain Merlin at 72 h after in-
fection, when infectious virion production was under way. An
Illumina DNA sequence dataset (DS) was generated from each of
two RNA preparations: a nondirectional DS (NDS; 24,439,691
reads) and a directional DS (DDS; 32,514,724 reads). Transcript
orientation could be inferred from the DDS but not the NDS.
The DSs were assembled against the 236-kbp HCMV genome,
which has the structure ab-UL-b′a′c′-US-ca, where UL and US
are unique regions ﬂanked by inverted repeats (ab/b′a′ and a′c′/
ca). Similar percentages (42.24 and 43.03, respectively) of NDS
and DDS reads originated from HCMV. The light yellow win-
dows in Fig. 1 depict transcription proﬁles, calculated from read
densities across the genome. In the lower windows, the NDS
proﬁle (gray) on a linear scale demonstrates that some regions
are transcribed abundantly (a few off-scale), whereas others are
expressed at very low levels. The NDS proﬁle (black) on a loga-
rithmic scale makes it clear that almost every region in the ge-
nome is transcribed at some level. As anticipated, the DDS
proﬁle (green) for rightward and leftward transcripts combined
on a logarithmic scale is similar to that for the NDS (black). The
plots in the upper windows show the DDS proﬁles for rightward
(magenta) and leftward (cyan) transcripts separately, on a loga-
rithmic scale, and demonstrate that ASTs are produced from
many regions. Further features of Fig. 1 are expanded on below.
Previously Unrecognized Transcripts. Selected transcribed regions
that apparently lack CRs were investigated by using RACE (Fig.
S1 and Table S1) and Northern blotting (NB) (Fig. S2). These
experiments led to the annotation of one previously unrecognized
CR (US33A), further characterization of a recently proposed CR
(UL30A) (4), mapping of an NNT (RNA4.9), and investigation of
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Fig. 1. Transcription and splicing of the HCMV genome. The genome is shown in ﬁve sections, with the inverted repeats (ab/b′a′ and a′c′/ca) shaded gray. CRs
are shown by color-shaded arrows and NNTs as white-shaded arrows, with gene nomenclature below. Introns connecting CRs or the RNA5.0 exons are shown as
narrow white bars. Colors applied to CRs indicate conservation among α-, β-, and γ-herpesviruses (core genes) or between β- and γ-herpesviruses (subcore
genes), with subsets of the noncore genes grouped into families of related genes. UL72 is both a member of the deoxyuridine triphosphatase-related protein
(DURP) gene family and a core gene. The light yellow windows depict transcription proﬁles (Methods) as explained in the key in the bottom right corner. The
plots in the lower windows show rightward and leftward transcripts combined: the NDS proﬁle on linear and logarithmic scales (right and left, respectively) and
the DDS proﬁle on a logarithmic scale. The plots in the upper windows show the DDS proﬁles for rightward and leftward transcripts separately, on a logarithmic
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ASTs. US33A, UL30A and RNA4.9 are included in Fig. 1 and
Fig. S3.
The size of the US33A transcript (1.3 kb) (Fig. S2) is consistent
with the locations of the 5′ and 3′ ends (Table S1 and Fig. S3). A
US34A probe also detected this RNA, plus major 0.9- and minor
0.4-kb transcripts (Fig. S2), suggesting that US34 and US34A are
3′-coterminal with US33A. US33A is conserved in chimpanzee
cytomegalovirus (CCMV), which is the closest relative of HCMV
(19) (Fig. S4).
UL30A is related to the adjacent gene UL30, conserved among
primate cytomegaloviruses, and potentially expressed from
a nonconventional initiation codon (ACG) (4). The location of
the 3′ end in the middle of UL30 (Table S1 and Fig. S3) is
consistent with the major 0.55-kb transcript (Fig. S2). Minor
RNAs of 5.7 and 3.5 kb were also apparent, the latter perhaps
representing a UL32 transcript that is 3′-coterminal with UL30A
and antisense to UL31.
The 5′ and 3′ ends of RNA4.9 (Table S1 and Fig. S3) accord
with the transcript size of 4.9 kb (Fig. S2). The location of the 3′
end of a major RNA apparently mapped from partial transcripts
is the same as that of this NNT (15, 20, 21). The majority
(65.1%) of viral polyA RNA transcription is committed to pro-
duction of NNTs, with 46.8, 7.9, 10.1, and 0.3% of appropriately
oriented DDS reads representing RNA2.7, RNA1.2, RNA4.9,
and RNA5.0, respectively. The RNA2.7, RNA1.2, RNA4.9, and
RNA5.0 populations comprise 65.7, 26.9, 7.2, and 0.2% of NNT
molecules, respectively. These statistics prompt the startling
observation that only about one-third of viral polyA RNA tran-
scription is protein-coding. The most abundant mRNA is that of
UL22A, which encodes an immunoregulatory RANTES (regu-
lated upon activation, normal T cell expressed and secreted)
decoy receptor (22) and accounts for 1.7% of appropriately
oriented DDS reads, equivalent to 14% of NNT molecules.
Extensive overlap of protein-coding RNAs speciﬁed by op-
posing strands of the HCMV genome is uncommon. Examples
examined include the 3′ ends of UL48A and UL53, which are
located well inside UL48 and UL54, respectively (Table S1 and
Fig. S3). In contrast, ASTs are apparent in most regions (Fig. 1).
Overall, they account for 8.7% of transcription from CRs and are
thus generally expressed at lower levels than their sense coun-
terparts, although there are exceptions (e.g., UL29). RACE data
indicate that one AST (UL115as) initiates at a speciﬁc location,
and that several terminate downstream from polyA signals, with
instances of a tail-to-tail arrangement in relation to other tran-
scripts (Table S1). Examples (followed by the sense gene and the
distance between polyA signals on the two strands) are UL16as
(putative UL15A, 35 b), UL30as (UL30A, 36 b), UL121as
(UL122, overlapping), UL145as (not arranged tail-to-tail),
UL142as (UL141, 193 and 245 b), UL139as (UL138, 28 b), and
IRS1as (UL150A, 1219 b).
Characterization of Splicing Patterns. The primary DS used for
splicing analysis was the NDS, rather than the DDS, because
fewer biochemical manipulations were involved in its generation.
Custom software, capable of coping with genomes that have a
high transcript density, was developed to identify reads con-
taining potential splice junctions, from which donor and acceptor
sites were proposed. These sites were required to be located
adjacent to the canonical GT or AG dinucleotides, respectively,
for the following reasons. Processing of RNA samples for deep
sequencing involved reverse transcription, during which template
switching may occur. This process involves transfer of an elon-
gating cDNA molecule from one template RNA molecule to
another, by repriming from a short sequence repeated in both
templates (23). Template switching has been acknowledged to
generate artifactual junctions in experimental studies (24). Also,
the vast majority (∼99%) of eukaryotic splice sites comply with
the GT/AG rule (25), all previously recognized HCMV sites
(described below) comply, and only a single noncompliant
HCMV site was identiﬁed in ancillary searches (see below).
Exerting the GT/AG rule resulted in the identiﬁcation of 264
potential donor and 178 acceptor sites.
The number of NDS reads supporting every possible junction
between these sites (regardless of order and orientation in the
genome, a total of 46,992 combinations) was determined. A
heuristic approach was taken to exclude junctions that most
probably arose from template switching and happened to comply
with the GT/AG rule. Excluded junctions were required to have
at least two properties consistent with template switching: orig-
inating from highly transcribed regions (especially RNA2.7),
supported by low read numbers, not involved in alternative
splicing (a site that is alternatively spliced is much less likely to
have been identiﬁed as a result of template switching than one
that is not), characterized by repeats at the cognate genome
locations, and not matching the wider consensuses for splice site
sequences (25). This analysis led to the identiﬁcation of 389
junctions supported by one or more reads, generated from 229
potential donor and 132 acceptor sites. Dataset S1 provides full
information on these sites, and Fig. 1 shows the locations of the
subset of sites supported by >10 reads. A total of 63 donor sites is
located in CRs, 115 in ASTs, and 51 between CRs or in regions
encoding NNTs. The corresponding numbers for the acceptor
sites are 69, 31, and 32, respectively. Overall, 58 CRs contain one
or more splice sites on the appropriate strand. The notation (e.g.,
D+27528) used below to denote a splice site is D (donor) or A
(acceptor), + (rightward) or – (leftward), and the nucleotide
location of the exon end. A solidus (/) indicates alternative sites,
and a caret (^) indicates a junction.
To conﬁrm splice junctions identiﬁed from the NDS analysis,
a large number (96) was tested by RT-PCR and sequencing (Fig.
S1). These were represented by 16–131,826 reads (Table S2 and
Dataset S1), a range that extends over nearly four orders of
magnitude. A total of 89 junctions was conﬁrmed, as indicated by
the colored borders of the cells in Dataset S1. For controls, two
junctions classed as having arisen from template switching were
tested and found negative (Table S2). RACE experiments car-
ried out to map RNA ends (see below) incidentally conﬁrmed
many junctions, including two of the seven not detected by RT-
PCR (Dataset S1). Moreover, three of the ﬁve not detected by
RT-PCR or RACE involved alternatively spliced sites that were
unlikely to have been identiﬁed as a result of template switching.
This left 2 of the 96 tested junctions (D+3005^A+3122 and D+
97900^A+97993) unsupported by RT-PCR and RACE and not
involved in alternative splicing. Overall, only 26 pairs of sites
identiﬁed by the NDS analysis were neither involved in alter-
native splicing nor tested by RT-PCR or RACE. From these
considerations, it seems likely that the inferred splicing patterns
are a close representation of reality.
Ancillary searches aimed at detecting sites that do not conform
to the GT/AG rule but are alternatively spliced to conforming sites
yielded a single example. This was D+192592 (as D+192592^A+
193169/A+193172), in which the GT dinucleotide is substituted by
GC, which is the most common noncanonical donor site (25).
Splice sites identiﬁed from the DDS accorded generally with
those identiﬁed from the NDS, although there was variation in
supporting read numbers (Dataset S1). Also, each DS yielded a
unique set of sites represented by low read numbers (usually 1).
These differences may have been due to the precise stage at
which RNA was harvested, the conditions used for sample pro-
cessing, and stochastic effects occurring during reverse tran-
scription of rare RNAs.
Previously Reported Splicing Patterns. Studies on various HCMV
strains have identiﬁed splice sites that are crucial for full-length
protein expression. They are located in UL22A (10), UL29 (5),
UL33 (26), UL36 (27), UL37 (27), UL89 (10), UL111A (28),
UL112 (29), UL119 (10), UL122 (30), UL123 (31, 32), UL128
(33), and UL131A (33). All were conﬁrmed in the present study.
Moreover, many reported sites that are not crucial were also
conﬁrmed. Examples are those within UL112 (29), US3 (34), and
UL122 (30, 35), and those linking UL122 and UL119 (10). The
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sites in RNA5.0 (10) were also identiﬁed. However, other
reported sites were not detected. Examples are those within
RNA2.7 (10), UL37 (36), and UL123 (IE19 and IE17.5) (37, 38),
and most instances in the UL115–UL119 region (39). Lack of
detection of these sites does not imply that the original identi-
ﬁcations were erroneous, as they may have been expressed at
very low levels or at other stages of the replication cycle, or they
may not be conserved in strain Merlin.
Previously Unrecognized Splicing Patterns. The NDS analysis detec-
ted splice sites sensitively, but was not capable of determining the
extent of exons or the ends of RNAs. These features were in-
vestigated in selected transcripts by using RACE (Fig. S1 and
Table S1) and NB (Fig. S2), which are less sensitive and identi-
ﬁed major species only. Key ﬁndings are summarized in Fig. 1
and Fig. S3.
Splicing in two genes (UL8 and US27) was revealed, using sites
that are conserved in CCMV. These sites had been predicted
previously, but experimental conﬁrmation was unsuccessful (10).
UL7 and UL8 are members of the RL11 gene family (Fig. 1), and
encode predicted membrane glycoproteins (40). An intron
(D+16449^A+16552) links UL7 and UL8, thus 5′-extending the
original UL8, with UL7 being expressed from the unspliced RNA
(Fig. 1 and Dataset S1). The expression ratio (ER) of spliced to
total RNA for UL8 was 0.57, the remainder presumably consti-
tuting the unspliced UL7 transcript. US27 is a member of the
GPCR (G protein-coupled receptor) gene family (Fig. 1). An
intron (D+224024^A+224100) is apparent in the 5′ leader (ER
= 0.85) (Fig. S3 and Dataset S1). RACE and NB experiments
conﬁrmed that the US27 and US28 transcripts (2.7- and 1.3-kb,
respectively) are 3′-coterminal (Table S1 and Fig. S2).
Five acceptor sites are notable in being spliced from one or
another of a large number of upstream exons: A–8196 (25
exons), A+108854 (46 exons), A+135253 (22 exons), A+174081
(9 exons), and a pair at A+193169/A+193172 (11 exons)
(Dataset S1). Excepting one of the pair, these superacceptor
sites (SASs) are conserved in CCMV, and each is located up-
stream from a potential CR (RL8A, UL74A, UL92, UL124, and
UL150A, respectively) (Fig. S3). The observation that RL8A,
UL92, UL124, and UL150A contain a potential ATG initiation
codon suggests that upstream exons may form untranslated
leaders, although this does not rule out the possibility that some
may 5′-extend the CR. In contrast, UL74A lacks an initiation
codon, and must be supplied with one by at least one upstream
exon. Because SASs form an unusual class of acceptor site, four
of the ﬁve examples were investigated in further detail.
The partial transcript arrangement in the vicinity of the SAS at
A–8196 has been deduced previously (12, 40, 41), and was ex-
tended to include transcripts from previously unrecognized genes
RL8A, which is downstream from the SAS, and RL9A (Fig. 1 and
Fig. S3). Both predicted proteins contain potential trans-
membrane regions and are conserved in CCMV (Fig. S4). In
RACE experiments, four 5′ ends of upstream exons spliced to
RL8A were identiﬁed, and two 5′ ends for RL9A, which is not
spliced, were mapped (Table S1 and Figs. S1 and S3). Both genes
share a 3′ end with RNA1.2 at 6755. They appear to be expressed
at low levels, as transcripts of the sizes inferred from RACE were
not detected by NB. The 4.2-kb transcript detected using an
RL8A probe (Fig. S2) is too large and of unknown provenance,
and no RL9A transcripts were detected.
The UL74A CR is preceded by the SAS at A+108854, con-
served among β-herpesviruses, and encodes a predicted mem-
brane glycoprotein (3). Four 5′ ends of upstream exons were
identiﬁed by RACE, and the 3′ end mapped to 109088 (Table S1
and Figs. S1 and S3). These locations are consistent with the
major 0.8-kb transcript (UL73; ER = 0.96) and heterogeneous
0.45-kb transcripts (UL74A; ER = 0.28) detected by NB (Fig.
S2). The origin of the minor 1.5-kb RNA is unknown. Some of
the features of UL74A in strain Merlin are equivalent to those
for the corresponding exon (UL73.5) in strain AD169 (3). In
particular, UL74A acquires an initiation codon from the
upstream exon spliced at D+108155 (Fig. 1 and Fig. S3). It is not
known whether initiation codons are also supplied by other up-
stream exons, thus generating UL74A proteins with heteroge-
neous N termini. Many of the upstream exons, and others
downstream from UL74A, are alternatively spliced to the SAS at
A+135253, which is upstream from a recognized ORF, UL92
(Dataset S1). This SAS was not characterized further.
A single 5′ end of an upstream exon spliced to the SAS at
A+174081, which precedes UL124, was identiﬁed, and the 3′ end
mapped to 174649 (Table S1 and Figs. S1 and S3). UL124 is
conserved in CCMV and encodes a predicted membrane glyco-
protein (19). The major 0.7-kb transcript detected by NB is
consistent with these locations (Fig. S2). A minor 5.5-kb tran-
script of unknown provenance was also apparent.
Four 5′ ends of upstream exons spliced to the SASs at
A+193169/A+193172 were identiﬁed by RACE, and the 3′ end
mapped to 194348 (Table S1 and Figs. S1 and S3). The two
protein-coding exons of previously unrecognized gene UL150A
(ER = 0.97), separated by an intron (D+193542^A+193654),
are located downstream from the SASs (Fig. 1 and Fig. S3). The
splice sites between the protein-coding exons are conserved in
CCMV, as is the encoded protein (Fig. S4). The intervening
intron speciﬁes one of the HCMV miRNAs (miR-UL148D)
(17). Sizes at the lower end of the heterogeneous transcripts
(1.2–1.6 kb) detected by NB are consistent with the RACE data
(Fig. S2). The UL150A CR is unusual in that it is entirely anti-
sense to a larger, unspliced CR (UL150; 7.5-kb RNA) (Fig. 1 and
Figs. S2 and S3), which is also conserved in CCMV (19). In the
region of overlap, the amino acid sequence of UL150A is better
conserved (47% identical) than that of UL150 (40%), and codon
bias is marginally more favorable (0.94 and 0.93, respectively,
using the UL54, UL82, and UL86 CRs for calibration). The
prediction of UL150A as a CR was tested by expressing V5-
tagged UL150A proteins in the context of HCMV infection. A
doublet at ∼34 kDa and a minor species at 50 kDa were detected
at 1, 3, and 6 d after infection (Fig. 2). The predicted mass of the
tagged primary translation product is 31 kDa. The detection of
more than one protein might reﬂect protein processing or
splicing from upstream exons that 5′-extend the CR.
The NDS analysis also yielded evidence for long-range splic-
ing, some of which was supported by RACE data, for example,
between US9 and the RL8A SAS (D–204854^A–8196) (Dataset
S1). Moreover, splicing was detected between exons that are
located out of order in, or on different strands of, the genome.
For example, some of the exons spliced to the RL8A or UL150A
SASs were alternatively spliced to the UL74A SAS (Dataset S1).
These junctions may have resulted from long-range transcription
of concatemeric genomes, in which UL and US are present in
either orientation.
Discussion
A number of technical limitations apply to the deep-sequencing
approach used. Certain spliced polyA RNAs would not have
been detected: those containing very short exons, and those not
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Fig. 2. Immunoblot analysis of V5-tagged UL150A proteins expressed in the
context of HCMV. Proteins harvested at 1, 3, and 6 d after infection frommock-
infected cells (MI) or cells infectedwith the HCMV recombinant (UL150A) were
probed using a V5-Tag antibody. Estimated masses (kDa) are shown.
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originating via alternative splicing and either consisting of exons
mapping <50 b or >32 kb apart in the genome or using non-
canonical splicing. Moreover, the data did not reliably facilitate
the characterization of intact transcripts, including the locations
of 5′ and 3′ ends. Points of interest in this regard were tested by
RT-PCR, RACE, and NB. Also, nonpolyA transcripts (including
miRNAs) would not have been represented.
The information arising from the study is as follows. Tran-
scripts encoded by four previously unrecognized genes (RL8A,
RL9A,UL150A, andUS33A) were mapped, and theUL150A CR,
which completely overlaps that of UL150, was shown to be
expressed as protein during virus infection. The number of NNTs
was expanded to four (RNA2.7, RNA1.2, RNA4.9, and RNA5.0).
ASTs were detected throughout the genome, some having discrete
5′ and 3′ ends and some mapping tail-to-tail with other RNAs.
Splicing is more common than recognized previously, and there is
evidence for long-range transcription. UL8 and UL150A were
added to the genes comprising multiple coding exons. Alternative
splicing is frequent, with four genes (RL8A, UL74A, UL124, and
UL150A) and perhaps one other (UL92) expressed via SASs.
These ﬁndings demonstrate that HCMV transcription is more
complex and multifaceted than recognized previously, with more
CRs, splicing, NNTs, and ASTs having become apparent. This
has implications for the potential sophistication of HCMV
functionality during infection. Approximately one-third (58/170)
of HCMV CRs contain splice sites, and the extent to which this
affects viral protein-coding capacity is now a question of great
interest. Some spliced RNAs are clearly crucial for expression of
full-length proteins, and others that are not so obviously in this
category may nonetheless have important roles. However, other
spliced RNAs may be nonfunctional, representing transcripts
that undergo a degree of splicing merely because their synthesis
happens to traverse splice sites. This may apply to spliced RNAs
that are very rare in comparison with their unspliced counter-
parts (e.g., ER = 0.003 for D–181199^A–181096 in UL146).
Members of one class of noncoding RNAs, NNTs, are encoded
by dedicated regions of the genome and likely to have important
roles, and more examples probably await discovery. A second
class of noncoding RNAs, ASTs, has its historical origins in an-
tiparallel (symmetric) transcripts, which were ﬁrst reported sev-
eral decades ago in herpes simplex virus (42). The most extensive
study of HCMV to date (15) used cDNA cloning of strain
AD169 transcripts to detect ASTs in 34 of the CRs annotated in
strain Merlin, and three (UL24as, UL36as, and UL102as) were
characterized further by NB. The DDS analysis indicates that
ASTs are associated with most CRs (Fig. 1), and that complex
splicing is evident in some (e.g., the UL114-UL121 region, which
contains UL115as) (Table S1 and Figs. S1 and S3). The functions
of ASTs are unknown, and it is possible that some ASTs result
from transcriptional proﬂigacy and have none. However, the
observation that the 3′ ends of some ASTs appear to have been
under evolutionary constraint in relation to neighboring genes
implies that they may be important. If so, roles can only be
guessed at this stage, with one obvious possibility being to reg-
ulate sense strand expression. Some ASTs may exert their effects
via cleavage into miRNAs (which represent another layer of
genomic complexity) or translation into short oligopeptides (43).
However, in these models only a very minor proportion of AST
content would be functional, leaving the role of the major pro-
portion in question. One practical outcome of HCMV transcript
complexity is that studies using mutants should be conducted
with a heightened degree of circumspection.
Deep sequencing represents a stage in HCMV genomics that
complements and extends previous approaches, such as micro-
array-based analyses (44). We have demonstrated the capability
of this approach to provide high-resolution information on
HCMV transcription and splicing. It can be extended readily to
studies of HCMV transcription in other strains and cell types,
expression kinetics during lytic and latent infections, compara-
tive properties of protein-coding and noncoding RNAs, and
transcription in vivo. It can also be applied to the genomics of
other nuclear DNA viruses.
Methods
Preparation of RNA. HCMV strain Merlin, which is stable in vitro by virtue of
point mutations in two genes (RL13 and UL128) (45), was grown at 37 °C in
human fetal foreskin ﬁbroblast cells (HFFFs; HFFF2, European Collection of
Cell Cultures 86031405) in DMEM containing 10% FCS. HFFF2 monolayers
(75-cm2) were infected with 5 pfu per cell of HCMV and incubated for 72 h.
Total infected cell RNA was isolated using TRI reagent (Sigma) or an RNeasy
Midi Kit (Qiagen). Three preparations were made, one in 2005 and two
in 2010.
Deep Sequencing. Data were generated by using an Illumina Genome Ana-
lyzer IIx in The Sir Henry Wellcome Functional Genomics Facility (University of
Glasgow). For the NDS, an Illumina mRNA-Seq prep kit was used: polyA RNA
was selected from 1 μg of the 2005 RNA preparation, fragmented, and
subjected to ﬁrst- and second-strand cDNA synthesis by using random pri-
mers. The DNA was then end-repaired, 3′-adenylated, ligated to adapters,
PCR-ampliﬁed, and size-selected (mode = 245 bp). For the DDS, Illumina
mRNA-Seq prep and small RNA sample prep kits were used: polyA RNA was
selected from 2 μg of one of the 2010 RNA preparations, fragmented,
phosphatased, phosphorylated, ligated to RNA adapters, subjected to ﬁrst-
strand cDNA synthesis and PCR-ampliﬁed by using adapter-speciﬁc primers,
and size-selected (mode = 188 bp).
Transcription Levels. Unaligned, 76-b reads with associated phred quality
scores were generated by using SCS v2.6 or v2.8, RTA v1.12, and CASAVA v1.7
(Illumina), and stored in fastq ﬁles. The NDS and DDS were then assembled
against a reference sequence by using Maq v0.7.1 under default alignment
settings (46). The assembly was visualized by using Tablet v1.10.05.21 (47).
The reference consisted of the strain Merlin genome sequence (GenBank
accession no. AY446894.2) (2) or a truncated version lacking all but 50 b of
the terminal repeats (ab and ca). DDS reads were also separated into DSs
representing rightward and leftward transcripts and assembled indepen-
dently. Transcription proﬁles were calculated from the number of reads
commencing in 10-b windows and summing these over 100-b windows (10-b
increment for each).
Splice Site Detection. A primary DS (NDS or DDS) was processed to gather
reads containing potential splice junctions by the following steps. The ra-
tionale was that at least 21 b of the 5′ and 3′ parts of a junction-containing
read must match two regions at least 50 b apart in the HCMV genome. Perl
scripts are available from the authors.
i) Duplicate readswere removed, and a regular expression (regexp) searchwas
conducted for reads that contain exact matches between the 21 b at the 5′
and 3′ ends (positions 1–21 and 56–76) and two different regions in the
reference, and that meet the following criteria: (i) matches on the same
strand of the reference, (ii) order of matching sequences in the read pre-
served in the reference, and (iii) matching sequences separated in the refer-
ence by 50 b to 32 kb.
ii) Each read was divided into two after position 21, and a regexp search
was conducted for exact matches of the entire 5′ and 3′ parts to the
reference. If criteria i–iii were met and the intervening genome se-
quence began with GT and ended with AG, a pair of 100 b exon–end
sequences was generated. This procedure was repeated iteratively until
position 55 was reached, to ensure that sequence redundancy at exon–
ends did not result in failure to identify precise locations. Two sets of
exon–end sequences were generated from the reads, one correspond-
ing to donor sites and the other to acceptor sites.
iii) Step ii was repeated for the reverse complement of the reference, and
the sets of exon–end sequences were combined with those sets from
step ii.
iv) To avoid problems associated with lower-quality data toward the 3′
ends of reads, they were trimmed to 60 and 50 b and steps i–iii were
repeated with appropriate modiﬁcations. The sets of exon–end sequen-
ces were combined with those from step iii, and duplicates were re-
moved.
v) The exon–end sequences from step iv were joined to give a set of 200-b
junctions comprising every donor site joined to every acceptor site in
pairwise combinations. The central 20 b was extracted from each, and a
sub-DS of reads speciﬁc to that sequence was generated by screening
the primary DS for exact matches. Each DS was then assembled against
the cognate 200-b sequence by using Maq. Thus, reads supporting each
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junction were required to match the reference exactly in the 20-b se-
quence (i.e., 10 b from each exon) and substantially in the ﬂanking
regions (<3 b mismatch in 56 b).
ERs for selected spliced RNAs were calculated as described in step v, by
extracting 20-b sequences (10 b each side of the spliced exon–exon junction
or unspliced exon–intron junctions) from the DDS, generating read sub-DSs,
assembling them against the cognate spliced or unspliced 200-b sequence,
and counting the numbers of appropriately oriented reads. Complete
splicing would yield an ER of 1.
RNA Mapping. RT-PCR, RACE, and NB were conducted using the 2010 RNA
preparations. Titanium One-Step RT-PCR and SMARTer RACE Kits (Clontech)
wereusedwithprimers listed inTables S2and S3, andproductswere sequenced
directly or from plasmid clones. For NB, RNA was transferred from 1% form-
aldehyde-agarose gels to membranes, and hybridized with biotin-labeled,
single-stranded RNA probes produced from plasmids (checked by sequencing)
using a DIG Northern Starter Kit (Roche) and primers listed in Table S4.
Tagged Protein Expression. Published methods (45) were used to introduce
a V5 epitope tag (checked by sequencing) at the C terminus of the UL150A
protein by modifying bacterial artiﬁcial chromosome pAL1111, which con-
tains the strain Merlin genome, and generating a recombinant virus (Table
S5). HFFFs were mock-infected or infected at 5 pfu per cell and incubated in
FCS-free DMEM for 1 or 2 d, or in DMEM containing 10% FCS for 3 d and
then FCS-free DMEM for 3 d. Cell extracts were electrophoresed in 10% SDS/
polyacrylamide gels, transferred to membranes, probed with a V5-Tag
mouse monoclonal antibody (MCA1360; AbD Serotec), and reprobed with
horseradish peroxidase-conjugated goat anti-mouse IgG (170-6516; Bio-
Rad). Signal was detected by using SuperSignal West Pico Chemiluminescent
Substrate (Thermo Scientiﬁc).
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